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9In cells, proteins are continuously synthesized 
and degraded to control protein levels and 
thereby regulate a wide variety of biochemi-
cal processes. The proteasome is the main 
cellular degradation machinery, responsible 
for the degradation of key proteins involved 
in the regulation of a wide range of cellu-
lar processes, including quality control, cell 
cycle progression, cell differentiation, signal 
transduction and apoptosis. In addition, the 
proteasome is involved in immunity. A broad 
repertoire of antigenic peptides is presented 
at the cell surface to the immune system by 
major histocompatibility complexes (MHC) 
class I, enabling the immune system to moni-
tor changes in intracellular protein content 
and sense malignant transformation or the 
presence of viral proteins. Recognition of 
foreign or abnormal peptides by CD8+ cyto-
toxic T cells ultimately results in the elimi-
nation of the antigen presenting cell. Both 
foreign and self MHC class I antigens are 
generated by the proteasome.
The proteasome has been identified as an at-
tractive pharmacological target. Inhibition of 
the proteasome causes disruption of many 
regulatory processes, eventually leading to 
cell death. The observation that many cancer 
cells are more sensitive to proteasome inhibi-
tion than normal cells has led to the develop-
ment of several proteasome inhibitors for the 
treatment of cancer. The drug velcade® with 
the proteasome inhibitor bortezomib as its 
active ingredient is used for the treatment of 
multiple myeloma and mantle cell lymphoma, 
while many clinical trials in other malignan-
cies are ongoing. The clinical success of borte-
zomib therapy has initiated the development 
of several second-generation proteasome in-
hibitors, which differ in their mode of inhibi-
tion and downstream mechanism of action. 
With several proteasome inhibitors becoming 
available for clinical use, the outstanding chal-
lenge is to define optimal treatment regimes 
and to choose the most suitable proteasome 
inhibitor for treatment.
Proteasome activity in its broadest sense is 
the central theme of this thesis. In chapter 
1, we describe the development and charac-
terization of different chemical proteasome 
activity probes that can be used to study 
proteasome activity in a wide range of tis-
sue types using a variety of assays. With the 
proteasome emerging as a therapeutic tar-
get for cancer treatment, accurate tools for 
monitoring proteasome activity are in de-
mand. Most methods however require prior 
cell lysis before activity measurements can be 
performed, or can only be used in genetically 
modified cells or organisms. chapter 1.2 de-
scribes the development of a dansylated pro-
teasome activity probe and SDS-PAGE based 
assays to monitor proteasome activity. This 
probe is the first in its class that could be used 
to study the activity of velcade® in intact cells 
conveniently without the need for laborious 
radiolabeling procedures. In chapter 1.3, flu-
orescent versions of this probe are described 
that allow a direct readout in SDS-PAGE based 
assays, circumventing the need for an anti-
body, while they can also be used for confocal 
microscopy and flow cytometry-based assays 
Preface
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to detect proteasome activity in cells directly. 
Chapter 2 focuses on different uses of these 
fluorescent proteasome activity probes. We 
assess the effects of different proteasome in-
hibitors in preclinical and clinical studies and 
use these probes to purify proteasome and 
characterize its activity and composition. In 
chapter 2.1, we compare the effects of bort-
ezomib and the novel proteasome inhibitor 
CEP-18770 in mouse tissues and in cell lines 
with acquired resistance to bortezomib due 
to a specific mutation in one of the protea-
some active sites. In chapter 2.2 we study the 
effects of marizomib therapy on patient blood 
samples and in the following chapter (2.3), 
we describe an activity-guided proteasome 
purification and determine the relative sub-
unit composition in purified bovine liver and 
spleen proteasomes by mass spectrometry. 
Proteasome activity is studied on a molecular 
level in chapter 3 and the role of the protea-
some in immunity is addressed. Recent stud-
ies have identified novel MHC class I epitopes 
in which two distant parts of a protein are 
excised and ligated together to form a novel 
peptide. These non-contiguous antigens are 
thought to be produced by the proteasome 
via a transpeptidation mechanism. In chap-
ter 3.2, the molecular mechanism of protea-
somal antigen splicing is studied, and rules 
that predict proteasomal antigen splicing are 
deduced. In contrast to current thoughts we 
show that this process can be remarkably ef-
ficient. Finally, in chapter 3.3, we show that 
proteasome splicing can produce a novel type 
of antigen, containing an isopeptide linkage. 
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The observation that tumour cells are more sensitive to pharmacological inhibition of the 
proteasome than normal cells has led to the development of the proteasome inhibitor bort-
ezomib. To date, this is the only proteasome inhibitor that has been approved for clinical use. 
The clinical success of bortezomib, combined with the occurrence of adverse effects and the 
development of clinical resistance against this compound, has initiated the development of 
a broad range of second-generation proteasome inhibitors as well as of assays that can be 
used to establish a relationship between the extent and type of proteasome inhibition and 
the effectiveness of a particular drug. In the present paper, we discuss new strategies that 
may be used in the future to overcome drug resistance and to broaden the use of protea-
some inhibitors for the treatment of both cancer and infectious and autoimmune disease.
Drug discovery and assay development in the 
ubiquitin–proteasome system
Celia R. Berkers* & Huib Ovaa*
THe UPS (UBIqUITIn–PrOTeASOme 
SySTem)
The UPS is responsible for the degradation of 
redundant and misfolded proteins, as well as 
for the turnover of many key regulatory pro-
teins that control a wide range of cellular pro-
cesses such as cell-cycle progression, cell dif-
ferentiation, apoptosis, stress response, DNA 
repair and signal transduction.1,2 Proteins that 
are destined for destruction are first post-
translationally modified with a polyubiquitin 
chain via the consecutive action of three dif-
ferent types of ubiquitinating enzymes3 (Fig-
ure 1). First, an E1 ubiquitin-activating enzyme 
activates ubiquitin in an ATP-dependent man-
ner and then transfers it to an E2 ubiquitin-
conjugating enzyme. In a final step, ubiquitin 
is conjugated to the target protein or a pre-
viously attached ubiquitin via the combined 
action of the E2 and an E3 ubiquitin ligase. 
The latter ligase is capable of interacting with 
both the E2 and the target protein and there-
by confers substrate specificity on the ubi- 
quitination cascade.
Sequential ubiquitination cycles lead to the 
formation of polyubiquitinated proteins, 
which are subsequently degraded by the 26S 
proteasome, a large threonine protease com-
plex. The proteolytic activity of the 26S pro-
teasome resides within its barrel-shaped 20S 
core, which is formed by four stacked rings of 
seven subunits each and has an overall archi-
tecture of α(1−7)β(1−7)β(1−7)α(1−7). Within 
the two inner β-rings, three different catalyti-
cally active subunits, termed β1, β2 and β5, 
are responsible for the proteasome’s caspase-
like, trypsin-like and chymotrypsin-like activ-
ity, respectively. In lymphoid tissues and upon 
induction with interferon-γ, these constitu-
*Correspondence may be addressed to either author (c.berkers@nki.nl or h.ovaa@nki.nl).
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Figure 1 |Ubiquitin conjugation and deconjugation, and proteasomal protein breakdown. DUB, deu-
biquitinating enzyme; Ub, ubiquitin.
tive subunits can be replaced by their immu-
noproteasome counterparts, termed β1i, β2i 
and β5i, to form the immunoproteasome, 
whereas mixed-type proteasomes have also 
been reported.4,5 The two outer α-rings pro-
vide stability to the 20S complex and serve 
as docking stations for the attachment of 19S 
regulatory complexes, which consist of a base 
that binds directly to the α-rings and which 
contain several ATPases. These 19S caps rec-
ognize and unfold the substrates and subse-
quently thread them into the 20S catalytic 
chamber for degradation. 
PrOTeASOme InHIBITOrS AS 
AnTICAnCer THerAPeUTICS
Proteasome inhibition is more cytotoxic to 
proliferating malignant cells than to quies-
cent normal cells, making the proteasome 
an attractive pharmacological target for the 
treatment of cancer.6 Bortezomib7 (velcade, 
PS341) (Figure 2) was the first proteasome in-
hibitor to enter the clinic, and has now been 
approved as a single agent for the treatment 
of relapsed/refractory MM (multiple my-
eloma) and mantle cell lymphoma, whereas 
many clinical trials in solid and haematologi-
cal tumours are ongoing. Although the clinical 
success of bortezomib is evident, bortezomib 
treatment has been associated with serious 
adverse effects.8 In addition, the occurrence 
of both primary and acquired resistance to 
bortezomib has been reported and although 
many haematological malignancies seem to 
respond well to proteasome inhibitor treat-
ment, results in treatment of solid tumours 
have been disappointing.9 This has initiated 
an ongoing search for novel proteasome in-
hibitors with distinct subunit specificity, lower 
toxicity or improved bioavailability. 
Several second-generation proteasome in-
hibitors that vary in their mode of binding 
are now in clinical trials, including carfilzomib 
(PR-171),10,11 NPI-0052 (salinosporamide A)12 
and CEP-1877013,14 (Figure 2). For all inhibi-
tors, the first step in proteasome inhibition is 
the deprotonation of the proteasomal Thr1 
Oγ, which is thought to occur by the N-termi-
nal amino group acting as a base, either di-
 19
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rectly or via a neighbouring water molecule.15 
The structure of bortezomib complexed to 
the yeast 20S proteasome16 has shown that 
for boronic acid-based inhibitors such as 
bortezomib and CEP-18770, subsequent nu-
cleophilic attack of the Thr1 Oγ results in a 
covalent interaction between the boron atom 
and the Thr1 Oγ (Figure 3A). The proteasome–
inhibitor complex is stabilized further by the 
Thr1 N, which forms a tight hydrogen bond 
with one of the acidic boronate hydroxyl 
groups.16 In the case of epoxyketone-based 
inhibitors, such as carfilzomib, nucleophilic 
attack of Thr1 Oγ  is thought to result in hemi-
acetal formation, followed by subsequent cy-
clization of Thr1 N onto the epoxide, resulting 
in the formation of a morpholino adduct (Fig-
ure 3B), as observed in the crystal structure of 
the 20S proteasome–epoxomicin complex.17 
NPI-0052 is a proteasome inhibitor isolated 
from the marine actinomycete Salinispora. 
Figure 2 |Structures of (clinically relevant) 20S proteasome inhibitors.
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The crystal structure of the 20S proteasome–
NPI-0052 complex18 suggests that nucleo-
philic attack by the catalytic Thr1 Oγ on the 
β-lactone ring results in the formation of an 
ester between the Thr1 Oγ and the carbonyl 
derived from the β-lactone ring (Figure 3C). 
Subsequent chlorine substitution then gives 
rise to a cyclic ether,18 resulting in an adduct 
resistant to further hydrolysis.
The proteasome inhibitors that are currently 
in use in the clinic also vary in their subunit 
specificity, downstream mechanisms of ac-
tion and bioavailability. Bortezomib and CEP-
18770 both reversibly inhibit β1 and β5 sub-
units,7,14,19 carfilzomib predominantly targets 
the β5 subunit,11 whereas NPI-0052 irrevers-
ibly inhibits all constitutive and immunopro-
teasome subunits.12 As a consequence, carfil-
zomib and CEP-18770 induce apoptosis via 
similar downstream mechanisms to that of 
bortezomib,11,14,20 whereas NPI-0052 induces 
20
apoptosis also via different pathways.12 Both 
carfilzomib and NPI-0052 were shown to be 
able to overcome bortezomib resistance, both 
in cell lines and in samples from patients with 
clinical bortezomib resistance.11,12 NPI-0052 
and CEP-18770 are orally bioavailable.12,14
PrOTeASOme ACTIVITy ASSAyS 
For effective treatment with proteasome in-
hibitors, it is essential to establish a relation-
ship between the effectiveness of the drug 
in a particular tumour type and the extent 
and type of proteasome inhibition.6 There is 
therefore an emerging need for proteasome 
activity assays that can profile the efficacy 
and specificity of proteasome inhibitors, both 
in vitro and in a cellular context. 
Traditionally, different fluorogenic substrates, 
which typically consist of a short peptide and 
Figure 3 | Proposed mechanisms of proteasome inactivation by (clinically relevant) 20S proteasome 
inhibitors.  Inhibitors are indicated in black, N-terminal threonine residues of active proteasomal 
β-subunits are in grey. Inactivation mechanism of A) boronic acid-based proteasome inhibitors (bor-
tezomib and CEP-18770),16 B) epoxyketone-based proteasome inhibitors (carfilzomib and PR-957),17 C) 
β-lactone-based NPI-005218 and D) 1,3,4-oxathiazol-2-one compounds (mycobacterial-specific protea-
some inhibitors).47
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a C-terminally attached fluorogenic reporter, 
are used to measure the activity of the differ-
ent proteasome active sites. The proteasome 
cleaves these substrates between the last 
amino acid and the reporter, resulting in the 
release of a fluorescent molecule.21 Fluoro-
genic substrates are widely used to measure 
effects of proteasome inhibitors,22 but often 
only the chymotrypsin-like activity is mea-
sured.21 It should be noted, however, that 
measuring only the chymotrypsin-like activity 
may not accurately reflect the degree of pro-
teasome inhibition, and that the activities of 
all active sites need to be assayed in order to 
reliably evaluate the efficacy of inhibitors.21,23 
Most fluorogenic substrates cannot be used 
in cells, and prior cell lysis is required before 
activity measurements can be performed. 
This treatment isolates the proteasome from 
its regulatory environment,6 and may lead 
to dissociation of the 19S caps. Efects of the 
19S regulatory particle or other associated 
proteins may thus not be accounted for.24 
Furthermore, fluorogenic substrates cannot 
distinguish between constitutive and immu-
noproteasome activity, as immunoprotea-
some-specific substrates have not been de-
scribed to date.6 
To measure proteasome activity in vivo, both 
cell-based assays25 and transgenic mouse 
models24,26 have been developed that are 
based on recombinant proteasome sub-
strates, typically ubiquitin–GFP (green fluo-
rescent protein) or ubiquitin–luciferase fusion 
protein. Under normal cellular conditions, 
these fusion proteins are rapidly degraded 
by the proteasome, and no fluorescence or 
luciferase activity can be detected, but when 
the proteasome is inhibited, degradation 
is impaired and intracellular fluorescence 
increases. These methods and models are 
useful in screening for new inhibitors and 
for testing bioavailability, but their activity 
readout depends on the balance between 
synthesis and degradation of fusion proteins, 
which involves many cellular factors other 
than the proteasome, including the rate of 
fusion protein synthesis. Moreover, because 
they are based on reporter proteins, their use 
remains confined to genetically altered cells 
and organisms and does not allow profiling of 
patient material.
A third type of assay uses chemical proteasome 
probes that allow profiling of proteasome ac-
tivity in cell lysates, cells and ex vivo.11,19,27-30 
In general, these probes consist of a reactive 
group that covalently modifies all active-site 
N-terminal threonine residues, which is at-
tached to a peptide-recognition motif to target 
the probe to the proteasome. A tag allows for 
visualization or isolation of the proteasome–
probe complex. An example of such a probe 
is dansyl-Ahx3Leu3vinylsulfone (where Ahx is 
aminohexanoic acid),19 which was used suc-
cessfully to profile bortezomib,19 NPI-005212 
and carfilzomib11 in cells using an antibody 
against the dansyl moiety. More recently, 
chemical probes in which the dansyl moiety 
has been replaced with a fluorescent tag have 
been developed.27,30 These probes are more 
sensitive and allow for easier visualization of 
proteasome activity either using SDS/PAGE 
or directly using confocal microscopy. Impor-
tantly, the incorporation of a fluorescent tag 
also enables the use of these probes in flow-
cytometry-based assays,27 which can be ap-
plied in a high-throughput fashion to screen 
for direct and indirect regulators of protea-
some activity. Chemical proteasome probes 
have also been used for patient tumour pro-
filing,31 thereby confirming that these probes 
can be used to quantitatively and qualitatively 
monitor proteasome blockage in patients re-
ceiving proteasome inhibitor therapy.6 Finally, 
proteasome active-site probes were used for 
the development of an ELISA-based activity 
assay.11,28,29 This assay combines the use of a 
biotinylated epoxyketone-based proteasome 
22
probe with subunit-specific antibodies to 
measure proteasome activities and has been 
used to profile the activity of carfilzomib and 
several recently developed immunoprotea-
some-specific inhibitors.
nOVel AnTICAnCer STrATegIeS
With the availability of a panel of differ-
ent proteasome inhibitors, the outstanding 
clinical challenge will be to define treatment 
schedules that offer a therapeutic advantage 
over bortezomib treatment.32 Different pro-
teasome inhibitors may find use in different 
therapeutic settings. Specific inhibitors of the 
β5 subunit, such as bortezomib, carfilzomib or 
CEP-18770, may offer a large therapeutic win-
dow in some tumours, whereas pan-protea-
some inhibitors that block all three activities 
may lead to improved proteasome inhibitor 
efficacy in others,29,33 depending on subunit 
activity profile, tissue type and disease. 
An interesting strategy to overcome resis-
tance to the current generation of protea-
some inhibitors may be the development of 
inhibitors that do not interfere with the 20S 
core, but with other elements of the UPS. 
An obvious strategy would be the develop-
ment of inhibitors of the 19S regulatory par-
ticle, especially inhibitors of the 19S ATPases, 
which also play non-proteolytic roles.34 The 
first compound of this type, RIP-1 (regula-
tory particle inhibitor peptoid-1) was recently 
identified and the 19S ATPase Sug2/Rpt4 was 
identified as its molecular target.34,35 A more 
advanced UPS-modulating compound that 
holds promise for the treatment of cancer is 
MLN4924,36 an inhibitor of NEDD8 (neural-
precursor-cell-expressed developmentally 
down-regulated 8)-activating enzyme, an es-
sential component of the NEDD8 conjugation 
pathway that, in turn, controls the activity 
of a subset of E3 ubiquitin ligases. MLN4924 
treatment induced apoptosis in human tu-
mour cells, and suppressed tumour growth in 
pre-clinical models.36 Currently, MLN4924 is 
being evaluated in clinical trials.
Proteasome inhibitors can be combined 
with other proteasome inhibitors or chemo-
therapeutics to increase their therapeutic 
potential. The combination of bortezomib 
and NPI-0052 remarkably induced synergistic 
cytotoxicity,12,33,37 indicating that combina-
tion therapy of proteasome inhibitors might 
improve patient outcome.6 It is tempting to 
speculate that combining proteasome inhibi-
tors that induce apoptosis via distinct mecha-
nisms, such as bortezomib and NPI-0052, may 
be particularly beneficial.6 Interesting in this 
respect is the recent identification of argyrin 
A,38 a cyclic peptide derived from the myco-
bacterium Archangium gephyra that inhibits 
all proteasome activities. Induction of apop-
tosis by argyrin A was shown to be dependent 
on p27kip1, but not on IκBα (inhibitor of nu-
clear factor κB α) stabilization, whereas the 
cytotoxic effects of bortezomib are mediated 
via IκBα stabilization, but are not dependent 
on p27.38 Argyrin A may therefore represent 
another class of proteasome inhibitors that 
can be successfully combined with other pro-
teasome inhibitors in anticancer therapy.
Many of the pathways used by tumour cells 
to survive chemotherapy are blocked by pro-
teasome inhibition, which provided the ratio-
nale for combining bortezomib with a variety 
of chemotherapeutics.9,39 The combination of 
bortezomib and PEGylated doxorubicin has 
been approved for the treatment of relapsed 
MM,40,41 and many treatment regimens com-
bining bortezomib and other proteasome in-
hibitors with conventional or novel anti-MM 
agents have yielded promising results.6,9,42,43 
Another strategy currently being evaluated 
is the simultaneous targeting of the protea-
somal and lysosomal degradation pathways 
using a combination of bortezomib and HDAC 
(histone deacetylase) inhibitors.6
 23
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new FrOnTIerS In UPS DrUg 
DisCoveRy
Proteasome inhibitor therapy may not remain 
restricted to the treatment of cancer, but may 
also be used to treat a variety of other disor-
ders. Recently, PR-957 (Figure 2), an epoxyke-
tone-based inhibitor specific for the immuno-
proteasomal β5i subunit, was developed.28 
Immunoproteasome is found predominantly 
in cells of haemopoietic origin. Specific 
immunoproteasome inhibitors may therefore 
be used for the treatment of haemopoietic 
tumours,  while causing fewer side effects 
in tissues that express only low levels of 
immunoproteasome subunits, such as neu-
rotoxicity or gastrointestinal side effects.9 
Immunoproteasome inhibitors may also be 
useful for the treatment of other disorders. 
Increased immunoproteasome expression 
has been observed in autoimmune diseases 
such as rheumatoid arthritis44 and has also 
been correlated to neurodegenerative dis-
ease states, including Huntington’s and Al-
zheimer’s disease.45,46 Consistent with this, 
Muchamuel et al.28 showed that PR-957 re-
versed signs of disease in mouse models of 
rheumatoid arthritis, providing a rationale 
for development of immunoproteasome in-
hibitors  for the treatment of autoimmune 
diseases. Furthermore, various infectious 
diseases may be treatable with proteasome 
inhibitors. Lin et al.47 identified two related 
1,3,4-oxathiazol-2-one compounds, HT1171 
and GL5 (Figure 2), as selective inhibitors of 
the proteasome of Mycobacterium tubercu-
losis. Nucleophilic attack of the proteasomal 
Thr1 Oγ on the oxathiazol-2-one is thought 
to result in the formation of a carbonated 
or carbonothioated enzyme intermediate on 
Thr1.47 Subsequent nucleophilic attack of the 
Thr1 N results in cyclocarbonylation of the ac-
tive-site threonine residue to form an oxazo-
lidin-2-one and prevents regeneration of the 
active protease (Figure 3D), thereby killing 
M. tuberculosis.47 It is important that these 
oxathiazol-2-one compounds did not signifi-
cantly inhibit the human proteasome nor a 
panel of cysteine, serine or metallo-proteases. 
The selectivity of these compounds for M. 
tuberculosis over mammalian proteasomes 
seemed to be conferred by residues distant 
from the active site, suggesting that a func-
tionally exploitable diversity exists between 
M. tuberculosis and human proteasomes and 
that compounds that are specific for different 
types of mycobacteria or a variety of other 
bacteria could also be developed, although in 
vivo data are required. This opens the way for 
the treatment of a variety of (myco)bacterial 
infections with proteasome inhibitors, either 
alone or in combination with other antibiotic 
strategies.
COnClUSIOn
Proteasome inhibition has emerged as a novel 
strategy for the treatment of cancer, as is evi-
dent from the clinical success of bortezomib, 
the first proteasome inhibitor to pass clini-
cal trials. The occurrence of side effects, the 
development of resistance and low success 
rates in the treatment of solid tumours, how-
ever, limits the use of this agent. The recent 
development of a broad range of second- 
generation proteasome inhibitors is likely to 
contribute to a more widespread use of this 
class of agents for the treatment of both 
haematological and solid tumours. The de-
velopment of compounds that interfere with 
the UPS via different mechanisms and the 
development of proteasome inhibitors that 
are specific for proteasome subtypes or other 
species may broaden the clinical application 
of UPS-modulating compounds in cancer and 
infectious and autoimmune diseases.
24
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Proteasome inhibitors, such as the dipeptide boronic acid bortezomib, are emerging as 
important tools in the treatment of the fatal hematologic malignancy multiple myeloma. 
Despite the recent US Food and Drug Administration approval of bortezomib (PS341, Vel-
cade) for the treatment of refractory multiple myeloma, many of the basic pharmaco-
logic parameters of bortezomib and its mode of action on myeloma cells remain to be 
determined. we describe the synthesis and use of a cell-permeant active site–directed 
probe, which allows profiling of proteasomal activities in living cells. when we compared 
proteasome activity patterns in cultured cells and crude cell extracts with this probe, we 
observed substantial differences, stressing the importance for bioassays compatible with 
live cells to ensure accuracy of such measurements. Using this probe, we investigated the 
in vivo subunit specificities of bortezomib and another inhibitor, mg132.
InTrODUCTIOn
The proteasome inhibitor bortezomib (2) 
(PS341, Velcade; Figure 1) is among the most 
promising pharmaceuticals developed for the 
treatment of multiple myeloma.1 The ability 
to target the proteasome pharmacologically 
without prohibitive toxicity is in itself remark-
able: the proteasome is a large proteolytic 
complex, which is abundant in the cytosol 
and the nucleus, and it is considered central 
to many different aspects of cellular physiol-
ogy, as polypeptides are continuously synthe-
sized and destroyed to maintain steady-state 
protein levels.2 Protein turnover by the pro-
teasome has many critical regulatory roles, 
including quality control by removing abnor-
mal proteins that arise by mutation, meta-
bolic damage or misfolding. 
Eukaryotic proteasomes consist of a 20S core, 
which is most often the central part of higher-
order complexes, of which the 26S protea-
some is the major active species (Figure 2). In 
26S proteasomes, the 20S core particle is com-
plexed at one or both ends with a 19S regula-
tory complex that modulates the entrance of 
substrates to the core and is required for the 
recognition of ubiquitin-tagged substrates 
and the unfolding of substrates prior to their 
threading into the proteolytic chamber.3 Hy-
§These authors contributed equally to this work. *Correspondence should be addressed to H.O. (h.ovaa@nki.nl).
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brid proteasomes, in which different regula-
tory caps are attached to the 20S core, also 
exist. The 20S core is a hollow, barrel-shaped 
protein complex4 composed of 14 α and 14 β 
subunits arranged in four stacked rings with 
an overall architecture of α(1–7)β(1–7)β(1–7)
α(1–7). The two outer α rings form gated 
channels through which substrates enter and 
products exit the catalytic core. In addition, 
the outer α rings provide binding sites for reg-
ulatory complexes such as the 19S caps. The 
proteolytic activity of the 20S particle resides 
in the two inner β rings. The proteasome has 
three distinct catalytic activities, caspase-like, 
tryptic-like and chymotryptic-like, each of 
which can be roughly correlated to the ac-
tion of an individual catalytic β subunit. These 
are termed β1, β2 and β5, respectively, and 
can be replaced by three interferon-inducible 
subunits, termed β1i, β2i and β5i to form 
immunoproteasomes—proteasomes with al-
tered catalytic specificity favoring production 
of antigenic peptides. The secondary alcohol 
of the N-terminal threonine of the active β 
subunits acts as the nucleophilic species. 
The dipeptide boronic acid bortezomib is a po-
tent inhibitor of the proteasome’s chymotryp-
tic-like activity.5 But variations in proteasomal 
composition alter the proteolytic specificities 
of the proteasome6–8 and may therefore af-
fect the sensitivity of the proteasome to the 
action of bortezomib. Little is known about 
the composition of active proteasomes in 
living multiple myeloma cells. Furthermore, 
most investigators measure proteasomal ac-
tivity in cell extracts using fluorogenic sub-
strates, and as a result, it has been difficult 
to assess the extent of inhibition of individual 
Figure 1 | representative structures of bortezomib and vinyl sulfone–based proteasome probes.
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catalytic activities in vivo after treatment with 
bortezomib. This underscores the need for 
improved tools that allow the accurate as-
sessment of proteasomal activity in vivo.
To facilitate proteomic research, activity-
based chemical probes have been developed 
for the study of serine, cysteine and threonine 
proteases.9–11 These probes form covalent ad-
ducts with active proteases of the class that is 
targeted, leading to a convenient readout of 
enzyme activity. Most of these probes, how-
ever, can not be used in intact living cells.12,13 
Tags that are incorporated to provide an en-
zymatic activity readout, such as [125I]iodo-
tyrosine, often render probes impermeant 
to cell membranes, thereby restricting their 
use to cell extracts. Furthermore, they are 
nonspecific and target many proteases at the 
same time. Thus, such probes do not provide 
information on in vivo activities of specific 
proteases. 
Peptide vinyl sulfone–based proteasome in-
hibitors9,14 such as ZL3VS (1) (Figure 1) modify 
catalytically active threonine residues through 
a Michael addition reaction, resulting in the 
formation of a covalent β-sulfonyl ether link-
age. When a detectable tag is attached to such 
inhibitors, they can be used to label and de-
tect proteasome active sites. Recently we set 
out to profile proteasome activity in multiple 
biological samples. A previously developed 
peptide vinyl sulfone–based inhibitor proved 
to be cell-permeant,15 but the need for sec-
ondary chemical labeling procedures made 
this method unsuitable as a rapid screen of 
proteasome inhibition in multiple samples. In 
need for fast, reproducible activity readouts 
we reasoned that the use of small haptens, 
which can be recognized by antibodies, may 
allow retention of cell permeability of probes 
and allow detection of labeled enzymes di-
rectly by SDS-PAGE and Western blot analysis. 
Therefore we synthesized an inhibitor with a 
dansyl-sulfonamidohexanoyl hapten as a fast 
and easy method to monitor proteasome ac-
tivity in living cells. Using this probe, we could 
profile active proteasome subunits in cell 
extracts and cultured cells. Furthermore, we 
investigated the in vivo subunit specificities 
of the proteasome inhibitors bortezomib and 
MG132. We found that the β1 and β1i sub-
units are additional targets for bortezomib 
and that MG132 inhibits all subunits.
reSUlTS
Synthesis and characterization of 
proteasome probes
We synthesized compound 3 (Figure 1) con-
taining a dansyl-sulfonamidohexanoyl hapten, 
as well as control 4 in which the reactive vinyl 
sulfone moiety is reduced by hydrogenation, 
rendering the overall probe unreactive. Using 
a cell-based assay,16 we tested proteasome in-
hibition by compounds 3 and 4, and compared 
the inhibition to that of other known inhibi-
tors. We exposed cells expressing a substrate 
fusion protein comprising ubiquitin, the ami-
no acid arginine and green fluorescent protein 
(ubiquitin-Arg-GFP) to proteasome inhibitors. 
Efficient proteasome inhibition results in the 
accumulation of GFP, which can be quanti-
tated by fluorescence activated cell sorting 
(FACS; Figure 3A,B). Whereas treatment with 
increasing amounts of 3 or Ada-Ahx3Leu3VS, 
the parent compound, resulted in a substan-
tial increase in fluorescence, treatment with Figure 2 |  Schematic of the 26S proteasome.
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the control inhibitor 4 was ineffective. The 
approximate half-maximal inhibitory concen-
tration (IC50) values for Ada-Ahx3Leu3VS and 
3 were 3 mM and 8 mM, respectively (Fig-
ure 3B). Thus, although the potency and/or 
bioavailability of compound 3 is somewhat 
lower than that of the parent compound, it 
is by far sufficient as a probe for activity mea-
surements. By observing the relatively weak 
fluorescence emitted by the dansyl moiety of 
inhibitor 3, we confirmed cell permeability 
of 3 by fluorescence microscopy (Figure 3C). 
After incubation with 20 mM of 3, we visual-
ized fluorescence throughout the cytosol and 
nucleus of cultured HeLa and EL4 cells. The 
microscopy results conclusively demonstrate 
the cell permeability of inhibitor 3. We next 
determined the subunit specificity of inhibi-
tor 3 by its ability to compete for proteasome 
subunit labeling with the fully characterized 
radiolabeled inhibitor Ada-125IYAhx3Leu3VS (5) 
(Figures 1 and 3D), that we have  previously 
shown to react with all active subunits of the 
proteasome.14,15 In a dose-dependent man-
ner inhibitor 3 could compete with Ada-125IY- 
Ahx3Leu3VS for labeling of all active protea-
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Figure 3 | Characterization of compounds 3 and 4. A,B) FACS analysis results of ubiquitin-Arg-GFP–ex-
pressing U37312 cells upon incubation with proteasome probes and proteasome inhibitors. Incubation 
with compound 3 resulted in an increase in fluorescence, comparable to that of known proteasome 
inhibitors, whereas incubation with inactive compound 4 did not (A). B) Graph shows the increase in 
fluorescence after a 5-h incubation with the indicated concentrations of compound 3 and the par-
ent compound Ada-Ahx3L3VS, from which an approximate IC50 value could be estimated. Graphs are 
of representative results obtained in two independent experiments. C) Visualization by fluorescence 
microscopy of the distribution of compound 3 in EL4 and HeLa cells. Bar, 10 mm. D) Competition ex-
periment between inhibitor 3 and inhibitor 5. Autoradiograph showing the proteasome subunits that 
have reacted with 5.
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some subunits in extracts from the multiple 
myeloma cell line MM.1S. We therefore con-
clude that compound 3 is a cell-permeant 
proteasome inhibitor that can be used to la-
bel all active proteasome subunits. 
Probing proteasome activity in cell extracts 
To directly visualize the proteins labeled by 3 
in EL4 cell extracts, we took advantage of the 
probe’s dansyl-sulfonamidohexanoyl tag. We 
incubated cell extracts with increasing con-
centrations of 3 followed by SDS-PAGE and 
immunoblotting for the dansyl-sulfonamido-
hexanoyl moiety (Figure 4A). We observed 
a clear labeling profile, devoid of spurious 
cross-reactivity attributable to the antibody 
used. At a concentration of 300 nM, inhibi-
tor 3 labeled all active proteasome subunits 
to a similar extent, despite weaker reactiv-
ity of the probe towards the β2i subunit. In 
the presence of increasing concentrations of 
inhibitor, the proteasomal active sites were 
rapidly saturated, and we observed a nonspe-
cific highmolecular-weight labeling profile at 
the higher concentrations. This underscores 
the need for a careful titration of directed 
activity-based probes. Notably, subunits mi-
grate slightly differently on the gels (Figure 
4A compared to Figure 3D); the migration of 
a particular subunit-probe complex on gel is 
probe-dependent, which explains the subtle 
differences. To validate the accuracy of the 
method, we performed proteasome activity 
measurements with fluorogenic substrates in 
parallel. We incubated extracts with increas-
ing concentrations of inhibitor 3 and then 
monitored the cleavage of SucLeuLeuVal-
TyrAMC (chymotryptic-like activity), ZAlaAr-
gArgAMC (tryptic-like activity) and ZLeuLeu-
GluβNA (caspase-like activity) to determine 
the remaining activities (Figure 4B). The ac-
tivity measurements with fluorogenic sub-
strates corresponded well to the immunoblot 
profile. At a concentration of 10 mM of 3, la-
beling of subunits with this inhibitor reached 
saturation, and activity against fluorogenic 
substrates was abolished almost completely, 
thus confirming the accuracy of the use of in-
hibitor 3 as a probe to measure proteasome 
activity in vitro. 
Probing proteasome activity in living cells
We next probed proteasomal activity in intact 
cells. We incubated cultured EL4 cells with 
increasing concentrations of 3, collected the 
cells, and immunoblotted for the dansyl group 
as described above (Figure 4C). We observed 
a dose-dependent labeling of active protea-
some subunits from EL4 cells, which confirms 
that probe 3 permeates cell membranes and 
modifies all active proteasome subunits. When 
we compared the labeling pattern obtained 
in experiments with EL4 extracts to that ob-
tained in experiments with cultured cells, we 
found that elevated concentrations of probe 
are needed to efficiently label active protea-
some subunits, probably owing to kinetics of 
membrane permeation. Furthermore, the in 
vivo labeling profile differed in comparison to 
the labeling pattern in cell extracts. In EL4 cell 
lysates, the β1 and β1i subunits appear to be 
quite active. But in vivo the β1 subunit was la-
beled only in the presence of high concentra-
tions of inhibitor 3, whereas the β1i subunit 
was not labeled at all. In contrast, the β5 sub-
units seem to be more active and therefore 
the target for the majority of the observed in 
vivo active-site labeling. The exact reason for 
the observed activity difference is not clear. 
Possible explanations include partial disso-
ciation of associated (19S) regulatory protea-
somal cofactors upon preparation of extracts, 
as well as disruption of transient associations 
of active proteasomes with cell membranes 
in detergent extracts. In addition, when we 
compared in vivo labeling experiments to ex-
periments in lysates, virtually no highmolec-
ular-weight adducts were observed despite 
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the presence of equal concentrations of in-
hibitor. Thus, inhibitor 3 labels proteasomes 
with greater selectivity in vivo. Next, we vali-
dated the in vivo activity pattern obtained 
with probe 3 by performing activity measure-
ments with fluorogenic substrates in extracts 
prepared from identical samples (Figure 4D). 
In vivo, the saturation of subunit labeling cor-
responded to the inhibition of proteasome 
activity. At 10 mM, compound 3 almost com-
pletely inhibited proteasome activity, as was 
the case in vitro, confirming that it is unlikely 
that an altered bioavailability of compound 3 
in vivo is responsible for the altered labeling 
pattern. Next, we used inhibitor 3 to profile 
the proteasome activity in HeLa cells in vivo. 
Again, the β5 subunits seemed to be most ac-
tive and therefore the targets for the majority 
of the in vivo active-site labeling (Supplemen-
tary Figure 1). We conclude that proteasome 
activity profiles obtained by performing mea-
surements in cell extracts are not necessarily 
representative of the in vivo activity patterns, 
stressing the need for live cell–based assays.
In vivo profiling of bortezomib and mg132
Next, we determined whether the probe could 
be used to accurately measure the remaining 
proteasome activity after inhibition by other 
proteasome inhibitors. We cultured EL4 cells 
Figure 4 | Profiling of proteasome activity in el4 cell extracts and cells. A,C) Immunoblots originating 
from the same gel showing results of a 1-h labeling experiment in EL4 cell extracts (A) or a 2-h labeling 
experiment in living EL4 cells (C) with the indicated concentrations of inhibitor 3 or 10 mM inactive 
control 4. B,D) Measurement with fluorogenic substrates of residual proteasome activity in EL4 cell 
extracts (B) or living EL4 cells (D) after a 1-h (B) or 2-h (D) treatment with the indicated concentrations 
of inhibitor 3. Results are representative of two independent experiments.
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in the presence of bortezomib or MG132, 
then incubated with inhibitor 3 and immu-
noblotted as described above. We performed 
activity measurements with fluorogenic sub-
strates in parallel before and after addition of 
inhibitor 3. The addition of bortezomib result-
ed in a very specific reduction in the ability of 
compound 3 to modify the proteasomal β5, 
β5i and β1 subunits, with maximum inhibi-
tion of these subunits by bortezomib reached 
at 40 nM (Figure 5A). The β2 and β2i subunits 
remained fully available for modification with 
compound 3 at all time points, indicating the 
lack of a substantial interaction of bortezomib 
with these subunits in vivo. Bortezomib was 
previously reported to be a specific inhibitor 
for the chymotryptic-like activity largely pro-
vided by the β5 subunits. Here, we identified 
the β1 subunits as additional targets for bort-
ezomib.
After incubation of EL4 cells with MG132, 
compound 3 only labeled the β2 subunit sug-
gesting that all other subunits are inhibited 
by MG132 at high-nM concentrations (Figure 
5B). Notably, MG132 completely inhibited 
the β2i subunit, which suggests a difference 
in the active-site chemistry between the β2 
and β2i subunits. The results we obtained 
with fluorogenic substrates correlated in both 
cases to the immunoblot experiments using 
inhibitor 3 (Figure 5C,D). Inhibitor 3, however, 
can be used to distinguish between constitu-
tive and immunoproteasome subunit activ-
ity, whereas fluorogenic substrates cannot. 
Therefore, we did not observe the difference 
in labeling between the β2i subunit and the 
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Figure 5 | In vivo profiling of proteasome inhibitors. A,B) Competition experiment between inhibitor 
3 and bortezomib (A) or MG132 (B) in EL4 cells. C,D) Measurement of residual proteasome activity 
with fluorogenic substrates after treatment of EL4 cells with bortezomib or a combination of bort-
ezomib and inhibitor 3 (C) or MG132 or a combination of MG132 and inhibitor 3 (D). Results are rep-
resentative of two independent experiments. CTL: chymotryptic-like, TL, tryptic-like; CL, caspase-like. 
e) Competition experiment between bortezomib and inhibitor 3 in MM.1S cells.
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β2 subunit using fluorogenic substrates. Com-
bined, these results  validate inhibitor 3 as a 
probe for measuring proteasome activity as 
well as for characterization of subunit speci-
ficity of proteasome inhibitors in vivo. Using 
inhibitor 3, we next determined the composi-
tion of the active proteasome in the multiple 
myeloma cell line MM.1S, as well as the pro-
teasomal targets of bortezomib in these cells. 
We cultured MM.1S cells in the presence or 
absence of 20 nM bortezomib, a concentra-
tion previously demonstrated to be toxic to 
this cell line.17 In this cell line, we observed 
that all constitutive and immunoproteasome 
catalytic subunits were active in the absence 
of interferon γ (Figure 5E). The labeling pat-
tern in MM.1S cells resembled the profile 
that was observed in EL4 cells. A notable dif-
ference was the activity of the β1i subunit in 
living MM1.S cells: we detected this subunit 
in extracts of EL4 cells, but not when we per-
formed the assay in living cells. As quickly as 
in 15 min, 20 nM bortezomib substantially in-
hibited the activity of all β5 and β1 subunits 
with maximum inhibition reached within 2 h 
(Figure 5E).
DISCUSSIOn
Of the proteasome inhibitors described to 
date, each has a varying ability to inhibit each 
of the three known catalytic activities.14,18,19 
With proteasome inhibition becoming widely 
used in the treatment of multiple myeloma, 
the composition of proteasomes may be an 
important determinant of clinical response 
to treatment with such agents. Most meth-
odologies in common practice for measuring 
proteasome activity use fluorogenic peptidyl 
substrates and often involve procedures to 
reduce potentially cross-reacting protease 
activities.5,20,21 More importantly, procedures 
that rely on the hydrolysis of fluorogenic sub-
strates do not distinguish between constitu-
tive and immunoproteasome activity and 
therefore do not reflect the relative activity of 
different proteasome subunits accurately.
Recently, cell-based assays16,22 as well as 
mouse models23,24 have been developed for in 
vivo monitoring of proteasome activity. These 
methods may be useful in screening for new 
inhibitors and testing bioavailability, respec-
tively, but their activity readout depends on 
the balance between synthesis and degrada-
tion of fusion proteins, which involves many 
cellular factors other than the proteasome, 
including the rate of fusion-protein synthesis. 
Therefore these methods may not accurately 
reflect true proteasomal activity. Moreover, 
the use of expressed fusion proteins makes 
these methods unfit for monitoring human 
samples. In addition, they do not provide in-
sight in the constitutive/immunoproteasome 
activity ratio and cannot be used to character-
ize the specific activity of proteasome inhibi-
tors in vivo. The small molecule–based assay 
described here overcomes these problems.
We have devised proteasome activity–profil-
ing probe 3 that freely reaches cellular targets 
in intact cells and that can modify covalently 
and irreversibly all of the proteasome’s ex-
posed catalytic subunits. Use of antibodies 
directed against the dansylsulfonamido-
hexanoyl hapten present in 3 allows direct 
measurement of activity of all proteasome 
subunits in living cells without the need for 
prior lysis or purification steps. This ensures 
not only a fast but also accurate activity read-
out, as under these conditions proteasomes 
remain in their native state. Using this probe, 
we characterized the anti-neoplastic agent 
bortezomib and revealed that the β1 and β1i 
subunits are targets for this drug, in addition 
to the previously identified β5 subunits.20 
We also characterized the widely used pro-
teasome inhibitor MG132 and  found that it 
inhibited all subunits, although the β2 sub-
unit was inhibited to a lesser extent. Notably, 
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MG132 was found to fully inhibit the immu-
noproteasome subunit β2i. 
We have described an easy method for char-
acterizing the specificity of (new) proteasome 
inhibitors that may be helpful in a clinical set-
ting and could be used to study resistance to 
this new class of drugs. Differences in label-
ing profiles observed in experiments with 
extracts and living cells, which can not be 
detected using methodology now used to 
measure proteasome activity, underscores 
the need for reliable in vivo labeling tech-
niques. The technique described here could 
be adapted for use with other proteases and 
optimized. Switching to a more chemoselec-
tive reactive group could improve both probe 
reactivity and selectivity, and improving the 
fluorescence yield may allow for in vivo local-
ization studies of active proteasomes and a 
truly high-throughput, in-gel readout.
mATerIAlS AnD meTHODS
materials
Unless indicated otherwise, chemicals were ob-
tained commercially of the highest available 
grade. Cell culture. The cell lines EL4 (mouse, 
thymoma) and MM.1S (human, multiple myelo-
ma) were cultured in RPMI 1640 medium. HeLa 
cells (human, cervix epitheloid carcinoma) and 
U373 cells (human, astrocytoma) were cultured 
in DMEM. Both media were supplemented with 
10% fetal calf serum (FCS), 100 units/ml penicillin 
and 100 mg/ml streptomycin.
Synthesis and characterization of proteasome 
probes
Detailed information on synthetic procedures 
and characterization can be found in the Supple-
mentary Methods and Supplementary Figures 
2–4 online. Compounds 3 and 4 were tested and 
compared to other inhibitors as described previ-
ously.16 U373 cells expressing an ubiquitin-Arg-
GFP fusion protein were exposed to various con-
centrations of compounds 3, 4, Ada-Ahx3Leu3VS 
and various other proteasome inhibitors. After 
5 h, we quantitated the accumulation of GFP by 
FACS. The specificity for proteasomal targets was 
determined by assaying competition for protea-
some inhibition with compound 5. We incubated 
equal amounts of protein, obtained by lysis of 
EL4 cells by glass beads (see below), with the 
indicated amounts (Figure 3D) of inhibitor 3 or 
DMSO for 1 h at 37 °C, and then incubated with 
compound 5 for 2 h at 37 °C. Proteins were dena-
tured by boiling in reducing sample buffer, sepa-
rated by 12.5% SDS-PAGE and autoradiographed. 
Probing proteasome activity in cell extracts
To obtain lysates for proteasome activity assays, 
we lysed cells with glass beads as previously de-
scribed.18 In brief, cells were washed twice with 
cold phosphate-buffered saline, pelleted and 
lysed with one volume of glass beads (<106 mi-
crons, acid-washed; Sigma) and an equal volume 
of homogenization buffer (50 mM Tris-HCl pH 7.4, 
1 mM dithiothreitol, 5 mM MgCl2, 2 mM ATP and 
250 mM sucrose) by vortexing at high speed for 
15–30 min at 4 °C. Beads, membrane fractions, 
nuclei and cell debris were then removed from 
the supernatant by centrifugation at 16,000g for 
5 min. We quantitated the protein content of ex-
tracts using the Bradford assay (BioRad) and then 
incubated equal amounts of protein with the in-
dicated amounts (Figure 4A) of probe 3, 10 mM 
control probe 4 or buffer for 1 h at 37 °C. Protea-
some activity was assayed as described below. 
Probing proteasome activity in living cells 
We incubated 10 x 106 EL4 cells in 10 mL RPMI 
1640 medium supplemented with 10% FCS and 
penicillin and streptomycin with the indicated 
amounts (Figure 4C) of probe 3 or 10 mM probe 
4, at 37 °C for 2 h. HeLa cells were incubated with 
10 mM probe 3 for the indicated time periods 
(Supplementary Figure 1). Cells were collected by 
centrifugation. We lysed cells using glass beads 
and assayed protein content using the Bradford 
assay. Proteasome activity was assayed as de-
scribed below.
In vivo profiling of bortezomib and mg132
We incubated 10 x 106 EL4 cells in 10 mL RPMI 
1640 medium supplemented with 10% FCS and 
penicillin and streptomycin with the indicated 
amounts of bortezomib (Figure 5A) or MG132 
(Figure 5B) for 1 h at 37 °C. When indicated, this 
was followed by a 2-h incubation at 37 °C with 10 
38
mM probe 3. We incubated 5 x 106 MM.1S cells 
in 5 mL RPMI 1640 medium supplemented with 
10% FCS and penicillin and streptomycin with 20 
nM bortezomib for the indicated time periods 
at 37 °C, followed by a 1-h incubation with 10 
mM probe 3 at 37 °C. We lysed cells using glass 
beads or by incubating them for 30 min in NP-
40 lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 1% NP-40])and centrifuged the lysates for 
5 min to remove membrane fractions, nuclei and 
cell debris. Proteasome activity was assayed as 
described below. 
Assaying proteasome activity by immunoblot-
ting
Equal amounts (typically 60 mg) of protein were 
denatured by boiling in reducing sample buffer, 
separated by 12.5% SDS-PAGE and electrotrans-
ferred onto polyvinylidene difluoride (PVDF) 
membranes. Immunoblotting was performed 
using a dansyl-sulfonamidohexanoyl polyclonal 
antibody (1:7,500, rabbit; Molecular Probes) and 
horseradish peroxidase–coupled goat or swine 
anti-rabbit secondary antibody (Southern Bio-
tech) followed by enhanced chemiluminescence 
(Western Lightning, Perkin-Elmer). 
Assaying proteasome activity with fluorogenic 
substrates 
Assays were performed as previously described25 
with minor changes. 10 mg of lysate was added 
to 100 mL of substrate buffer, containing 20 mM 
HEPES (pH 8.2), 0.5 mM EDTA, 1% DMSO, 1 mM 
ATP and 30 mM ZAlaArgArg-AMC (tryptic-like), 
60 mM ZGlyGlyLeuAMC (chymotryptic-like), 60 
mM SucLeuLeuValTyr-AMC (chymotryptic-like) or 
60 mM ZLeuLeuGlu-βNA (caspase-like). SDS was 
omitted from the substrate buffer. Fluorescence 
was measured every minute for 25 min at 37 
°C using a Fluostar Optima 96-well plate reader 
(BMG lab technologies) (l ex/em = 355/450 nm 
for AMC and 320/405 nm for βNA) and the in-
crease in fluorescence per minute was used to 
calculate specific activities of each sample. Cells 
were incubated with 1 mM epoxomicin (Affiniti) 
at 37 °C for 1 h to determine the nonspecific ac-
tivity, which was subtracted from each measure-
ment.
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supplementary information
SUPPlemenTAry meTHODS
Inhibitors: Bortezomib was synthesized as previ-
ously described1. Dansyl-Ahx3L2-OH (5) was syn-
thesized (Supplementary Scheme 1) on Wang 
resin using standard Fmoc-based solid-phase 
peptide synthesis protocols and purified by silica 
gel chromatography using a gradient of 10% to 
20% of MeOH in CH2Cl2. 5 was coupled by N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDCI)-mediated condensation 
with (S,E)-5-methyl-1-(methylsulfonyl)hex-1-en-
3-amine (leucine vinyl sulfone, LeuVS) 7 to af-
ford 3. MS(ESI): calculated 990.5 (M+H)+ 1012.5 
(M+Na)+. Observed 990.5 (M+H)+ 1012.5 (M+Na)+. 
Hydrogenation and deprotection of 6 followed 
by condensation of the resulting (S)-5-methyl-1-
(methylsulfonyl)hexan-3-amine 9 with 5 afforded 
the negative control 4. MS(ESI): calculated 992.5 
(M+H)+ 1014.5 (M+Na)+. Observed 992.5 (M+H)+ 
1014.5 (M+Na)+.
SUPPlemenTAry InFOrmATIOn 
OnlIne
Detailed information on the characterization 
of compound 3 can be found in Supplementary 
Figures 2–4. This material is available via the In-
ternet at http://www.nature.com/nmeth, as sup-
plementary information of Nature Methods 2, 
357-362 (2005).
SUPPlemenTAry reFerenCeS
Adams, J. et al. Potent and selective inhibitors of 1. 
the proteasome: dipeptidyl boronic acids. Bioorg. 
Med. Chem. Lett. 8, 333-338 (1998).
Supplementary Scheme 1 | a) Fmoc based SPPS then TFA, (78%). b) TFA quant. c) EDCI, DIPEA, CH2Cl2/
DMF (3: 64%, 4: 84%). d) 10% Pd/C, H2, MeOH (98%).
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Supplementary Figure 1 | Incubation of Hela cells 
with inhibitor 3. 
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with proteasome inhibitors in use in the clinic for the treatment of multiple myeloma 
and with clinical trials in progress investigating the treatment of a variety of hematologic 
and solid malignancies, accurate methods that allow profiling of proteasome inhibitor 
specificity and efficacy in patients are in demand. Here, we describe the development, 
full biochemical validation, and comparison of fluorescent proteasome activity reporters 
that can be used to profile proteasome activities in living cells with high sensitivity. Seven 
of the synthesized probes tested label proteasomes in lysates, although the fluorescent 
dye used affects their specificity. Two differentially labeled probes tested are suitable for 
studying proteasome activity in living cells by gel-based assays, by confocal laser scan-
ning microscopy, and by flow cytometry. we established methods using these fluores-
cent reporters to profile proteasome activity in different mouse tissues, carefully avoiding 
postlysis artifacts, and we show that proteasome subunit activity is regulated in an organ-
specific manner. The techniques described here could  be used to study pharmacological 
properties of proteasome inhibitors. 
Profiling proteasome activity in tissue with 
fluorescent probes
Celia r. Berkers,a,§ Fijs w. B. van leeuwen,a,§ Tom A. groothuis,b Victor Peperzak,c erica 
w. van Tilburg,a Jannie Borst,c Jacques J. neefjesb & Huib Ovaaa,*
InTrODUCTIOn
The clinical value of proteasome inhibition 
has recently become evident. The protea-
some inhibitor bortezomib1 is currently used 
to treat multiple myeloma, while a thera-
peutic effect on several other (solid) tumors 
has also been shown.2 The proteasome is re-
sponsible for the degradation of misfolded 
and redundant proteins3 as well as a variety 
of key proteins involved in the regulation of 
cell proliferation and survival.4 Proteasome 
inhibition disrupts these pathways, leading to 
the suppression of NF-κB activity and stabili-
zation of the tumor suppressor p53,5 among 
others. Both suppression of NF-κB activity 
and p53 stability have been suggested to be 
at least in part responsible for the observed 
apoptotic effects.2,5 Since side effects of bort-
ezomib are substantial and since a response 
is observed only in a subset of patients,2 there 
is an emerging demand for methods for ac-
curately assessing the inhibitory action and 
efficacy of proteasome inhibitors in clinical 
subjects. Such a method may allow treatment 
to be adjusted to individual cases, minimiz-
ing side effects and strengthening treatment 
responses. Next to diagnostic applications, 
§These authors contributed equally to this work. *Correspondence should be addressed to H.O. (h.ovaa@nki.nl).
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of proteasome subunit availability in cell 
lysates. A) All probes are based on structure 1, 
which contains a reactive vinylsulfone part (VS) 
coupled to three leucine residues (L3) and a 
spacer consisting of three aminohexanoic acid 
moieties (Ahx3). A dansyl moiety or different 
fluorophores can be coupled to this inhibitory segment, yielding the dansyl probe 2 and benchmark 3 
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of a labeling experiment with 500 nM probes 3–9 (1 h) in HeLa and EL4 cell lysates. Proteins were sepa-
rated using a 12.5%, 20 cm SDS–PAGE gel, affording separation of most subunits in a one-dimensional 
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proteasome probes are also likely to advance 
basic research in proteasome action since this 
line of research heavily depends on the sensi-
tivity of tools available.
The catalytic activity of the proteasome re-
sides within the 20S core and is provided by 
three constitutive subunits, termed β1, β2, 
and β5, and/or their inducible immunopro-
teasome counterparts β1i, β2i, and β5i. It is 
widely accepted that immunoproteasome 
subunits are mainly expressed in lymphoid tis-
sues,6 e.g., spleen, lymph nodes, and thymus. 
In addition, it is rapidly becoming apparent 
that different organs express different ratios 
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of constitutive, immuno, and hybrid protea-
somes.7,8 These proteasome subtypes differ 
with regard to their activity against (fluoro-
genic) peptide and protein substrates.7,8 Con-
sequently, proteasome activity and specificity 
could be organ-specific.6,7 This is, however, 
not experimentally validated and requires 
sensitive techniques to enable the detection 
of active subunit compositions.
Three different methods are currently used 
to monitor proteasome activity: fluorogenic 
assays,9,10 small molecule–based activity as-
says,11–14 and models based on recombinant
reporter proteins.15–18 Fluorogenic and most 
small molecule assays cannot be used to 
probe living cells or tissue, whereas the use of 
reporter proteins remains confined to geneti-
cally altered cells or organisms and thus does 
not allow profiling of patient material. Re-
cently, we reported the development of the 
dansylated vinylsulfone–based proteasome 
inhibitor 2 (Figure 1), which contains an α,β-
unsaturated sulfone part that reacts with the 
γ-hydroxyl of the N-terminal threonine resi-
due of catalytic subunits of the proteasome,19 
while the use of antibodies against the dansyl 
moiety allows the detection of labeled sub-
units by SDS-PAGE and Western blot analysis. 
This probe is the first of its kind to profile the 
specificity of proteasome inhibitors in living 
cells.19,20
Since probe 2 requires Western blotting to 
produce an activity–based readout, we rea-
soned that this probe could be further opti-
mized by replacing the environment sensitive 
and low-quantum yield dansyl fluorophore 
with high-quantum yield fluorophores. This 
allows direct scanning of the gel for fluores-
cence emission for visualization of labeled 
subunits. We recently showed14 in an initial 
report that this concept affords a more reli-
able and sensitive readout in cell lysates, liv-
ing cells, and tissue using inhibitor 3. The use 
of fluorescent probes allows profiling of large 
numbers of samples, and the method should 
be applicable to patient material, allowing 
tumor profiling, which is likely to improve 
responses to proteasome inhibitor therapy. 
For these reasons, we embarked on the syn-
thesis of a range of fluorescent inhibitors 
so we would be able to select for effective 
fluorescent proteasome inhibitors with good 
biochemical and biophysical properties. We 
furthermore describe the full validation of all 
probes described; we report the development 
of procedures that distinguish live cell label-
ing events from in vitro postlysis artifacts, and 
we have extended the live cell labeling proce-
dures into flow cytometry-based assays. The 
latter approach could alter diagnostic means 
for (overall) proteasome activities and sus-
ceptibility to inhibition since it allows for sig-
nificant throughputs using minimal amounts 
of material.
reSUlTS AnD DISCUSSIOn
Probe preparation and characterization in 
cell lysates 
All probes were based on an H2N-Ahx3Leu3-
VS inhibitory segment (1) (Figure 1A) and 
functionalized with different types of fluo-
rophores. Since different fluorophores pos-
sess different biophysical properties, such 
as membrane permeability, a library of fluo-
rescent proteasome probes was synthesized 
(see the Supplementary Information and Fig-
ure 1 therein for experimental procedures). 
The following probes were selected for fur-
ther investigation: BodipyFL-Ahx3Leu3VS (4), 
Bodipy530/550-Ahx3Leu3VS (5), TAMRA-
Ahx3Leu3VS (6), Cy3(SO3-)2-Ahx3Leu3VS (7), 
Cy5(SO3-)2-Ahx3Leu3VS (8), and Cy5-Ahx3- 
Leu3VS (9). They were compared to the con-
trol probe BodipyTMR-Ahx3Leu3VS (3) (Figure 
1A) about which we recently communicated 
our findings.14 These probes span a large 
emission spectrum, ranging from green (4, 
48
l em ≈ 510 nm) to orange/red (3 and 5–7, l 
em ≈ 590 nm) and far red (8 and 9, l em ≈ 
670 nm), which makes it possible to combine 
them with other fluorescent biomolecules 
(such as GFP and RFP) and with each other in 
pulse–chase experiments.
The ability of these probes to provide an in-
gel readout of proteasome subunit availabil-
ity was investigated (Figure 1B). Lysates from 
both HeLa cells (human, cervix carcinoma) 
and EL4 cells (murine thymoma) were incu-
bated with probes 3–9. Proteins were sepa-
rated by SDS-PAGE, and the wet gel slab was 
directly scanned using a fluorescence scanner 
with appropriate filter settings. As shown in 
Figure 1B, probes 3–9 labeled a distinct set 
of proteins in both HeLa and EL4 cell lysates. 
These proteins could be specifically immu-
noprecipitated using anti-proteasome an-
tibodies (data not shown) and identified as 
the indicated proteasome active subunits on 
the basis of the labeling patterns found with 
probe 2, the identities of which we recently 
confirmed by mass spectrometry.21 Nonspe-
cific labeling in high-molecular weight regions 
was not observed (Supplementary Figure 2), 
suggesting that these probes are specific for 
proteasomes in cell lysates at the concentra-
tions used.
The different fluorescent moieties were found 
to affect the fine specificities of individual 
probes. Both benchmark 3 and BodipyFL-la-
beled probe 4 afforded quite uniform label-
ing patterns (Figure 1B, lanes 1–4), suggest-
ing that these probes have similar affinities 
for all catalytically active subunits. The other 
probes exhibited enhanced reactivity toward 
particular subunits (Figure 1B, lanes 5–14). In 
HeLa cells, probes 5–9 labeled the β5 subunit 
more efficiently than the β1 and β2 subunits. 
In addition, probe 6 and in particular probe 
9 poorly labeled β1 subunits. Furthermore, 
Figure 1B shows that most subunits labeled 
with probes 3–5 can be resolved by one-di-
mensional SDS-PAGE. Subunits labeled with 
probes 6–9 are more difficult to separate with 
good resolution. This suggests that Bodipy-
labeled probes allow easier interpretation of 
complex labeling patterns. Altogether, results 
indicate that all probes give an in-gel read-
out that correlates with proteasome activity. 
Nonetheless, probes 3 and 4 are preferred for 
in-gel readouts.
Proteasome labeling in living cells
To study which probes can be used to probe 
living cells, flow cytometry experiments were 
performed. MelJuSo cells (human melanoma) 
were incubated with individual probes, and 
fluorescence intensity was measured. Supple-
mentary Figure 3 shows that benchmark 3 as 
well as probes 4–6 and 9 accumulated in living 
cells. Probes 7 and 8 on the other hand were 
not taken up by these cells and were there-
fore not subjected to further studies, but may 
be used in experiments on cell lysates.
Proteasome inhibition by 3–6 and 9 in living 
cells was studied, using MelJuSo cells stably 
expressing ubiquitin-R-GFP (Ub-R-GFP).15 Fol-
lowing the N-end rule, Ub-R-GFP is rapidly de-
graded by the proteasome under steady state 
conditions. Upon inhibition of the protea-
some, the GFP concentration in the cells will 
increase over time, which can be quantified 
by flow cytometry. Cells were incubated with 
probe or the general proteasome inhibitor 
MG132 (ZL3CHO, 10). The percentage of cells 
responding to MG132 was taken to be 100%, 
and GFP induction in other samples was nor-
malized accordingly. Since the fluorescence 
emitted by 4 is comparable in wavelength to 
GFP fluorescence (l ex/em = 480/530 nm), 
nontransfected MelJuSo cells incubated with 
this probe were used to normalize the signal 
(Supplementary Figure 4). Figure 2A shows 
that cellular accumulation did not necessarily 
result in proteasome binding and inhibition. 
Only probes 3 and 4 induced substantial GFP 
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fluorescence, confirming that only these two 
compounds efficiently inhibit proteasomes in 
cultured cells.
Confocal laser scanning microscopy (CLSM) 
allows us to study probe localization in liv-
ing cells, as demonstrated previously.14 To 
validate that probes 5, 6, and 9 accumulate 
in the cells but do not bind the proteasome, 
MelJuSo cells were incubated and imaged. 
Figure 2B shows that probe 5 was mainly vis-
ible in granular structures near the nucleus. 
Probes 6 and 9, both lipophilic and cationic 
probes (Figure 1A), were found to accumulate 
in mitochondria, as visualized by colocaliza-
tion with MitoTracker green (Figure 2B), and 
remained there for extended periods of time. 
Lipophilic cations are often found to accumu-
late in mitochondria due to the mitochondrial 
membrane potential.22 Upon fixation with 
formaldehyde, 6 and 9 gave a distribution 
similar to that observed for GFP-labeled pro-
teasomes,23 indicating that these probes are 
not covalently bound to mitochondria but 
merely accumulate there (Supplementary 
Figure 5).
To study colocalization of proteasomes with 
benchmark 3 and probe 4, both of which inhib-
ited proteasomes in living cells, MelJuSo cells 
that stably expressed either β1i-GFP23 or β7-
red fluorescent protein (RFP) were incubated 
with individual probes, washed to remove ex-
cess probe, and imaged by CLSM. As shown in 
Figure 2C, GFP- and RFP-labeled proteasomes 
were distributed uniformly throughout the 
nucleus and cytoplasm, with the exception of 
nucleoli, the nuclear envelope, and the ER/
Golgi, consistent with previous reports.14,23 
Compound 3 afforded a similar distribution, 
as reported,14 as did compound 4, and the 
overlays of proteasome and probe signals 
revealed substantial colocalization of both 
probes with GFP- and RFP-labeled protea-
somes. Non-colocalizing, free probe could be 
observed in vesicular structures (Figure 2C), 
which are likely to be endosomes, since lipo-
philicity and high molecular weight are fac-
tors known to promote uptake via the endo-
somal pathway.24 To verify the actual labeling 
of proteasomes in this experiment, cells were 
treated as described and lysed and proteins 
resolved by SDS-PAGE (Supplementary Figure 
6). A clean proteasome labeling pattern was 
obtained, confirming that at least part of the 
colocalizing probe is proteasome-bound.
To further study whether all colocalizing 
probe is proteasome-bound, cells were 
pulsed with MG132, washed, and chased 
with either benchmark 3 or probe 4. Figure 
2D (merge) reveals that under these condi-
tions, probes no longer colocalized with GFP- 
and RFP-labeled proteasomes. This effect 
could be visualized best in nuclei, which can 
be recognized from their unstained nucleoli. 
Instead, probe that was taken up by the cells 
now remained confined to the plasma mem-
brane and the perinuclear area as free probe. 
MG132 treatment is reported to block all 
catalytic sites of the proteasome,25 preventing 
probe binding. Since inhibition with MG132 
can only alter the intracellular distribution 
of proteasome-bound probe, but not of free 
probe, it provides a reliable method for con-
trolling for nonspecific interactions of probes 
3 and 4. Supplementary Figure 6 shows that 
MG132 treatment resulted in 85–94% block 
of proteasome labeling. Labeling of addition-
al proteases was not observed, suggesting 
that only free probe was left in the cells after 
MG132 treatment. These results suggest that 
the signal observed in cytosol and nucleus in 
Figure 2C can fully be attributed to protea-
some-bound probe and that probes 3 and 4 
can be used to study proteasome distribution 
and profile the activity of proteasomes in liv-
ing cells. 
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Optimization of in-gel activity assay in living 
cells
Next, we set out to optimize the gel assay de-
scribed above. In CLSM experiments, some 
residual free probe 3 and 4 was observed in 
membrane structures (Figure 2C). Since cells 
have to be lysed for a gel-based readout, in-
ternal membrane structures are destroyed, 
which may release unbound probe. This poten-
tially results in additional labeling, disturbing 
the accuracy of readouts. To prevent postlysis 
labeling, cells were pulsed with either probe 
3 or 4 for various periods of time and chased 
with MG132 to block residual catalytic sites 
(Figure 3A, lanes 2–6). To show the contribu-
tion of postlysis labeling, cells were pulsed 
for 1 h and harvested directly (Figure 3A, lane 
1). Proteins were separated using a mini-gel 
system, which does not separate the β1i, β5, 
and β5i subunits from each other, explaining 
the slightly different labeling patterns in Fig-
ure 3 compared to Figure 1B. A 1-h pulse with 
3 or 4 followed by a MG132 chase revealed 
substantial proteasome labeling (Figure 3A, 
lane 2). Labeling intensities increased with 
incubation time and were saturated at an in-
cubation time of 4 h. Since the relative label-
ing patterns did not change (Figure 3A, lanes 
3–6), the 1-h labeling period (Figure 3A, lane 
2) was sufficient to obtain a representative 
proteasome labeling profile. When samples 
were not chased, additional labeling could be 
observed (in Figure 3A, compare lanes 1 and 
2), suggesting that postlysis artifacts are likely 
to occur. To verify that this procedure ensures 
a proper live cell readout, the experiment was 
repeated with probe 2, which should afford a 
live cell readout,19 and with probes 6 and 9, 
which localize to the mitochondria and should 
therefore barely label proteasomes in living 
cells. Cells were pulsed with probes 2, 6, and 
9 and either chased with MG132 or harvested 
directly. When probe 2 was used,19 the results 
were similar to those observed with probes 3 
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Figure 3 | Probes 3 and 4 function as highly sensitive proteasome subunit activity reporters in liv-
ing cells. A,B) Gel images and immunoblot showing proteasome labeling in living EL4 cells that were 
pulsed with probe 3 or 4 (375 nM, indicated times) (A) or with probes 6 and 9 (375 nM, 1 h) or 2 (5 
mM, 2 h) (B) and either harvested directly or chased with 5 mM MG132 (1 h). C,D) Gel image and immu-
noblot showing proteasome labeling in living EL4 cells, incubated with probe 2 or 4 (2 h), with either 
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separated using mini-gels (that do not separate the β1i subunit from the β5 subunits).
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and 4 (Figure 3B, lanes 1 and 2). The MG132 
chase completely abolished labeling using 
probes 6 and 9 (Figure 3B, lanes 4 and 6). 
Without an MG132 chase, on the other hand, 
both probes afforded proteasome labeling 
(Figure 3B, lanes 3 and 5). These observations 
confirm the validity of the method applied 
and are a warning for post-lysis labeling that 
can be mistaken for a genuine live cell label-
ing event. It is, therefore, important to chase 
with a non-fluorescent pan-proteasome in-
hibitor like MG132, to ensure a correct inter-
pretation of the results.
Fluorescent probe 4 versus dansylated 
probe 2
Having optimized the in-gel activity assay as 
described above, we compared dansylated 
probe 2 to fluorescent probe 4. EL4 cells were 
pulsed with various concentrations of probe 
2 or 4, followed by a MG132 chase. Figure 3C 
shows that for a clear and equal visualization 
of all subunits, cells needed to be incubated 
with 5 mM 2, while 50 nM 4 was sufficient. 
To confirm these data, EL4 cells were pulsed 
with probe 2 or 4 and chased with MG132, 
after which different amounts of total lysate 
were analyzed by SDS-PAGE. As seen in Fig-
ure 3D, 300 ng of total lysate was sufficient 
for proteasome visualization when probe 4 
was used. Although cells were incubated with 
a 5-fold molar excess of probe 2 (5 mM) com-
pared to probe 4 (1 mM), 2.5 mg of total lysate 
was needed to generate sufficient signal us-
ing probe 2. From these results, it can be 
concluded that when living cells are probed 
for proteasome activity using the pulse-chase 
procedure described here, fluorescent probe 
4 affords an up to 100-fold improvement in 
sensitivity compared to the dansylated probe 
2 described previously and properties com-
parable to that of 3, in principle allowing 
bioorthogonal use of multiple probes.
Profiling mouse tissues
Several methods have been used to study the 
bioavailability of proteasome inhibitors (see 
above).17,18 However, sensitive methods that 
can be used to study the in vivo subunit-spe-
cific activity of proteasome inhibitors are in 
great demand. In our previous setup,  probe 
was injected into the mouse, after which or-
gans could be imaged and analyzed.14 This 
setup is, however, not suitable for studying 
proteasome activity in patient material or in 
tissues where these probes may not accumu-
late sufficiently. We therefore employed an ex 
vivo approach, using probe 4 to identify the 
tissue-specific activity of the different cata-
lytic subunits of proteasomes in freshly iso-
lated organs. To determine whether probe 4 
was effectively taken up in different cell types, 
segments of different organs were incubated 
with 4 (Figure 4A). Due to the complex nature 
of tissues (e.g., muscle cells in the heart), 
nuclear staining (DAPI) was used as counter 
stain (Supplementary Figure 7). Images were 
obtained by sequential scanning, and auto-
fluorescence was found to be minimal (Sup-
plementary Figure 7). Figure 4A shows that 
probe 4 was taken up by all cell types.
Next, we profiled proteasome activity in this 
panel of mouse tissues (Figure 4B). To this 
end, single-cell suspensions were obtained 
and red blood cells lysed. Cells were pulsed 
with compound 4 and chased with MG132. 
Samples were normalized to either cell num-
ber or protein content without observing sig-
nificant differences in the results that were 
obtained. Band intensities were quantified 
and plotted as a percentage of the total pro-
teasome labeling intensity (Figure 4B, bottom 
panel). A great variation in subunit-specific 
labeling was observed, depending on the or-
gan that was probed (Figure 4B). Substantial 
labeling of immunoproteasome subunits was 
found in lymphoid organs (Figure 4B, lanes 
1, 2, and 5). Immunoproteasome subunits 
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showing the quantification of band intensities, plotted as a percentage of total proteasome labeling 
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could also be detected in lung tissue (Figure 
4B, lane 3), although at lower intensities. In 
brain, liver, heart, and kidney tissue (Figure 
4B, lanes 4 and 6–8), active immunoprotea-
some subunits could not be detected. Im-
munoproteasome expression favors the pro-
duction of antigenic peptides for MHC class I 
antigen presentation, and high-level immuno-
proteasome expression has been reported for 
lymphoid organs (spleen, lymph nodes, and 
thymus),6 correlating with the immunopro-
teasome labeling by 4. Thus, probe 4 seems 
well suited to visualization of immunoprotea-
some regulation. 
Next to the presence of immunoproteasome 
subunits, an additional level of proteasomal 
activity regulation appeared visible. Although 
equal amounts of subunits β1, β2, and β5 
are thought to be incorporated in functional 
proteasomes, different labeling intensities 
were observed in different tissues (Figure 
4B), in line with the existence of different 
proteasome subtypes.7,8 In lung and thymus, 
all subunits contributed equally to the total 
proteasome activity (Figure 4B, lanes 3 and 
5). In brain, β2 and β5 subunits were labeled 
with the greatest intensity (Figure 4B, lane 4), 
while mainly β1 and β2 subunit labeling was 
observed in spleen and lymph nodes (Figure 
4B, lanes 1 and 2). In the liver, kidney, and 
heart (Figure 4B, lanes 6–8), β2 subunits were 
most intensely labeled. These results indicate 
that different cell types display different ratios 
of proteasomal activities, suggesting that sub-
unit activity is regulated in an organ-specific 
manner. This may influence substrate degra-
dation, as well as the response to proteasome 
inhibitors.  Probe 4 labeled an additional pro-
tein as well, which could not be immunopre-
cipitated with an antibody raised against the 
20S proteasome (data not shown). Labeling 
in spleen tissue could be abolished by pre-
incubation with MG132 (Figure 4C), which is 
known to inhibit cathepsins.25 In H929 cells 
(human, multiple myeloma) and in spleen cell 
lysates, labeling was abolished by both the 
pan-cathepsin inhibitors LHVS26,27 and JPM-
56528,29 (Supplementary Figure 8), suggesting 
that this band represents a cathepsin.
To validate whether an ex vivo approach 
would allow profiling of the pharmacodynam-
ics of proteasome inhibitors in intact organs, 
intact tissue segments of spleen and thymus 
were incubated with different concentrations 
of MG132 and the broad-spectrum protea-
some inhibitor epoxomicin (11) and chased 
with probe 4 (Figure 4C). Intact tissue seg-
ments were less sensitive to proteasome in-
hibitors, compared to single-cell suspensions. 
In the latter, 5 mM MG132 or 1 mM epoxomi-
cin was sufficient to inhibit 90% of the pro-
teasomal activity (Supplementary Figure 9). 
In intact tissue segments, on the other hand, 
25 mM MG132 and 10 mM epoxomicin did not 
fully inhibit all proteasomal activities (Figure 
4C). These results stress the importance of 
methods that can profile the in vivo inhibi-
tory action of proteasome inhibitors. The 
specificity of both proteasome inhibitors in 
intact tissue segments could be profiled with 
ease.  While MG132 exhibited a preference 
for the β5 and β1 subunits at low concentra-
tions, as described previously,19 epoxomicin 
inhibited all subunits with equal affinity.30 
Furthermore, MG132 inhibited not only the 
proteasomal subunits but also a cathepsin,25 
while epoxomicin was highly specific for the 
proteasome30 (Figure 4C). To study whether 
these results could be confirmed by flow cy-
tometry experiments, single-cell suspensions 
obtained from spleen tissue were pulsed with 
proteasome inhibitor and chased with 4, or 
incubated with 4 alone. Cells were washed, 
and fluorescence was measured. As seen in 
Figure 4D, both inhibitors induced a substan-
tial shift in intracellular fluorescence, indicat-
ing proteasome inhibition.
Together, these data indicate that two of the 
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fluorescent probes described here could be 
used to profile the in vivo pharmacological 
properties of proteasome inhibitors, both 
quantitative, using flow cytometry, and quali-
tative, using SDS-PAGE readouts to profile dis-
tinct proteasomal active subunits. Although 
our studies have been limited to mouse tis-
sue, the method used should be equally ap-
plicable to any other sample, enabling pro-
teasome profiling and competition assays in 
clinical settings.
COnClUSIOn
We devised a range of fluorescent protea-
some activity reporters. Two probes, Bodipy-
TMR-labeled 3,14 and BodipyFL-labeled probe 
4, can efficiently bind to all catalytically ac-
tive subunits of proteasomes in living cells. 
Other probes described herein may be used 
for the analysis of cell homogenates. In addi-
tion, when probe 4 is compared to previously 
developed methods for probing proteasome 
activity in living cells (probe 2), the newly de-
veloped probe is up to 100-fold more sensi-
tive. Using probe 4, we set up gel-based and 
flow cytometry methods to study proteasome 
activity in living cells and to probe organ-spe-
cific proteasome activity. Our results indicate 
that different tissue types exhibit a different 
subunit labeling pattern, suggesting that sub-
unit activity is regulated in an organ-specific 
manner. Furthermore, the tools and methods 
described here should be well-suited to the 
performance of pharmacological studies with 
proteasome inhibitors under clinical evalua-
tion. In addition, the methodology described 
here should be applicable to monitoring pro-
teasome activity in samples from patients 
that are treated with proteasome inhibitors.
mATerIAlS AnD meTHODS
general methods
Bodipy and TAMRA dyes were purchased from 
Invitrogen or Molecular Probes. Sulfated cya-
nine (Cy3 and Cy5) dyes were purchased from 
Amersham, whereas the nonsulfated Cy5 ana-
logue was synthesized according to a published 
procedure.31 Peptide building blocks were pur-
chased from Novabiochem and appropriately 
functionalized resins from Applied Biosystems. 
All solvents were purchased from Biosolve at the 
highest grade available. All other chemicals were 
purchased from Aldrich at the highest available 
purity. All solvents and chemicals were used as 
received. Liquid chromatography–mass spec-
troscopy (LC–MS) analyses were carried out on 
a WATERS LCT mass spectrometer in line with a 
WATERS 2795 HPLC system and a WATERS 2996 
photodiode array detector. Analytical and pre-
parative HPLC runs were performed on a Waters 
1525 EF HPLC system coupled to a Waters 2487 
dual l absorbance detector. 
Probe synthesis
See the Supplementary Information for detailed 
information on synthetic procedures and purity 
analysis.
Cell culture
EL4 (mouse, thymoma) and H929 (human, mul-
tiple myeloma) cells were cultured in RPMI 1640 
(Invitrogen). Cell lines HeLa (human, cervix car-
cinoma) and MelJuSo (human, melanoma) were 
cultured in DMEM  (Invitrogen). MelJuSo cells 
expressing β1i-GFP,23 β7-RFP, or Ub-R-GFP15 were 
cultured in DMEM in the presence of zeomycin 
(RFP) and geomycin (GFP) selection. Prior to CLSM 
imaging, cells were cultured overnight in DMEM 
lacking phenol red to prevent autofluorescence 
of the medium. All media were supplemented 
with 10% fetal calf serum (FCS), 100 units/mL 
penicillin, and 100 mg/mL streptomycin.
In-gel profiling of proteasomes in cell lysates
EL4 and HeLa cells were mechanically lysed us-
ing glass beads.11 To this end, cells were washed 
with PBS, pelleted, and lysed by being vortexed 
at high speed at 4 °C for 45 min with 1 volume of 
glass beads (<106 mm, acid-washed, Sigma) and 
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1 volume of homogenization buffer [50 mM Tris 
(pH 7.4), 5 mM MgCl2, 250 mM sucrose, 1 mM 
DTT, and 2 mM ATP]. Beads, membrane fractions, 
and cell debris were removed by centrifugation 
at 16000g for 5 min. Protein concentrations were 
determined using the Bradford assay (Bio-Rad), 
and 50 mg of protein was incubated with com-
pounds 3–9 (500 nM) for 1 h at 37 °C. Proteins 
were denatured by being boiled in reducing sam-
ple buffer and analyzed by 12.5% SDS–PAGE us-
ing a PROTEAN II xi Cell system (Bio-Rad).
In-gel profiling of proteasomes in living cells
MelJuSo cells were incubated with 500 nM probe 
3 or 4 or pulsed with 5 mM MG132 and chased 
with 500 nM 3 or 4, both followed by a wash step. 
EL4 cells (1 × 106) in 1 mL of RPMI were incubated 
with 375 nM compound 3 or 4 for 1–5 h, 375 nM 
probe 6 or 9 for 1 h, or 5 mM 2 for 2 h, followed by 
a 1 h chase with 5 mM MG132. Control samples 
were incubated with 375 nM probe 3, 4, 6, or 9 
alone for 1 h or with 5 mM 2 alone for 2 h. Cells 
were harvested and lysed for 30 min in NP40 lysis 
buffer [50 mM Tris (pH 7.4), 150 mM NaCl, and 
1% NP40] at 4 °C. The Bradford assay was used to 
measure protein content. For experiments using 
cathepsin inhibitors, H929 cells were incubated 
with 500 nM 4 (1 h) or pulsed with 10 or 50 mM 
LHVS or JPM-565 (1 h) and chased with 500 nM 
4 (1 h). Cells were lysed in NP40 lysis buffer as 
described above.
Comparison between dansylated and fluores-
cent proteasome probes
EL4 cells (1 × 106/mL) were pulsed for 2 h with 
the indicated (Figure 4C) concentrations of probe 
2 or 4, followed by a 1 h chase with 5 mM MG132. 
Cells were harvested and lysed in NP40 lysis buf-
fer. The Bradford assay was used to measure pro-
tein content, and equal amounts of protein were 
analyzed by 12.5% SDS-PAGE. Alternatively, EL4 
cells (1 × 106/mL) were pulsed for 2 h with 5 mM 
2 or 1 mM 4, and chased with MG132 (5 mM, 1 h). 
Cells were lysed in NP40 lysis buffer, and protein 
content was determined as described above.
mouse tissue analysis by SDS-PAge 
C57BL/6 mice were bred under pathogen-free 
conditions according to national and institutional 
guidelines and were sacrificed at 6–10 weeks of 
age. Subsequently, spleen, lymph nodes, lungs, 
liver, heart, kidneys, brain, and thymus were iso-
lated. Single-cell suspensions were made using 
70 mm nylon cell strainers (BD Biosciences). Heart 
tissue was pretreated with 1 mg/mL collagenase 
V (Sigma) and 1% DNase I (Ambion) for 30 min 
at 37 °C before single-cell suspensions were ob-
tained. Red blood cells were lysed by hypotonic 
lysis, and cells were resuspended at a density 
of 5 × 106 cells/mL. Cells were incubated for 2 h 
with 500 nM 4, followed by a 1 h chase with 5 
mM MG132 to block postlysis labeling. Cells were 
harvested and lysed for 30 min at 4 °C using NP40 
lysis buffer. Protein concentrations were deter-
mined using the Bradford assay. Lysate from 1 × 
106 cells or equal amounts of protein were dena-
tured by being boiled in reducing sample buffer, 
and polypeptides were analyzed by 12.5% SDS-
PAGE using a PROTEAN II xi Cell system (Bio-Rad). 
To assess the effect of treatment with different 
proteasome inhibitors, whole tissue segments of 
spleen and thymus were placed in 1 mL of DMEM. 
In addition, a single-cell suspension was obtained 
from thymus (5 × 106 cells/mL). Tissue segments 
and single-cell suspensions were pulsed with 
MG132 (5 and 25 mM), epoxomicin (1 and 10 
mM), or DMSO (1 h, 37 °C), chased with 500 nM 
4 (1 h, 37 °C), and washed with fresh DMEM (1 h, 
37 °C). Cells and tissue segments were lysed at 4 
°C using NP40 lysis buffer. Protein concentrations 
were determined using the Bradford assay. Equal 
amounts of protein were denatured by being 
boiled in reducing sample buffer, and polypep-
tides were analyzed by 12.5% SDS-PAGE using a 
mini-gel system (Bio-Rad). For experiments using 
cathepsin inhibitors, spleen cells were lysed me-
chanically as described above. Equal amounts of 
protein were either incubated with 1 mM probe 4 
(1 h) or pulsed with 10 or 50 mM LHVS or JPM-565 
(1 h) and chased with 1 mM 4 (1 h).
In-gel fluorescence measurements
Proteins were denatured by being boiled in re-
ducing sample buffer and analyzed by 12.5% 
SDS-PAGE. Wet gel slabs were imaged for 2 min, 
with a resolution of 100 mm, using a ProXPRESS 
2D Proteomic imaging system (Perkin Elmer), 
using the following filter settings: probe 4, l ex/
em = 480/530 nm; probes 3 and 5–7, l ex/em = 
550/590 nm; probes 8 and 9,  l ex/em = 625/680 
nm. Images were analyzed using Totallab analysis 
software (Nonlinear Dynamics, Newcastle upon 
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Tyne, U.K.).
Assaying proteasome activity by immunoblot-
ting (probe 2)
Proteins were denatured by being boiled in re-
ducing sample buffer and separated by 12.5% 
SDS-PAGE gel followed by electro-transfer onto 
PVDF membranes. Immunoblotting was per-
formed using an antidansyl-sulfonamidohexanoyl 
polyclonal Ab (1:1000, rabbit, Molecular Probes) 
and HRP-coupled swine anti-rabbit secondary 
antibody (DAKO) followed by enhanced chemi-
luminescence (SuperSignal West Dura Extended 
Duration, Pierce). 
Flow cytometry experiments
Flow cytometry experiments were performed 
on a FACSCalibur 2 apparatus (BD Biosciences). 
For uptake experiments, MelJuSo cells were in-
cubated with 500 nM probes 3–9 for 1 h. Cells 
were washed, trypsinized, and resuspended 
in medium, and intracellular fluorescence was 
measured. For inhibition experiments in cultured 
cells, both MelJuSo cells (control) and MelJuSo 
cells stably expressing a Ub-R-GFP construct 
were incubated with 500 nM probes 3–9 for 12 h. 
Cells were washed, trypsinized, and resuspended 
in medium. Subsequently, GFP fluorescence was 
measured. As a control for Ub-R-GFP expression, 
cells were incubated with 5 mM MG132 for 1.5 h, 
followed by analysis of GFP fluorescence. Since 
the fluorescence emitted by 4 is comparable 
in wavelength to GFP fluorescence (l ex/em = 
480/530 nm), nonengineered MelJuSo cells incu-
bated with this probe were used to normalize the 
signal. For inhibition experiments in mouse tis-
sue, a single-cell suspension from mouse spleen 
was obtained (see above). Samples were pulsed 
with either MG132 (5 mM) or epoxomicin (1 mM) 
for 1 h at 37 °C and chased with 50 nM 4 for 1 h 
at 37 °C. As a control, cells were incubated with 
4 alone or not incubated. Cells were washed 
three times with fresh DMEM for 20 min at 37 
°C. Subsequently, intracellular fluorescence was 
measured.
ClSm imaging of cultured cells
CLSM images were recorded using a Leica-SP2 
system connected to an inverted microscope 
(Leica DM IR/E 2) and a tissue culture box at 37 
°C. MelJuSo cells expressing β7-RFP or β1i-GFP 
were incubated for 1 h with 500 nM 3, 4, or 5. 
Cells were washed with medium before being im-
aged. For the pulse–chase studies, MelJuSo cells 
expressing β1i-GFP or β7-RFP were incubated for 
1 h with 5 mM MG132, washed with medium, and 
chased for 1 h with 500 nM 3 or 4, respectively. To 
study probe 6 or 9, MelJuSo cells were incubated 
for 1 h with either probe (500 nM) and washed. 
To visualize mitochondria, 200 nM MitoTracker 
green  (Invitrogen) was added (30 min), and the 
cells were washed.
ClSm imaging of tissue slices
CLSM images were recorded using a Leica-SP2 
AOBS system connected to an inverted micro-
scope (Leica DM IR/E 2) and a tissue culture box 
at 37 °C with 5% CO2. All images were obtained by 
sequential scanning and with identical settings. 
Spleen, lymph nodes, lungs, liver, heart, kidneys, 
brain, and thymus were isolated from C57BL/6 
mice and sliced into small segments (~ 0.5 mm 
thick). Tissue segments were placed in 1 mL of 
DMEM and incubated with 500 nM 4 and 2 × 10-3 
mg/mL DAPI. After incubation, the wet segment 
was placed on a glass coverslip with a drop of 
fresh medium, covered by a secondary coverslip, 
and imaged. To obtain autofluorescence images, 
tissue segments were not incubated, but directly 
imaged using identical settings.
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supplementary information
Supplementary Figure 1 | a) Fmoc-based solid phase peptide synthesis then TFA. b) Di-tert-butyl-
dicarbonate, DIPEA, DMF. c) TFA. d) EDC, DIPEA, CH2Cl2/DMF. e) TFA. f) Activated ester of fluorescent 
dye, DMF, DIPEA, overnight, room temperature.
Boc-Ahx3L2OH (1A, Supplementary Figure 1) after 
concentration under reduced pressure. Boc-Ahx3 
L2OH was purified by silica column chromatog-
raphy (10 % to 20% MeOH in CH2Cl2 containing 
0.1 % HOAc). Alternatively, the crude could be 
used directly in the next step without further pu-
rification. MS(ESI): 684.46 (M+H)+, calc: 684.48 
(M+H)+.
Boc-Ahx3l3-VS (1B)
Boc-Leu-VS was synthesized as described.1 Briefly, 
deprotection of the Boc-group was achieved with 
TFA to yield LeuVS as a white powder upon con-
centration in vacuo and precipitation with dieth-
ylether. The resulting white powder (1.5 equiva-
lents) was directly coupled to Boc-Ahx3L2OH by 
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC, 1.5 equivalents)-mediated 
condensation in the presence of DIPEA (3 equiv-
alents) in DMF. The solution was stirred for 3 
SUPPlemenTAry meTHODS
Boc-Ahx3l2-OH (1A)
Fmoc-Ahx3L2-Wang resin was synthesized using 
standard Fmoc-based solid-phase peptide syn-
thesis protocols. Fmoc-L-Leu-PEG-polystyrene 
resin (Applied Biosystems) was subjected to sub-
sequent coupling cycles, in which deprotection of 
the Fmoc-group with piperidine/NMP (1:4 v/v), 
was followed by coupling with Fmoc-Leu-OH or 
Fmoc-Ahx-OH (3 equivalents) and Di-isopropyl 
ethylamine (DIPEA, 3 equivalents). After the final 
coupling step, the Fmoc group was removed and 
subsequently the pentapeptide was released from 
the resin by treating the resin with TFA for 30 min 
to afford H2N-Ahx3L2-OH, which was judged suf-
ficiently pure by LCMS to be condensed directly 
with Di-tert-butyl-dicarbonate (1.2 equivalents) 
and DIPEA (5 equivalents) in DMF. The resulting 
suspension was stirred overnight to yield crude 
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5(6)TAMRA-, Cy3(SO3-)2-, Cy5(SO3-)2-, and Cy5-NHS 
ester (1 mg), respectively, as described above. 
Purification was achieved by HPLC as described, 
using the following gradients: 50%-80% CH3CN 
(0.05% TFA), 50%-95% CH3CN (0.05% TFA), 46%-
56% CH3CN (0.05% TFA), 30%-80% CH3CN(0.05% 
TFA), and 30%-80% CH3CN (0.05% TFA) in H2O 
(0.05% TFA), to obtain 5-9, respectively. HPLC re-
vealed all products to be of at least 95% purity 
(Supplementary Figures 10D-H, for probes 5-9, 
respectively). 
Determination of probe concentrations
A dilution series of fluorophore-NHS ester in 
DMSO was made. 5 mL of each dilution in 500 
mL total volume (ethanol) was excited at l ex 
max and fluorescent emission at l em max was 
measured using a Perkin Elmer LS50B lumines-
cence spectrometer. Data obtained were fitted 
onto a standard curve and extrapolated. Puri-
fied dye-labeled probe was dissolved in DMF. A 
dilution series of dye labeled-probe was made in 
ethanol and fluorescence measurements were 
performed as described above with identical 
wavelength settings. Using the curve obtained 
from fluorophore-NHS ester measurements, the 
concentration fluorophore-labeled probe in DMF 
was calculated subsequently. 
SUPPlemenTAry InFOrmATIOn 
OnlIne
HPLC profiles of compounds 1B and 3-9 can be 
found in Supplementary Figure 10. This mate-
rial is available via the Internet at http://pubs.
acs.org, as supporting information of Molecular 
Pharmaceutics 4, 739-748 (2007).
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hours and concentrated under reduced pressure. 
Silica gel column chromatography (10 % MeOH 
in CH2Cl2) yielded homogeneous Boc-Ahx3L3-VS 
(1B, Supplementary Figure 1), as shown by HPLC 
(Supplementary Figure 10A) and LC-MS. 
BodipyTmr-Ahx3l3VS (3)
BodipyTMR-Ahx3L3VS2 (3) was prepared from 
Boc-Ahx3L3VS (1B) (10.0 mg, 11.6 mmol) and Bo-
dipy TMR STP ester (5mg, 7.7 mmol) as described 
above. Purification was achieved using condi-
tions identical to those described above to afford 
8.0 mg of the title compound (3) (6.18 mmol, 80% 
yield two steps). Rf 0.65 (20% MeOH in CH2Cl2). 
HPLC revealed a single product (>95% purity) 
(Supplementary Figure 10B). 
BodipyFl-Ahx3l3VS (4)
Boc-Ahx3L3VS (1B) (10.0 mg, 11.6 mmol) was dis-
solved in TFA (1 mL) and left at room temperature 
for 30 minutes. The solution was concentrated 
under reduced pressure and co-evaporated with 
toluene (2 mL 2x) and precipitated with ether (1 
mL), which was carefully decanted and discarded. 
To the resulting white film was added a freshly 
prepared solution of Bodipy FL STP ester (5 mg, 
9.2 mmol) in a mixture of DMF (0.5 mL) and DI-
PEA (50 mL). The resulting solution was left stir-
ring overnight at room temperature under an ar-
gon atmosphere. The solution was concentrated 
under reduced pressure and purified by silica 
gel column chromatography (0 to 15% MeOH in 
EtOAc followed by 20% MeOH in CH2Cl2) fractions 
containing the title compound were pooled, con-
centrated, and further purified by reversed phase 
HPLC over a C-18 preparative column using a 
gradient of 75%-95% CH3CN (0.05% TFA) in H2O 
(0.05% TFA). Homogeneous fractions containing 
product (as judged by both TLC and LC-MS) were 
pooled and concentrated to a small volume and 
freeze-dried to afford 8.0 mg of the homogeneous 
(>99% pure) title compound (4) (2.7 mmol, 29% 
yield two steps). Rf 0.65 (20% MeOH in CH2Cl2). 
Analytical HPLC revealed a single product (>99% 
purity) (Supplementary Figure 10C). 
general procedure preparation probes 5-9
Bodipy530/550-Ahx3L3VS (5), TAMRA-Ahx3L3VS 
(6), Cy3(SO3-)2-Ahx3L3VS (7), Cy5(SO3-)2-Ahx3L3VS 
(8), and Cy5-Ahx3L3VS (9) were prepared from Boc-
Ahx3L3VS (1B) (2.0 mg) and from Bodipy530/550-, 
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supplementary figures
Supplementary Figure 2 | no unspecific labeling by 
the probes is observed in cell lysates. Gel images 
showing full scans of Figure 1B. 
Supplementary Figure 3 | Probes 3, 4, 5, 6, and 9 enter cells. Flow cytometry plots showing the fluo-
rescence of a population of non-incubated MelJuSo cells (black) vs. MelJuSo cells incubated with 500 
nM probes 3-9 (1h) (red).
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Supplementary Figure 4 | Flow cytometry 
plots showing normalization of Ub-r-gFP sig-
nal in probe 4 treated cells. Upon incubation 
with MG132, part of the Ub-R-GFP expressing 
cells show a shift in fluorescence (compare 
blue to black). Upon incubation with probe 4, 
a similar shift is observed compared to non-
transfected cells (compare green to red). We 
therefore concluded that probe 4 inhibits the 
proteasome in a similar percentage of cells as 
MG132 does. 
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Supplementary Figure 5 | localization of probes 6 and 9 
upon fixation. CLSM images showing MelJuSo cells, incu-
bated for 1 hour with 500 nM 6 or 9, followed by fixation 
with formaldehyde.
Supplementary Figure 6 | mg132 inhibits proteasome 
in melJuSo cells. Gel images showing the result of a la-
beling experiment where cells were either pulsed with 
probe (1 h) and chased with MG132 (1 h) or pulsed 
with MG132 (1 h) and chased with probe (1 h). 
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Supplementary Figure 7 | Autofluorescence was found to be minimal when tissue segments were 
imaged by ClSm. CLSM images showing whole tissue segments from indicated organs incubated for 
one hour with 500 nM 4 (red) and 2 × 10-3 mg/mL DAPI (green), and the autofluorescence of different 
tissues.
3 +
 M
G1
32
-ch
as
e
4 +
 M
G1
32
-ch
as
e
M
G1
32
-p
uls
e +
 3
220
M
G1
32
-p
uls
e +
 4
10
 Inhibition of labeling:   94%        85%  
β2
β5
 63
Chapter 1.3   |   Fluorescent proteasome activity probes
4 10
 m
M
 L
H
V
S 
+ 
4
Spleen cell lysates
β2
β2i
H929 cells
β1,5,5i
β1i
cathepsin
50
 m
M
 L
H
V
S 
+ 
4
10
 m
M
 JP
M
-5
65
 +
 4
50
 m
M
 JP
M
-5
65
 +
 4
410
 m
M
 L
H
V
S 
+ 
4
50
 m
M
 L
H
V
S 
+ 
4
10
 m
M
 JP
M
-5
65
 +
 4
50
 m
M
 JP
M
-5
65
 +
 4
Supplementary Figure 9 | low concentrations of mg132 and epoxomicin are sufficient to fully inhib-
it the proteasome in single cell suspensions. Gel images showing the active subunit labeling in single 
cell suspensions obtained from mouse thymus, that were pulsed with the indicated concentrations of 
MG132 and epoxomicin (1 h) and chased with 500 nM probe 4 (1 h). 
Supplementary Figure 8 | labeling of additional band by probe 4 in mouse tissue and H929 cells 
can be abolished by preincubation with cathepsin inhibitors. Gel image showing the active subunit 
labeling in H929 cells and cell lysates obtained from mouse spleen cells, pulsed with the indicated 
concentrations of LHVS and JPM-565 (1 h) and chased with probe 4 (1 h). Note that the image contrast 
settings were adjusted to visualize the cathepsin band, which was weakly labeled in these samples, 
causing relative intense proteasome band intensities.
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Comparison of the specificity and activity profiles of 
the proteasome inhibitors bortezomib and CeP-18770
Celia r. Berkers,a karianne g. Schuurman,a yves leestemaker,a Bruce ruggeri,b 
Susan Jones-Bolin,b michael williamsb & Huib Ovaaa,*
InTrODUCTIOn
The ubiquitin-proteasome system is responsi-
ble for the degradation of proteins involved in 
a wide variety of cellular processes, including 
cell proliferation and survival, cell-cycle con-
trol, transcriptional regulation and cellular 
stress responses, as well as for the destruc-
tion of abundant and misfolded proteins.1,2 
The catalytic activity of the 26S proteasome 
resides within its 20S core and is mediated 
by three catalytically active constitutive 
β-subunits termed β1, β2, and β5. These have 
three different catalytic activities, caspase-
like, tryptic and chymotryptic activity, respec-
tively. In lymphoid tissues or after induction 
with interferon γ, these subunits can be re-
placed by their immunoproteasomal counter-
parts, termed β1i, β2i, and β5i, to form the 
immunoproteasome,  while mixed-type hy-
brid proteasomes have also been reported.3-6 
The increased sensitivity of malignant cells to 
proteasome inhibitors has resulted in protea-
some inhibition emerging as a novel strategy 
*Correspondence should be addressed to H.O. (h.ovaa@nki.nl).
aDivision of Cell Biology II, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Nether-
lands. bCephalon Inc, Discovery Research, West Chester, PA, USA. 
The ubiquitin proteasome system is an attractive pharmacological target for the treat-
ment of cancer. The proteasome inhibitor bortezomib has been approved for the treat-
ment of multiple myeloma (mm) and mantle cell lymphoma, but is associated with sub-
stantial adverse effects and the occurrence of resistance, underscoring the continued 
need for novel proteasome inhibitors. In this study, bortezomib and the novel protea-
some inhibitor CeP-18770 were compared for their ability to inhibit proteasome activity 
using both fluorogenic substrates and a recently developed chemical proteasome activity 
probe. Bortezomib and CeP-18770 were equipotent in inhibiting distinct subunits of the 
proteasome in a panel of cell lines in vitro. In a preclinical mm model, both inhibitors in-
hibited the proteasome in normal tissues to a similar extent. Tumor proteasome activity 
was inhibited to a significantly higher extent by CeP-18770 (60%) compared to bortezomib 
(32%). In addition, CeP-18770 was able to overcome bortezomib resistance in vitro. the 
present findings demonstrate that proteasome activity probes can accurately monitor the 
effects of proteasome inhibitors on both normal and tumor tissues in preclinical mod-
els. Furthermore, the data presented here indicate that CeP-18770 has a favorable phar-
macodynamic profile compared to bortezomib, and provide rationale for further clinical 
development of CeP-18770.
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for cancer treatment.2 In addition to eliciting 
direct apoptotic effects, proteasome inhibi-
tion may also enhance sensitivity and over-
come drug resistance to standard chemo- and 
radiation therapy.7 Bortezomib8 (Figure 1), the 
active ingredient of velcade®, was the first pro-
teasome inhibitor to be approved as a single 
agent for the treatment of relapsed or refrac-
tory multiple myeloma (MM)9-11 and mantle 
cell lymphoma12 and, in combination with PE-
Gylated doxorubicin, for the treatment of re-
lapsed MM.13,14 Bortezomib induces apoptosis 
via stabilization of a number of proapoptotic 
and/or regulatory proteins. Both stabilization 
of p53 and inhibition of NF-κB (nuclear factor 
κB) mediated transcription via stabilization 
of its inhibitor IκBα, are thought to play im-
portant roles in bortezomib-induced apopto-
sis,15,16 although additional  mechanisms have 
been implicated to explain the anti-tumor ef-
ficacy of bortezomib.17,18
Bortezomib treatment is associated with 
manageable but substantial side effects e.g., 
thrombocytopenia and peripheral neuropa-
thy10 and the occurrence of both primary and 
acquired drug-resistance.18 Consequently, 
there is an ongoing need for the development 
of novel proteasome inhibitors, and several 
second-generation proteasome inhibitors 
are now entering clinical trials. These include 
carfilzomib (PR-171),19-21 an irreversible ep-
oxyketone peptidyl inhibitor, and marizomib 
(NPI-0052),22,23 an orally available proteasome 
inhibitor isolated from the marine actinomy-
cete, Salinispora spp (Figure 1). Both these 
inhibitors demonstrate a favorable cytotoxic-
ity profile as compared to bortezomib and can 
overcome bortezomib resistance in vitro.19,20,22 
Another second-generation proteasome in-
hibitor in clinical development is CEP-1877024 
(Figure 1). Like bortezomib, CEP-18770 is a 
reversible boronic acid-based inhibitor that 
suppresses NF-κB-mediated transcription, 
and induces apoptosis in human MM cell 
lines and patient derived cells to a similar ex-
tent.25 It has a favorable cytotoxicity profile 
towards a variety of normal human cell lines 
as compared to bortezomib.25 In a preclinical 
model of human MM, CEP-18770 evidenced 
significant and sustained proteasome inhibi-
Figure 1 | Structures of bortezomib, CeP-18770, nPI-0052, carfilzomib and proteasome activity 
probe 1 (me4BodipyFl-Ahx3leu3VS).
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tion in tumors relative to normal tissues and 
anti-tumor efficacy, resulting in complete tu-
mor regression of MM xenografts.25 Impor-
tantly, CEP-18770 is orally bioavailable, and 
oral administration of CEP-18770 resulted 
in significant reduction in tumor weight and 
dose-related incidence of complete tumor 
regression with minimal changes in animal 
body weight.25,26
In the present study, the proteasome inhibi-
tory capacities of bortezomib and CEP-18770 
were profiled side by side in vitro and in a va-
riety of in vivo preclinical models, using both 
fluorogenic substrates and a recently devel-
oped chemical proteasome activity probe, 
that allows profiling of all constitutive and 
immunoproteasomal activities in live cells 
and ex vivo.27 These studies demonstrate that 
both bortezomib and CEP-18770 inhibit β1 
and β5 subunits to a similar extent in a panel 
of multiple myeloma cell lysates and cells. 
Furthermore, in a preclinical model of human 
MM, CEP-18770 inhibited tumor proteasome 
activity to a significantly higher extent (60% 
inhibition of total activity) compared to bort-
ezomib (32% inhibition of total activity), while 
CEP-18770 inhibited the proteasome in nor-
mal tissues with equal potency compared to 
bortezomib. Finally, our data show that CEP-
18770 is able to overcome bortezomib resis-
tance in vitro.
 
reSUlTS 
 
Bortezomib and CeP-18770 show comparable 
inhibition profiles in a panel of cell lysates
CEP-18770 and bortezomib are chemically re-
lated (Figure 1) and have a comparable ability 
to induce apoptosis in MM cell lines and in pu-
rified primary human MM explants cultures, 
but show substantial differences in their cy-
totoxicity profile towards normal cells and in 
their antitumor-efficacy.25 To assess whether 
these differences can be related to differenc-
es in proteasome inhibition, the proteasome 
inhibitory potential of CEP-18770 and borte-
zomib were first compared in cell lysates using 
fluorogenic substrates for the different pro-
teasomal activities. Lysates from RPMI8226, 
H929, JJN3 (all MM) and HeLa (cervical car-
cinoma) cells were pre-incubated for 1 hour 
with increasing concentrations of CEP-18770 
and bortezomib after which residual protea-
some activity was measured (Figure 2A). IC50 
values for the chymotryptic and caspase-like 
activities of the proteasome were calculated 
(Figure 2B). Bortezomib (black lines) and CEP-
18770 (grey lines) showed almost identical 
inhibition profiles in all cell lines tested (Fig-
ure 2A) and inhibited both the chymotryptic 
activity (thin solid lines) and the caspase-like 
activity (dotted lines), but not the tryptic ac-
tivity (thick solid lines), as has been described 
for bortezomib.25,28 IC50 values for inhibition 
of the chymotryptic activity were 10–25 nM 
depending on the cell line used and did not 
differ significantly between bortezomib and 
CEP-18770 (Figure 2B). When IC50 values were 
compared between different tumor cell lines, 
RPMI8226 and H929 MM cells were more sen-
sitive than JJN3 and HeLa cells to inhibition of 
chymotryptic activity. Whereas in RPMI8226 
and H929 cells IC50 values between 9 and 13 
nM were measured, HeLa and JJN3 cells re-
quired 20–24 nM of CEP-18770 or bortezomib 
for 50% inhibition (Figure 2B). Consistent with 
the finding that low concentrations of CEP-
18770 inhibit the proteasome to a higher ex-
tent in H929 or RPMI8226 cells compared to 
JJN3 cells, a low concentration of CEP-18770 
induced apoptosis in RPMI8226 and H929 
cells, but not in JJN3 cells.25 IC50 values for in-
hibition of the caspase-like activity were 40–
75 nM depending on the cell line used. CEP-
18770 was more specific for the chymotryptic 
activity as compared to bortezomib in both 
JJN3 and HeLa cells, but a significant differ-
ence between IC50 values (p<0.05) was only 
72
observed in JJN3 cells (Figure 2B). 
Bortezomib and CeP-18770 show compara-
ble inhibition patterns in cells
The proteasome inhibitory effects of bort-
ezomib and CEP-18770 in intact RPMI8226, 
H929, and HeLa cells were investigated. To 
this end, active proteasome subunits in cells 
were labeled using a fluorescent proteasome 
activity probe (Me4BodipyFL-Ahx3Leu3VS (1); 
Figure 1) that contains a vinyl sulfone reactive 
group that covalently modifies all N-termi-
nal threonine residues of catalytically active 
proteasomal subunits, and a fluorescent tag 
that allows in-gel visualization of the subunit-
probe complex in an SDS-PAGE gel. When one 
or more proteasome active sites are targeted 
by CEP-18770 or bortezomib treatment, probe 
labeling is hampered, resulting in a decrease 
in in-gel fluorescence intensity and ultimately 
in the disappearance of specific bands.27 
Cells were pulsed for 1 h with increasing con-
centrations of bortezomib and CEP-18770, 
followed by a 2-h chase with probe 1, a close 
analog of the bodipyFL probe described pre-
viously.27 Cells were then lysed, subunits 
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Figure 2 | Bortezomib and CeP-18770 have identical proteasome inhibition profiles in cell lysates. A) 
Representative proteasome inhibitory profiles in RPMI8226, H929, JJN3 and HeLa cell lysates after ad-
dition of increasing concentrations of bortezomib (black lines) or CEP-18770 (grey lines), obtained us-
ing fluorogenic substrates for the different proteasomal activities. Results were plotted as percentage 
activity compared to non-treated lysates. Thick solid lines: tryptic activity; thin solid lines: chymotryp-
tic activity; dotted lines: caspase-like activity. B) IC50 values of CEP-18770 (grey bars) and bortezomib 
(black bars) in RPMI8226, H929, JJN3 and HeLa cell lysates determined using fluorogenic substrates for 
the different proteasomal activities. IC50 values were determined in three independent experiments 
and error bars indicate SEM. • p<0.05
73
Chapter 2.1   |   Comparison between bortezomib and CEP-18770
separated by SDS-PAGE and the gel scanned 
for fluorescence emission (Figure 3A). In un-
treated cells, the proteasome probe labeled 
all active subunits, and differences in sub-
unit activity could be seen between different 
cell lines (Figure 3A, first lane). In H929 and 
RPMI8226 cells both constitutive and im-
munoproteasome subunits were active, as 
shown previously in RPMI8226 cells,29 while 
in HeLa cells only constitutive subunits were 
labeled.27,28 When cells were preincubated 
with either bortezomib or CEP-18770, the la-
beling of the β1 and β5 subunits disappeared 
in a concentration-dependent manner in all 
cell lines with estimated IC50 values in the low 
nanomolar range, while the labeling of the β2 
subunits remained largely visible. These data 
confirm results in cell lysates and suggest that 
bortezomib and CEP-18770 are equipotent in 
inhibiting β1 and β5 subunits, but that they 
do not inhibit the β2 subunits in live cells. 
Validating ArP-1 cells as a model system to 
compare bortezomib and CeP-18770 treat-
ment in vivo
In a previous report, the in vivo efficacies of 
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Figure 3 | Bortezomib and CeP-18770 induce near identical proteasome inhibition profiles and re-
covery patterns in live cells. A) In-gel fluorescence measurements showing representative protea-
some activity profiles in RPMI8226, H929 and HeLa cells after a 1-hour incubation with increasing 
concentrations of bortezomib or CEP-18770. Results were obtained by incubating cells with inhib-
itor, followed by active proteasome labeling by probe 1, and SDS-PAGE analysis. B) In-gel fluores-
cence measurements showing representative proteasome activity profiles in ARP-1 cells after a 2- or 
24-hour incubation period with increasing concentrations of bortezomib and CEP-18770. Results were 
obtained by incubating cells with inhibitor, followed by active proteasome labeling by probe 1, and 
SDS-PAGE analysis and fluorescence scanning. C) In-gel fluorescence measurements showing repre-
sentative proteasome activity profiles in ARP-1 cells after a 1-hour incubation with 100 nM of borte-
zomib or CEP-18770, followed by the indicated recovery periods. Results were obtained by incubating 
cells with inhibitor, followed by active proteasome labeling by probe 1, and SDS-PAGE analysis.
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CEP-18770 and bortezomib were compared 
in a RPMI8226 subcutaneous xenograft mod-
el of human MM, and in an ARP-1 systemic 
model of human MM.25  In these models, dif-
ferences were found between bortezomib 
and CEP-18770 in the extent and duration of 
tumor proteasome inhibition and antitumor 
efficacy. To assess whether the use of specific 
MM cell lines that respond differentially to 
CEP-18770 or bortezomib treatment were re-
sponsible for these observations, the effects 
of bortezomib and CEP-18770 were further 
studied in ARP-1 cells. ARP-1 cells were pulsed 
with increasing concentrations of bortezomib 
and CEP-18770 for 2 or 24 h, followed by a 
2-h chase with proteasome probe 1. Cells 
were then lysed, labeled subunits separated 
by SDS-PAGE and the resulting gel scanned for 
fluorescence emission. As can be seen in Fig-
ure 3B, both immuno- and constitutive pro-
teasome subunits were labeled in untreated 
ARP-1 cells (Figure 3B, lane 1). In accord with 
results inform the RPMI8226, H929 and HeLa 
cells, bortezomib and CEP-18770 showed 
near identical inhibition profiles in ARP-1 cells 
(Figure 3B). After a 2-hour incubation period, 
both compounds dose-dependently inhibited 
β1 and β5 subunits with IC50 values between 
3 and 10 nM, while β2 subunits remained 
relatively unaffected. Also after 24 h, both 
compounds inhibited β1 and β5 subunits, but 
in addition the labeling of β2 subunits was 
largely abolished at higher concentrations. 
As bortezomib and CEP-18870 do not interact 
with β2 subunits directly at the concentra-
tions investigated (Figure 2A), this may be due 
to a secondary cellular response. 
To investigate whether ARP-1 MM cells show 
differences in proteasome activity recovery 
after either bortezomib or CEP-18770 treat-
ment, ARP-1 cells were pulsed for 1 h with 
100 nM bortezomib or CEP-18770, washed 
and either probed directly (Figure 3C, lane 3), 
or allowed to recover for the indicated time 
periods before being analyzed. The patterns 
of activity recovery after withdrawal of either 
bortezomib or CEP-18770 were very similar 
(Figure 3C). After withdrawal of either inhibi-
tor, proteasome activity recovered only slow-
ly. After a 20-h recovery period, activity of the 
β5 subunits had not completely returned to 
baseline levels, while the activity of the β1i 
subunit was not detected (Figure 3C). These 
results indicate that although boronic-acid 
based proteasome inhibitors inhibit the pro-
teasome in a reversible manner, proteasome 
synthesis, which occurs only after longer time 
periods, is the predominant factor contribut-
ing to recovery. Together, these data demon-
strate that ARP-1 cells respond similarly to 
bortezomib and CEP-18770 treatment with 
respect to both proteasome inhibition and 
proteasome recovery patterns. 
CeP-18770 shows an improved pharmacody-
namic profile compared to bortezomib
To evaluate whether bortezomib and CEP-
18770 show differences in proteasome inhibi-
tion in vivo, proteasome probe 1 was used to 
profile proteasome inhibition using an ex vivo 
approach.27 NOD/SCID mice bearing subcuta-
neous ARP-1 tumor xenografts (n=5/group) 
were administered with the maximum toler-
ated dose (MTD) of bortezomib (1.2 mg/kg in-
travenous), CEP-18770 (4 mg/kg intravenous) 
or Solutol/PBS vehicle. At 2 h, 8 h or 24 h post 
dosing, mice were sacrificed and heart, lung, 
liver, spleen and tumor tissue obtained. Tissue 
cells were lysed, and lysates probed for pro-
teasome activity, followed by SDS-PAGE. The 
resulting gels were scanned for fluorescence 
emission (Figure 4A) and the intensities of all 
bands were quantified using a sypro stain to 
control for protein loading. In all tissues, ve-
hicle treatment had no effect on proteasomal 
subunit activity over a 24-h period (data not 
shown). Proteasome subunit activities in CEP-
18770 and bortezomib treated samples were 
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Figure 4 | CeP-18770 shows an improved pharmacodynamic profile compared to bortezomib in an 
ArP-1 mm tumor model. NOD/SCID mice (n=5/group) bearing ARP-1 tumor xenografts received a 
single injection of the maximum tolerated dose of bortezomib or CEP-18770 or vehicle, and tissues 
were removed at t = 2 h, 8 h, or 24 h post dosing. Tissues were lysed, followed by active proteasome 
labeling by probe 1 and SDS-PAGE analysis. A) In-gel fluorescence measurements showing representa-
tive proteasome activity profiles in mouse heart, lung, liver, spleen and tumor tissues after bortezomib 
or CEP-18770 treatment for the indicated time periods. B) Quantification of proteasome activity pro-
files in mouse heart, lung, liver, spleen and tumor tissues after bortezomib or CEP-18770 treatment 
for the indicated time periods. The proteasome subunit activity in treated samples was plotted as a 
percentage of the subunit activity in vehicle treated mice and total proteasome activity was defined 
as the sum of all individual activities. Error bars represent SEM. Statistical analysis was performed 
using GraphPad Prism software. CEP-18770 treated samples in which inhibition differed significantly 
from the corresponding bortezomib treated samples are indicated with dots. • p<0.05; •• p<0.01; 
••• p<0.001
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calculated as a percentage of the activities in 
vehicle-treated samples and averaged (Figure 
4B). Total proteasome activity was defined as 
the sum of all individual activities. 
In normal murine tissues, CEP-18770 and 
bortezomib showed comparable inhibition 
and recovery patterns, although subtle dif-
ferences in inhibition patterns could be ob-
served between the two inhibitors as well as 
between different tissue types. Bortezomib 
and CEP-18770 inhibited β1 and β5 subunits 
(Figure 4B, blue bars) to a similar degree in all 
tissues at all time points, with residual activi-
ties ranging between 20–50% for the β5,5i,1 
subunits (dark blue bars) and 0–10% for the 
β1i subunit (light blue bars). The β2 subunit 
(red bars) was least affected by compound 
treatment. A small decrease in labeling was 
only observed in lung tissue. Labeling of the 
β2i subunit (orange bars) was decreased to 
a somewhat higher extent in lung, liver and 
spleen, predominantly at later time points. 
These results are in line with the results from 
ARP-1 cells (Figure 3B), suggesting that this 
was a secondary cellular response to pro-
teasomal β1 and β5 subunit inhibition. Ad-
ditional, little recovery of the activity of indi-
vidual subunits was seen in this model over 
a period of 24 h, although in individual mice, 
proteasome activity appeared to recover in 
spleen, liver and heart after treatment with 
either compound (data not shown). Total pro-
teasome activity (Figure 4B, yellow bars) was 
only partially inhibited in all normal tissues, 
predominantly because the β2,2i activities 
substantially contributed to total proteasome 
activity in all tissues examined (Figure 4A). The 
largest effects on total activity were observed 
in lung, where 40% residual proteasome activ-
ity was measured. In heart and liver, 60–70% 
of total proteasome activity remained after 
CEP-18770 and bortezomib treatment, while 
in spleen, total proteasome activity hardly 
decreased compared to vehicle (Figure 4B). 
No significant differences in total proteasome 
inhibition were observed between CEP-18770 
and bortezomib in healthy murine tissue at all 
time points.
In ARP-1 tumor xenografts, differences be-
tween the inhibition produced by CEP-18770 
and bortezomib were more pronounced. In 
primary tumor tissues β5 and β1 subunits 
were inhibited to a significantly higher ex-
tent by CEP-18770 treatment compared to 
bortezomib treatment at all time points, with 
residual activities ranging between 10–20% 
after CEP-18770 treatment and 60–80% after 
bortezomib treatment (Figure 4B). CEP-18770 
induced maximal inhibition of these subunits 
within 2 h while maximal inhibition by bort-
ezomib occurred only after 8–24 hours. Ad-
ditionally, treatment with either compound 
resulted in small decreases in β2 and β2i 
labeling over time, as described above for 
normal tissues. As a result, the residual pro-
teasome activity was significantly lower in 
CEP-18770-treated tumors as compared to 
bortezomib-treated tumors at 2 h and 24 h 
(Figure 4B). CEP-18770 reduced total protea-
some activity to 40–50%, suggesting that this 
compound inhibited tumor proteasome to a 
similar or greater extent than proteasome in 
normal tissues. In contrast, the residual activ-
ity in bortezomib-treated tumor samples was 
70–100%, suggesting that bortezomib inhib-
ited proteasome activity in tumors to a lesser 
extent than in most normal tissues. Collec-
tively, these data indicate that CEP-18770 
induces a more favorable pharmacodynamic 
response in the ARP-1 MM tumor model as 
compared to bortezomib. 
CeP-18770 displays activity against cells that 
are resistant to bortezomib
We next investigated whether CEP-18770 
could overcome bortezomib resistance in the 
bortezomib resistant cell line THP1/BTZ100.30 
THP1/BTZ100 cells acquired bortezomib resis-
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tance by exposure to stepwise increasing con-
centrations of bortezomib (2.5 to 100 nM). 
Study of the molecular mechanism of borte-
zomib resistance in these cells revealed an Al-
a49Thr mutation in the β5 subunit protein.30 
This mutation has also been observed in Jur-
kat cells (human lymphoblastic T cells) with 
acquired bortezomib resistance.31,32 THP1/
BTZ100 cells were shown to be cross-resistant 
to other proteasome inhibitors that target 
the β5 subunit, including MG132, MG262 and 
4A6.30 
First, we compared the proteasome inhibito-
ry potential of CEP-18770 and bortezomib in 
cell lysates of THP1/BTZ100 and THP1 wild type 
(THP1/WT) cells using fluorogenic substrates 
for the different proteasomal activities as de-
scribed above. Lysates were pre-incubated 
for 1 hour with increasing concentrations of 
CEP-18770 and bortezomib after which re-
sidual proteasome activity was measured 
(Figure 5A) and IC50 values were calculated for 
the chymotryptic activity of the proteasome 
(Figure 5B). Bortezomib (black lines) and CEP-
18770 (grey lines) showed near identical inhi-
bition profiles in THP1/WT cells (dotted lines), 
in accordance with data obtained in other cell 
types (Figure 2A). Higher concentrations of 
bortezomib were required to inhibit the chy-
motryptic activity in THP1/BTZ100 cells as com-
pared to THP1/WT cells, as expected (Figure 
5A,B). Remarkably, CEP-18770 inhibited the 
chymoptryptic activity in THP1/BTZ100 cells 
with equal potency compared to the WT cell 
line (Figure 5A,B). In THP1/BTZ100 cells, no dif-
ferences between bortezomib and CEP-18770 
were observed in the degree of inhibition of 
the tryptic and caspase-like activities of the 
proteasome (Figure 5A).
Next, we set out to confirm that CEP-18770 
was able to inhibit the β5 subunit in intact 
THP1/BTZ100 cells. To this end, THP1/WT and 
THP1/BTZ100 cells were pulsed with increasing 
concentrations of bortezomib and CEP-18770 
for 3 or 24 h, followed by a 2-h chase with 
proteasome probe. Cells were then lysed, la-
beled subunits separated by SDS-PAGE and 
the resulting gel scanned for fluorescence 
emission. In line with results inform other 
cell lines tested, bortezomib and CEP-18770 
showed near identical inhibition profiles in 
THP1/WT cells (Figure 5C, left panels). After 
a 3-hour incubation period, both compounds 
dose-dependently inhibited β1 and β5 sub-
units with IC50 values between 3 and 10 nM, 
while β2 subunits remained relatively unaf-
fected. After 24 h, the labeling of β2 subunits 
by probe 1 was  also hampered at higher con-
centrations of bortezomib and CEP-18770. In 
contrast, CEP-18770 and bortezomib showed 
different inhibition profiles in THP1/BTZ100 
cells (Figure 5C, right panels). CEP-18770 in-
hibited the β5 subunits in THP1/BTZ100 cells 
with IC50 values between 3 and 10 nM, while 
higher concentrations of bortezomib were re-
quired to reach a similar extent of β5 inhibi-
tion. These differences are in accordance with 
results found in cell lysates using fluorogenic 
substrates and suggest that the β5 subunits 
in bortezomib resistant THP1 cells can still be 
inhibited by CEP-18770.
Finally, we investigated how the cell viabil-
ity of THP1/BTZ100 and THP1/WT cells was 
influenced by bortezomib and CEP-18770 
treatment. To this end, cells were exposed 
to increasing concentrations of bortezomib 
and CEP-18770 for 24 h or 48 h, after which 
cell viability was assessed using a cell titer 
blue assay. Values were normalized to con-
trol samples that were incubated with DMSO 
only and results were plotted as percentage 
compared to control values (Figure 5D). EC50 
values, defined as the concentration of inhibi-
tor causing 50% cell death, were determined 
at 48 h (Figure 5E). In accord with the protea-
some inhibitory profiles found in these cells 
using probe 1, THP1/WT cells responded simi-
larly to bortezomib and CEP-18770 treatment 
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Figure 5 | CeP-18770 can overcome bortezomib resistance. A) Proteasome inhibitory profiles in THP1/
WT and THP1/BTZ100 cell lysates after addition of increasing concentrations of bortezomib (black lines) 
or CEP-18770 (grey lines), obtained using fluorogenic substrates for the different proteasomal activi-
ties. Results were plotted as percentage activity compared to non-treated lysates. Solid lines: THP1/
BTZ100 cells; dotted lines: THP1/WT cells. Error bars represent SEM of technical triplicates. B) IC50 values 
of CEP-18770 (grey bars) and bortezomib (black bars) in THP1/WT and THP1/BTZ100 cell lysates for 
inhibition of the chymotryptic activity. C) In-gel fluorescence measurements showing representative 
proteasome activity profiles in THP1/WT and THP1/BTZ100 cells after a 3 or 24-hour incubation with 
increasing concentrations of bortezomib or CEP-18770. Results were obtained by incubating cells with 
inhibitor, followed by active proteasome labeling by probe 1, and SDS-PAGE analysis. D) Viability of 
THP1/WT and THP1/BTZ100 cells after incubation with increasing concentrations of bortezomib (black 
lines) or CEP-18770 (grey lines) for 24h or 48h. Results were plotted as percentage viability compared 
to a DMSO control. Solid lines: THP1/BTZ100 cells; dotted lines: THP1/WT cells. Error bars represent 
SEM of technical triplicates. e) EC50 values of CEP-18770 (grey bars) and bortezomib (black bars) in 
THP1/WT and THP1/BTZ100 cells.
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(Figure 5D). In THP1/BTZ100 cells on the other 
hand, bortezomib showed higher EC50 val-
ues as compared to THP1/WT cells, whereas 
THP1/BTZ100 and THP1/WT cells were equally 
sensitive to CEP-18770 (Figure 5D,E). The 
EC50 value of CEP-18770 in THP1/BTZ100 cells 
was approximately 30 nM, whereas 100 nM 
bortezomib was not sufficient to kill 50% of 
all THP1/BTZ100 cells (Figure 5E). From the 
data obtained in THP1/BTZ100 and THP1/WT 
cells we conclude that THP1/BTZ100 cells are 
resistant to bortezomib due to a mutation in 
the β5 protein, which prevents bortezomib 
binding. Remarkably, THP1/BTZ100 cells are 
still equally sensitive to proteasome inhibi-
tion by CEP-18770 as compared to THP1/WT 
cells, and as a consequence, CEP-18770 dis-
plays similar EC50 values in THP1/BTZ100 and 
THP1/WT cells. Therefore, our data suggest 
that CEP-18770 can overcome acquired bort-
ezomib resistance in vitro.
DISCUSSIOn
Proteasome inhibition is a validated strategy 
for the treatment of cancer, as evidenced by 
bortezomib, a boronic acid-based proteasome 
inhibitor, which is the active ingredient of vel-
cade® and which is currently the only protea-
some inhibitor approved for human use.  Bort-
ezomib treatment is however associated with 
adverse effects,10 including thrombocytope-
nia33 and peripheral neuropathy,34 and with 
both primary and secondary resistance.18 This 
has led to the search for new proteasome in-
hibitors with an improved cytotoxicity profile 
and the potential to overcome bortezomib 
resistance. CEP-18770, a novel proteasome 
inhibitor that is structurally similar to bort-
ezomib, is one of several second-generation 
inhibitors in clinical trials.24,25
In the present study the proteasome inhibi-
tory profiles of bortezomib and CEP-18770 
were compared in cell lysates, whole cells and 
ex vivo in a mouse model of human MM, us-
ing both fluorogenic substrates and a chemi-
cal proteasome activity reporter that allows 
profiling of proteasome activity with high 
sensitivity in a wide range of cell types and 
tissues.27 In addition, we investigated the pro-
teasome inhibitory profiles of CEP-18770 and 
bortezomib in cells with acquired resistance 
to bortezomib, and assessed the effect of ei-
ther CEP-18770 or bortezomib treatment on 
the cell viability of these cells.
CEP-18770 and bortezomib showed com-
parable inhibition patterns in a panel of hu-
man tumor cell lines. Both compounds were 
equipotent in inhibiting the β1 (caspase-like 
activity) and β5 (chymotryptic activity) sub-
units and had little effect on the β2 subunit 
activity (tryptic activity), in agreement with 
previous reports.25,28 IC50 values in cell lysates 
were 40–75 nM and 10–25 nM for inhibition 
of the caspase-like and chymotryptic activity, 
respectively. In cell lines, IC50 values of both 
compounds for both the β1 and β5 subunits 
ranged between 3–10 nM. These data are in 
agreement with a previous report, in which 
bortezomib and CEP-18770 showed com-
parable effects in cells downstream of pro-
teasome inhibition, including a comparable 
accumulation of polyubiquitinated proteins 
and the appearance of activated caspases-3, 
-7, and -9 with a comparable kinetic profile.25 
Data obtained using either fluorogenic sub-
strates in cell lysates or using probe 1 in intact 
cells were similar, indicating the use of probe 
1 provides a reliable method to assess protea-
some activity. 
Proteasome activity recovered similarly after 
withdrawal of either inhibitor from cells, with 
immediate but very slow recovery of β5(i)/1 
subunit activity, and no recovery of the β1i 
activity within 20 hours. The slow rate of pro-
teasome activity recovery after inhibition by 
either compound indicates that proteasome 
synthesis, and not the reversibility of boronic-
80
acid based proteasome inhibitors, is the pre-
dominant factor contributing to recovery, as 
suggested previously.19 The factors contribut-
ing to a differential recovery of proteasomal 
activities are unknown, but differences in re-
covery between subunits have been report-
ed.22,35 After treatment with bortezomib, the 
recovery of caspase-like activity was delayed 
compared to that of chymotryptic activity.22 
Furthermore, continuous bortezomib treat-
ment can abrogate immunoproteasome sub-
unit expression and thus induce an altered 
subunit composition of newly synthesized 
proteasomes.35 
In contrast to the finding that CEP-18770 and 
bortezomib have near identical effects on tu-
mor cell proteasome activity in vitro, marked 
differences between CEP-18770 and bort-
ezomib were found in vivo in an ARP-1 MM 
xenograft model. In tumor xenografts, CEP-
18770 showed a significantly higher degree 
of inhibition of β1 and β5 subunits at all time 
points measured as compared to bortezomib 
(80–90% inhibition by CEP-18770 as com-
pared to 40–60% inhibition by bortezomib), 
resulting in a significantly higher degree of 
overall proteasome inhibition (60% inhibition 
by CEP-18770 as compared to 32% inhibition 
by bortezomib), while the response of nor-
mal, healthy murine tissues to treatment with 
the maximum tolerated dose of bortezomib 
or CEP-18770 was near identical. CEP-18770 
thus reduced proteasome activity in tumors 
to a greater extent than in most normal tis-
sues, while bortezomib inhibited proteasome 
activity in tumors to a lesser extent than in 
most normal tissues, resulting in a favorable 
pharmacodynamic profile for CEP-18770 as 
compared to bortezomib. These results are in 
agreement with Piva et al., who have shown 
that in a RPMI8226 MM tumor xenograft 
model, CEP-18770 induced a similar degree 
of proteasome inhibition in normal mouse 
peripheral tissues compared to bortezomib, 
but a greater and more-sustained inhibition 
of tumor proteasome activity.25 Consistent 
with these findings, CEP-18770 treatment has 
been shown to have a greater in vivo antitu-
mor efficacy, and CEP-18770 administration 
resulted in a dose-related induction of com-
plete tumor regression, whereas bortezomib 
treatment only delayed tumor growth.25 Other 
studies have shown that bortezomib reduced 
proteasome activity in tumors to a lesser ex-
tent as compared to other tissues or whole 
blood samples19,36,37 and similar observations 
have been reported for marizomib38 and 
carfilzomib.19 While the anti-tumor efficacy 
of bortezomib results in effective anti-tumor 
therapy, the improved response of CEP-18770 
in tumors that can be correlated with its pre-
viously reported improved anti-tumor effi-
cacy may result in further benefit in a clinical 
setting. In addition, the data obtained in mice 
ex vivo show that probe 1 can be successfully 
used for detailed studies of the effects of pro-
teasome inhibitors on both normal and tumor 
tissues in preclinical models.
Finally, our data show that CEP-18770 dis-
plays activity against a bortezomib resistant 
cell line in vitro. The cell line THP1/BTZ100 is 
resistant to concentrations of bortezomib up 
to 100 nM. Study of the molecular mecha-
nism of bortezomib resistance in these cells 
revealed an Ala49Thr mutation in the β5 
subunit protein.30 Ala49 is a highly conserved 
residue among many prokaryotic and mam-
malian species and very likely involved in tight 
interactions with the pyrazine-2-carboxy-
phenylalanyl backbone of bortezomib, as can 
be reasoned from the bortezomib liganded 
yeast 20S proteasome structure.39 Therefore, 
mutation of this residue to threonine is likely 
to have a profound effect on binding of bort-
ezomib and of other proteasome inhibitors 
that target the β5 subunit. Our data show 
that CEP-18770 binding was not influenced 
by the Ala49Thr mutation. Bortezomib and 
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CEP-18770 are structurally similar, but differ 
in their P2 and P3 residues, suggesting that 
even small changes to the backbone structure 
of bortezomib can be sufficient to overcome 
bortezomib resistance. The data presented 
here suggest that the development of second-
generation proteasome inhibitors will likely 
result in the generation of inhibitors that can 
overcome resistance and may ultimately con-
tribute to better patient outcome and that 
this outcome can be predicted with the use of 
activity reporter reagents.
 
mATerIAlS AnD meTHODS
Reagents
The THP1/BTZ100 cell line was kindly provided 
by Dr. G. Jansen (VU University Medical Centre, 
Amsterdam, The Netherlands). Fluorogenic sub-
strates were purchased from Bachem (Weil am 
Rhein, Germany).  All solvents were purchased 
from Biosolve (Valkenswaard, the Netherlands) at 
the highest grade available. Bortezomib and CEP-
18770 were synthesized at Cephalon Inc for this 
study. All other chemicals were purchased from 
Sigma-Aldrich (Zwijndrecht, the Netherlands) at 
the highest available purity. 
Probe synthesis and characterization
Detailed information on synthetic procedures and 
characterization can be found in the Supplemen-
tary Information and Supplementary Schemes 1 
and 2 therein.
Cell culture
RPMI8226 (human, multiple myeloma), ARP-1 
(human, multiple myeloma), THP1/WT (human 
monocytic/macrophage) and H929 (human, mul-
tiple myeloma) cells were cultured in RPMI 1640 
medium (Invitrogen). THP1/BTZ100 cells were cul-
tured in RPMI 1640 medium supplemented with 
100 nM bortezomib. JJN3 cells were cultured in 
RPMI 1640 medium containing 10mM HEPES (In-
vitrogen). HeLa cells (human, cervix carcinoma) 
were cultured in DMEM medium (Invitrogen). All 
media were supplemented with 10% fetal calf se-
rum (FCS), 100 units/mL penicillin and 100 mg/mL 
streptomycin. 
Inhibition experiments in cell lysates
Cells were washed with phosphate-buffered sa-
line (PBS), pelleted and lysed with one volume of 
glass beads (<106 microns, acid-washed; Sigma) 
and an equal volume of homogenization buffer 
(50 mM Tris pH 7.4, 1 mM dithiothreitol (DTT), 
5 mM MgCl2, 2 mM ATP and 250 mM sucrose)
by vortexing at high speed for 45 minutes at 4 
°C. Beads, membrane fractions, nuclei and cell 
debris were then removed from the supernatant 
by centrifugation at 14,000 g for 5 minutes. Pro-
tein contents were quantified using the Bradford 
method (BioRad, Veenendaal, the Netherlands) 
or with a nanodrop spectrophotometer. Equal 
amounts of protein were incubated with 1, 3, 10, 
30 or 100 nM bortezomib or CEP-18770 for 1 h 
at 37 °C. Control samples were incubated with 
1 mM epoxomicin. To assay proteasome activity, 
10 mg of lysate was added to 100 mL of substrate 
buffer (20 mM Tris pH 7.4, 5 mM MgCl2, 1 mM 
DTT, 1 mM ATP and 100 mM BzValGlyArg-AMC 
(tryptic activity), 100 mM SucLeuLeuValTyr-AMC 
(chymotryptic activity) or 50 mM ZLeuLeuGlu-
AMC (caspase-like activity)). Fluorescence was 
measured every minute for 25 minutes at 37 °C 
using a fluostar optima 96 well plate reader (BMG 
labtechnologies) (l ex/em = 355/450 nm) and the 
increase in fluorescence per minute was used to 
calculate specific activities of each sample. Non-
specific activities were determined using 1 mM 
epoxomicin, which specifically inhibits all pro-
teasomal activity at this concentration, and the 
background signal obtained was subtracted from 
each measurement. IC50 values were determined 
in three independent experiments and averaged. 
Data were analyzed by using GraphPad Prism 
software (GraphPad, La Jolla, CA, USA).
Probing proteasome inhibition in whole cells
H929, RPMI8226, ARP-1 or HeLa cells (0.5 × 106 
cells/mL) were pulsed with 0, 1, 3, 10, 30 or 100 
nM bortezomib or CEP-18770 for 1, 2 or 24 hours 
at 37 °C, followed by a 2 hour chase with 500 nM 
proteasome activity probe 1. Alternatively, ARP-
1 cells were pulsed with 100 nM bortezomib or 
CEP-18770 for 1 hour, washed, and either chased 
directly with 500 nM proteasome activity probe 
1 or left to recover for 0.25, 0.5, 1, 2, 3, 4 or 20 
hours before being chased with probe 1. THP1/
WT or THP1/BTZ100 cells (0.5 × 106 cells/mL) were 
pulsed with 0, 1, 3, 10, 30 or 100 nM bortezomib 
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or CEP-18770 for 1 or 22 hours at 37 °C, followed 
by a 2 hour chase with 200 nM proteasome activ-
ity probe 1. Cells were harvested, washed with 
cold PBS and lysed for 30 min. in NP40 lysis buf-
fer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP40)
at 4 °C. The Bradford assay was used to measure 
protein content.
Ex vivo evaluations
Nod/Scid mice with established human ARP-1 
MM subcutaneous tumor xenografts (n=5/group) 
were dosed at Cephalon (West Chester, PA) with 
the maximum tolerated dose of bortezomib (1.2 
mg/kg i.v.), CEP-18770 (4 mg/kg i.v.) or Solutol/
PBS vehicle.  Experiments were approved by the 
Institutional Animal Care and Use Committee 
of Cephalon. At 2 h, 8 h, and 24 h post dosing 
heart, liver, lung, spleen and tumor tissue were 
obtained, rinsed in cold PBS and flash frozen in 
a tissue cassette under liquid N2. Organs were ly-
sed in homogenization buffer using glass beads 
as described above. Protein concentrations were 
determined using the Bradford assay, and equal 
amounts of protein were incubated with 1 mM 
probe 1 for 1 h at 37 °C. Statistical analyses were 
performed using by using GraphPad Prism soft-
ware (GraphPad, La Jolla, CA, USA).
In-gel fluorescence measurements
Equal amounts of protein were denatured by boil-
ing in LDS (Lithium dodecyl sulfate) sample buffer 
(Invitrogen) containing 2.5% β-mercaptoethanol 
and polypeptides were resolved by 12% SDS-
PAGE using the NuPAGE system from invitro-
gen. Wet gel slabs were imaged for 2 min, with 
a resolution of 100 mm, using the ProXPRESS 2D 
Proteomic imaging system (Perkin Elmer), using 
appropriate filter settings (l ex/em = 480/530 
nm). To verify protein loading, gels were stained 
with ruthenium II tris bathophenanthroline dis-
ulfonate, as described,40,41 and imaged using ap-
propriate filter settings (l ex/em = 460/680 nm). 
Probe signals were then normalized to the sypro 
signal. Images were analyzed using Totallab anal-
ysis software (Nonlinear Dynamics, Newcastle 
upon Tyne, UK) to quantify the intensity of the 
bands detected. 
Cell viability assay 
THP1/WT or THP1/BTZ100  cells (2 × 105 cells/mL 
were incubated with 0, 1, 3, 10, 30 or 100 nM 
bortezomib or CEP-18770 for 24 or 48 hours, fol-
lowed by incubation with 20 mg/mL resazurin. 
The increase in fluorescence was measured af-
ter 8 hours using a PE envision plate reader. All 
results were expressed as percentage relative to 
untreated THP1/WT cells (100%).
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Supplementary information
slowly added in 5 portions to a solution of methyl 
4-acetyl-5-oxohexanoate (5 mL, 28.6 mmol) in 
acetic acid (15 mL) kept at 65 °C. Simultaneously, 
a mixture of zinc dust (3 g, 45.9 mmol) and so-
dium acetate (3 g, 36.6 mmol) was added in por-
tions such that zinc/sodium acetate was in excess 
of dione. After stirring the mixture for 2 more 
hours at 65 °C it was poured into ice water and 
left slowly stirring for 16 hours, allowing the mix-
ture to warm up to room temperature. The pre-
cipitate, including product and zinc residues was 
filtered off using a glass filter. The residue was 
taken up in ethyl acetate (100 mL) and the organic 
layer was dried with magnesium sulfate (MgSO4). 
The MgSO4 was filtered off and the filtrate was 
concentrated in vacuo to dryness, yielding tetra-
substituted pyrrole 2 as a light brown solid (2.87 
g, 10.2 mmol, 59 % yield), which was used with-
out further purification in the next step.
III: methyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-
3-yl)propanoate (3)
Pyrrole 2 (1 g, 3.55 mmol) was dissolved in TFA 
(20 mL) and stirred for 20 minutes on ice. Triethy-
lorthoformate (2 mL, 12 mmol) was added slowly 
and the solution was stirred gently at 0 °C for 15 
minutes. Water (2 mL) was added and the solu-
tion was stirred for 10 minutes at 0 °C. The solu-
tion was coevaporated with toluene in vacuo to 
dryness at room temperature. The crude product 
was purified by flash column chromatography us-
ing ethyl acetate as the eluent to yield aldehyde 
3 as a brown solid (469 mg, 2.25 mmol, 63 % 
yield). 
IV: (Z)-2-((3,5-dimethyl-2H-pyrrol-2-ylidene)
methyl)-4-(3-methoxy-3-oxopropyl)-3,5-dime-
thyl-1H-pyrrol-1-ium (4)
Aldehyde 3 (469 mg, 2.25 mmol) was dissolved 
in absolute ethanol (8 mL) and cooled to 0 °C. 
2,4-dimethylpyrrole (256 mg, 2.69 mmol) was 
added under an argon atmosphere and 4 mL of 
cold 4N HCl in dioxane was added. After Stirring 
for 15 minutes at 0 °C, the solution was trans-
ferred to a 50 mL Falcon tube and centrifuged 
at 1500g for 10 minutes at 4 °C. The supernatant 
was discarded and the resulting orange solid was 
SUPPlemenTAry meTHODS
Fmoc peptide building blocks were from Nov-
abiochem. All solvents were purchased from 
Biosolve at the highest grade available. All other 
chemicals were purchased from Aldrich at the 
highest available purity. All solvents and chemi-
cals were used as received. L-Leucinyl vinyl sul-
fone was prepared as reported.1-4 Nuclear mag-
netic resonance (NMR) spectra were recorded in 
the indicated solvent using a Bruker Avance 300 
(1H: 300 MHz; 13C: 75 MHz) spectrometer. LC-MS 
analyses were carried out on a WATERS LCT mass 
spectrometer in line with a WATERS 2795 HPLC 
system and a WATERS 2996 photodiode array de-
tector. Reversed phase runs were performed on 
a 3 mm Atlantis T3, C18 RP, 2.1 x 100 mm column 
(Waters) using gradient elution with H2O/0.1% 
formic acid as solvent A and acetonitrile/0.1% 
formic acid as solvent B at a flow rate of 0.4 mL/
min. Reversed phase HPLC runs were performed 
on a Waters 1525 EF HPLC system in line with a 
Waters 2487 dual l absorbance detector using 
gradient elution with H2O/0.05% TFA as solvent A 
and acetonitrile/0.05% TFA as solvent B. Analyti-
cal runs were performed on a 10 mm 4.6x150 mm 
Atlantis dC18 column (Waters) at a flow rate of 
1.4 ml/min and preparative runs were performed 
on a 10 mm 19x250 mm Atlantis dC18 column 
(Waters) at a flow rate of 18 mL/min.
Synthesis of me4BodipyFl-nHS ester (Supple-
mentary Scheme 1)
i: (Z)-tert-butyl 2-(hydroxyimino)-3-oxobutano-
ate (1)
A solution of sodium nitrite (1.4 g, 20.3 mmol) in 
deionized water was added dropwise over 5 min-
utes to a stirred mixture of tert-butyl acetoac-
etate (2.80 g, 17.4 mmol) in acetic acid (4 mL), 
while keeping the reaction vessel in an ice-bath. 
The reaction mixture was stirred at 4 °C for an 
additional 16 hours.
II: tert-butyl 4-(3-methoxy-3-oxopropyl)-3,5-di-
methyl-1H-pyrrole-2-carboxylate (2)
The resulting solution containing oxime 1 was 
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resuspended in cold diethylether (40 mL) and 
centrifuged again. The supernatant was decant-
ed and the residue was dried under a stream of 
nitrogen, yielding crude dipyrrole 4 as an orange 
solid, which was used in the next step without 
further purification.
V: me4BodipyFl-methyl ester (5)
Dipyrrole 4 was suspended in 1,2-dichloroben-
zene (20 mL) under an argon atmosphere and 
triethylamine (1 mL, 7.16 mmol) and boron trif-
luoride diethyl etherate (1 mL, 8.12 mmol) were 
added in concert. The resulting metallic solution 
was stirred for 30 minutes at 100 °C and allowed 
to cool to room temperature. The solution was 
diluted with dry hexanes (25 mL) and applied di-
rectly onto a silica gel column for purification by 
flash column chromatography using 25% EtOAc 
in toluene as the eluent to afford Me4BodipyFL-
methyl ester 5 as an orange solid (481 mg, 1.44 
mmol, 64 % yield starting from aldehyde 3). 
VI: me4BodipyFl-OH (6)
Me4BodipyFL-methyl ester 5 (400 mg, 1.24 
mmol) was dissolved in ethanol (6 mL) and 1 
M lithium hydroxide (LiOH) solution was added 
(1.3 mL). The solution was stirred until TLC (elu-
ent: EtOAc containing 0.1% acetic acid) revealed 
complete conversion. Ethyl acetate (40 mL) and 
0.1 M HCl (30 mL) were added and the two layers 
were separated. The organic layer was dried with 
MgSO4 and concentrated in vacuo to dryness to 
obtain an orange solid. Purification by flash col-
umn chromatograpy using EtOAc containing 0.1% 
acetic acid as the eluent afforded Me4BodipyFL-
OH 6 as an orange solid (306 mg, 0.95 mmol, 77 
% yield). 1H NMR (CDCl3): δ 7.09 (s, 1H), 6.10 (s, 
1H), 2.66 (dd, J=8.2 Hz, J=7.1 Hz, 2H), 2.59 (s, 6H), 
2.60-2.53 (m, 2H), 2.31 (s, 3H), 2.27 (s, 3H). 13C 
NMR (CDCl3): δ 178.2 (CO), 156.5 (Cq), 155.3 (Cq), 
141.0 (Cq), 138.1 (Cq), 133.3 (Cq), 132.6 (Cq), 127.8 
(Cq), 119.7 (CH), 118.9 (CH), 33.9 (CH2), 19.2 (CH2), 
14.6 (CH3), 12.7 (CH3), 11.2 (CH3), 9.6 (CH3).
VII: me4BodipyFl-nHS ester (7)
Me4BodipyFL-OH 6 (306 mg, 0.95 mmol) was 
dissolved in  dichloromethane (60 mL) and N-
hydroxy succinimide (120 mg, 1.05 mmol), EDCI 
(201 mg, 1.05 mmol) and DMAP (11 mg, 0.1 
mmol) were added. The mixture was stirred for 
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Supplementary Scheme 1 | Synthesis of me4BodipyFl-nHS ester 7. Step numbers correspond to step 
numbers outlined in the text.
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16 hours at room temperature, 0.05 M HCl (40 
mL) was added the two layers separated. The 
organic layer was dried with MgSO4 and concen-
trated in vacuo to dryness to obtain an orange 
solid, which was purified by flash column chro-
matography using EtOAc : hexanes (2:3 v/v) as 
the eluent to obtain Me4BodipyFL-NHS ester 7 as 
a dark orange solid (242 mg, 0.85 mmol) in 61 % 
yield. 1H NMR (CDCl3): δ 7.02 (s, 1H), 6.02 (s, 1H), 
2.85-2.78 (m, 6H), 2.75-2.70 (m, 2H), 2.50 (s, 6H), 
2.22 (s, 3H), 2.19 (s, 3H). 13C NMR (CDCl3): δ 169.0 
(2xCO), 167.7 (CO), 156.9 (Cq), 154.8 (Cq), 141.3 
(Cq), 138.0 (Cq), 133.4 (Cq), 132.5 (Cq), 126.7 (Cq), 
119.9 (CH), 119.0 (CH), 31.1 (CH2), 25.6 (2xCH2), 
19.2 (CH2), 14.6 (CH3), 12.6 (CH3), 11.2 (CH3), 9.6 
(CH3). 
Synthesis of me4BodipyFl-Ahx3leu3VS (Supple-
mentary Scheme 2)
The synthesis of H2N-Ahx3Leu2-OH involving stan-
dard Fmoc-based solid-phase peptide synthesis 
(SPPS) protocols and the subsequent coupling of 
fluorescent dye and vinyl sulfone electrophile to 
yield the final proteasome probe are depicted in 
Scheme 2.
I: Boc-Ahx3leu2OH (8)
Hyper acid-labile H-Leu-2-ClTrt resin (novabio-
chem) (1 g, 0.3 mmol equivalents) was subjected 
to four coupling cycles, in which deprotection of 
the Fmoc-group with piperidine/NMP (1:4 v/v; 10 
mL/g of dry resin), was followed by a coupling cy-
cle with 3 equivalents of Fmoc-protected amino 
acid, 3 equivalents of DIPEA and 3 equivalents of 
PyBop coupling reagent in NMP (10 mL/g of dry 
resin). Coupling steps were performed with Fmoc-
Leu-OH (1x), Fmoc-6-aminohexanoic acid (Fmoc-
Ahx-OH) (2x) and Boc-Ahx-OH (1x) sequentially. 
The peptide was cleaved from the resin using 2% 
TFA in dichloromethane and the compound was 
concentrated under reduced pressure. The prod-
uct was purified by flash column chromatography 
using a gradient of 10 % to 20% MeOH in CH2Cl2 
containing 0.1 % acetic acid as the eluent to ob-
tain Boc-Ahx3Leu2OH 8 as a white solid (205 mg, 
0.3 mmol) in > 80 % yield.
II: Boc-Ahx3leu3VS (9)
L-Leucinyl vinyl sulfone (LeuVS, 50 mg, 0.26 
mmol) was dissolved in DMF and Boc-Ahx3Leu2OH 
8 (116 mg, 0.17 mmol), DIPEA (89 mL, 0.51 mmol) 
and EDCI (50 mg, 0.26 mmol) were added. The 
solution was stirred for 3 hours at room tempera-
ture and then concentrated in vacuo to dryness 
to yield an off-white solid. The product was puri-
fied by flash column chromatography using 10 % 
MeOH in CH2Cl2  as the eluent to obtain Boc-Ahx3-
Leu3VS 9 as a white solid (103 mg, 0.12 mmol) in 
71 % yield. 
Supplementary Scheme 2 | Synthesis of me4BodipyFl-Ahx3leu3vs.  Step numbers correspond to step 
numbers outlined in the text.
88
iii: h2n-Ahx3leu3VS (10)
Boc-Ahx3Leu3VS 9 (12 mg, 14 mmol) was dissolved 
in TFA (1 mL) and left at room temperature for 30 
minutes. The product was precipitated by adding 
cold diethylether (40 mL) and isolated by centrif-
ugation at 1000g (low brake speed) for 5 minutes 
at 4 ˚C to afford H2N-Ahx3Leu3VS 10 as a white 
solid (10.6 mg, 14 mmol) in > 98 % yield. 
IV: me4BodipyFl-Ahx3leu3vs
H2N-Ahx3Leu3VS 10 (10.6 mg, 14 mmol) was dis-
solved in DMF (1 mL) and Me4BodipyFL-NHS es-
ter 7 (6.4 mg, 15.5 mmol) and DIPEA (24 mL, 0.14 
mmol) were added. The resulting solution was 
stirred at room temperature for 16 hours. The 
solution was concentrated in vacuo to dryness 
and purify by reversed phase HPLC to obtain the 
fluorescent proteasome probe Me4BodipyFL-
Ahx3Leu3VS (6 mg, 5.7 mmol) in 40% yield. MS 
(ESI): 1058.66 (M+H)+; 520.27 (M+H-F)2+; 1080.91 
(M+Na)+
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InTrODUCTIOn
Proteasome inhibition has emerged as a pow-
erful approach for the treatment of cancer, as 
evidenced by the clinical success of the protea-
some inhibitor bortezomib (Figure 1).1 Bort-
ezomib has been approved for the treatment 
of relapsed and newly diagnosed multiple 
myeloma (MM)2-4 and mantle cell lymphoma5 
and in combination with PEGylated doxorubi-
cin for the treatment of relapsed MM.6,7 Bort-
ezomib treatment is associated with substan-
tial side effects, and the occurrence of both 
primary and secondary resistance has been 
reported.8 Consequently, there is an ongoing 
search for novel proteasome inhibitors that 
are able to overcome bortezomib resistance 
and that are better tolerated to increase their 
therapeutic potential. Several second-gen-
eration proteasome inhibitors have entered 
clinical trials, including marizomib (NPI-0052; 
Salinosporamide A)9 (Figure 1), CEP-18770,10 
 *Correspondence should be adressed to H.O. (h.ovaa@nki.nl).
aDivision of Cell Biology II, The Netherlands Cancer Institute, Amsterdam, The Netherlands. bNereus Pharmaceuti-
cals, San Diego, CA, USA. cThe Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-
Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
marizomib (nPI-0052; Salinosporamide A) is a irreversible proteasome inhibitor isolated 
from the marine actinomycete Salinispora tropica that has demonstrated activity in a 
wide range of preclinical tumor models. Clinical trials with marizomib are currently ongo-
ing, enabling a detailed study of patient response to marizomib treatment. In the present 
study, we used a fluorescent proteasome activity probe to profile proteasome inhibition 
in both packed whole blood (PwB) and peripheral blood mononuclear cells (PBmCs) from 
patients on marizomib therapy. we show that PwB, which contains >98% red blood cells 
in which immunoproteasome is not expressed, responds differently to proteasome inhibi-
tors and recovers slower from proteasome inhibition compared to PBmCs. In addition, we 
demonstrate that proteasome activity levels prior to treatment differ between patients, 
and that this initial proteasome activity level is an important determinant of the sensitiv-
ity of cells to proteasome inhibitors. Furthermore, we show that PBmCs are able to rap-
idly change their proteasomal subunit composition in response to marizomib treatment, 
which seems to account for a quick recovery, suggesting that this ability may mediate sen-
sitivity of tumor cells to proteasome inhibition. Together, these data indicate that fluores-
cent proteasome probes can be used to profile patient blood samples and that they may 
enable prediction of patient responses to proteasome inhibitors, which can contribute to 
a more personalized proteasome inhibition strategy to improve the therapeutic potential 
of this class of drugs and finally clinical outcome of proteasome targeted therapy.  
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and Carfilzomib (PR-171).11
The proteasome is a large threonine protease 
complex responsible for the degradation of 
redundant and misfolded proteins and for the 
turnover of regulatory proteins that control 
a wide range of cellular processes, including 
cell cycle regulation, apoptosis and prolifera-
tion.12,13 Mammalian 26S proteasomes con-
sist of a 20S catalytic core, complexed at one 
or both ends with 19S regulatory caps. The 
20S core is composed of four stacked rings 
of seven subunits each and has an overall ar-
chitecture of α(1-7)β(1-7)β(1-7)α(1-7). The 
two outer α-rings stabilize the complex and 
serve as docking stations for the binding of 
regulatory caps, while the catalytic activity 
resides within the two inner β-rings. Three 
constitutive β-subunits, termed β1, β2 and 
β5, provide the proteasomal caspase-like, 
tryptic and chymotryptic activity, respective-
ly. In lymphoid tissues and in cells exposed to 
INF-γ and TNF-α, these subunits are replaced 
by their immunoproteasomal counterparts 
β1i, β2i and β5i to form the immunoprotea-
some,14 which is thought to favor the produc-
tion of antigenic peptides,15 while the exis-
tence of mixed-type hybrid proteasomes has 
also been reported.16,17
Marizomib is an orally available proteasome 
inhibitor isolated from the marine actino-
mycete Salinispora tropica.9 Marizomib irre-
versibly inhibits the proteasome via a two-
step mechanism. In an initial step an ester is 
formed between the catalytic Thr1 Oγ of the 
proteasome and the carbonyl derived from 
the β-lactone ring. Subsequent chlorine sub-
stitution then gives rise to a cyclic ether.18 In 
contrast to bortezomib which targets the β5 
and β1 subunits, marizomib has been shown 
to inhibit all constitutive and immunoprotea-
some subunits.9 Recent studies have shown 
that inhibition of multiple activities is a pre-
requisite for a significant inhibition of protein 
degradation, depending on the protein that is 
degraded,19 suggesting that blocking all three 
activities may be therapeutically advanta-
geous. Marizomib showed efficacy as a single 
agent or in combination with conventional 
chemotherapy in a variety of preclinical solid 
tumor and hematologic tumor models20-22 and 
was able to overcome bortezomib resistance 
in tumor cells purified from MM patients that 
had relapsed from prior therapies including 
bortezomib treatment.9 Interestingly, combi-
nation treatment with bortezomib and mari-
zomib both in vitro and in vivo induced syner-
gistic cytotoxicity in MM and Waldenstrom’s 
macroglobulinemia.23,24 Marizomib is current-
ly being evaluated in phase I clinical trials for 
the treatment of both solid and hematologic 
tumors.
Proteasome activity is traditionally mea-
sured using fluorogenic substrates for the 
different catalytic activities.25 The use of re-
cently developed chemical proteasome activ-
ity reporters provides an alternative method 
for assaying proteasome activity in a wide 
range of tissues.26-28 In this study, we used a 
fluorescent proteasome activity reporter27 
to compare the inhibitory profiles of mari-
zomib and bortezomib in rat blood samples, 
and established that this probe can be used 
to accurately profile both packed whole blood 
(PWB) and peripheral blood mononuclear cell 
(PBMC) samples. In addition, we developed 
a protocol that enables the use of this fluo-
rescent probe to profile blood samples from 
patients that are treated with proteasome 
inhibitors. The data presented here give for 
the first time insight into patient response to 
and recovery from marizomib treatment and 
show that both the initial proteasome activ-
ity in cells and the ability of cells to change 
the composition of newly synthesized protea-
somes may mediate sensitivity to this novel 
class of drugs. In addition, we show that im-
munoproteasome is not expressed in PWB, 
which contains >98% red blood cells. As red 
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Figure 1 | Structures of bortezomib, marizomib, and proteasome activity probe 1.
blood cells have a relatively high, micromo-
lar intracellular proteasome concentration,25 
they are thought to sequester intravenously 
administered proteasome inhibitors in vivo.29 
Consequently, proteasome inhibitors likely 
saturate proteasomes in red blood cells be-
fore peripheral sites can be reached. Specific 
immunoproteasome inhibitors, however, may 
saturate blood proteasome at relatively low 
concentrations, which may result in higher 
inhibitor concentrations in tumor cells. This 
suggests that immunoproteasome inhibitors 
may in future provide a good alternative for 
tumors that have high intrinsic immunopro-
teasome activity.
reSUlTS
Profiling marizomib and bortezomib in rat 
blood samples ex vivo
To profile the effects of proteasome inhibi-
tors on blood proteasome in both rats and 
patients ex vivo, fluorescent proteasome ac-
tivity reporter 1 (Me4BodipyFL-Ahx3Leu3VS, 
described in chapter 2.1) was used.27 Probe 
1 consists of a proteasome-targeting motif, 
a vinyl sulfone reactive group that covalently 
reacts with the N-terminal threonine of all ac-
tive subunits and a fluorescent tag (Figure 1). 
This tag allows the use of an SDS-PAGE based 
assay to visualize proteasome (subunit) label-
ing by scanning the gel for fluorescence emis-
sion. Prior inhibition of proteasome subunits 
prevents probe binding, which results in the 
disappearance of fluorescent signal. There-
fore, the measured fluorescence intensity 
directly correlates to the activity of a labeled 
β-subunit. To study whether proteasome in-
hibition could be reliably measured in blood 
samples using probe 1, the inhibition and 
recovery patterns of bortezomib and mari-
zomib were evaluated in rat blood samples. 
Rats (n=15/group) were treated with vehicle, 
0.15 mg/kg bortezomib or 0.05 or 0.10 mg/kg 
marizomib (which will be referred to as mari-
zomib low and marizomib high treatment, re-
spectively). Blood samples were taken from 3 
rats per dosing group per time point (1.5 h, 24 
h, 48 h 72 h or 168 h after injection), packed 
whole blood (PWB) or PBMC lysates were 
obtained, and lysates were incubated with 
probe 1. Proteins were then separated on 
SDS-PAGE, and the resulting gel was scanned 
for fluorescence emission. Figure 2A shows 
representative gel images of labeled PWB and 
PBMC samples. 
Red blood cells (RBCs), which do not express 
immunoproteasome, form the majority of 
H
N
O
N
H
O
B
N
N
OH
OH
H OHH
O
H
N O
O
H
Cl
Bortezomib Marizomib
N
N
BF
F
O
OH
N
Proteasome activity probe 1
N
H
H
N
O
N
H
O
S
O O
3
94
PWB (>99%), and as a result mainly constitu-
tive proteasome subunits were labeled in PWB 
samples (Figure 2A). In PBMCs, which consist 
mainly of white blood cells, both the consti-
tutive β1, β2, and β5 subunits and the im-
munoproteasomal β2i and β1i subunits were 
clearly labeled (Figure 2A). In both PBMC and 
PWB samples, no substantial differences were 
found between untreated and vehicle treated 
mice. The contribution of each subunit to to-
tal activity was constant, indicating that ve-
hicle treatment did not influence proteasome 
activity (Supplementary Figure 1). Total pro-
teasome activity differed somewhat between 
individual mice within treatment groups (data 
not shown). Upon treatment with marizomib 
or bortezomib, both total proteasome activ-
ity (Figure 2A; lanes 7-15) and the relative 
subunit labeling (Supplementary Figure 1) 
changed, indicating inhibition. 
marizomib and bortezomib have differential 
effects on PBmCs but not on PwB
To evaluate the effects of marizomib and bort-
ezomib treatment on total proteasome activi-
ty, total fluorescence intensity in each sample 
was quantified, averaged per group, and plot-
ted as percentage of untreated samples ± SEM 
(Figure 2B). In PBMCs a single dose of 0.05 
mg/kg (low) or 0.10 mg/kg (high) marizomib 
reduced total proteasome activity to 20-30% 
residual activity, whereas a single dose of 
bortezomib (0.15 mg/kg) reduced total pro-
teasome activity to 60%. Differences between 
marizomib high and bortezomib treatment 
remained significant up to 72 h after dosing, 
while marizomib low and bortezomib treat-
ment had similar effects at time points 24 h 
to 168 h after dosing. Total proteasome ac-
tivity recovered fully within one week for all 
treatment schedules. In PWB, all treatment 
regimes inhibited total proteasome activity 
almost completely. Recovery was hardly evi-
dent at time points up to 48 h, and one week 
after dosing (168 h) only 50% of proteasome 
activity had recovered. Rats treated with a 
high dose of marizomib showed somewhat 
less recovery of total proteasome activity at 
72 h and 168 h post dosing compared to bort-
ezomib treated rats, but differences were not 
significant. 
To study how individual subunits contributed 
to total proteasome activity, the fluorescence 
intensity of individual subunits was quan-
tified, averaged per group, and plotted as 
the percentage of untreated samples ± SEM 
(Figure 2C). Since the β2 and β2i subunits re-
sponded similarly to all treatments (data not 
shown), β2 activity was defined as the sum of 
both bands. In PBMCs, the combined β5(i)/
β1 activity was inhibited to a higher extent 
by marizomib high dose treatment compared 
to bortezomib treatment, while the β1i sub-
unit was inhibited to a similar extent by both 
treatment regimes. The β2 subunits were in-
hibited by marizomib, but not by bortezomib. 
These data suggest that the more potent and 
sustained inhibition of proteasome activity in 
marizomib high dose-treated rats compared 
to bortezomib treated rats is mediated by 
marizomib’s ability to inhibit all proteasome 
activities. When bortezomib treatment was 
compared to marizomib low dose treatment 
schedules, inhibition of the β5(i)/β1 subunits 
was comparable, but differences were ob-
served in inhibition of both the β2 and β1i 
subunits. Inhibition of β2 activities was found 
only in marizomib low treated rats, but not 
in bortezomib treated rats, as also previously 
reported.9 Inhibition of β1i activity was much 
more pronounced in bortezomib treated rats 
which recovered slowly, resulting in <50% re-
covery one week post-dosing. Together, these 
data suggest that the long-term effect of bort-
ezomib and marizomib treatment on total 
proteasome activity was mediated via the in-
hibition of different sets of subunits. In PWB, 
differences between treatment regimes were 
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Figure 2 | marizomib and bortezomib have different inhibition profiles in rat PBmC and PwB sam-
ples. Rats (n=15/group; 3/time point per dosing group) received a single injection of 0.05 or 0.10 mg/
kg marizomib, 0.15 mg/kg bortezomib or vehicle. PWB and PBMC samples were obtained at 1.5 h, 24 
h, 48 h, 72 h or 168 h post dosing. Samples were lysed, followed by proteasome labeling with probe 
1 and SDS-PAGE analysis. A) In-gel fluorescence measurements showing proteasome activity profiles 
in rat PWB and PBMC samples 1.5 h after treatment with marizomib or bortezomib. B) Quantification 
of total proteasome activity in rat PWB and PBMC samples after marizomib or bortezomib treatment 
for the indicated periods. Total proteasome activity was defined as the sum of all individual activities 
and was plotted as a percentage of activity in untreated rats. Error bars represent SEM. Data were 
analyzed by GraphPad Prism software. • p<0.05; •• p<0.01. C) Quantification of proteasome subunit 
activity in rat PWB and PBMC samples after marizomib or bortezomib treatment for the indicated time 
periods. Subunit activities were plotted as percentage of subunit activity in untreated rats. Error bars 
represent SEM. 
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largely absent compared to PBMC samples. 
Both marizomib and bortezomib inhibited all 
subunits, and recovery was also largely com-
parable between treatment schedules. The 
main difference was found at the level of the 
β1i activity, which recovered from marizomib 
high or marizomib low treatment at a similar 
rate as the β2 and β5(i)/β1 activity, but did 
not recover from bortezomib treatment. Since 
β1i activity was hardly present in PWB sam-
ples (see above), the effect of this difference 
on total proteasome activity was negligible. 
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Remarkably, both bortezomib and marizomib 
treatment resulted in the disappearance of 
β2 labeling by probe 1, whereas bortezomib 
has been shown to somewhat enhance and 
not inhibit the activity of β2 subunits in PWB 
using fluorogenic substrates.9 A similar dis-
appearance of β2 labeling after bortezomib 
treatment has been observed using probe 1 
in cell lines in vitro and ex vivo in mouse tis-
sues (see Chapter 2.1). 
Probe 1 can profile proteasome activity in 
marizomib treated patients ex vivo
Having established that probe 1 can be used to 
assay the effects of proteasome inhibitors in 
both PBMC and PWB samples ex vivo, we next 
used probe 1 to evaluate the effect of mari-
zomib treatment on patients suffering from 
different types of cancer (Table 1). Marizomib 
was administered intravenously at Day 1 (D1), 
Day 8 and Day 15 (D15) during 28-day treat-
ment cycles (indicated with C1-C2). In the first 
treatment cycle, patients were dosed with 
concentrations of marizomib ranging from 
0.55 mg/m2 to 0.9 mg/m2. Due to the occur-
rence of dose-limiting toxicities, marizomib 
concentrations were adjusted to 0.7 mg/m2 
or 0.8 mg/m2 in subsequent cycles (Table 1). 
Blood was taken pre- and post-marizomib 
treatment; PBMCs and PWB samples were 
obtained and prepared in cell pellets. To study 
proteasome inhibition in PWB samples, PWB 
samples were lysed and incubated with probe 
1. Labeled subunits were separated by SDS-
PAGE, and the resulting gels were scanned for 
fluorescence emission. An example of such a 
gel is shown in Figure 3A. Analogous to results 
found in rat blood samples, only constitutive 
proteasome subunits were labeled in PWB. 
Marizomib treatment decreased the activ-
ity of both β2 and β5/β1 subunits in PWB in 
all patients. Although in most patients some 
proteasome activity recovery was observed 
before the next dose of marizomib was given, 
proteasome activity never recovered to base-
line levels in any of the patients (Figure 3A, 
pre treatment samples). These data are in ac-
cord with a previous report which suggested 
that PWB proteasome activity could be titrat-
ed with repeated dosing.29
To validate that probe 1 could be used to ac-
curately study the effects of proteasome in-
hibitors on patient blood samples, we com-
pared probe 1 with the use of fluorogenic 
substrates for the different activities in PWB 
samples obtained at C1D1 (Cycle 1 Day 1) and 
C1D15 (Cycle 1 Day 15) post treatment (Fig-
ure 3B). For both assays, the residual activity 
of different subunits was plotted as a percent-
age of the baseline activity before the start of 
treatment. As the β1 and β5 subunits labeled 
by probe 1 were not completely resolved on 
gel, we averaged the β1 and β5 activity levels 
obtained using fluorogenic substrates to be 
able to compare the two methods. Results 
obtained with probe 1 were very similar to re-
sults found using fluorogenic substrates (Fig-
ure 3B). Both methods revealed a higher inhi-
bition of the β1/β5 activity compared to the 
β2 activity. In addition, both methods showed 
table 1 | Treatment regimes of patients #1 to #5. 
Patient Malignancy Cycle 1 Subsequent cycles
#1 Prostate carcinoma 0.9 mg/m2 0.7 mg/m2
#2 Anorectal squamous carcinoma 0.9 mg/m2 0.7 mg/m2
#3 Hodgkin’s lymphoma 0.8 mg/m2 0.8 mg/m2
#4 Colon carcinoma 0.8 mg/m2 0.7 mg/m2
#5 Non-Hodgkin’s lymphoma 0.8 mg/m2 0.7 mg/m2
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Figure 3 | Ex vivo profiling of proteasome activity in patient PwB samples. Patients with different 
malignancies (Table 1) were treated with varying doses of marizomib. Marizomib was administered at 
day 1, day 8, and day 15 in 28-day treatment cycles. Blood was taken pre and post dosing at days 1 and 
15; PWB samples were prepared, lysed, and incubated with probe 1. Labeled proteasome subunits 
were separated using SDS-PAGE, and the resulting gels were scanned for fluorescence emission. A) 
In-gel fluorescence measurements showing proteasome activity profiles in PWB samples of patient 
#1 that were obtained during marizomib treatment. B) Comparison of residual proteasome activities 
in PWB samples from patients #1 to #5 obtained at Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15) 
post treatment. Residual activities compared to baseline values were calculated using probe 1 or fluo-
rogenic substrates. ND: not determined. C) Quantification of the relative contribution of the β2 and 
β5/β1 subunits to total baseline proteasome activity in patient PWB samples prior to marizomib treat-
ment. D) Quantification of baseline total proteasome activity levels in PWB samples of patients #1 
to #5 before the start of marizomib treatment. Baseline activities were normalized to patient #1. e) 
Quantification of residual total proteasome activity levels at Cycle 2 Day 15 (C2D15) post treatment 
compared to baseline proteasome activity levels in PWB samples obtained from patients #1 to #5. F) 
Quantification of the absolute amount of inhibited proteasome activity at C2D15 post treatment com-
pared to baseline values in PWB samples of patients #1 to #5. Samples were normalized to baseline 
proteasome activity in patient #1. 
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that repeated dosing resulted a higher extent 
of inhibition (compare C1D15 to C1D1 in Fig-
ure 3B). Both methods also revealed that the 
inhibition in PWB was dose-dependent, es-
pecially at C1D15 post treatment. Patients #1 
and #2 were treated with 0.9 mg/m2 in the 
first treatment cycle, while patients #3, #4 
and #5 received 0.8 mg/m2 during the first 
treatment cycle. In accord, patients #3 and #4 
showed higher residual β2 and β5 activities at 
C1D15 post treatment compared to patients 
#1 and #2 (for patient #5 no PWB sample was 
available at C1D15 post treatment). Together, 
these results indicate that probe 1 can be reli-
ably used to assay proteasome activity in pa-
tient blood samples ex vivo. 
Proteasome inhibition by marizomib differs 
between individual patients 
We quantified proteasome inhibition as pro-
filed using probe 1 in PWB samples of patients 
#1 to #5 (obtained during C1 and C2). In PWB 
baseline samples of different patients that 
were obtained before the start of marizomib 
treatment, identical β2/β5,1 ratios (Figure 
3C) with different total proteasome activity 
levels (Figure 3D) were observed. To compare 
inhibition profiles between patients, protea-
some activity at C2D15 (Cycle 2 Day 15) post 
dosing was compared to baseline activity for 
patients #1 to #5. In accord with marizomib’s 
inhibition profile, inhibition of the β5 and β1 
subunits was approximately 2 fold higher than 
inhibition of the β2 subunit in all patients 
(Supplementary Figure 2A). Total proteasome 
inhibition, however, differed substantially 
between patients, with residual proteasome 
activities ranging from 13% to 50% (Figure 
3E). The residual proteasome activity corre-
lated well to the initial proteasome activity 
in all patients. Patients with high initial pro-
teasome activity also displayed high residual 
activity, while patients with low initial activity 
also showed low residual proteasome activ-
ity (compare Figures 3D and 3E). This sug-
gested that all patients lost a similar absolute 
amount of proteasome activity as a result of 
marizomib administration. To investigate this, 
we subtracted the total fluorescence intensity 
at C2D15 post dosing from the baseline fluo-
rescence intensity in each patient to calculate 
the loss of fluorescence intensity over the 
course of two treatment cycles (Figure 3F). As 
the total fluorescence intensity directly cor-
relates to total proteasome activity in these 
samples, the loss of fluorescence directly 
correlates to the loss of proteasome activ-
ity. As can be seen from Figure 3F, a similar 
amount of proteasome activity was inhibited 
in all patients in PWB at the end of the sec-
ond treatment cycle. Therefore, the residual 
proteasome activity in PWB after marizomib 
treatment is mainly determined by the initial 
amount of proteasome activity. 
Initial proteasome activity determines PBmC 
response to marizomib
Next we investigated proteasome inhibition 
by marizomib in patient PBMCs. To this end, 
PBMCs were lysed and incubated with probe 
1. Labeled subunits were separated by SDS-
PAGE and the resulting gels were scanned for 
fluorescence emission. An example of such a 
gel is shown in Figure 4A. Analogous to results 
found in rat blood samples, both constitutive 
and immunoproteasome subunits were la-
beled in PBMCs (Figure 4A). In contrast to re-
sults found in PWB, the relative contribution 
of subunits to total proteasome activity dif-
fered between patients (Figure 4B). Diverse 
labeling patterns were observed, ranging 
from almost equal contribution of all subunits 
to total activity in patient #3, to subunits be-
ing responsible for over 50% (β2i and β1i sub-
units in patients #2 and #5, respectively) or 
less than 5% (β2 in patients #1 and #5) of total 
proteasome activity. In PBMCs baseline sam-
ples of different patients, total proteasome 
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activity levels were variable (Figure 4C) and 
resembled initial proteasome activity levels 
in the corresponding PWB samples. In both 
types of samples, high initial proteasome ac-
tivity was found in patients #3 and #4, patient 
#1 had intermediate activity, while the lowest 
activity was found in patients #2 and #5 (Fig-
ures 3D and 4C). Administration of marizomib 
decreased the activity of all subunits in all 
patients. In contrast to results found in PWB, 
total proteasome activity was largely restored 
to baseline levels before a new dose of mari-
zomib was administered (Figure 4A). 
We quantified proteasome inhibition and 
recovery in PBMC samples of patients #1 to 
#5 (obtained during C1 and C2). Since pro-
teasome activity recovers between doses in 
PBMCs, the residual proteasome activity at 
C2D15 post treatment compared to baseline 
levels depended on the extent of recovery. 
However, each dose resulted in a similar re-
duction in proteasome activity in post treat-
ment samples compared to the preceding pre 
treatment sample, independent of the extent 
of recovery in this pre treatment sample. 
Therefore, we first normalized the inhibition 
in each post treatment sample to the corre-
sponding pre treatment sample, and plotted 
the average residual activity ± SEM. In PBMCs, 
the average residual proteasome activity dif-
fered between patients and ranged from 33% 
to 52% (Figure 4D). In addition, the average re-
sidual proteasome activity correlated well to 
the initial proteasome activity in all patients, 
as observed in PWB. In accord with results 
found in PWB, inhibition of the β2,2i subunits 
in PBMCs was two fold lower compared to in-
hibition of the β5,5i and β1,1i subunits, with 
the exception of patient #5 in which all sub-
units were equally inhibited (Supplementary 
Figure 2B). Next, total fluorescence intensity 
in each post treatment sample was subtract-
ed from the total fluorescence intensity in 
each corresponding pre treatment sample. 
On average, a similar absolute amount of 
proteasome activity was inhibited in PBMCs 
as a result of each marizomib administration 
in all patients (Figure 4E). This suggests that 
the initial amount of proteasome activity in 
PBMCs is one of the factors determining the 
residual amount of proteasome activity after 
marizomib treatment.
Patient PmBCs change their proteasome 
composition in response to marizomib
Next, we studied the influence of recovery on 
proteasome inhibition in patient PBMCs sam-
ples. To take recovery effects into account, we 
calculated the residual activity at C2D15 post 
treatment compared to baseline activity be-
fore the start of treatment (Figure 4F, shaded 
bars). We compared these values to the av-
erage residual activity (Figure 4F, filled bars) 
in which recovery effects were not taken into 
account (as plotted in Figure 4D). In patient 
#1, activity recovered almost completely be-
tween doses and therefore little difference 
was observed between the average residual 
activity and the residual activity at C2D15 
post treatment. In patient #4, activity recov-
ered >100%, resulting in an increase in pro-
teasome levels over time. As a consequence, 
the residual activity at C2D15 post treatment 
was higher compared to the average residual 
activity. In patients #2, #3 and #5, protea-
some activity did not completely recover to 
baseline levels between doses, and therefore 
the residual proteasome activity at C2D15 
post treatment was lower compared to the 
average residual activity. Together, these data 
suggest that the extent of activity recovery 
between administrations influences the ef-
ficacy of marizomib treatment over multiple 
treatment cycles. 
To study recovery in individual patients in 
more detail, we quantified the relative contri-
bution of individual subunits to total protea-
some activity in PBMC samples from patients 
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Figure 4 | Ex vivo profiling of proteasome activity in patient PBmC samples. Patients with differ-
ent malignancies (Table 1) were treated with varying doses of marizomib. Marizomib was adminis-
tered at day 1, day 8 and day 15 in 28-day treatment cycles. Blood was taken pre and post dosing at 
days 1 and 15 and PBMC samples were prepared, lysed and incubated with probe 1. Labeled pro-
teasome subunits were separated using SDS-PAGE and the resulting gels were scanned for fluores-
cence emission. A) In-gel fluorescence measurements showing proteasome activity profiles in PBMC 
samples of patient #1 that were obtained during marizomib treatment. B) Quantification of the rela-
tive contribution of the β2, β2i, β1/5/5i and β1i subunits to total baseline proteasome activity in pa-
tient PBMC samples prior to marizomib treatment. C) Quantification of baseline total proteasome 
activity levels in PBMC samples of patients #1 to #5 before the start of marizomib treatment. Base-
line activities were normalized to patient #1. D) Quantification of residual total proteasome activ-
ity levels post marizomib treatment in PBMC samples obtained from patients #1 to #5. Proteasome 
activity in each post treatment sample was normalized to the preceding pre treatment sample and
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#1 to #5 in which activity had recovered (pre 
treatment samples obtained during cycles 1 
and 2). Both the contribution of the β2 activ-
ity to total proteasome activity (defined as 
the sum of the β2 and β2i activities, which 
are least targeted by marizomib; Figure 4G), 
and the contribution of constitutive activities 
to total activity (Figure 4H) were calculated. 
In patients #1 and #4, in which proteasome 
activity fully recovered between marizomib 
administrations, the relative β2 activity in-
creased steadily over time in response to 
marizomib treatment, independent of the 
initial active subunit composition. In patients 
#2 and #3 in which proteasome activity did 
not fully recover between doses, the rela-
tive β2 activity increased less in response to 
marizomib treatment, while in patient #5 in 
which least proteasome activity recovery was 
observed the relative β2 activity somewhat 
decreased over time. In addition, the relative 
constitutive activity increased in all patients 
with the exception of patient #3. A similar 
shift from immunoproteasome to constitutive 
proteasome was observed in vitro in cells with 
acquired resistance to bortezomib. In these 
cells, this shift was accompanied by the up-
regulation of constitutive activities that could 
no longer be inhibited by bortezomib and of 
apoptosis resistance.30 Together, these data 
suggest that the rapid modification of pro-
teasome composition and thereby cleavage 
specificity allow PBMCs to adapt and survive 
marizomib treatment. The ability to upregu-
late β2 activities, which are less sensitive to 
inhibition by marizomib, seems to correlate 
to the ability of PBMCs to fully recover pro-
teasome activity between administrations. 
Whether upregulation of β2 activities results 
in a decreased sensitivity and thereby less cell 
death in response to marizomib treatment re-
mains to be determined.  These data indicate 
that PBMCs modify their active subunit com-
position in response to marizomib treatment 
and that this may be a factor contributing to 
marizomib response.
DISCUSSIOn
Marizomib is a second-generation protea-
some inhibitor isolated from the marine ac-
tinomycete Salinispora tropica that binds 
all active proteasome subunits irreversibly.9 
Marizomib has been evaluated in a wide 
range of preclinical models and has demon-
strated clinical activity against both hemato-
logic and solid tumors.21 Clinical trials with 
marizomib are currently ongoing in both he-
matologic and solid tumors, enabling for the 
first time a thorough evaluation of patient re-
sponse to marizomib treatment. Proteasome 
probe 1 is a recently developed reagent that 
enables profiling of all proteasome activities 
in a single measurement in a wide range of 
averaged over all administrations. Error bars represent SEM. e) Quantification of the absolute amount 
of proteasome activity that disappeared on average in PBMC samples of patients #1 to #5 after each 
administration of marizomib. Samples were normalized to baseline proteasome activity in patient #1. 
F) Quantification of the average residual proteasome activity after each administration in PBMCs ob-
tained from patients #1 to #5 (solid bars). Quantification of the residual proteasome activity at C2D15 
(Cycle 2 Day 15) post treatment compared to baseline proteasome activity levels in PBMCs obtained 
from patients #1 to #5 (shaded bars). g) Quantification of the relative contribution of the β2 + β2i 
activities to total proteasome activity in patients #1 to #5 during treatment cycles 1 and 2 in PBMC 
samples in which activity has recovered (pre treatment samples). H) Quantification of the relative con-
tribution of constitutive proteasome to total proteasome activity in patients #1 to #5 during treatment 
cycles 1 and 2 in PBMC samples in which activity has recovered (pre treatment samples). 
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tissue types, both in vitro and ex vivo.27 The 
present study shows that probe 1 can be used 
to profile the effects of proteasome inhibitors 
on blood samples, derived both from animals 
and, importantly, from patients that are treat-
ed with this type of drug. Inhibition profiles 
of marizomib and bortezomib in rat PBMCs 
were in accord with previous reports9,26 and 
revealed that marizomib inhibited all subunits 
with the highest affinity for β5 subunits, while 
bortezomib inhibited the β5 and β1 but not 
the β2 subunits. Parallel measurement of the 
proteasomal activities using both probe 1 and 
fluorogenic substrates in patient PWB sam-
ples gave similar results, further validating 
the use of probe 1 for assaying proteasome 
activity in blood samples. It has been shown 
that measuring only the chymotryptic activity 
may not accurately reflect the total protea-
some activity, and that both the caspase-like 
and tryptic activities may considerably con-
tribute to overall proteasome activity.19 The 
use of chemical probes to assay proteasome 
activity has the advantage that the activity of 
all constitutive and immunoproteasome sub-
units can be profiled in a single measurement. 
In addition, probe 1 has equal affinity for all 
proteasome active sites and can therefore be 
used to establish the relative contribution of 
each subunit to total proteasome activity and 
to reliably measure total proteasome activity. 
Recovery patterns in PWB, which consists 
predominantly of erythrocytes (>99%) that 
are devoid of a nucleus, differed substantially 
from results found in PBMCs. Whereas in rat 
PBMCs total proteasome activity recovered 
within 72 h to 168 h post dosing, proteasome 
activity in PWB samples was only recovered by 
20 to 50% after 168 h. In patients, PBMC pro-
teasome activity recovered almost complete-
ly between doses, while recovery was near 
absent in PWB. These differences in recovery 
can be explained by the inability of erythro-
cytes to synthesize proteins, which makes 
proteasome activity recovery completely de-
pendent on the slow turnover of erythrocytes 
(t1/2 = 15-17 weeks).25 It has been suggested 
previously that blood proteasome inhibition 
does not correlate with tumor proteasome 
inhibition or inhibitor efficacy.11,29 The data 
presented here are a further indication that 
erythrocytes respond to and recover from 
proteasome inhibitors uniquely and caution 
against the use of PWB as a model system to 
monitor the effects of proteasome inhibitors 
in animals or patients, as is routinely done. 
Probe 1 enabled a detailed study of patient 
response to marizomib treatment. Although 
proteasome activity was monitored in a small 
group of patients, factors that may mediate 
sensitivity to proteasome inhibition could be 
derived from these data. The data presented 
here indicate for the first time that marizomib 
treatment results in inhibition of similar abso-
lute amounts of proteasome activity in both 
PWB and PBMCs. This suggests that both the 
relative and absolute residual proteasome ac-
tivities after marizomib treatment are deter-
mined by the initial level of total proteasome 
activity. Therefore, total proteasome activity 
is likely one of the factors determining the 
sensitivity of cells to marizomib and possibly 
other proteasome inhibitors, as has been sug-
gested earlier.8,31 In accord with this, cells with 
acquired bortezomib resistance have shown 
increased expression and activity of the pro-
teasome in vitro.30,32,33 Initial proteasome ac-
tivity in PWB seemed to correlate to initial ac-
tivity in PBMCs, suggesting that proteasome 
activity levels may be regulated similarly in 
different cell types. Therefore, the initial pro-
teasome activity in blood may be indicative of 
the initial activity in hematologic malignan-
cies. Measuring the initial proteasome activ-
ity in PWB compared to a benchmark sample 
may thus be an easy approach to determine 
whether a patient is likely to respond to pro-
teasome inhibitor therapy and could be a first 
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step towards personalized proteasome inhibi-
tor therapy. 
The ability of cells to shift their active subunit 
composition in response to proteasome inhib-
itor therapy may be another factor that medi-
ates sensitivity to this class of compounds. Pa-
tient PBMCs responded to marizomib therapy 
by shifting their proteasome activity profile 
towards a higher degree of β2 activity and a 
higher degree of activity of constitutive sub-
units, in line with observations made in vit-
ro.30 These shifts probably enable PBMCs to 
better survive proteasome inhibition. There-
fore, the (partial) absence of these shifts in 
tumor cells likely renders cells more vulner-
able to proteasome inhibition. It is tempting 
to speculate that certain tumor types lack 
the ability to shift their active subunit com-
position in response to proteasome inhibitor 
therapy, suggesting that tumor types that are 
especially sensitive to proteasome inhibitors 
could be identified. Alternatively, it would be 
interesting to define the cellular mechanisms 
that mediate these shifts, as pharmacological 
interference with such pathways may over-
come resistance to and enhance the thera-
peutic potential of proteasome inhibitors.
Finally, differences in initial subunit activ-
ity distribution are likely to influence the re-
sponse of tumors to different proteasome in-
hibitors, as was suggested previously by Krauss 
et al.32 Both red and white blood cells, which 
have a relatively high, micromolar intracellu-
lar proteasome concentration,25 are thought 
to sequester proteasome inhibitors in vivo,29 
as blood cells are the first cell type to come 
in contact with intravenously administered 
proteasome inhibitors. Consequently, protea-
some inhibitors likely saturate proteasomes 
in red blood cells, which constitute 99% of 
all blood cells, before peripheral sites can be 
reached,29 which may limit inhibitor concen-
trations in tumor cells. PR-957 is a novel β5i-
specific proteasome inhibitor that showed ac-
tivity against immunoproteasomes in mice.34 
As red blood cells do not express immunopro-
teasome, specific immunoproteasome inhibi-
tors may saturate blood proteasome at rela-
tively low concentrations, resulting in higher 
inhibitor concentrations in tumor cells. In 
addition, immunoproteasome inhibitors are 
suggested to cause fewer side effects in tis-
sues that express only low levels of immuno-
proteasome subunits.8 Therefore, PR-957 or 
other immunoproteasome inhibitors may in 
future provide a good alternative for tumors 
that originate from immune tissues that have 
intrinsic immunoproteasome activity, such as 
spleen, lymph nodes and thymus.27 The data 
presented here also suggest that the relative 
contribution of subunits to total proteasome 
activity may differ between patients and simi-
lar observations were made in primary hu-
man leukemia cells.32 In addition, analysis of 
rat PBMCs suggest that proteasome inhibitor 
profiles may differ substantially, especially at 
low concentrations. Whereas the β1i subunit 
was especially susceptible to bortezomib inhi-
bition, the β2 subunits could only be inhibited 
by marizomib. Probing tumor cells with probe 
1 before treatment will establish which sub-
units are most active. This will enable match-
ing of tumor proteasome profile to a comple-
mentary inhibitor or multiple inhibitors to 
personalize proteasome inhibitor therapy and 
maximize therapy response. 
mATerIAlS AnD meTHODS
Reagents
All solvents were purchased from Biosolve (Valk-
enswaard, the Netherlands) at the highest grade 
available. All other chemicals were purchased 
from Sigma-Aldrich (Zwijndrecht, the Nether-
lands) at the highest available purity. Bortezomib 
(obtained commercially) and marizomib synthe-
sized at Nereus (San Diego, CA). Probe 1 was syn-
thesized as described in chapter 2.1. 
Ex vivo profiling rat blood samples using fluores-
104
cent probe 1
Male Sprague-Dawley rats (280-325 grams) were 
treated once intravenously with 40% Propylene 
glycol/50% citrate buffer/10% ethanol based ve-
hicle with or without marizomib (0.05 or 0.1 mg/
kg) or bortezomib (0.15 mg/kg in saline). Fifteen 
rats served as untreated controls. At 90 minutes, 
24, 48, 72, and 168 hours post dose, 3 rats per 
time point per dosing group were anesthetized 
and approximately 6-7 mL of whole blood was 
collected via the abdominal aorta into Na-Hepa-
rin vacutainer tubes. To obtain a PWB pellet, 2 mL 
of whole blood was centrifuged for 10 minutes 
at 800g; the blood pellet was then washed once 
with cold 1X PBS (supernatant was discarded) 
and frozen at -80 °C. PBMCs were isolated using 
Lympholyte®-Mammal (Cedarlane Laboratories, 
Ontario, Canada): 4 mL of whole blood was dilut-
ed 1:1 with 4 mL of PBS and the tube was inverted 
2-3 times to mix; 4 mL of the diluted blood was 
then layered onto 3 mL of Lympholyte®-Mammal 
in a 15 ml centrifuge tube and centrifuged at 
room temperature for 20 minutes at 800g. The 
PBMC layer at the interface was transferred to a 
new centrifuge tube, diluted 1:1 with PBS, and 
pelleted for 10 minutes at 800g. The supernatant 
was discarded; the PBMCs were washed once in 
PBS and frozen at -80 °C. 
PBMC and PWB pellets were thawed on ice. 50 
mL of ice-cold 5 mM EDTA pH8 lysis buffer was 
added to the PBMC pellets, and 2 mL lysis buf-
fer to the PWB pellets. Pellets were resuspended 
and lysed on ice for 1 h. Lysates were then cen-
trifuged for 10 min at 16,000 x g at 4 °C, and the 
supernatants were aliquoted and stored at -80°C. 
Protein concentration was determined using a 
Bradford assay (Biorad). Protein concentrations 
were adjusted to 2 mg/mL with HR-buffer (50 mM 
Tris-HCl pH 7.4, 250 mM sucrose, 5 mM MgCl2, 1 
mM dithiothreitol (DTT), 2 mM ATP), and lysates 
were incubated with 1 mM probe 1 for 1 hour at 
37 °C. Data were analyzed by using GraphPad 
Prism software (GraphPad, La Jolla, CA, USA).
Ex vivo profiling patient blood samples 
At indicated time points according the clinical 
protocol, 5 mL of blood was drawn in heparinized 
vacutainers. Blood samples were obtained pre 
dosing or within 2.5 h to 5 h post dosing for all pa-
tients. 1 mL of the heparinized whole blood was 
centrifuged at 2000g for 10 min at room temper-
ature (RT) and the PWB pellet was washed once 
in 5 times the pellet volume of ice-cold 1X DPBS 
(Dulbecco’s Phosphate Buffered Saline) with 
Ca+2/Mg+2. After centrifugation (2000g, 10 min 
RT) and discarding of supernatants, PWB pellets 
were frozen and stored at -70oC. The remaining 
4 mL of heparinized whole blood was diluted by 
adding an equal volume of Hanks Balanced Salt 
Solution and layered over 6 mL of Ficoll-Paque™ 
PLUS. After centrifugation for 40 min at 400g at 
room temperature (RT), PBMCs located at the 
interphase were collected, transferred to a new 
tube, and washed with at least three volumes 
of Hanks Balanced Salt Solution. To lyse any co-
isolated RBCs, PBMC pellets were resuspended in 
1x BD PharmLyseTM buffer and incubated at RT for 
5 minutes. 9 mL of Hanks Balanced Salt Solution 
was then added and cells were centrifuged for 
10 min at 1000g (RT). PBMCs were resuspended 
in Hanks Balanced Salt Solution, an aliquot was 
taken for a viability cell count by a Flow based 
7-Amino-actinomycin D (7-AAD) staining proce-
dure and the remaining PBMC solution was cen-
trifuged for 10min at 1000g (RT). Supernatant 
was discarded, and PBMC cell pellets were flash 
frozen and stored at -70 °C. 
For ex vivo profiling of proteasome activities us-
ing probe 1, cell pellets were lysed in HR lysis buf-
fer (50 mM Tris pH 7.4, 1 mM dithiothreitol (DTT), 
5 mM MgCl2, 2 mM ATP and 250 mM sucrose) by 
sonifcation using the Bioruptor sonicator (Diag-
enode, Liège, Belgium). Lysates were centrifuged 
at 16,000g to remove cell debris and protein con-
centration was determined using the Bradford 
assay (Biorad). Protein concentrations were ad-
justed to 1 mg/mL (PBMC) or 5 mg/mL (PWB), and 
lysates were incubated with 1 mM probe 1 for 1 
h at 37 °C. To measure proteasome activities ex 
vivo using fluorogenic substrates, cells were ly-
sed in ice-cold 5 mM EDTA pH8 lysis buffer and 
protein concentrations were determined using a 
BCA (bicinchoninic acid) assay. The 20S protea-
some activities in cell lysates were measured as 
described previously.25,35 In brief 20 mg of protein 
was used in a total volume of 200mL consisting 
of assay buffer (20 mM HEPES, 0.5 mM EDTA, pH 
8.0) with a final SDS concentration of 0.035% and 
20 mM of the peptide substrates Suc-LLVY-AMC 
(Chymotryptic activity), Z-ARR-AMC (Tryptic ac-
tivity) or Z-LLE-AMC (caspase-like activity) (Cal-
biochem). Fluorescence (l ex/em = 390/460 nm) 
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was measured every 5 min for 2 hr using a Fluo-
roskan Ascent 96-well microplate reader (Thermo 
Electron, Waltham, MA). 
In-gel fluorescence measurements
Incubated samples were denatured by boiling in 
LDS sample buffer (Invitrogen) containing 2.5% 
β-mercaptoethanol and polypeptides were re-
solved by 12% Bis-Tris gels using the NuPAGE sys-
tem from invitrogen. Wet gel slabs were imaged 
for 10s to 120s, with a resolution of 100 mm, us-
ing the ProXPRESS 2D Proteomic imaging system 
(Perkin Elmer) with appropriate filter settings (l 
ex/em = 480/530 nm). To verify protein loading, 
gels were stained with coomassie and probe sig-
nals were normalized accordingly. Images were 
analyzed using TotalLab analysis software (Non-
linear Dynamics, Newcastle upon Tyne, UK) to 
quantify the intensity of the bands detected. To 
compare baseline proteasome activities between 
patients, samples were rerun on a single gel.
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Supplementary figures
Supplementary Figure 1 | Proteasome activity profiles are identical in untreated and vehicle treated 
rat blood samples. A) Quantification of the relative contribution of the β2 and β5/1 subunits to total 
proteasome activity in rat PWB samples 1.5 h post treatment. B) Quantification of the relative contri-
bution of the β2, β2i and β5/5i/1/1i subunits to total proteasome activity in rat PBMC samples 1.5 h 
post treatment.  
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Supplementary Figure 2 | residual proteasome activities in marizomib treated patients. A) Quantifi-
cation of the residual activity of individual subunits after marizomib treatment in patient PWB samples 
normalized to baseline activity levels. B) Quantification of the residual activity of individual subunits 
after marizomib treatment in patient PBMC samples. Activities in post treatment samples were nor-
malized to the preceding pre treatment sample and averaged over all administrations. Error bars rep-
resent SEM. 
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Automated online sequential isotope labeling 
for protein quantitation applied to proteasome 
tissue-specific diversity
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Albert J. r. Hecka,* & Shabaz mohammeda,*
InTrODUCTIOn
Comparative quantitation of proteins be-
tween biological samples is an important en-
deavor in the identification of proteins that 
play specific roles in biological pathways or 
diseases. In the past, the most common way 
to analyze and compare whole proteomes 
was by two-dimensional polyacrylamide gel 
electrophoresis (PAGE), with quantitative in-
formation being gleaned from the intensity 
of the spots observed after staining the sepa-
rated proteins in the gel. Perhaps the most 
common quantitation methods in proteomics 
in use today are based on the application of 
differential stable isotopic labeling of protein 
samples (using for example 2H, 13C, 15N, or 18O), 
combined with detection by mass spectrom-
etry, allowing both identification and quanti-
tation of the sample components.1,2 There are 
two main distinguishable methods commonly 
used for stable isotopic labeling of samples. 
aBiomolecular Mass Spectrometry and Proteomics Group, Bijvoet Center for Biomolecular Research and Utrecht 
Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, the Netherlands. 
bDivision of Cellular Biochemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The 
Netherlands.
quantitation of protein abundance is a vital component in the proteomic analysis of bio-
logical systems, which can be achieved by differential stable isotopic labeling. To analyze 
tissue-derived samples, the isotopic labeling can be performed using chemical labeling of 
the peptides post-digestion. Standard chemical labeling procedures often require many 
manual sample handling steps, reducing the accuracy of measurements. Here, we describe 
a fully automated, online (in nanolC columns), labeling procedure, which allows protein 
quantitation using differential isotopic dimethyl labeling of peptide n termini and lysine 
residues. we show that the method allows reliable quantitation over a wide dynamic 
range and can be used to quantify differential protein abundances in lysates and, more 
targeted, differences in composition between purified protein complexes. we apply the 
method to determine the differences in composition between bovine liver and spleen 20 S 
core proteasome complexes. we find that although all catalytically active immunoprotea-
some subunits were up-regulated in spleen (compared with liver), only one of the normal 
catalytic subunits was down-regulated, suggesting that the tissue-specific immunoprotea-
some assembly is more diverse than previously assumed.
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The first is the incorporation of stable iso-
topes in proteins by supplying these isotopes 
to the growth media consumed and metabo-
lized by cells or smaller organisms, generally 
termed metabolic labeling. The isotope label 
is then either incorporated as the single car-
bon or nitrogen source3 or incorporated via 
specific auxotrophic amino acids that contain 
isotopes, called SILAC (stable-isotope labeled 
amino acids in cell culture).4 The second 
method involves isotope labeling of isolated 
proteins or peptides with chemically identical 
tags that are isotopomers. The latter method 
is particularly advantageous for human or ani-
mal tissue samples where metabolic based in-
corporation cannot easily be achieved.1 
Many approaches have been described for 
the chemical labeling of proteins and pep-
tides to allow quantitation.1 These include 
the labeling of free cysteines in proteins by 
ICAT (isotope-coded affinity tagging)5 and 
the labeling of free amines in the peptides 
obtained after protein digestion using N-
hydroxysuccinimide esters like those used in 
the iTRAQ (isobaric Tagging for Relative and 
Absolute Quantification) approach.6 One of 
the most efficient reactions for chemical la-
beling of peptides is the specific dimethyla-
tion of free amines (peptide N termini and 
Lysine residues) by reductive amination using 
formaldehyde and cyanoborohydride.7 In this 
reaction, which is performed in near neutral 
conditions (between pH 6 and pH 8.5), the 
primary amines react with formaldehyde to 
create a Schiff base, which is then reduced 
by the cyanoborohydride. The label causes a 
mass increase of 28 Da per primary amine for 
regular formaldehyde and a mass increase of 
32 Da when deuterated formaldehyde is used. 
The reaction is fast, does not create spurious 
side products, and does not adversely affect 
the identification of the peptides from the 
MS/MS spectra.
As all chemical labeling procedures are sensi-
tive to small deviations in the reaction condi-
tions and to human error in the handling of 
samples prior to and during labeling events, 
accuracy and reproducibility of quantitative 
experiments can benefit from automated la-
beling procedures. Here, we present a fully 
automated, online, and on-column sequen-
tial stable isotope labeling procedure based 
on the dimethylation of primary amines. We 
show that on-column double labeling, which 
we use in combination with high resolution 
MS/MS analysis,8,9 is as sensitive as offline 
labeling, whereas the overall on-column pro-
cedure is more efficient and open to automa-
tion. The method is validated using model 
samples of varying complexity and can be 
used both to analyze protein levels in whole 
lysates as well as in specific proteins or in pro-
tein complexes. Finally, we apply the method 
to determine quantitatively differences in 
composition between proteasomes purified 
from different tissues.
reSUlTS
Online sequential labeling
To test the feasibility of performing the dime-
thylation reaction on-column, we designed an 
online reaction protocol consisting of 5 main 
steps, all of which were performed on our 
regular nanoLC system, consisting of a six-port 
switching valve, a 100-mm i.d. trapping col-
umn, and a 50 mm i.d. analytical column (Fig-
ure 1A).10 During sample loading and online 
labeling (steps 1 to 4), the restrictor is closed 
and the flow speed is 5 mL/min. The first step 
is the loading of the first peptide sample onto 
the trapping column, which is then chemi-
cally labeled by flushing the trapping column 
with 40 ml of light labeling reagent (CH2O/
NaBH3CN) in the second step. After a short 
wash with 5% formic acid, the second peptide 
sample is loaded onto the trapping column 
in step three followed by chemical labeling 
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Figure 1  |  A) Schematic showing the LC-MS setup and the main steps involved in the sequential online 
stable isotope labeling of two samples and subsequent LC-MS/MS analysis. Initially, the six-port valve 
closes the restrictor, directing the flow via the trapping column to the waste. In step 1, the first peptide 
sample (pink) is loaded onto the trapping column. The peptides now retained by the trapping column 
are chemically labeled in step 2 (purple) by flushing the trapping column with labeling reagent. Fol-
lowing a short wash, the second peptide mixture (orange) is loaded on the trapping column in step 3. 
During step 4, the trapping column is flushed with the second labeling reagent, containing the heavy 
isotope, labeling all peptides from the second sample (purple). After this step, the valve switches 
(opening the restrictor) and the flow speed increases, thus allowing flow over the analytical column to 
the mass spectrometer to perform a regular LC-MS analysis of all peptides. B) the estimated time in-
volved in all of the steps, both automated online (top) and manual offline (bottom) procedures, with
color coding taken from A. In green are the steps that are not required in the online method. Indicated 
in the middle is a time-scale providing an indication of the time involved. 
calculated from extracted ion chromatograms of the different isotopic
variants using MS-Quant software (11). Very low intensity peptides
(extracted ion chromatogram intensity � 3000) as well as peptides with
a poor extracted ion chromatogram or MS/MS spectrumwere excluded
after manual inspection. The program StatQuant2 was used to normal-
ize the quantitation and calculate standard deviations of the log 2 of th
ratios of all quantified peptides per protein. Where appropriate, quota-
tion experiments were repeated with the light and heavy labels
switched. All quantitation results shown are listed in tables S1–S4. All
identification results have been uploaded to PRIDE (under project title
“Sequential Labeling for Protein Quantitation”) and identificati n details
for the proteasome proteins are supplied in table S5.
RESULTS
Online Sequential Labeling—To test the feasibility of per-
forming the dimethylation reaction on-column, we designed
an online reaction protocol consisting of 5 main steps, all of
which were performed on our regular nanoLC system, con-
sisting of a six-port switching valve, a 100-�m i.d. trapping
column, and a 50 �m i.d. analytical column (Fig. 1A) (13).
During sample loading and online labeling (steps 1 to 4), the
restrictor is closed and the flo speed is 5 �l/min. The first
step is the loading of the first peptide sample onto the trap-
ping column, which is then chemically labeled by flushing the
trapping column with 40 �l of light labeling reag nt (CH2O/
NaBH3CN) in the second step. After a short wash with 5%
2 B. van Breukelen, H. van den Toorn, M. Drugan, and A. J. R. Heck,
in preparation.
FIG. 1. A, schematic showing the
LC-MS setup and the main steps in-
volved in the sequential online stable
isotope labeling of two samples and
subsequent LC-MS/MS analysis. Ini-
tially, the six-port valve closes the re-
strictor, directing the flow via the trap-
ping column to the waste. In step 1, the
first peptide sample (pink) is loaded onto
the trapping column. The peptides now
retained by the trapping column are
chemically labeled in step 2 (purple) by
flushing the trapping column with label-
ing reagent. Following a short wash, the
second peptide mixture (orange) is
loaded on the trapping column in step 3.
During step 4, the trapping column is
flushed with the second labeling rea-
gent, containing the heavy isotope, la-
beling all peptides from the second sam-
ple (purple). After this step, the valve
switches (opening the restrictor) and the
flow speed increases, thus allowing flow
over the analytical column to the mass
spectrometer to perform a regular
LC-MS analysis of all peptides. B, the
estimated time involved in all of the
steps, both automated online (top) and
manual offline (bottom) procedures, with
color coding taken from A. In green are
the steps that are not required in the
online method. Indicated in the middle is
a time-scale providing an indication of
the time involved.
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calculated from extracted ion chromatograms of the different isotopic
variants using MS-Quant software (11). Very low intensity peptides
(extracted ion chromatogram intensity � 3000) as well as peptides with
a poor extracted ion chromatogram or MS/MS spectrumwere excluded
after manual inspection. The program StatQuant2 was used to normal-
ize the quantitation and calculate standard deviations of the log 2 of the
ratios of all quantified peptides per protein. Where appropriate, quota-
tion experiments were repeated with the light and heavy labels
switched. All quantitation results shown are listed in tables S1–S4. All
identification results have been uploaded to PRIDE (under project title
“Sequential Labeling for Protein Quantitation”) and identification details
for the proteasome proteins are supplied in table S5.
RESULTS
Online Sequential Labeling—To test the feasibility of per-
forming the dimethylation reaction on-column, we designed
an online r action protocol co sisting of 5 main steps, all of
which were p rfor ed on ur regular nanoLC system, con-
sisting of a six-port switching valve, a 100-�m i.d. tra ping
column, and a 50 �m i. . analytical colum (Fig. 1A) (13).
During sample loading and onli e labeling (steps 1 to 4), the
restrictor is closed and the flow speed is 5 �l/min. The first
tep is the loading f the first peptide sample onto the trap-
ping column, whi h is then c mically labeled by flushing the
t apping col mn with 40 � of light abeling reagent (CH2O/
NaBH3CN) in the se ond step. After short wash with 5%
2 B. van Breukelen, H. van den Toorn, M. Drugan, and A. J. R. Heck,
in preparation.
FIG. 1. A, schematic showing the
LC-MS setup and the main steps in-
volved in the sequential online stable
isotope labeling of two samples and
subsequent LC-MS/MS analysis. Ini-
tially, the six-port valve closes the re-
strictor, directing the flow via the trap-
ping column to the waste. In step 1, the
first peptide sample (pink) is loaded onto
the trapping column. The peptides now
retained by the trapping column are
chemically labeled in step 2 (purple) by
flushing the trapping column with label-
ing reagent. Following a short wash, the
second peptide mixture (orange) is
loaded on the trapping column in step 3.
During step 4, the trapping column is
flushed with the second labeling rea-
gent, containing the heavy isotope, la-
beling all peptides from the second sam-
ple (purple). After this step, the valve
switches (opening the restrictor) and the
flow speed increases, thus allowing flow
over the analytical column to the mass
spectrometer to perform a regular
LC-MS analysis of all peptides. B, the
estimated time involved in all of the
steps, both automated online (top) and
manual offline (bottom) procedures, with
color coding taken from A. In green are
the steps that are not required in the
online method. Indicated in the middle is
a time-scale providing an indication of
the time involved.
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formic acid, the second peptide sample is loaded onto the
trapping column in step three followed by chemical labeling of
that sample in step four when the column is flushed with the
heavy labeling reagent (CD2O/NaBH3CN). Finally, again after
a short wash with 5% FA, in the fifth step the valve switches,
and the flow speed is increased to �400 �l/min. This results
in a pressure of�150 bar and an effective flow of�100 nl/min
for a regular LC-MS analytical gradient to analyze all labeled
peptides. The minimal time for the protocol is around 90 min,
compared with about 170 min for an offline labeling (including
desalting of the sample) and LC-MS analysis (Fig. 1B). As the
procedure is fully automated, no handling of the samples is
required after digestion and loading the samples in the au-
tosampler. In the offline method, several additional manual
steps are required, including drying and mixing the samples,
steps that are sensitive to sample loss and human error,
respectively.
When performing a sequential labeling online it is of vital
importance that the reaction goes to completion as otherwise
the second label will also partially label the first sample,
causing inaccurate quantitation. To test this, we first per-
formed the online double labeling as described above, but
although only injecting actual digested protein sample (bovine
serum albumin (BSA), 100 fmol) in either the first (light) or the
second (heavy) labeling step, though still performing the la-
beling in both steps. Fig. 2 shows the averaged mass spec-
trum of one of the trypic peptides of BSA, YICDNQDTISSK
(amino acids 286–297), which is detected as a doubly
charged peptide ion at an m/z value of 722.33 when cysteine
residues are carbamidomethylated. These spectra are aver-
aged over the complete retention time span of the unmethy-
lated and the fully methylated version of the peptide, to be
able to see any intermediates. In Fig. 2A, the unmodified
peptide is seen from a regular LC-MS analysis. After dimeth-
ylation, the m/z of this peptide is expected to be 750 for the
light label and 754 for the heavy label, as the peptide is
dimethylated at both the N terminus as well as the C-terminal
lysine residue. As can be seen for the light and heavy label in
Fig. 2, B and C, respectively, the online reaction goes to
completion because no input peptide or any intermediates are
visible after labeling. Fig. 2D shows the same mass spectrum
but now for a double labeling (two times 100 fmol) in which
both the light and heavy labeled peptide are visible, in a ratio
very close to 1:1. More examples of BSA peptides before and
after double labeling can be found in supplementary Fig. S1.
We also analyzed this sample with a Mascot search with all
dimethylation events set as variable modifications to deter-
mine the extent of identification of partially dimethylated pep-
tides. The result of that search can be found in Supplementary
Fig. S2 and showed that at a Mascot ion score cutoff of 25,
98% of all identified spectra were dimethylated. Of the 157
identified spectra, four were not fully methylated and only one
contained mixed light and heavy dimethylation. Because of
the 30 s dynamic exclusion set in the mass spectrometer,
these results strongly over-represent low intensity peptides,
meaning the actual labeling percentage is much higher, as
indicated in Fig. 2. To check for recovery of peptides after the
extended washing steps, we compared an online double la-
beling run of two times 20 fmol tryptic BSA with a subsequent
normal LC-MS run of 20 fmol tryptic BSA. The observed
signal intensities were similar, showing a near 100% recovery
of the peptides following isotopic labeling. This behavior was
typical and observed for most tryptic peptides analyzed in this
way.
To test the dynamic range of the online labeling, different
amounts of tryptic BSA peptides were loaded in the first and
second sample loading step, varying between ratios of 30:1 to
1:30. Following the LC-MS analysis of the labeling, the ratio of
BSA between the light and heavy label was determined from
the average of the ten most intense peptide pairs using MS-
Quant. As can be seen in Fig. 3, the method is linear in the
base 2 log of the ratios and accurate over a wide dynamic
range (the correlation between expected and observed ratios
has an R2 of 0.9997). The average ratios for all combinations
tested fell within a 0.5 deviation on a base 2 log scale, which
equates to a variation of �41%. The standard deviations
calculated from the log 2 ratios of each set of 10 peptides
tend to be larger when the second (heavy) sample con-
tains less peptide compared with the first (light) sample. This
shows that with this method ratios can be reliable calculated
as low as for 1.5-fold changes, although usually a 2-fold
change (100% variation) would be used as a cut-off in these
types of experiments.
FIG. 2. Mass spectra of the doubly charged BSA peptide YICD-
NQDTISSK (amino acids 286–297) in its original form (panel A,
calculated mono-isotopic mass 722.33) and after online labeling
in either the light labeling step (panel B, calculated mono-isoto-
pic mass 750.36), the heavy labeling step (panel C, calculated
mono-isotopic mass 754.38), or both (panel D). All mass spectra
are zoomed in on m/z range 710 to 760 and are averaged over the
range in the chromatogram that includes the elution times of all three
m/z values.
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formi acid, th second peptide sample is loaded nto the
trapping column in step three followed by chemical labeling of
that sample in step four when the column is flushed with the
heavy labeling reagent (CD2O/NaBH3CN). Finally, again after
a short wash with 5% FA, in the fifth step the valve switches,
and the flow speed is incr ased to �400 �l/min. This re ults
in a pressure of�150 bar and an effective fl w of�100 nl/min
for a regular LC-MS analytical gradient to analyze ll labeled
peptides. The minimal time for the protocol is around 90 min,
compared with about 170 min for an offline labeling (including
desalting of the sample) and LC-MS analysis (Fig. 1B). As the
procedure is fully automated, no ha dling of the samples is
required after digestio and loading the samples in the au-
tosampler. In the offline method, several additional manual
steps are required, including drying and mixing the samples,
steps th t ar ensitive to sample loss and human error,
respectively.
When performing a sequenti l labeling online it is of vital
importance that the reaction goes t completion as otherwise
th second label will also p rtially label the fir t sample,
causing inaccurate quantitation. To test this, we first per-
formed the online double labeling as described above, but
although only injecting actual dig sted protein sample (bovine
serum albumin (BSA), 100 fmol) in either the first (light) or the
second (heavy) labeling step, though still performing the la-
beling in both steps. Fig. 2 shows the averaged ma s spec-
trum f one of the trypic peptides of BSA, YICDNQDTISSK
(amino acids 286–297), w ich is det cted as a doubly
charged peptide ion at an m/z value of 722.33 when cyst ine
residues are c rbamidomethylated. The e spectra are aver-
aged over the complete retention time span of the unmethy-
lated and the fully methylated versi n of th peptide, to be
able to see any intermediates. In Fig. 2A, the unmodified
peptide is seen from a regular LC-MS analysis. After dimeth-
ylation, the m/z of this peptide is exp cted to be 750 for the
light label and 754 for t heavy label, as the peptide is
dimethylated at both the N terminu as well as the C-terminal
lysine residue. As can b seen for the light and heavy label in
Fig. 2, B and C, respectively, the onlin reaction goes to
completion because o input peptide or a y intermediates are
visible after labeling. Fig. 2D shows the sa e ma s spectrum
but now for a double labeling (two times 100 fmol) in w ich
both the light and heavy labeled peptide are visible, in a ratio
very close to 1:1. More examples of BSA peptides before and
after double labeling can be found in suppl mentary Fig. S1.
We also analyzed this sample with a Mascot search with all
dimethylation events set as variable modifications to deter-
mine the xtent of identificati n of p rtially dimethylated pep-
tides. The result of that sear h can be fou d in Suppl mentary
Fig. S2 and showed that at a Masc t ion score cut ff of 25,
98% of all identified spectra were dimethylated. Of the 157
identified spectra, four were not fully methylated and only one
contained mixed light and heavy dimethylation. Because of
the 30 s dynamic exclusion set in the ma s spectrometer,
these re ults strongly ov r-r present low i tensity peptides,
meaning the actu l labeling p rcentage is much igher, as
indicated in Fig. 2. To check for recovery of peptides after the
xtended washing steps, we compared a online double la-
beling run of two times 20 fmol tryptic BSA with a subsequent
normal LC-MS run of 20 fmol tryptic BSA. The obs rved
signal i tensities were similar, showing a near 100% recovery
of th peptides following isotopic labeling. This behavior was
typical and obs rved for most tryptic peptides analyzed in this
way.
To test the dynamic range of the online labeling, different
amounts of tryptic BSA peptides were loaded in the first and
second sample loading step, varying b tween rati s of 30:1 to
1:30. Following the LC-MS analysis of the labeling, the ratio of
BSA b tween the light and heavy label was determined from
the average of the ten most i t ns peptide pair using MS-
Quant. As can b seen in Fig. 3, the method is linear in the
base 2 l g of the ratios and accurate over a wi e dynamic
range (the correlation b twe n exp cted and obs rved ratios
h s an R2 of 0.9997). The average ratios for all combinations
t sted fell within a 0.5 deviati on base 2 log scale, w ich
equates to variation of �41%. The stan ard deviations
alculated from the log 2 rati s of each set of 10 peptides
tend to be larger when th second (heavy) sample con-
tain less peptide compared with the first (light) sample. This
shows that with this method ratios can be reliable alculated
as low as for 1.5-fold changes, although usually a 2-fold
change (100% variation) would be used s a cut-off in these
types of experiments.
FIG. 2. Mass spectra of the doubly charged BSA peptide YICD-
NQDTISSK (amino acids 286–297) in its original form (panel A,
calculated mon -isotopic mass 722.33) and after online labeling
in ither the light labeling step (panel B, calculated mon -isoto-
pic mass 750.36), t heavy labeling step (panel C, calculated
mon -isotopic mass 754.38), or both (panel D). All mass spectra
are zoomed i on m/z range 710 to 760 and re averaged over the
range in the chromatogram that includes the elution times of all three
m/z values.
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of that sample in step four when the column 
is flu hed with the heavy labeling reage t 
(CD2O/NaBH3CN). Finally, again ft r a short 
wash with 5% FA, in the fifth step the valve 
switches, and the flow speed is increased 
to ~400 ml/min. This results in a pressure of 
~150 bar and an effective flow of ~100 nl/min 
for a regular LC-MS analytical gradient to ana-
lyze all labeled peptides. The mini al time for 
the protocol is round 90 min, compared with 
about 170 min for an offline labeling (includ-
ing desalting of the sample) and LC-MS analy-
sis (Figure  1B). As the procedure is fully auto-
mated, no handling of the samples is required 
after digestion and loading the samples in the 
autosampler. In the offline method, several 
additional manual steps are required, includ-
ing drying and mixing the samples, steps that 
are sensitive to sample loss and human error, 
respectively.
When performi g a sequential labeling on-
line it is of vital importance that the reaction 
goes to completion as o herwis  the second 
l bel will also partially lab l the first sample, 
causing inaccurate quantitation. To test this, 
we first performed the online double label-
ing as described above, but although only 
injecting actual digested protein sample (bo-
vine serum albumin (BSA), 100 fmol) in either 
the first (light) or the second (heavy) labeling 
step, though still performing the labeling in 
both steps. Figure 2 shows the averaged mass 
spectrum of one of the trypic peptides of BSA, 
YICDNQDTISSK (amino acids 286–297), which 
is d tected as a doubly charged peptide ion 
at an m/z value of 722.33 when cystein  resi-
dues are carbamidomethylated. Th se spec-
tra ar  averaged over the c mpl te retention 
time span of the unmethylated and the fully 
methylated version of the peptide, to be able 
to see any intermediates. In Figure 2A, the 
unmodified peptide is seen from a regular LC-
MS analysis. After dimethylation, the m/z of 
this peptide is expected to be 750 for the light 
label and 754 for the heavy label, as the pep-
tide is dimethylated at both the N terminus as 
well as the C-terminal lysine residue. As can 
be seen f r the light and heavy lab l in Figure 
2, B and C, respectively, the onli  reaction 
g es to completion because no input pepti e 
or any intermediates are visible after lab ling. 
Figure 2D shows the same mass spectrum 
but now for a double labeling (two times 100 
fmol) in which both the light and heavy la-
Figure 2 | mass spectra of t e 
doubly charged BSA peptide yICD-
nqDTISSk (amino acids 286–297) 
in its original form (panel A, calcu-
lated mono-isotopic mass 722.33) 
and after online labeling in either 
the light labeling step (panel B, 
calculated mono-isotopic mass 
750.36), the heavy labeling step 
(panel C, calculated mono-isotopic 
mass 754.38), or both (panel D). 
All mass spectra are zoomed in on 
m/z range 710 to 760 and are av-
eraged over the range in the chro-
matogram that includes the elution 
times of all three m/z values.
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beled peptide are visible, in a ratio very close 
to 1:1. More examples of BSA peptides be-
fore and after double labeling can be found 
in supplementary Figure S1. We also analyzed 
this sample with a Mascot search with all di-
methylation events set as variable modifica-
tions to determine the extent of identification 
of partially dimethylated peptides. The result 
of that search can be found in Supplementary 
Figure S2 and showed that at a Mascot ion 
score cutoff of 25, 98% of all identified spec-
tra were dimethylated. Of the 157 identified 
spectra, four were not fully methylated and 
only one contained mixed light and heavy 
dimethylation. Because of the 30 s dynamic 
exclusion set in the mass spectrometer, these 
results strongly over-represent low intensity 
peptides, meaning the actual labeling per-
centage is much higher, as indicated in Figure 
2. To check for recovery of peptides after the 
extended washing steps, we compared an on-
line double labeling run of two times 20 fmol 
tryptic BSA with a subsequent normal LC-MS 
run of 20 fmol tryptic BSA. The observed sig-
nal intensities were similar, showing a near 
100% recovery of the peptides following iso-
topic labeling. This behavior was typical and 
observed for most tryptic peptides analyzed 
in this way.
To test the dynamic range of the online label-
ing, different amounts of tryptic BSA peptides 
were loaded in the first and second sample 
loading step, varying between ratios of 30:1 
to 1:30. Following the LC-MS analysis of the 
labeling, the ratio of BSA between the light 
and heavy label was determined from the av-
erage of the ten most intense peptide pairs 
using MSQuant. As can be seen in Figure 3, the 
method is linear in the base 2 log of the ratios 
and accurate over a wide dynamic range (the 
correlation between expected and observed 
ratios has an R2 of 0.9997).  The average ratios 
for all combinations tested fell within a 0.5 
deviation on a base 2 log scale, which equates 
to a variation of ±41%. The standard devia-
tions calculated from the log 2 ratios of each 
set of 10 peptides tend to be larger when the 
second (heavy) sample contains less peptide 
compared with the first (light) sample. This 
shows that with this method ratios can be reli-
Figure 3 | linearity of the online double 
stable isotope labeling procedure. Plotted 
is the correlation between the expected 
(x axis) and determined (y axis) ratio for 
several online labeling experiments involv-
ing different amounts of BSA, as indicated 
below the graph. The ratios are calculated 
from the 10 most intense peptide peak 
pairs of each analysis. Plotted are the log 
2 values of the actual ratios, with the pink 
line (squares) indicating the expected ra-
tios and the blue line (circles) the observed 
ratios. The dark blue shading indicates the 
spread of 0.5 log units from the expected 
value and the light blue shading a spread of 
1 log unit. Bars indicate the standard devia-
tion between the ten quantified peptides 
for each sample.
Of course, regular experiments would involve a large num-
ber of different proteins, with varying n mbers of peptides
that can be used for q ant tation. To examine the behavi r f
the method under more complex conditions, a mouse lung
tissue extract was run n a SDS-PAGE gel, cut into several
bands, and the proteins present in the gel bands were sub-
jected to in-gel tryptic digestion. These tryptic peptides were
then first applied in equal amounts for heavy and light label-
ing, allowing us to determine the normal variation in the de-
termined ratios introduced by the method. As can be seen in
Fig. 4A, we quantified just under 80 proteins, from three gel
bands, with at least two peptides per protein. Similar to the
quantitation of tryptic BSA, the variation of the average ratios
did not exceed �41%, and the standard deviation of the
rati s observed for different peptides of the same protein was
small. A “rough check” for the efficiency of labeling was
performed via a Mascot search with all dimethylation ev nts
set as variable modificatio s. In this experiment 98% of all
identified peptides were fully labeled, 1.6% were partially
labeled, and 0.4% had mixed light and heavy labeling at a
Mascot ion score cutoff of 25. The result of the search can be
found in supplementary Fig. S3 as well as in PRIDE (see
“Materials and Methods” for details). Next, we mixed the gel
bands in three different ratios (4:1, 1:1, and 1:4) and repeated
the procedure. Fig. 4B shows that the quantified proteins
nicely grouped into three ratios. With three exceptions, most
likely caused by proteins being present in multiple slices of
the gel (see “Discussion”), all proteins were again quantified
within �0.5 of the expected log 2 ratio (corresponding to
�41% of the actual ratios).
Compositional Analysis of Protein Complexes—To test
whether the method could be applied to analyze the differen-
tial composition of protein complexes, we purified the 20 S
core of the proteasome from bovine liver and spleen samples,
usi g ammonium sulfate precipitation, sucrose gradient cen-
trifugati n, and DEAE separation (see “Materials and Meth-
ods”). Following this procedure, relatively pure proteasome
samples were obtained from both tissues, as evidenced by
SDS-PAGE and Coomassie Brilliant Blue staining of the puri-
fication (Fig. 5A). To determine the presence and activity of
catalytically active (�) subunits, the purified proteasomes
were first incubated with a fluorescent probe followed by
SDS-PAGE separation and fluorescence imaging. This re-
vealed that both proteasome purifications contained a num-
ber of active (�) subunits, but also that there were significant
FIG. 3. Linearity of the online double stable isotope labeling
procedure. Plotted is the correlation between the expected (x axis)
and determined (y axis) ratio for several online labeling experiments
involving different amounts of BSA, as indicated below the graph. The
ratios are calculated from the 10 most intense peptide peak pairs of
each analysis. Plotted are the log 2 values of the actual ratios, with the
pink line (squares) indicating the expected ratios and the blue line
(circles) the observed ratios. The dark blue shading indicates the
spread of 0.5 log units from the expected value and the light
blue shading a spread of 1 log unit. Bars indicate the standard
deviation b t een the ten quantified peptides for each sample.
FIG. 4. Quantified ratios from mouse lung tissue proteins. Indi-
cated on the x axis are the number of proteins that were identified
from several gel bands that were mixed either all in a 1:1 ratio (panel
A) or with several gel bands mixed in different ratios (panel B). Ratios
are calculated for all proteins from which at least two peptides were
found that could be quantified and are plotted as the log 2 of the
determined ratio. Shaded in blue, red, and green are the spread of 0.5
log units from the expected 1:1, 4:1, and 1:4 ratios, respectively. Bars
indicate the standard deviation between the quantified peptides for
each protein.
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Of course, regular experiments would involve a large num-
ber of different proteins, with varying numbers of peptides
that can be used for quantitation. To examine the behavior of
the method under more complex conditions, a mouse lung
tissue extract was run on a SDS-PAGE gel, cut into several
bands, and the proteins present in the gel bands were sub-
jected to in-gel tryptic digestion. These tr ti peptides were
then first applied in equal amounts for heavy and light label-
ing, allowing us to determine the normal variation in the de-
termined ratios introduced by the method. As can be seen in
Fig. 4A, we quantified just under 80 proteins, from three gel
bands, with at least two peptides per protein. Similar to the
quantitation of tryptic BSA, the variation of the average ratios
did not exceed �41%, and the standard deviation of the
ratios observed for different peptides of the same protein was
small. A “rough check” for the efficiency of labeling was
performed via a Mascot search with all dimethylation events
set as variable modifications. In this experiment 98% of all
identified peptides were fully labeled, 1.6% were partially
labeled, and 0.4% had mixed light and heavy labeling at a
Mascot ion score cutoff of 25. The result of the search can be
found in supplementary Fig. S3 as well as in PRIDE (see
“Materials and Methods” for details). Next, we mixed the gel
bands in three different ratios (4:1, 1:1, and 1:4) and repeated
the procedure. Fig. 4B shows that the quantified proteins
nicely grouped into three ratios. With three exceptions, most
likely caused by proteins being present in multiple slices of
the gel (see “Discussion”), all proteins were again quantified
within �0.5 of the expected log 2 ratio (corresponding to
�41% of the actual ratios).
Compositional Analysis of Protein Complexes—To test
whether the method could be applied to analyze the differen-
tial composition of protein complexes, we purified the 20 S
core of the proteasome from bovine liver and spleen samples,
using ammonium sulfate precipitation, sucrose gradient cen-
trifugation, and DEAE separation (see “Materials and Meth-
ods”). Following this procedure, relatively pure proteasome
samples were obtained from both tissues, as evidenced by
SDS-PAGE and Coomassie Brilliant Blue staining of the puri-
fication (Fig. 5A). To determine the presence and activity of
catalytically active (�) subunits, the purified proteasomes
were first incubated with a fluorescent probe followed by
SDS-PAGE separation and fluorescence imaging. This re-
vealed that both proteasome purifications contained a num-
ber of active (�) subunits, but also that there were significant
FIG. 3. Linearity of the online double stable isotope labeling
procedure. Plotted is the correlation between the expected (x axis)
and determined (y axis) ratio for several online labeling experiments
involving different amounts of BSA, as indicated below the grap . Th
ratios are calculated from the 10 most intense peptide peak pairs of
each analysis. Plotted are the log 2 values of the actual ratios, with the
pink line (squares) indicating the expected ratios and the blue line
(circles) the observed ratios. The dark blue shading indicat s the
spread of 0.5 log units from the expected value and the light
blue shading a spread of 1 log unit. Bars indicate the standar
deviation between the ten quantified peptides for each sample.
FIG. 4. Qua tified ratios fr m mouse lung tissue prot ins. Indi-
cated on the x axis are the number of proteins that were identified
from several gel bands that were mixed either all in a 1:1 ratio (panel
A) or with several gel bands mixed in different ratios (panel B). Ratios
are calculat d f r all proteins fr m which at le st two eptides were
found t at could be quantified a d are plotted as the log 2 of the
determined ratio. Shaded in blue, red, and green are the spread of 0.5
log units from the expected 1:1, 4:1, and 1:4 ratios, respectively. Bars
indicate the standard deviation between the quantified peptides for
each pr tein.
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Of course, regular experiments would involve a l rge num-
ber of differ nt proteins, with varying numbers of peptides
that can be used for quantita ion. To examine the behavior of
th method under more complex conditions, a mouse lung
tissue xtract was run on a SDS-PAGE gel, cut i to se ral
bands, and the proteins pres nt in the gel bands wer sub-
jected to in-gel tryptic digestion. Thes tryptic peptides wer
then first applied in equal amounts for heavy and light label-
ing, allowing u to det rmine the normal vari tion in the de-
termined ratios introduced by the method. As can be seen i
Fig. 4A, we quantified just under 80 proteins, from three gel
bands, with at least two peptides per protein. Similar to the
quantita ion of tryptic BSA, the vari tion of the average ratios
di not exceed �41%, and the standard eviation of the
ratios observed for differ nt e ti es of the same protein as
small. A “roug check” f r the fficiency of labeling was
performed via Mascot search with all di ethylation ev nts
set as vari ble modifications. In this experiment 98% of all
identified peptides wer fully label d, 1.6% wer partially
label d, and 0.4% had mixed light and heavy labeling at a
Mascot ion score cutoff of 25. The result of the search can be
found in supplementary Fig. S3 as well as in PRIDE (see
“Materials and Methods” for details). Next, we mixed the gel
bands in three differ nt ratios (4:1, 1: , and 1:4) and repeated
the procedure. Fig. 4B shows that he quantified proteins
nicely grouped into three ratios. With three xceptions, ost
likely caused by proteins being pres nt in multiple slices of
the gel (see “Discussion”), all proteins wer again quantified
within �0.5 of the xpected log 2 ratio (corresponding to
�41% of the actual ratios).
Compositional Analysis of Protein Complex s—To test
whether the method could be applied to an lyze the differ n-
ial composition of p otein complex s, we purified the 20 S
core of the prote s m from bovine liver and spleen samples,
u ing am onium sulfate precipita ion, sucrose gradient cen-
trifugation, and DEAE separ tion (see “Materials and Meth-
ods”). Foll wing this procedure, relatively pure proteasome
samples wer obtained from both tissues, as evidenced by
SDS-PAGE and Coomassie Brilliant Blue staini g of the puri-
fication (Fig. 5A). To det rmine the pres nce and activity of
cat lytically active (�) subunits, the purified proteasomes
wer first incubated with a fluorescent probe foll wed by
SDS-PAGE separ tion and fluorescence imaging. This re-
vealed that both proteasome purifications contained a num-
ber of active (�) subunits, but also that ther wer significant
FIG. 3 Linearity of the onli e double stable isot pe labeling
procedure. Plotted is the correlation between the xpected (x axis)
and et rmined (y axis) ratio for sev ral onli e labeling experiments
involving differ nt amounts of BSA, as indicated below the graph. The
ratios are calculated from the 10 most intense pe tide peak pairs of
each an lysis. Plotted are the log 2 values of the actual ratios, with e
pink line (squares) indicating the xpected ratios and the blue line
(cir les) the observed ratios. The dark blue shading indicates the
spread of 0.5 log units from the xpected value and the light
blue shading a spread of 1 log unit. Bars indicate the standard
deviat on between the t n quantified pe tides for each sample.
FIG. 4 Quantified ratios from ouse lung tissue proteins. Indi-
cated on the x axis are the number of proteins that wer identified
from sev ral gel bands that wer mixed either all in a 1:1 ratio (panel
A) or with sev ral gel bands mixed in differ nt ratios (panel B). Ratios
are calculated for all proteins from which at least two pe tides wer
found that could be quantified and are plotted as the log 2 of the
determined ratio. Shade in blue, red, and green are the spread of 0.5
log units from the expected 1:1, 4:1, and 1:4 ratios, respectively. Bars
indi te the standard eviat on between the quantified pe tides for
each protein.
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Of course, regular experime ts would involve a large num-
ber of different protein , with varying numbers of peptides
that can be used for quantitation. To examine the b havior of
the method under more complex conditi ns, a mouse lung
tissue extract was run on a SDS-PAGE gel, cut into several
bands, and the proteins present in the gel bands were sub-
jected to in-gel tryptic digestion. These tryptic peptides were
then first applied in equal amounts for heavy and light label-
ing, allowing us to determine the normal variation in the de-
termined ratios introduced by the method. As can be seen in
Fig. 4A, we quantified just under 80 proteins, from three gel
bands, with at least two peptides per protein. Similar to the
quantitation of tryptic BSA, the variation of the average ratios
did not exceed �41%, and the standard deviation of the
ratios observed for different peptides of the same protein was
small. A “rough check” for the efficiency of labeling was
performed via a Mascot search with all dimethylation events
set as variable modifications. In this experiment 98% of all
identified peptides were fully labeled, 1.6% were partially
labeled, and 0.4% had mixed light and heavy labeling at a
Mascot ion score cutoff of 25. The result of the search can be
found in supplementary Fig. S3 as well as in PRIDE (see
“Materials and Methods” for details). Next, we mixed the gel
bands in three different ratios (4:1, 1:1, and 1:4) and repeated
the procedure. Fig. 4B shows that the quantified proteins
nicely grouped into three ratios. With three exceptions, most
likely caused by proteins being present in multiple slices of
the gel (see “Discussion”), all proteins were again quantified
within �0.5 of the expected log 2 ratio (corresponding to
�41% of the actual ratios).
Compositional Analysis of Protein Complexes—To test
whether the method could be applied to analyze the differen-
tial composition of protein complexes, we purified the 20 S
core of the proteasome from bovine liver and spleen samples,
using ammonium sulfate precipitation, sucrose gradient cen-
trifugation, and DEAE separation (see “Materials and Meth-
ods”). Following this procedure, relatively pure proteasome
samples were obtained from both tissues, as evidenced by
SDS-PAGE and Coomassie Brilliant Blue staining of the puri-
fication (Fig. 5A). To determine the presence and activity of
catalytically active (�) subunits, the purified proteasomes
were first incubated with a fluorescent probe followed by
SDS-PAGE separation and fluorescence imaging. This re-
vealed that both proteasome purifications contained a num-
ber of active (�) subunits, but also that there were significant
FIG. 3. Linearity of the onlin double stable isotope labeling
procedure. Plotted is the correlation between the expected (x axis)
and determined (y xis) ratio for several online labeling experiments
involving different amounts of BSA, as indicated below the graph. The
ratios ar calculated from the 10 most intense peptide peak pairs of
each analys s. Plo ted ar the log 2 values of the actual rati s, with the
pink line ( quar s) indicating the expected ratios and the blue line
(circles) the observ d ratios. The dark blue shading indicates the
spread of 0.5 log units from the exp cted value and the light
blue sha ing a spread of 1 log unit. Bars indicate the standard
deviation b tw en t ten qu ntified pep ides for each sampl .
FIG. 4. Qua tified ratio from mo e lung tissue proteins. Indi-
cated on the x axis are the number of proteins that were identified
from sever l gel band that wer mixed either all in a 1:1 ratio (panel
A) or with several gel bands mixed in different ratios (panel B). Ratios
are calculated for all proteins from which at least two peptides were
found that could be quantified and are plotted as the log 2 of the
dete mined r tio. Sh ded in blue, r d, and gre n are the spread of 0.5
log units from the expected 1:1, 4:1, and 1:4 r tios, respectively. Bars
indicate the standard d viation between the quantified peptides for
each protei .
Automated Online Isotope Labeling for Protein Quantitation
Molecular & Cellular Proteomics 7.9 1759
116
able calculated as low as for 1.5-fold changes, 
although usually a 2-fold change (100% varia-
tion) would be used as a cut-off in these types 
of experiments.
Of course, regular experiments would involve 
a large number of different proteins, with 
varying numbers of peptides that can be used 
for quantitation. To examine the behavior of 
the method under more complex conditions, 
a mouse lung tissue extract was run on a SDS-
PAGE gel, cut into several bands, and the pro-
teins present in the gel bands were subjected 
to in-gel tryptic digestion. These tryptic pep-
tides were then first applied in equal amounts 
for heavy and light labeling, allowing us to 
determine the normal variation in the deter-
mined ratios introduced by the method. As 
can be seen in Figure 4A, we quantified just 
under 80 proteins, from three gel bands, with 
at least two peptides per protein. Similar to 
the quantitation of tryptic BSA, the variation 
of the average ratios did not exceed ±41%, and 
the standard deviation of the ratios observed 
for different peptides of the same protein was 
small. A “rough check” for the efficiency of 
labeling was performed via a Mascot search 
with all dimethylation events set as variable 
modifications. In this experiment 98% of all 
identified peptides were fully labeled, 1.6% 
were partially labeled, and 0.4% had mixed 
light and heavy labeling at a Mascot ion score 
cutoff of 25. The result of the search can be 
found in supplementary Figure S3 as well as in 
PRIDE (see “Materials and Methods” for de-
tails). Next, we mixed the gel bands in three 
different ratios (4:1, 1:1, and 1:4) and repeat-
Figure 4 | quantified ratios from 
mouse lung tissue proteins. Indi-
cated on the x axis are the number 
of proteins that were identified 
from several gel bands that were 
mixed either all in a 1:1 ratio (A) 
or with several gel bands mixed in 
different ratios (B). Ratios are cal-
culated for all proteins from which 
at least two peptides were found 
that could be quantified and are 
plotted as the log 2 of the deter-
mined ratio. Shaded in blue, red, 
and green are the spread of 0.5 log 
units from the expected 1:1, 4:1, 
and 1:4 ratios, respectively. Bars 
indicate the standard deviation be-
tween the quantified peptides for
each protein.
Of course, regular experiments would involve a large num-
ber of different proteins, with varying numbers of peptides
that can be used for quantitation. To examine the behavior of
the method under more complex conditions, a mouse lung
tissue extract was run on a SDS-PAGE gel, cut into several
bands, and the proteins present in the gel bands were sub-
jected to in-gel tryptic digestion. These tryptic peptides were
then first applied in equal amounts for heavy and light label-
ing, allowing us to determine the normal variation in the de-
termined ratios introduced by the method. As can be seen in
Fig. 4A, we quantified just under 80 proteins, from three gel
bands, with at least two peptides per protein. Similar to the
quantitation of tryptic BSA, the variation of the average ratios
did not exceed �41%, and the standard deviation of the
ratios observed for different peptides of the same protein was
small. A “rough check” for the efficiency of labeling was
performed via a Mascot search with all dimethylation events
set as variable modifications. In this experiment 98% of all
identified peptides were fully labeled, 1.6% were partially
labeled, and 0.4% had mixed light and heavy labeling at a
Mascot ion score cutoff of 25. The result of the search can be
found in supplementary Fig. S3 as well as in PRIDE (see
“Materials and Methods” for details). Next, we mixed the gel
bands in three different ratios (4:1, 1:1, and 1:4) and repeated
the procedure. Fig. 4B shows that the quantified proteins
nicely grouped into three ratios. With three exceptions, most
likely caused by proteins being present in multiple slices of
the gel (see “Discussion”), all proteins were again quantified
within �0.5 of the expected log 2 ratio (corresponding to
�41% of the actual ratios).
Compositional Analysis of Protein Com lexes—To test
whether the method could e applied to analyze the differen-
tial c mposition of protein complexes, we urified the 20 S
core of the proteasome from bovine liver and spleen samples,
using ammonium sulfate precipitation, sucrose gradient cen-
trifugation, and DEAE separation (see “Materials and Meth-
ods”). Following this procedure, relatively pure proteasome
samples were obtained from both tissues, as evidenced by
SDS-PAGE and Coomassie Brilliant Blue staining of the puri-
fication (Fig. 5A). To determine the presence and activity of
catalytically active (�) subunits, the purified proteasomes
were first incubated with a fluorescent probe followed by
SDS-PAGE separation and fluorescence imaging. This re-
vealed that both proteasome purifications contained a num-
ber of active (�) subunits, but also that there were significant
FIG. 3. Linearity of the online double stable isotope labeling
procedure. Plotted is the correlation between the expected (x axis)
and determined (y axis) ratio for several online labeling experiments
involving different amounts of BSA, as indicated below the graph. The
ratios are calculated from the 10 most intense peptide peak pairs of
each analysis. Plotted are the log 2 values of the actual ratios, with the
pink line (squares) indicating the expected ratios and the blue line
(circles) the observed ratios. The dark blue shading indicates the
spread of 0.5 log units from the expected value and the light
blue shading a spread of 1 log unit. Bars indicate the standard
deviation between the ten quantified peptides for each sample.
FIG. 4. Quantified ratios from mouse lung tissue proteins. Indi-
cated on the x axis are the number of proteins that were identified
from sev ral gel bands that were mixed either all in a 1:1 ratio (panel
A) or with several gel bands mixed in different ratios (panel B). Ratios
are calculated for all proteins from which at least two peptides were
found that could be quantified and are plotted as the log 2 of the
determined ratio. Shaded in blue, red, and green are the spread of 0.5
log units from the xpected 1:1, 4:1, and 1:4 ratios, respectiv ly. Bars
indicate the standard deviation between the quantified peptides for
each protein.
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Of course, regular experiments would involve a large num-
ber of different proteins, with varying numbers of peptides
that can be used for quantitation. To examine the behavior of
the method under more complex conditions, a mouse lung
tissue extract was run on a SDS-PAGE gel, cut into several
bands, and the proteins present in the gel bands were sub-
jected to in-gel tryptic digestion. These tryptic peptides were
then first applied in equal amounts for heavy and light label-
ing, allowing us to determine the normal variation in the de-
termined ratios introduced by the method. As can be seen in
Fig. 4A, we quantified just under 80 proteins, from three gel
bands, with at least two peptides per protein. Similar to the
quantitation of tryptic BSA, the variation of the average ratios
did not exceed �41%, and the standard deviation of the
ratios observed for different peptides of the same protein was
small. A “rough check” for the efficiency of labeling was
performed via a Mascot search with all dimethylation events
set as variable modifications. In this experiment 98% of all
identified peptides were fully labeled, 1.6% were partially
labeled, and 0.4% had mixed light and heavy labeling at a
Mascot ion score cutoff of 25. The result of the search can be
found in supplementary Fig. S3 as well as in PRIDE (see
“Materials and Methods” for details). Next, we mixed the gel
bands in three different ratios (4:1, 1:1, and 1:4) and repeated
the procedure. Fig. 4B shows that the quantified proteins
nicely grouped into three ratios. With three exceptions, most
likely caused by proteins being present in multiple slices of
the gel (see “Discussion”), all proteins were again quantified
within �0.5 of the expected log 2 ratio (corresponding to
�41% of the actual ratios).
Compositional Analysis of Protein Complexes—To test
whether the method could be applied to analyze the differen-
tial composition of protein complexes, we purified the 20 S
core of the proteasome from bovine liver and spleen samples,
using ammonium sulfate precipitation, sucrose gradient cen-
trifugation, and DEAE separation (see “Materials and Meth-
ods”). Following this procedure, relatively pure proteasom
samples were btaine from bo tissues, as evidenced by
SDS-PAGE and Coomassie Brilliant Blue staining of th puri-
fication (Fig. 5A). To determine the presence and activity of
catalytically active (�) subunits, the purified proteasomes
were first incubated with a fluorescent probe followed by
SDS-PAGE separation and fluorescence imaging. This re-
vealed that both proteasome purifications contained a num-
ber of active (�) subunits, but also that there were significant
FIG. 3. Linearity of the online double stable isotope labeling
procedure. Plotted is the correlation between the expected (x axis)
and determined (y axis) ratio for several online labeling experiments
involving different amounts of BSA, as indicated below the graph. The
ratios are calculated from the 10 most intense peptide peak pairs of
each analysis. Plotted are the log 2 values of the actual ratios, with the
pink line (squares) indicating the expected ratios and the blue line
(circles) the observed ratios. The dark blue shading indicates the
spread of 0.5 log units from the expected value and the light
blue shading a spread of 1 log unit. Bars indicate the standard
deviation between the ten quantified peptides for each sample.
FIG. 4. Quantified ratios from mouse lung tissue proteins. Indi-
cated on the x axis are the number of proteins that were identified
from several gel bands that were mixed either all in a 1:1 ratio (panel
A) or with several gel bands mixed in different ratios (panel B). Ratios
are c lculated for all proteins from which at least two peptides were
found that could be quantified and are plotted as the log 2 of the
determined ratio. Shaded in blue, red, and green are the spread of 0.5
log units from the expected 1:1, 4:1, and 1:4 ratios, respectively. Bars
indicate the standard deviation between the quantified peptides for
each protein.
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ed the procedure. Figure 4B shows that the 
quantified proteins nicely grouped into three 
ratios. With three exceptions, most likely 
caused by proteins being present in multiple 
slices of the gel (see “Discussion”), all pro-
teins were again quantified within ±0.5 of the 
expected log 2 ratio (corresponding to ±41% 
of the actual ratios).
Compositional analysis of protein 
complexes
To test whether the method could be applied 
to analyze the differential composition of pro-
tein complexes, we purified the 20S core of 
the proteasome from bovine liver and spleen 
samples, using ammonium sulfate precipita-
tion, sucrose gradient centrifugation, and 
DEAE separation (see “Materials and Meth-
ods”). Following this procedure, relatively 
pure proteasome samples were obtained 
from both tissues, as evidenced by SDS-PAGE 
and Coomassie Brilliant Blue staining of the 
purification (Figure 5A). To determine the 
presence and activity of catalytically active (β) 
subunits, the purified proteasomes were first 
incubated with a fluorescent probe followed 
by SDS-PAGE separation and fluorescence 
imaging. This revealed that both proteasome 
Figure 5 | quantitation of differences between purified bovine liver and spleen proteasome com-
plexes. A) the purified proteasome samples are shown after SDS-PAGE, stained using Coomassie Bril-
liant Blue. Lane 1 shows the purified liver proteasome, lane 2 the mixture of both proteasome sam-
ples, and lane 3 the purified spleen proteasome. The location of the proteasome proteins on the gel 
is indicated with an asterisk. B) the same proteasome purifications of liver (lane 1) and spleen (lane 
2), but now stained using a fluorescent probe for catalytically active subunits. C) the relative quanti-
tation of all Mascot identified proteasome subunits, with α-subunits indicated in green, β-subunits 
indicated in light blue (normal subunits), or dark blue (immunosubunits) and PA28 subunits indicated 
in orange. Bars indicate the standard deviation between the quantified peptides for each protein. D) 
the structure of the constitutive proteasome core and of the immunoproteasome core with the PA28 
cap complex attached.
differences in composition between these two proteasome
samples (Fig. 5B). Most likely, these differences ar caus d by
differences in the amount of onstitutive proteasome and
immunoproteasome between bovine liver and spleen sam-
ples, in agreement with previously reported data for mouse
spleen and liver proteasomes (10). After in-solution tryptic
digestion, we used the online dimethylation method to further
characterize and quantify these differences, with the liver
proteasome being light labeled and the spleen proteasome
being heavy labeled. All Mascot identified proteasome com-
ponents in the sample were quantified using MS-Quant, and
the data set was normalized on the median of the average of
all � proteasome subunits, as these were expected not to
change between the two proteasome samples. In Fig. 5C, the
base 2 logarithms of the measured ratios (intensity of the
extracted ion chro atogram for the heavy labeled peptide
divided by that of the light peptide) are plotted for all protea-
some subunits. When using a cutoff value of 100% up- or
down-regulation (which equals 1 unit on the log 2 scale), two
proteins of the 20 S proteasome core were more abundant in
the proteasome purification from liver (subunits �5 and �7).
Three core proteins were more abundant in the spleen sample
(�5i, �2I, and �1i), corresponding exactly to the three catalyt-
ically active immunoproteasome subunits. In addition, two
other 20 S proteasome-associated proteins (PSME1 and
PSME2) were found more abundantly in the spleen protea-
some, which together can form an alternative cap of the
proteasome that facilitat s degradation of peptides for major
histocompatibility complex (MHC) presentation (14), called
the PA28 (proteasome activator) or REG complex. Fig. 5D
displays a structural model of the differences between the
regular constitutive proteasome and the immunoproteasome
associated with the PA28 cap complex. To verify these re-
sults, the experiment was repeated with this time, the liver
proteasome being heavy labeled and the spleen proteasome
being light labeled. Although small differences were observed
in the ratios calculated for the subunits having a log 2 ratio
around 0, the same proteins were identified as being up- or
down-regulated in the spleen sample, as compared with the
liver protea ome (d ta not show ).
DISCUSSION
Quantitative proteomics by using stable isotope labeling in
combination with mass spectrometry is an extensively used
technique for the comparison of protein abundance in com-
plex biological samples. To analyze tissue-derived samples,
chemical labeling after digestion is the most often used
method to determine relative quantities of peptides and pro-
teins in these samples. As the efficiency of chemical labeling
of samples is often sensitive to small (manual) errors and
differences in sample preparation and handling, automation of
the labeling process can reduce these errors and allow more
FIG. 5. Quantitation of differences between purified bovine liver and spleen proteasome complexes. A, the purified proteasome
samples are shown after SDS-PAGE, stained using Coomassie Brilliant Blue. Lane 1 shows the purified liver proteasome, lane 2 the mixture
of both proteasome samples, and lane 3 the purified spleen proteasome. The location of the proteasome proteins on the gel is indicated with
an asterisk. B, the same proteasome purifications of liver (lane 1) and spleen (lane 2), but now stained using a fluorescent probe for catalytically
active subunits. C, the relative quantitation of all Masc identified proteasome subunits, with �-subunits indicated in green, �-subunits
indicated in light blue (normal subunits), or dark blue (im unosubunits) and PA28 subunits indicated in orang . Bars indicate the standard
deviation between the quantified peptides for each protein. D, the structure of the constitutive proteasome core and of the immunoproteasome
core with the PA28 cap complex attached.
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differences in composition between these two proteasome
samples (Fig. 5B). Most likely, these differences are caused by
differences in the amount of constitutive proteasome and
immunoproteasome between bovine liver and spleen sam-
ples, in agreement with previously reported data for mouse
spleen and liver proteasomes (10). After in-solution tryptic
digestion, we used the online dimethylation method to further
characterize and quantify these differences, with the liver
proteasome being light labeled and the spleen proteasome
being heavy labeled. All Mascot identified proteasome com-
ponents in the ample were quantified u ng MS-Quant, an
the data set was normalized on the median of the average of
all � proteasome subunits, as these were expected not to
change between the two proteasome samples. In Fig. 5C, the
base 2 logarithms of the measured ratios (intensity of the
extracted ion chromatogram for the heavy labeled peptide
divided by that of the light peptide) are plotted for all protea-
some subunits. When using a cutoff value of 100% up- or
down-regulation (which equals 1 unit on the log 2 scale), two
proteins of the 20 S proteasome core were more abundant in
the proteasome purification from liver (subunits �5 and �7).
Three core proteins were more abundant in the spleen sample
(�5i, �2I, and �1i), corresponding exactly to the three catalyt-
ically active immunoproteasome subunits. In addition, two
other 20 S proteasome-associated proteins (PSME1 and
PSME2) were found more abundantly in the spleen protea-
some, which together can form an alternative cap of the
proteasome that facilitates degradation of peptides for major
histocompatibility complex (MHC) presentation (14), called
the PA28 (proteasome activator) or REG complex. Fig. 5D
displays a structural model of the differences between the
regular constitutive proteasome and the immunoproteasome
associated with the PA28 cap complex. To verify these re-
sults, the experiment was repeated with this time, the liver
proteasome b i g h avy labeled and the spleen proteasome
b ing light labeled. Although small differences were observed
in the ratios calculated for the subunits having a log 2 ratio
around 0, the same prot ins were identified as being up- or
down-regulated in the spleen sample, as compared with the
liver proteasome (data not shown).
DISCUSSION
Quantitative proteomics by using stable isotope labeling in
combination with mass spectrometry is an extensively used
technique for the comparison of protein abundance in com-
plex biological samples. To analyze tissue-derived samples,
chemical labeling after digestion is the most often used
method to determine relative quantities of peptides and pro-
teins in these samples. As the efficiency of chemical labeling
of samples is often sensitive to small (manual) errors and
differences in sample preparation and handling, automation of
the labeling process can reduce these errors and allow more
FIG. 5. Quantitation of differences between purified bovine liver and spleen proteasome complexes. A, the purified proteasome
samples are shown after SDS-PAGE, stained using Coomassie Brilliant Blue. Lane 1 shows the purified liver proteasome, lane 2 the mixture
of both proteasome samples, and lane 3 the purified spleen proteasome. The location of th proteasome prot ins on the gel is indicated with
an asterisk. B, the same proteasome purifications of liver (lane 1) and spleen (lane 2), but now stained using a fluorescent probe for catalytically
active subunits. C, the relative quantitation of all Mascot identified proteasome subunits, with �-subunits indicated in green, �-subunits
indicated in light blue (normal subunits), or dark blue (immunosubunits) and PA28 subunits indicated in orange. Bars indicate the standard
deviation between the quantified peptides for each protein. D, the structure of the constitutive proteasome core and of the immunoproteasome
core with the PA28 cap complex attached.
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differences in composition between these two proteasome
samples (Fig. 5B). M st likely, these differences are caused by
differences in the amount of constitutive proteasome and
immunoproteasome between bovine liver and spleen sam-
ples, in agreement with previously reported data for mouse
spleen and liver proteasomes (10). After in-solution tryptic
digestion, we used the online dimethylation met d to further
characterize and quantify these differ nces, with the liv r
proteasome being light labeled and the spleen proteasome
being heavy labeled. All Mascot identified proteasome com-
ponents in the sample were quantified using MS-Quant, and
the data set was normalized on the median of the average of
all � proteasome subunits, as these were expected not to
change between the two proteasome samples. In Fig. 5C, the
base 2 logarithms of the measured ratios (intensity of the
extracted ion chromatogram for the heavy labeled peptide
divided by that of the light peptide) are plotted for all protea-
some subunits. When using a cutoff value of 100% up- or
down-regulation (which equals 1 unit on t e log 2 scale), two
proteins of the 20 S proteasome core were more abundant in
the proteasome purification from liver (subunits �5 and �7).
Three core proteins were more abundant in the spleen sample
(�5i, �2I, and �1i), corresponding exactly to the three catalyt-
ically active immunoproteasome subunits. In addition, two
other 20 S proteasome-associated proteins (PSME1 and
PSME2) were found more abundantly in the spleen protea-
some, which together can form an alternative cap of the
proteasome that facilitates degradati n of peptides for major
histocompatibility complex (MHC) presentation (14), called
the PA28 (proteasome activator) or REG complex. Fig. 5D
displays a structural model of the differences between the
regular constitutive proteasome and the immunoproteasome
associated with the PA28 cap complex. To verify these re-
sults, the experiment was repeated with this time, the liver
proteasome being heavy labeled and the spleen proteasome
being light labeled. Although small differences were observed
in the ratios calculated for the subunits having a log 2 ratio
around 0, the same proteins were identified as being up- or
down-regulated in the spleen sample, as compared with the
liver proteasome (data not shown).
DISCUSSION
Quantitative proteomics by using stable isotope labeling in
combination with mass sp ctrometry is an extensively used
technique for the comparison of protein abundance in com-
plex biological amples. To analyze ti sue-derived samples,
chemical labeling after digestion is the most often used
method to determine relative quantities of peptides and pro-
teins in these samples. As the efficiency of chemical labeling
of samples is often sensitive to small (manual) errors and
differences in sample preparation and handling, automation of
the labeling process can reduce these errors and allow more
FIG. 5. Quantitation of differences between purified bovine liver and spleen proteasome complexes. A, the purified proteasome
samples are shown after SDS-PAGE, stain d using Coomassie Brilliant Blue. Lane 1 shows the purified liver proteasom , lane 2 the mixture
of both proteasome samples, and lane 3 the purified spleen prot asome. The loc tion of the prot asom proteins on the g l is indicat d with
an asterisk. B, the same prot asome purifications of liver (lane 1) and sple n (lane 2), but now stained using a fluoresce t prob for catalytically
active subunits. C, the relativ quantitation of all Mascot id ntified prot asom su nits, with �-subunits indicated in gre n, �-subunits
indicat d in light blue (norm l subunits), or dark blue (immunosubunits) and PA28 subunits indicated in orange. Bars indicate the standard
deviation between the quantified peptides for each prot in. D, the s ructure of the constitutive prote some core and of the immunoproteasome
cor with the PA28 cap complex ttached.
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purifications contained a number of active (β) 
subunits, but also that there were significant 
differences in the amount of constitutive pro-
teasome and immunoproteasome between 
bovine liver and spleen samples, in agree-
ment with previously reported data for mouse 
spleen and liver proteasomes.11 After in-solu-
tion tryptic digestion, we used the online dim-
ethylation method to further characterize and 
quantify these differences, with the liver pro-
teasome being light labeled and the spleen 
proteasome being heavy labeled. All Mascot 
identified proteasome components in the 
sample were quantified using MS-Quant, and 
the data set was normalized on the median of 
the average of all α proteasome subunits, as 
these were expected not to change between 
the two proteasome samples. In Figure 5C, 
the base 2 logarithms of the measured ratios 
(intensity of the extracted ion chromatogram 
for the heavy labeled peptide divided by that 
of the light peptide) are plotted for all protea-
some subunits. When using a cutoff value of 
100% up- or down-regulation (which equals 
1 unit on the log 2 scale), two proteins of the 
20S proteasome core were more abundant in 
the proteasome purification from liver (sub-
units β5 and β7). Three core proteins were 
more abundant in the spleen sample (β5i, β2i, 
and β1i), corresponding exactly to the three 
catalytically active immunoproteasome sub-
units. In addition, two other 20S proteasome-
associated proteins (PSME1 and PSME2) were 
found more abundantly in the spleen protea-
some, which together can form an alternative 
cap of the proteasome that facilitates degra-
dation of peptides for major histocompatibil-
ity complex (MHC) presentation,12 called the 
PA28 (proteasome activator) or REG complex. 
Figure 5D displays a structural model of the 
differences between the regular constitutive 
proteasome and the immunoproteasome as-
sociated with the PA28 cap complex. To verify 
these results, the experiment was repeated 
with this time, the liver proteasome being 
heavy labeled and the spleen proteasome 
being light labeled. Although small differ-
ences were observed in the ratios calculated 
for the subunits having a log 2 ratio around 
0, the same proteins were identified as being 
up- or down-regulated in the spleen sample, 
as compared with the liver proteasome (data 
not shown).
DISCUSSIOn
Quantitative proteomics by using stable iso-
tope labeling in combination with mass spec-
trometry is an extensively used technique 
for the comparison of protein abundance in 
complex biological samples. To analyze tis-
sue-derived samples, chemical labeling after 
digestion is the most often used method to 
determine relative quantities of peptides and 
proteins in these samples. As the efficiency of 
chemical labeling of samples is often sensi-
tive to small (manual) errors and differences 
in sample preparation and handling, automa-
tion of the labeling process can reduce these 
errors and allow more reproducible results. 
However, care should still be taken in sample 
preparation to avoid human error prior to 
isotopic labeling as is the case with any other 
derivatization method.
Online labeling method
Here, we present a method for online, on-
column, sequential derivatization of peptides, 
allowing relative quantitation of the peptides, 
by dimethylation using cyanoborohydride and 
either regular or deuterated formaldehyde.7 
The online quantitation procedure provided 
reliable quantitation over a wide dynamic 
range and allowed us to quantify differences 
between proteasome complexes purified 
from different tissue samples. 
Online derivatization of peptides has been 
demonstrated before to enhance the frag-
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mentation of the peptides in tandem mass 
spectrometry,13 but for online sequential 
labeling,  it is very important that the label-
ing reaction goes to completion to prevent 
bleeding of the samples. In our method, no 
intermediates or unmodified peptides were 
present at detectable levels, as demonstra- 
ted in Figure 2. Also, to prevent preferred 
binding of the first sample, the amount of pep-
tide loaded on the trap column must be well 
below the capacity of the column. Therefore 
the method is especially suitable for anali- 
zing differences between single proteins or 
purified protein complexes, where the total 
amount of protein is unlikely to exceed the 
capacity of the column. When analyzing a 
mixture of ratios generated from bands cut 
from a gel containing mouse lung extract, we 
noticed a few proteins with unexpected ra-
tios. Because some proteins might be present 
in multiple isoforms, with varying molecular 
weights, they might be present in more than 
one of the bands that were used for this ex-
periments, causing the ratio to shift away 
from the expected value. This will not be a 
significant problem, however, as in most ap-
plications either in-solution digests or similar 
gel bands, but from different samples, will be 
compared. Evidently, in-solution digests will 
not resolve isoforms of the proteins,14 but 
this would lead to inter-protein differences 
of quantified peptides rather than shifted ra-
tios. 
When automating the online labeling method, 
the stability of the reagent is another impor-
tant issue. Using a colorimetric assay to de-
termine cyanoborohydride concentrations15 
and by performing identical runs over a pro-
longed period of time, we found that the mix-
ture of formaldehyde and cyanoborohydride 
was stable over at least 24 h when stored 
at 4 °C (supplemental Figure S4), whereas 
many other reagents used for chemical label-
ing (like iTRAQ) often required the reagent 
to be mixed immediately prior to the reac-
tion. This stability makes the dimethylation 
reaction very suitable for the online labeling 
procedure, as it allows automated labeling 
and analyses of the samples to take place 
overnight or even longer period of time. Al-
though the throughput speed of our method 
is higher than offline labeling when two sam-
ples are compared (Figure 1), offline labeling 
gets more favorable when larger numbers of 
samples have to be analyzed, as they can then 
all be labeled at the same time, rather than 
sequentially.
Compositional analysis of tissue-specific 
proteasomes
After comparing the 20S core proteasomes 
purified from bovine liver and spleen we ob-
served that proteasome subunit β5 was sig-
nificantly less abundant in spleen and to a 
lesser extent also β7 (although the standard 
deviation for the latter was high). The immu-
noproteasome subunits β1i, β2i, and β5i were 
all more abundantly present in the spleen-
derived proteasome preparation. These dif-
ferences between the proteasome complexes 
purified from bovine liver and spleen can be 
partially explained by the high abundance of 
immunoproteasome complexes in spleen, 
compared with liver, in full agreement with 
previous observations.11 Still, it is remarkable 
that a single catalytic constitutive protea-
some subunit is less abundant in the spleen-
derived proteasome sample. This observation 
suggests that not only immunoproteasome 
complexes exist in which all constitutive ac-
tive subunits are replaced by their immuno-
proteasome counterparts, but that “hybrid” 
proteasome complexes are present as well, 
in which only one of the β-subunits has been 
replaced by an immunosubunit. Such hybrid 
proteasome complexes have been suggested 
before, but their exact composition remains 
so far unclear.16 Also, because only β5 was 
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relatively less abundant, and all three immu-
nosubunits were more abundant, it cannot be 
excluded that β5 might be replaced by either 
β1i, β2i, or β5i in such a hybrid proteasome 
species.
Next to immunoproteasome subunits, we 
also found PSME1 and PSME2 to be almost 
uniquely present in the bovine spleen purified 
proteasomes. Together, these two highly ho-
mologous proteins form the alternative PA28 
cap (also called 11S regulator) of the 20S pro-
teasome, a heptameric ring containing most 
likely 4 subunits of PSME2 and 3 of PSME1.12,17 
The PA28 cap can replace the 19S regulator 
and is, like the catalytically active immuno-
subunits, up-regulated by interferon-γ.18 The 
fact that we found the 11S complex in the 
proteasome purified from spleen, but did not 
find any subunits of the 19S complex, might 
suggest that the 11S regulator is more tightly 
bound to the proteasome core as the 19S cap 
is known to dissociate under the isolation 
conditions.
COnClUSIOn
Here, we presented an online, sequential la-
beling procedure using differential stable iso-
topic dimethlylation of N termini and lysine 
residues. The method allows automated se-
quential labeling and LC-MS/MS analysis of 
complex biological samples. We validated the 
method on model proteins and a whole cell 
lysate and identified the differences in com-
position between proteasome complexes 
purified from bovine liver and spleen. The 
method is efficient, performs similar to other 
chemical labeling methods, and can be gener-
ally applied. The method is especially suitable 
for the quantitative analysis of gel bands or 
purified protein complexes, and its full auto-
mation permits easier analysis of large sam-
ple numbers with a greatly reduced chance of 
inaccuracy due to human error.
mATerIAlS AnD meTHODS
nanolC-mS/mS
All analyses were performed on nanoLC-LTQ-Or-
bitrap at a resolution of 60,000 or nanoLC-LTQ-
FTICR at a resolution of 100,000. (Thermo, San 
Jose, CA) mass spectrometers. For nanoLC, Agi-
lent 1100 series LC systems were equipped with 
20-mm Aqua C18 (Phenomenex, Torrance, CA) 
trapping columns (packed in-house, i.d., 100 mm; 
resin, 5 mm) and 250 mm ReproSil-Pur C18-AQ 
(Dr. Maisch GmbH, Ammerbuch) analytical col-
umns (packed in-house, i.d., 50 mm; resin, 3 mm). 
Solvents used where 0.6% HAc (buffer A) and 
0.6% HAc/80% acetonitrile (ACN) (buffer B). Trap-
ping was performed at 5 mL/min for 10 min, and 
elution was achieved with a gradient of 0–45% 
B in 45 min, 45–100% B in 1 min, 100% B for 4 
min. The flow rate was passively split from 0.36 
mL/min to 100 nL/min. Nanospray was achieved 
using a distally coated fused silica emitter (New 
Objective, Cambridge, MA) (outer diameter, 360 
mm; i.d., 20 mm, tip i.d. 10 m) biased to 1.8 kV. 
The mass spectrometer was operated in the da-
ta-dependent mode to automatically switch be-
tween MS and MS/MS. Survey full scan MS spec-
tra were acquired from m/z 350 to m/z 1500, and 
the three most intense ions were fragmented in 
the linear ion trap using collisionally induced dis-
sociation. The target ion setting was 5e5 for the 
Orbitrap, with a maximum fill-time of 250 ms 
and 1e6 for the FTICR, with a maximum fill-time 
of 250 ms. Fragment ion spectra were acquired 
in the LTQ with a target ion setting of 3e4 and a 
maximum fill-time of 500 ms. Dynamic exclusion 
for selected precursor ions was set at 30 s.
online labeling
All online labeling steps were performed at a 
flow speed of 5 mL/min with a continuous flow 
of buffer A. All reagents were injected with the 
autosampler using short injection programs of 
5–20 min, depending on the injected volume. Af-
ter loading the trap column with the first sample 
in 5% formic acid (FA), light isotope labeling was 
performed by flushing the trap column with 40 
mL of 0.04% formaldehyde and 6 mM cyanoboro-
hydride in 50 mM sodium phosphate buffer, pH 
7.5. After washing the trap column with 10 mL 
of 5% FA, the second sample was loaded. Heavy 
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isotope labeling was then performed using 40 mL 
of 0.04% deuterated formaldehyde and 6 mM 
cyanoborohydride in 50 mM sodium phosphate 
buffer, pH 7.5. Finally, after washing with 40 mL of 
5% FA, regular LC/MS analysis was performed as 
described above.
Proteasome purification
Proteasome samples were purified from bovine 
liver and spleen. The purification was monitored 
in each step using fluorescent probes for protea-
some activity, followed by SDS-PAGE as has been 
described before.11 After homogenization of the 
tissues in phosphate buffered saline, the extracts 
were clarified by centrifugation (27000  g, 4 °C, 
50 min.). After precipitating unwanted proteins 
using 40% saturated ammonium sulfate and cen-
trifugation, the proteasome-containing fraction 
was precipitated by increasing the ammonium 
sulfate concentration to 60% saturation. After 
centrifugation, precipitated proteins were dis-
solved in 10 mM Tris-HCl (pH 7.4) and dialyzed 
against the same buffer to remove all ammonium 
sulfate. The dialyzed solutions were further puri-
fied using a 10–40% sucrose gradient at 28,000 
rpm at 4 °C for 16 h. Fractions containing liver and 
spleen proteasome activity were pooled for DEAE 
(diethylaminoethyl) separation (DEAE-Sephadex 
A25 and DEAE-Sephacel resin, respectively). Af-
ter incubating the proteins with the DEAE resin 
for 30–60 min (80 mM potassium acetate buffer 
containing 20 mM Tris-HCl, pH 7.2, and 5 mM 
magnesium acetate for the Sephadex resin and 
10 mM Tris-HCl, pH 8.0 containing 1 mM EDTA for 
the Sephacel resin), the resin was washed, and 
proteins were eluted using and increasing NaCl 
concentrations. All proteasome-containing frac-
tions were pooled and concentrated by means 
of a nitrogen filter and protein concentrations 
determined using the Bradford assay (Bio-Rad). 
Proteasome preparation were stored at -80 °C. To 
check the purity of the proteasome preparations, 
samples were freeze-dried, boiled in reducing 
sample buffer, and analyzed by 12.5% SDS-PAGE 
using a PROTEAN II xi Cell system (Bio-Rad) fol-
lowed by Coomassie Brilliant Blue staining. To 
visualize the active subunit composition of liver 
and spleen proteasome samples, 1 mg of protea-
some was incubated with 500 nM of Me4Bodipy-
FL probe (a close analog of the bodipyFL-probe 
described previously) for 1 h at 37 °C. Proteins 
were denatured by being boiled in reducing sam-
ple buffer and analyzed by 12% SDS-PAGE using 
the NuPAGE pre-cast gel system (Invitrogen). The 
gel was then scanned for fluorescence emission 
using a ProXPRESS two-dimensional Proteomic 
imaging system (Perkin Elmer).
Trypsin digestion
Whole tissue lysates were separated by 12% SDS-
PAGE followed by staining with Coomassie Bril-
liant Blue. Gel lanes were cut into slices, which 
were washed with MilliQ and 0.6% HAc/80% 
acetonitrile (ACN). Prior to in-gel digestion, pro-
teins were reduced with 1,4-dithiothreitol (6.5 
mM) and alkylated with iodoacetamide reagent 
(54 mM). After thorough washing, pieces were 
rehydrated in trypsin solution (10 ng/l) on ice. 
After addition of 30 ml of NH4HCO3 (50 mM, pH 
8.5), samples were digested for 16 h at 37 °C. 
Supernatant of the digest was collected. The gel 
pieces were washed for 30 min in 5% formic acid 
at room temperature, after which the superna-
tant of this washing step was combined with 
the earlier fraction and stored at 30 °C until the 
analysis. Purified proteins and proteins complex-
es were digested in-solution after reduction and 
alkylation. Digestion was performed using 50 mM 
NH4HCO3 at 37 °C for 16 h, with a protein/trypsin 
ratio of 1:100 by weight. Prior to injection, sam-
ples were diluted in MilliQ water containing 5% 
formic acid.
Data processing and analysis
Raw MS data were converted to peak lists using 
Bioworks Browser software, version 3.1.1. For 
protein identification, MS/MS data were com-
pared with the International Protein Index murine 
(v3.36, 51424 entries searched) or bovine (v3.22, 
32915 entries searched) data bases (depending 
on the sample analyzed) using Mascot Version 
2.1 (Matrix Science) with trypsin at the enzyme, 
allowing 1 missed cleavage. Precursor and frag-
ment mass tolerances were set at 6 ppm and 0.9 
Da deviation, respectively. As fixed modifications, 
carbamidomethylation (Cys) and dimethylation 
(Lys, N-terminal) were set as well as the following 
variable modifications: dimethylation: 2H(4) (Lys, 
N-terminal) and Oxidation (Met). Proteasome 
proteins were identified with a minimal Mascot 
protein score of 48 using at least two identified 
peptides with a Mascot ion score of >35 and an 
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expect value of <0.005. At these settings, the false 
discovery rate was 0.68% as determined using a 
decoy data base. The only exception was the pro-
tein PSME2, which was identified with only one 
peptide (Mascot peptide score 48) fulfilling those 
criteria. The Mascot MS/MS annotation of that 
peptide is supplied in Figure S5. Relative peptide 
abundance was calculated from extracted ion 
chromatograms of the different isotopic variants 
using MS-Quant software.19  Very low intensity 
peptides (extracted ion chromatogram intensity 
< 3000) as well as peptides with a poor extracted 
ion chromatogram or MS/MS spectrum were 
excluded after manual inspection. The program 
StatQuant20 was used to normalize the quantita-
tion and calculate standard deviations of the log 
2 of the ratios of all quantified peptides per pro-
tein. Where appropriate, quotation experiments 
were repeated with the light and heavy labels 
switched. 
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SUPPlemenTAry InFOrmATIOn 
OnlIne
More examples of BSA peptides before and after 
double labeling can be found in supplementary 
Figure S1. All quantitation results shown are list-
ed in tables S1–S4. All identification results have 
been uploaded to PRIDE (under project title “Se-
quential Labeling for Protein Quantitation”) and 
identification details for the proteasome proteins 
are supplied in table S5. This material is available 
via the Internet at http://www.mcponline.org, as 
supporting information of Molecular & Cellular 
Proteomics 7, 1755-1762.
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Summary and prospects: 
development and use of chemical proteasome probes 
The ubiquitin-proteasome system is responsi-
ble for the degradation of proteins involved in 
a wide variety of cellular processes, including 
cell proliferation and survival, cell-cycle con-
trol, transcriptional regulation and cellular 
stress responses, as well as for the destruc-
tion of redundant and misfolded proteins. 
The ubiquitin proteasome system is an attrac-
tive pharmacological target for the treatment 
of cancer, because of the higher sensitivity of 
malignant cells to proteasome inhibition com-
pared to normal cells, and the proteasome 
inhibitor bortezomib has been approved for 
the treatment of multiple myeloma (MM) 
and mantle cell lymphoma. Bortezomib treat-
ment is however associated with substantial 
adverse effects, and the occurrence of both 
primary and secondary resistance has been 
reported. Consequently, there is an ongoing 
search for novel proteasome inhibitors that 
are able to overcome bortezomib resistance 
and that are better tolerated to increase their 
therapeutic potential. Several second-gener-
ation proteasome inhibitors, which differ in 
their mode of inhibition and subunit specific-
ity, have entered clinical trials, including mari-
zomib and CEP-18770. 
Techniques that are commonly used to moni-
tor proteasome activity include the applica-
tion of fluorogenic substrates, small mole-
cule-based activity assays and models based 
on recombinant reporter proteins. Tradition-
ally, fluorogenic substrates are used to mea-
sure the activity of the different proteasome 
active sites, but most fluorogenic substrates 
cannot be used in cells, and prior cell lysis is 
required before activity measurements can 
be performed. Reporter proteins can be used 
in living cells, but their use is limited to genet-
ically altered cells or organisms and therefore 
does not allow profiling of patient material. 
In addition, their activity readout depends on 
the balance between synthesis and degrada-
tion of fusion proteins, which involves many 
cellular factors other than the proteasome, 
including the rate of fusion-protein synthesis. 
With proteasome inhibitors in use in the clinic 
and with clinical trials in progress investigat-
ing the treatment of several proteasome in-
hibitors for a variety of hematologic and solid 
malignancies, accurate methods that allow 
profiling of proteasome inhibitor specificity 
and efficacy in patients are in demand. 
In chapter 1, the development of chemical 
proteasome probes that provide such meth-
ods is described. In chapter 1.2, we describe 
the first small molecule-based activity assay 
in its class that could be used to profile the 
specificity of proteasome inhibitors in living 
cells. This dansylated vinylsulfone based pro-
teasome probe contains an α,β-unsaturated 
sulfone part that reacts through a Michael 
addition reaction with the γ-hydroxy moiety 
of the N-terminal threonine residue of cata-
lytic β-subunits of the proteasome, resulting 
in the formation of a β-sulfonyl ether link-
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age. Antibodies against the dansyl moiety are 
used for detection of labeled active subunits 
by SDS-PAGE and Western blot analysis. Using 
this probe, we investigated the in vivo sub-
unit specificities of bortezomib and another 
inhibitor, MG132. When we compared the 
specificities in cultured cells and in crude cell 
extracts, we observed substantial differences 
in activity patterns, stressing the importance 
for bioassays compatible with live cells to 
ensure accuracy of such measurements. In 
chapter 1.3, we describe the further optimi-
zation of this probe by replacement of the 
environment sensitive and low quantum yield 
dansyl fluorophore by high quantum yield 
fluorophores that allowed for direct scanning 
of the SDS-PAGE gel for fluorescence emission 
of fluorescently labeled subunits. In order to 
be able to select for effective fluorescent pro-
teasome inhibitors with good biochemical 
and biophysical properties, we embarked on 
the synthesis of a range of fluorescent inhibi-
tors. Two differentially labeled probes tested 
proved suitable to study proteasome activity 
in cell extracts, living cells and murine tissues 
using a range of techniques including SDS-
PAGE, confocal laser scanning microscopy and 
flow cytometry.
In chapter 2, these fluorescent proteasome 
probes were used to study to the proteasome 
inhibitory profiles of two second-generation 
proteasome inhibitors, CEP-18770 and mari-
zomib, in a preclinical model of MM and in pa-
tients in clinical trials, respectively. In chapter 
2.1, we compared bortezomib and CEP-18770 
in a variety of in vitro and preclinical ex vivo 
models. In a panel of cell lysates and cell lines, 
both proteasome inhibitors were equipotent 
in inhibiting distinct subunits of the protea-
some, with proteasome activity recovering 
similarly after withdrawal of either inhibitor. 
In contrast, in a preclinical MM model, CEP-
18770 inhibited tumor proteasome activity 
to a significantly higher extent compared to 
bortezomib, while the two inhibitors had an 
equal capacity to inhibit the proteasome in 
normal tissues. In addition, we showed that 
CEP-18770 was able to inhibit proteasomes 
and overcome bortezomib resistance in cells 
with acquired bortezomib resistance in vit-
ro. Marizomib is currently being evaluated 
in phase I clinical trials for the treatment of 
both solid and hematologic tumors, enabling 
a detailed study of patient response to mari-
zomib treatment. In chapter 2.2, we validated 
the use of a fluorescent proteasome activity 
probe for profiling proteasome inhibition in 
both packed whole blood (PWB) and periph-
eral blood mononuclear cells (PBMCs) using 
marizomib- or bortezomib-treated rats. In ad-
dition, we developed a protocol that enables 
the use of this fluorescent probe to profile 
blood samples from patients that are treated 
with proteasome inhibitors. We showed that 
PWB, which contains >98% red blood cells, re-
sponded differently to proteasome inhibitors 
and recovered slower from proteasome inhibi-
tion compared to PBMCs. These data caution 
against the use of PWB as a model system to 
monitor the effects of proteasome inhibitors 
in animals or patients, as is routinely done. 
In addition, we used the fluorescent activity-
based probe to demonstrate that both initial 
proteasome activity level in cells and the abil-
ity of cells to change their proteasomal sub-
unit composition in response to marizomib 
treatment may be important determinants of 
sensitivity to proteasome inhibitors. 
Collectively, the findings presented in chap-
ter 2 demonstrate that chemical proteasome 
activity probes can reliably assay proteasome 
activity in vitro and ex vivo in a broad range 
of tissue types, both in preclinical models 
and during clinical trials. Furthermore, these 
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probes may enable prediction of patient re-
sponses to proteasome inhibitors, which can 
contribute to a more personalized protea-
some inhibition strategy to improve the ther-
apeutic potential of this class of drugs. 
We expect that the development of second-
generation proteasome inhibitors will likely 
result in the generation of inhibitors that 
can overcome resistance and may ultimately 
contribute to better patient outcome. Intra-
venously administered proteasome inhibitors 
likely saturate proteasomes in red blood cells, 
which predominantly display constitutive 
activity, before peripheral sites are reached. 
Specific immunoproteasome inhibitors may 
saturate blood proteasome at relatively low 
concentrations, resulting in higher inhibitor 
concentrations in tumor cells. This suggests 
that immunoproteasome inhibitors may in 
future provide a good alternative for tumors 
that have high intrinsic immunoproteasome 
activity. An interesting strategy to overcome 
resistance to the current generation of pro-
teasome inhibitors may be the development 
of inhibitors that do not interfere with the 
20S core, but with other elements of the UPS. 
Experiments setting up a high-throughput 
flow cytometry-based assay that can be used 
to measure both proteasome activation and 
proteasome inhibition in both cultured and 
primary cells are currently ongoing. This as-
say allows screening of large compound or 
siRNA libraries to identify either direct regula-
tors of proteasome activity, such as inhibitors 
of the 20S core, or modulators that interfere 
elsewhere in the ubiquitin-proteasome path-
way. This assay is currently optimized for the 
flow cytometry assisted measurement of 
overall proteasome inhibition in tumor cells 
originating from complex patient samples. 
We expect that our flow-cytometry based 
proteasome activity assay will not only iden-
tify proteasome inhibitors, but also activators 
of the ubiquitin proteasome system. These 
activators may find use in the treatment of 
neurodegenerative diseases, which are often 
characterized by a decrease in intracellular 
proteasome activity. In addition, the devel-
opment of proteasome inhibitors that are 
specific for proteasome subtypes or bacterial 
proteasome may broaden the clinical applica-
tion of UPS-modulating compounds in cancer, 
infectious- and autoimmune diseases.

Chapter 3
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Transpeptidation and reverse proteolysis and their 
consequences for immunity
Celia r. Berkers,§ Annemieke de Jong,§ Huib Ovaa* & Boris rodenko
InTrODUCTIOn
A broad repertoire of antigenic peptides is 
presented at the cell surface to the immune 
system by major histocompatibility complexes 
(MHCs) class I and class II, which are known in 
humans as human leukocyte antigens (HLAs) 
class I and class II. Intracellular proteins form 
the source of antigens that are presented by 
MHC class I, enabling the immune system to 
monitor changes in intracellular protein con-
tent and sense malignant transformation or 
the presence of viral proteins. Recognition of 
these foreign or abnormal peptides by CD8+ 
cytotoxic T cells ultimately results in the elimi-
nation of the antigen presenting cell.1,2 MHC 
class I antigens are primarily generated in the 
cytosol, where proteins are initially degraded 
by the proteasome into smaller fragments. In 
order to fit the MHC class I binding groove, 
these peptides undergo further N-terminal 
trimming by various aminopeptidases,3,4 that 
include tripeptidylpeptidase II (TPPII), bleomy-
cin hydrolase, thymet oligopeptidase, puro-
mycin sensitive aminopeptidase, neurolysin, 
and leucine aminopeptidase, although many 
other proteases may be involved in this trim-
ming process. After processing, these pep-
tides are transported into the endoplasmic 
reticulum (ER), where some can be loaded 
onto MHC class I directly, while others may 
require additional N-terminal trimming by ER-
associated aminopeptidase (ERAAP).5
Antigens generated from exogenous  patho-
gens are presented via the MHC class II path-
way, which leads to the activation of CD4+ T 
helper cells. Following endocytosis by profes-
sional antigen presenting cells, exogenous 
proteins are degraded in early endosomes, 
late endosomes and lysosomes in a pH-de-
pendent manner. Association of thus formed 
peptides with MHC class II can take place 
in any of these compartments,6 but occurs 
mainly in late endocytic structures called MIIC 
compartments. Cysteine proteases, including 
cathepsins S, L, B, F, H and V as well as aspar-
Division of Cellular Biochemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The 
Netherlands. 
reverse proteolysis and transpeptidation lead to the generation of polypeptide sequences 
that cannot be inferred directly from genome sequences as they are post-translational 
phenomena. These phenomena have so far received little attention although the physi-
ological consequences may reach far. The protease mediated synthesis of several immu-
nodominant mHC class I antigens was recently reported, underscoring its importance to 
immunity. reverse proteolytic and transpeptidation mechanisms as well as conditions 
that favor successful protease-catalyzed synthetic events are discussed here.
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agine endopeptidase (AEP), have mainly been 
implicated in antigen processing, but various 
metallo-, aspartic acid- and serine-proteases 
have been shown to be involved in MHC class 
II antigen processing as well .6
Recently, it has become apparent that not 
only contiguous antigens, but also non-con-
tiguous antigens, that consist of two post-
translationally fused peptides, can be pre-
sented to the immune system.1,7,8 The ligation 
that produces these epitopes is thought to be 
catalyzed by proteases in vivo. Here, we sum-
marize how and under which conditions pro-
teases catalyze peptide ligation, as well as the 
consequences of this process for immunity.
PrOTeASe-CATAlyZeD PePTIDe 
lIgATIOn
Based on their proteolytic mechanism, pro-
teases can be divided into five classes,9,10 
and broadly form two groups: cysteine, ser-
ine, and threonine proteases, that hydrolyze 
peptide bonds via the formation of an acyl-
enzyme intermediate (Figure 1), and aspartic- 
and metalloproteases, that act via the direct 
activation of a water molecule that acts as the 
primary hydrolyzing species. Since proteases 
are catalysts, they alter the rate at which the 
thermodynamic equilibrium of the protein 
hydrolysis reaction is reached, but they do not 
change the overall thermodynamic equilibri-
um between starting materials and proteolyt-
ic products.11,12 Consequently, all proteases 
are also able to catalyze the reverse reaction, 
i.e. peptide bond synthesis, provided that the 
reaction conditions favor this process, which 
is referred to as reverse proteolysis (Scheme 
1). Furthermore, proteases that act via an 
acyl- enzyme intermediate can catalyze pep-
tide bond formation via a transpeptidation 
mechanism, which competes with hydrolysis 
(Figure 1).
reVerSe PrOTeOlySIS
Peptide ligation by reverse proteolysis was 
first reported in the 1930s, when papain and 
chymotrypsin, a cysteine and serine pro-
tease, respectively,were used as catalysts for 
enzymatic synthesis.13-16 Reverse proteolysis 
involves the direct reversal of catalytic hy-
drolysis by proteases, as shown in Scheme 
1, in which Kion is the equilibrium constant 
of ionization and Kpept is the equilibrium con-
stant of peptidation.11,12,17 In an aqueous en-
vironment, the reaction will be driven in the 
direction of hydrolysis.11 Furthermore, the li-
gation of peptide fragments is an endergonic 
process (entropy is lost) and is therefore ener-
getically unfavorable.17 One strategy to direct 
the equilibrium towards ligation is based on 
the law of mass action.12,17,18 In vitro, prod-
uct removal by precipitation,19-22 the use of 
biphasic systems,23 the use of a large molar 
excess of one of the substrates,11,17 or a con-
formational trap22,24,25 have all been shown 
to promote ligation. Alternatively, the equi-
librium of ionization can be manipulated to 
enhance ligation.12,17,18 Peptide bond forma-
tion is dependent on the concentration of un-
charged substrates formed in the ionization 
equilibrium, which is dependent on their pKa 
values. Therefore, the pH optimum for liga-
tion lies in the range between the pKa of the 
scheme 1 | mechanism of reverse proteolysis. 
RN and RC refer to the N-terminal and C-terminal 
ligation partners, respectively. Kion and Kpept refer 
to the ionization and peptidation equilibrium 
constants, respectively.
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Figure 1  |  general mechanism of protease mediated hydrolysis and transpeptidation via an acyl-
enzyme intermediate. (i) The protein or peptide substrate with its P1, P2, P3 and P1', P2' and P3' residues 
docks into the complementary S1, S2, S3 and S1', S2' and S3' pockets of the protease. (ii) Nucleophilic 
attack of the reactive residue on the enzyme results in formation of the acyl-enzyme intermediate. (iii) 
The cleaved C-terminal substrate fragment leaves the active site and hydrolysis of the acyl-enzyme 
intermediate can take place - path a - under release of the N-terminal peptide or protein fragment. (iv) 
Alternatively, the vacated S1', S2' and S3' binding sites are subsequently occupied by a protein or pep-
tide fragment containing complementary P1', P2' and P3' residues. Aminolysis by the free N-terminus 
- path b - results in net transpeptidation, and competes with hydrolysis - path a.
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α-carboxylic group of the N-terminal compo-
nent and the amino group of the C-terminal 
substrate, which is normally found between 
pH 6 and 7.17 Several water-miscible organic 
co-solvents can reduce the acidity of the 
α-carboxy group of the N-terminal compo-
nent, which shifts Kion in favor of ligation, and 
have therefore been used in vitro to influence 
the ionization equilibrium.18 Furthermore, or-
ganic co-solvents reduce the activity of water 
by lowering its concentration, thereby ham-
pering the hydrolysis reaction.11 
Under physiological conditions, the equilib-
rium as shown in Scheme 1 favors hydrolysis 
and ligation is thought by many to be negli-
gible in vivo.11 It has been postulated, how-
ever, that macromolecular crowding, defined 
by the high total concentration of background 
molecules, such as lipids, proteins, nucleic 
acids and carbohydrates that are present in 
cells, shifts the equilibrium towards ligation in 
vivo.26,27 Due to non-specific steric repulsions, 
the presence of a significant volume fraction 
of macromolecules places constraints on the 
placement of additional macromolecules.28 
Macromolecules therefore exclude volume 
to each other. This excluded volume effect 
reduces the configurational entropy,29 which 
is energetically unfavorable. Therefore, pro-
cesses that are accompanied by a reduction 
in excluded volume, such as macromolecular 
compaction and association, are facilitated 
in a macromolecularly crowded environ-
ment.26-29 Consequently, molecular crowding 
has been shown to promote peptide liga-
tion24,25,30,31 as well as the synthesis of proteins 
from partly structured large polypeptides,32,33 
in cases where ligation led to a large reduc-
tion in excluded volume. This suggests that 
in vivo, proteases might also catalyze peptide 
bond synthesis in addition to their ability to 
function as hydrolases.
TrAnSPePTIDATIOn
Transpeptidation occurs when the rate of 
aminolysis is faster than or comparable to the 
rate of hydrolysis, which is dependent on the 
competition between nucleophilic compo-
nents and water for the nucleophilic attack 
on the acyl-enzyme intermediate (Figure 1). 
In vitro, the use of water-miscible organic 
co-solvents or biphasic systems can help to 
reduce the water content and therefore fa-
vor aminolysis over hydrolysis.34-37 High reac-
tant concentrations36,38,39 and a high pH,39,40 
preferably higher than the pKa of the attack-
ing nucleophile to ensure its unprotonated 
state,11,41 have also been shown to promote 
transpeptidation. Evidently, the specificity of 
the protease for the reactants, is also a cru-
cial factor17 as its active site has to be able 
to accommodate reactants for productive 
reactions. Both in vitro studies, in which dif-
ferent amino acids or peptides were used as 
nucleophiles,38,39,42-45 and an in vivo study46 
(see below) indicate that ligation efficiencies 
are highly dependent on the fit of the amino 
acids at the P1', P2' and/or P3' positions in the 
S' binding sites (Figure 1). 
Examples of protease-catalyzed transpepti-
dation occurring in vivo are scarce, but few 
examples have been reported. Asparaginyl 
endopeptidases (AEPs) have been implicated 
in the catalysis of two distinct transpeptida-
tion events inplants: (1) the post-translational 
processing of the lectin concanavalin A (con 
A) in maturing jack beans47,48 and (2) the bio-
synthesis of the backbone of plant-produced 
cyclotides,46,49 the largest family of circular 
proteins that are notoriously stable, due to 
the combination of a cyclic backbone and a 
cysteine knot of three disulfide bonds.
During cleavage of pro-con A into smaller 
fragments, two of these fragments are ligated 
in the reverse order by AEP in a transpeptida-
tion reaction to form mature con A.47 Both the 
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increased stability of mature con A compared 
to its unligated precursor48 and the occur-
rence of a proximity effect may explain why 
transpeptidation is favored over hydrolysis in 
vivo. If protein complexation or conformation 
positions the amine-donating component in-
volved in transpeptidation in close proximity 
to the acyl ester component, this will facilitate 
its nucleophilic attack on the acyl-enzyme in-
termediate and hence favor aminolysis. Al-
though such an effect has never been impli-
cated in con A transpeptidation, the proposed 
structure of pro-con A50 indicates this is likely 
the case.
Plant-produced cyclotides exhibit a broad 
range of bioactivities, amongst which are an-
timicrobial-, hemolytic-, anti-HIV- and insecti-
cidal activities.46,49 Although the mechanism is 
not fully understood, cyclization of these pro-
teins in vivo is thought to be the result of an 
AEP-catalyzed transpeptidation reaction.46,49 
The cysteine knots are believed to keep the 
amine-donating and carboxy-donating com-
ponents involved in transpeptidation in close 
proximity to each other, indicating that a 
proximity effect facilitates ligation in vivo. 
Furthermore, a tripeptide binding motif at 
the N-terminus of the AEP bound propeptide 
binds, after release of the cleaved C terminal 
propeptide fragment, to the vacated S1', S2' 
and S3' subsites, which facilitates cyclization.46 
This suggests that substrate specificity further 
enhances transpeptidation.
The proteasome, a threonine protease, has 
been shown to catalyze transpeptidation dur-
ing the production of antigens for presenta-
tion by MHC class I. To date, three non-con-
tiguous immunodominant antigens, formed 
by the ligation of two peptides from the same 
parental protein during proteasomal degra-
dation, have been identified. The first non-
contiguous antigen, which resulted from the 
fusion of residues 172–176 and 217–220 from 
fibroblast growth factor-5 was identified from 
a patient with renal cell carcinoma.8 Vigneron 
et al. identified a second non-contiguous tu-
mor antigen, composed of residues 40–42 
and 47–52 of the melanocytic glycoprotein 
gp100, in a melanoma patient.7 Subsequent-
ly, an antigen was identified in a recipient of 
MHC-matched hematopoietic cell transplan-
tation, consisting of two peptides from the 
SP110 nuclear body protein, ligated in the re-
verse order.1 Proteasomal involvement in the 
ligation events was suggested,1,7,8 and in vitro 
digestion experiments with purified 20S pro-
teasome confirmed this notion.1,7 Further ex-
periments showed that both cleavage of the 
carboxy component and a free N-terminus 
at the amine-donating reaction component 
were required for ligation, indicating that 
splicing in the proteasome occurs via a trans-
peptidation mechanism.1,7 In most cytosolic 
proteases the reaction products diffuse away 
too quickly under physiological conditions to 
promote ligation. However, in barrel-shaped, 
self-compartmentalizing proteases such as 
the proteasome,51 reaction partners are gen-
erated in situ and remain confined to a small 
volume, resulting in their high local concen-
trations and a high degree of substrate speci-
ficity, which likely facilitates peptide ligation 
in vivo.
COnSeqUenCeS FOr ImmUnITy
Several reports showthat transpeptidation oc-
curs readily under physiological conditions in 
vitro, during digestion of proteins for structur-
al analysis. Trypsin,52-56 Staphylococcus aureus 
V8 protease,52,56 and Lys-C endoprotease56 
were all shown to catalyze transpeptidation. 
Based on their observations, Fodor and Zhang 
stated that transpeptidation occurs more of-
ten than was known previously. 56 Schaefer et 
al. emphasized that available database search 
algorithms fail to detect transpeptidation 
products, as they cannot be inferred from the 
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genome.55 In vivo, the extent to which pro-
teases catalyze transpeptidation rather than 
hydrolysis is fully dependent on specific local 
conditions. γ-Glutamyltranspeptidases, for 
example, which bind glutathione and function 
predominantly as hydrolases in vitro,57 are as-
sumed by many to mainly catalyze transpepti-
dation reactions in vivo due to the presence of 
high concentrations of amino acids in kidney 
as amine-donating reaction components.58,59 
The conditions promoting ligation described 
above, including molecular crowding, proxim-
ity effects, a high degree of substrate speci-
ficity or confinement can certainly be met 
by proteases other than AEPs and the pro-
teasome, suggesting that protease-catalyzed 
peptide ligation represents a more wide-
spread and common mechanism than cur-
rently assumed. Macromolecular crowding in 
the cytosol may facilitate ligation of non-con-
tiguous polypeptides to form novel proteins. 
During proteasomal degradation of cytosolic 
proteins into peptides, transpeptidation pro-
duces spliced and reordered antigens. 1,7,8 No-
tably, both bleomycin hydrolase60.61 and TP-
PII,62,63 peptidases that process these antigens 
downstream of the proteasome, are thought 
to assemble into self-compartmentalizing 
proteases, which may facilitate transpeptida-
tion. Bleomycin hydrolase has been shown to 
be able to convert itself into a peptide ligase 
in vitro.64 This suggests that transpeptidation 
is likely to occur during MHC class I epitope 
trimming downstream of the proteasome. 
Furthermore, functional homologs of mam-
malian AEP, which is actively involved in MHC 
class II antigen production, have been shown 
to catalyze transpeptidation in plants.46,49
In our current understanding of the cellular 
antigen presenting pathways, proteins are 
cleaved in contiguous sequences,65 creating 
antigens that can traditionally be inferred 
from genomic sequences, and in which re-
verse proteolysis and transpeptidation have 
not been taken into account. The repertoire 
and diversity of both foreign and self antigens 
in the MHC routes may thus be significantly 
broader than currently thought. Amplifying 
the diversity of epitopes increases the chance 
that one or more of these epitopes are rec-
ognized by CD4+ and CD8+ T cells, which ul-
timately results in the elimination of infected 
or malignant cells. It is thus likely that the 
expansion of the epitope repertoire as a re-
sult of transpeptidation or reverse proteolysis 
events, results in enhanced anti-tumor im-
munity as well as in better protection from 
pathogens. Increasing diversity by V(D)J re-
combination is essential for protection from a 
constantly changing bacterial and viral reper-
toire.65 V(D)J recombination results in a large 
variety of antibodies and T cell receptors, 
while differential splicing of RNA in B lympho-
cytes results in the production of either mem-
brane bound or secreted antibody molecules. 
The protease-catalyzed ligation of peptides or 
even proteins could be yet another way of the 
immune system to increase diversity and en-
hance protection.
The increased diversity of self-antigens on the 
other hand demands additional negative se-
lection to prevent autoimmunity. During T cell 
development, the thymus is responsible for 
the negative selection of T cells, resulting in 
a T cell repertoire that only recognizes foreign 
antigens.66 Autoimmunity against spliced anti-
gens may occur if self-antigens are spliced dif-
ferently in antigen presenting cells compared 
to cells in the thymus, thereby evading nega-
tive selection. Differential splicing in different 
tissue types will occur if splicing is a random 
process. However, both transpeptidation and 
reverse proteolysis reactions only take place 
under specific circumstances, requiring, for 
instance, a high degree of substrate specific-
ity. Therefore, it is likely that splicing is a con-
trolled process that is performed identically 
in different cell types. Little data is available 
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to confirm this notion, but notably, Vigneron 
et al. have found identical results with pro-
teasomes purified from either a human renal 
cell carcinoma line or human erythrocytes.7 In 
splicing experiments performed by Warren et 
al. also constitutive and immunoproteasomes 
seem to behave in a similar fashion.1 These 
findings may indicate that proteasomes from 
different cell types all behave similarly and 
point to a tightly controlled splicing process, 
which is carried out identically in different cell 
types or even with different proteasome com-
positions. The spliced antigens produced by 
both constitutive and immunoproteasomes 
in the thymus are therefore not likely to be 
different from antigens produced in other 
tissues. It should be noted that Murata et al. 
have discovered a thymus-specific protea-
some type, which contains a novel catalytic 
subunit (β5t) and displays different catalytic 
properties.67 However, these thymoprotea-
somes are not involved in negative T cell se-
lection,67 and the antigens produced by this 
type of proteasome are therefore not inter-
fering with autoimmunity control. Together, 
these reports suggest that transpeptidation 
and reverse proteolysis reactions in the cell 
are not likely to lead to an increase in the rec-
ognition of self-antigens.
It is imperative to know the identity of the 
antigens presented by the MHC pathways, 
as they mediate T cell responses to cancer 
and transplants, as well as bacterial and viral 
infection. The characterization of novel anti-
gens is therefore important for vaccine devel-
opment, T cell-based therapeutic strategies as 
well as pharmacological immunosuppression. 
Further studies need to show the contribu-
tion of different proteases to the production 
of noncontiguous antigens and to elucidate 
their role in immunity. 
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How the proteasome cleaves and religates peptides to 
expand the antigen repertoire
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InTrODUCTIOn
Following malignant transformation or vi-
ral infection, a broad repertoire of antigenic 
peptides is presented on the cell surface by 
MHC class I complexes, enabling CD8+ T cells 
to sense the change in intracellular protein 
content, which eventually leads to a kill of 
the antigen presenting cell.1 The 26S pro-
teasome, a large threonine protease com-
plex, is largely responsible for the genera-
tion of these antigenic peptides in vivo. The 
26S proteasome consists of a 20S core, in 
which the catalytic activity resides, and 19S 
regulatory caps, which regulate the entry of 
substrates into the 20S core. The 20S core is 
formed by four stacked rings consisting of 7 
subunits each, with an overall architecture of 
α(1-7)β(1-7)β(1-7)α(1-7). Catalytic activity 
is provided by three β subunits, termed β1, 
β2 and β5, which are responsible for the 
caspase-like, tryptic and chymotryptic activ-
Divisions of aCell Biology II and bImmunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amster-
dam, The Netherlands. cThe Netherlands Vaccine Institute, Unit Research and Development, P.O. Box 457, 3720 AL 
Bilthoven, The Netherlands.
recently, three HlA class I epitopes have been reported, in which two distant parts of a 
protein are excised and ligated together to form a novel peptide. Such non-contiguous an-
tigens can be produced by the proteasome via a transpeptidation mechanism, suggesting 
that splicing rules are likely to exist. In the present study we use small libraries of short 
peptides to identify amino acid sequences that are likely to promote this transpeptidation 
process and to deduce splicing rules for both the primed and non-primed proteasomal 
sites. Subsequently, we use a long viral polypeptide from the Influenza A neuraminidase 
1 protein as a model to validate these rules. we quantify peptide ligation using a model 
peptide and demonstrate that it can occur with up to 30% ligation efficiency if structural 
requirements for ligation are met by both ligating partners. In addition, we show that 
protein splicing preferentially occurs via intrastrand recombination (recombination of 
peptides from the same protein) and that many spliced products may be formed from a 
single protein, some of which are likely to be immunogenic. Our data suggest that protein 
splicing occurs frequently and may occur at least 1,000 times more efficient as assumed 
previously. Therefore, protein splicing may play a much more significant role in immunity 
than previously assumed. The splicing rules presented here will facilitate the prediction 
and detection of spliced antigens to study their roles in immunity. 
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ity of the proteasome, respectively, and all 
have different cleavage preferences. The β1 
subunit cleaves behind acidic amino acid resi-
dues, the β2 subunit prefers to cleave after 
basic residues, and the β5 subunit cleaves 
behind hydrophobic or aromatic residues. 
In immune tissues or under influence of the 
cytokine interferon-γ, these subunits are re-
placed by their immunoproteasomal coun-
terparts, termed β1i, β2i and β5i to form the 
immunoproteasome,2 while the existence 
of mixed-type hybrid proteasomes has also 
been reported.3-5
Recently, it has become apparent that not only 
contiguous antigens, but also non-contiguous 
antigens, that consist of two post-translation-
ally fused peptides, can be presented to the 
immune system.6-8 To date, three immuno-
genic, spliced antigens have been described, 
RTK-QLYPEW,7 NTYAS-PRFK6 and SLPRGT-STPK8 
(where the dash indicates the site of ligation). 
To form RTK-QLYPEW and NTYAS-PRFK, liga-
tion occurred in-line (i.e. ligation of peptide 
fragments in the order in which they occurred 
in the parent protein), whereas SLPRGT-STPK 
was formed by religation of peptide frag-
ments in the reverse order to that in which 
they occur in the parent protein. The ligation 
that produces these epitopes is thought to 
be catalyzed by the proteasome in vivo via 
a transpeptidation mechanism.7-9 During hy-
drolysis, the N-terminal threonine residue of 
a catalytically active subunit reacts with the 
scissile peptide bond to form an O-acyl en-
zyme intermediate, resulting in the release of 
the C-terminal part of the peptide. In a second 
Figure 1 | Proposed splicing mechanism. The 
protein or peptide substrate (the N-terminal 
precursor) with its P1, P2, P3, P4 (red) and P1' and 
P2' residues (orange) docks into the comple-
mentary S1, S2, S3, S4 and S1' and S2' pockets of 
the proteasome. Nucleophilic attack of the hy-
droxyl group of the N-terminal threonine resi-
due of an active subunit results in formation of 
the O-acyl enzyme intermediate. The cleaved 
C-terminal substrate (orange) fragment leaves 
the active site. The vacated S1', S2' and S3', bind-
ing sites are subsequently occupied by a pro-
tein or peptide fragment containing comple-
mentary P1', P2' and P3' residues (the C-terminal 
ligation fragment, blue). Aminolysis by the free 
N-terminus then results in transpeptidation 
and the formation of a novel peptide.
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step, water reacts with the intermediate ester 
resulting in the release of the N-terminal part 
of the peptide. During a transpeptidation re-
action, the amino group of a second peptide 
competes with water for reaction with the in-
termediate ester, resulting in the formation of 
a new peptide bond (Figure 1).10
Proteasomal splicing results in a genuine 
post-translational modification, which can 
increase the diversity of the antigenic pep-
tides presented, but which may also serve 
other yet unknown functions. A greater di-
versity of epitopes increases the chance that 
one or more of these epitopes are recognized 
by CD8+ T cells, which ultimately may result 
in more efficient elimination of infected or 
malignant cells.10-12 It is currently not known 
whether proteasome splicing is a random 
event, or governed by explicit rules. As trans-
peptidation will only be able to compete 
with the hydrolysis reaction when both the 
N-terminal and C-terminal ligation fragments 
fit the active site pockets such that splicing is 
favored (Figure 1), it is not unlikely that splic-
ing rules exist.10 In addition, in barrel-shaped 
proteases such as the proteasome, reaction 
partners are generated in situ and remain 
confined to a small volume, which likely fa-
cilitates peptide ligation.10 Because the vari-
ous proteasomal active sites have different 
architectures, such rules, if existent, are likely 
site-specific. 
In this study, we use short peptides to identify 
amino acid sequences that are likely to pro-
mote transpeptidation reactions, enabling the 
deduction of splicing rules. We validate these 
rules using a long viral polypeptide to mimic 
protein degradation in cells. In addition, we 
quantify the absolute amount of peptide li-
gation and demonstrate that it can occur ef-
ficiently with up to 30% ligation efficiency. 
Finally, we show that protein splicing prefer-
entially occurs via intrastrand recombination 
(recombination of peptides from the same 
protein) and not via random recombination 
of peptides derived from different proteins. 
The elucidation of these splicing rules will fa-
cilitate the prediction and detection of spliced 
antigens to study their roles in immunity. 
reSUlTS
 
rules for proteasomal antigen splicing 
exist
Two types of fragments participate in protea-
somal ligation reactions: 1) N-terminal precur-
sors, that fit into the proteasomal substrate 
binding non-primed pockets, so called S-pock-
ets (S1, S2, S3…Sn, depending on their proximity 
to the scissile peptide bond) and 2) C-terminal 
ligation partners, that fit into the proteasomal 
primed pockets (S1', S2', S3'…Sn').11 Residues in 
the substrate that interact with these protea-
somal specificity pockets are referred to as P1, 
P2, P3…Pn and P1', P2', P3'…Pn', accordingly (Fig-
ure 1).11 For both types of ligation partners, 
rules predicting proteasomal peptide ligation 
were deduced by comparing small libraries 
of potential ligation partners in digestion as-
says. To investigate which C-terminal ligation 
partners were likely to participate in ligation 
reactions, the N-terminal precursor YLDW|SY 
(where the vertical line indicates the site of 
cleavage) was incubated with proteasome in 
the presence of a 5-fold molar excess of the 
C-terminal ligation partner XXXSV in separate 
reactions (in which X is any natural amino 
acid). Transpeptidation led to the accumula-
tion of YLDW-XXXSV, which has affinity for 
MHC class I (where the dash indicates the 
newly formed peptide bond). The extent of 
formation of MHC binders through transpep-
tidation in each sample could be measured us-
ing a fluorescence polarization (FP) assay13,14 
scoring for ligation efficiency (See Supple-
mentary Information and Supplementary Fig-
ure 1 for details). By incubating YLDW|SY with 
proteasome in the presence of XLPSV (where 
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X is any natural amino acid) in 20 separate 
reactions, we established which amino acid 
resides on P1' promoted ligation (Figure 2A). 
In subsequent experiments, YLDW|SY was 
incubated with proteasome in the presence 
of the peptides KXPSV (Figure 2B) or KLXSV 
(Figure 2C) in vitro to define transpeptidation 
rules for the P2' and P3' position. All ligation 
efficiencies were related to the efficiency of 
YLDW-KLPSV formation, which was included 
in all experimental runs. To investigate which 
N-terminal precursors were likely to promote 
Figure 2 | Splicing rules to predict peptide ligation in the proteasome. A-C) Relative ligation efficien-
cies of different C-terminal ligation fragments measured in fluorescence polarization assays, indicating 
splicing preferences for the P1' (A), P2' (B) and P3' (C) positions. Efficiencies were normalized to the 
efficiency of KLPSV, which was included in all experiments and set to 1. Values are averaged over at 
least two independent experiments; error bars represent SEM. Residues that favored ligation on a 
particular position are underlined. D,e) Relative ligation efficiencies of different N-terminal ligation 
precursors measured in LC-MS assays, indicating splicing preferences for the P1 (D) and P2 (e) positions. 
Efficiencies were normalized to the efficiency of YLGL|SY, which was included in all experiments and 
set to 1. Residues that favored ligation on a particular position are underlined. Error bars represent 
SEM. ND: Not determined. F) Summary of the antigen splicing rules determined in these assays. Φ = 
hydrophobic residue; X = any natural amino acid.
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transpeptidation reactions, the N-terminal 
precursor YLXX|SY was incubated with pro-
teasome in the presence of one equivalent of 
the C-terminal ligation partner RLPSV for dif-
ferent time periods in separate reactions, in 
which transpeptidation led to the formation 
of YLXX-RLPSV. In contrast to experiments 
described above, hydrolysis rates differed 
between precursors (Supplementary Figure 
2), hampering analysis of ligation efficiencies 
using the FP assay, which requires a constant 
hydrolysis rate for quantitative comparison of 
transpeptidation efficiencies. Therefore, we 
switched to LC-MS analysis of digestion mix-
tures. Ligation efficiency was defined as the 
percentage of YLXX|SY cleavages that resulted 
in ligation. Although MS is not generally used 
to quantify peptide levels, these peptides dif-
fer by a single amino acid per series and we 
compared efficiencies semi-quantitatively. By 
incubating YLGX|SY or YLXL|SY (where the 
vertical line is the site of cleavage and X is 
any natural amino acid) with proteasome in 
the presence of RLPSV in separate reactions, 
splicing rules for the P1 and P2 positions were 
determined (Figures 2D and 2E). Ligation effi-
ciencies were determined for each time point 
and were normalized to the ligation efficiency 
of YLGL|SY, which was included in all experi-
mental runs. Maximum ligation efficiencies 
were plotted for each residue position in Fig-
ures 2D and 2E.
From these data, distinct peptide motifs that 
are likely to either participate in or to abol-
ish antigen splicing could be deduced for 
both the primed and the non-primed sites 
(Figure 2F). In general, rules seemed most 
strict for positions close to the actual site of 
transpeptidation (P1, P1', P2 and P2'), whereas 
multiple residues on P3' favor transpeptida-
tion. N-terminal precursors that favored liga-
tion fell into the following categories: Type I 
precursors, which contained aspartate or a 
polar uncharged residue on P1 combined with 
a small or polar (but not charged) residue on 
P2 showed high ligation efficiencies but low 
cleavage rates (Figure 2F and Supplementary 
Figure 2A). Type II precursors, which com-
bined a hydrophobic residue on P1 with a ba-
sic or, to a lesser extent, polar residue on P2, 
showed lower ligation efficiencies, but high 
cleavage rates (Figure 2F and Supplementary 
Figure 2A). The higher ligation efficiency of 
Type I precursors and the higher turnover rate 
of Type II precursors suggest that in proteins 
substantial amounts of ligation products may 
be produced from both types of precursor. 
C-terminal ligation partners that promoted li-
gation mostly contained a basic residue (K/R) 
on P1' combined with hydrophobic residue on 
the P2'. An additional hydrophobic residue or 
P/G on P3' enhanced ligation further. Peptides 
containing a second charged residue on P2' or 
P3' in addition to K or R or P1' did not serve as 
C-terminal ligation partners (Figure 2F). 
We conclude from Supplementary Figure 2 
that hydrolysis rates of N-terminal precursors 
were highest when a hydrophobic residue 
was present on P1, suggesting that cleavage 
and thus ligation reactions were performed 
by the β5 subunit, for which the non-primed 
sites are well characterized.15,16 Apart from 
the preference for a basic residue on P1', the 
primed sites on the other hand have so far 
been only poorly characterized.11,15 The amino 
acid preferences for ligation described above 
suggest that ligation efficiencies are highest 
with C-terminal ligation partners that have a 
good fit in the primed sites, judging from the 
requirement of K or R on P1' for successful 
ligation. In addition, they further define the 
architecture of the β5 primed sites and sug-
gest that hydrophobic residues are preferred 
on P2' and to a lesser extent on P3'. N-terminal 
ligation precursors on the other hand seemed 
more likely to be involved in ligation if the fit 
of the side chains of residues on the P1 and P2 
positions in the corresponding S pockets was 
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sub-optimal, as inferred from the lower turn-
over rates for non hydrophobic residues (type 
I precursors).15,16
Splicing of optimized peptide sequences 
occurs with high efficiency
Next, we set out to characterize the effi-
ciency and mechanism of splicing using an 
optimized model peptide. We combined the 
optimized N-terminal precursor YLGD (a) with 
the optimized C-terminal ligation fragment 
RLPSV (c), separated by a two amino acid se-
quence (SY; b) and we incubated this peptide 
YLGD|SY|RLPSV (a|b|c) with proteasome 
(where the vertical lines indicate proteasomal 
cleavage sites). The resulting reaction mix-
tures were analyzed by HPLC by monitoring 
absorption at 280 nm at various time points. 
At 280 nm, only the tyrosine residues in this 
peptide give rise to absorption, enabling 
quantification of hydrolysis and transpepti-
dation events. After a 2-h incubation period, 
the precursor peptide abc was still the main 
component in the digestion mixture (Supple-
mentary Figure 3, red trace), while smaller 
amounts of the hydrolysis products a, ab and 
bc were also visible. In addition, various li-
gation products were formed (Peaks I to IV; 
Supplementary Figure 3) and identified by 
LC-MS as a-a, a-c, a-ab and a-abc (where the 
dash indicates the site of ligation). This sug-
gests that peptide a is a very good precursor 
for ligation, as cleavage of the peptide bond 
between a and b (ab cleavage) resulted in the 
recombination of peptide a with other hy-
drolysis products or the complete precursor 
peptide to form a variety of ligation products. 
When the reaction was allowed to continue, 
the peak ratio changed. Precursor peptide 
abc almost completely disappeared, while hy-
drolysis product a became the main compo-
nent in the digestion mixture (Supplementary 
Figure 3, black trace). 
Ligation efficiency was defined as the per-
centage of ab cleavages that resulted in a liga-
tion event. At 2h, the total ligation efficiency 
was 14% (Figure 3A), suggesting that one li-
gation product was formed every 7 times the 
ab bond was processed by the proteasome. 
Total ligation efficiency decreased gradually 
over time, while the ratio of different liga-
tion products shifted from a-abc to shorter 
products. It is likely that the decrease in the 
amount of precursor abc over time led to 
increased processing of other peptides, in-
cluding ligation products. Therefore, these 
shorter ligation products were probably pre-
dominantly formed by secondary processing 
of a-abc, the most abundant ligation product. 
When the concentration of precursor peptide 
abc was increased, hydrolysis rates increased, 
but the relative ratio of hydrolysis products 
did not shift (data not shown), indicating that 
the proteasomal cleavage preference was not 
altered. However, a 4-fold increase in peptide 
concentration doubled the ligation efficiency 
at 2 h from 15% to 30% (Figure 3B), suggest-
ing that in vitro as many as 1 in 3 ab cleavages 
can result in a ligation event. Especially a-abc, 
resulting from the recombination of peptide a 
with the precursor abc was formed more ef-
ficiently (Figure 3B), suggesting that not only 
the sequence but also the concentration of C-
terminal ligation partner in the proteasome is 
an important determinant for splicing. When 
reactions were allowed to continue, total liga-
tion efficiencies decreased (data not shown), 
in accordance with data shown in Figure 3A. 
The ligation efficiencies of splicing reactions 
for two reported spliced epitopes, RTK-
QLYPEW7 and NTYAS-PRFK6 have been esti-
mated. One spliced molecule of RTK-QLYPEW 
was estimated to be formed from ~ 1 x 104 
precursor molecules RTK|AWNR|QLEPW.7 
The estimated efficiency of NTYAS-PRFK for-
mation was even lower, with roughly one 
spliced peptide formed from ~ 5 x 105 precur-
sor molecules.9 Notably, these low splicing ef-
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Figure 3 | Splicing of optimized peptide sequences occurs with high efficiency and predominantly 
via intrastrand splicing. A) Ligation efficiencies of the formation of different ligation products result-
ing from a|b|c digestion, measured at various time points. B) Ligation efficiencies of the formation 
of different ligation products resulting from digestion of increasing concentrations of a|b|c. C) Mass 
spectrum of a-c, formed during digestion of a|b|c (left panel). Isotope pattern derived from the mass 
spectrum of a-c by integration of mass peaks (right panel). D) Mass spectrum of 15Na-15Nc, formed dur-
ing digestion of 15Na|b|15Nc (left panel). Isotope pattern derived from the mass spectrum of 15Na-15Nc by 
integration of mass peaks (right panel). e) Calculated isotope distribution pattern for intrastrand splic-
ing of a 1:1 digestion mixture of a|b|c and 15Na|b|15Nc. F) Calculated isotope distribution pattern for 
random recombination of a 1:1 digestion mixture of a|b|c and 15Na|b|15Nc. g) Mass spectrum resulting 
from the digestion of a 1:1 mixture of a|b|c and 15Na|b|15Nc (left panel), showing a mixture of a-c and 
15Na-15Nc. Observed isotope pattern of a 1:1 digestion mixture of a|b|c and 15Na|b|15Nc (middle panel). 
Comparison of the observed isotope distribution pattern with the calculated isotope pattern of 56% 
random recombination and 44% intrastrand splicing (right panel). 
ficiencies of 0.0002% – 0.01% were sufficient 
to produce immunogenic epitopes that were 
presented at the cell surface by MHC class I 
to evoke an immune response. The splicing 
reactions creating these epitopes require two 
cleavage steps and for the model peptide de-
scribed above the equivalent reaction would 
be the formation of a-c from abc. Splicing 
efficiencies for a-c formation were between 
1.5% and 3% depending on concentration 
and reaction time. This indicates that splicing 
efficiencies may be several orders of magni-
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tude higher than previously described if op-
timized N- and C-terminal ligation fragments 
are recombined. Therefore, spliced epitopes 
may be presented on the surface of cells to a 
larger extent than previously assumed. 
Splicing of a model peptide occurs mainly via 
intrastrand splicing
Next, the mechanism of abc splicing was 
studied in more detail. In theory, a-c can be 
formed from abc via random recombination 
or via intrastrand splicing of a and c. In the 
latter case, abc is first be processed to ab and 
c. The liberated ab fragment then serves as 
precursor for ligation of the liberated c frag-
ment derived from the same polypeptide 
chain. In contrast, a random ab or abc peptide 
can serve as precursor for c ligation, in which 
case recombination is said to occur randomly. 
To distinguish between random recombina-
tion and intrastrand splicing, a precursor 
peptide was used in which a 15N-labeled ami-
no acid was incorporated in part a and part 
c (15Na|b|15Nc). First, either abc or 15Nab15Nc 
were incubated with proteasome separately, 
and the resulting digestion mixtures were 
analyzed by LC-MS for the presence of a-c 
or 15Na-15Nc (Figures 3C,D). In the digestion 
mixture of abc, a peak with an m/z value of 
476.2 (M0), corresponding to [a-c+2H]2+ could 
be detected (Figure 3C, left panel), which 
showed a characteristic isotope pattern (Fig-
ure 3C, right panel). In the digestion mixture 
of 15Nab15Nc, a peak with an m/z value of 477.2 
and thus with a mass of +2 Dalton (M+2), cor-
responding to [15Na-15Nc+2H]2+, was detected 
(Figure 3D, left panel), displaying a similar 
isotope pattern as a-c (Compare Figures 3C 
and 3D, right panels). Next, a 1:1 mixture of 
abc and 15Nab15Nc was incubated with protea-
some. In this experiment, intrastrand splicing 
would yield equal amounts of two products 
(a-c, and 15Na-15Nc) with masses M0 and M+2. 
The resulting isotope pattern would therefore 
resemble the sum of Figures 3C and 3D, as 
shown in Figure 3E. When recombination of 
a and c in the mixture would be completely 
random on the other hand, indicating that 
intrastrand splicing is not preferred, four dif-
ferent peptides would be formed (a-c, 15Na-c, 
a-15Nc, and 15Na-15Nc) with masses M0, M+1 and 
M+2 in a 1:2:1 ratio, resulting in a isotope dis-
tribution pattern as shown in Figure 3F. The 
actual MS spectrum and isotope distribution 
pattern of the 1:1 incubation mixture of abc 
and 15Nab15Nc are shown in Figure 3G. The 
observed isotope pattern is an intermediate 
between Figures 3E and 3F, suggesting that 
both random and intrastrand recombination 
occur. The ratio between these two processes 
could be estimated by calculating the isotope 
distribution patterns of different ratios of ran-
dom recombination and intrastrand splicing. 
The observed isotope pattern resembled an 
experiment in which 56% random recombi-
nation and 44% intrastrand splicing occurred 
(Figure 3G, right panel). 
To interpret these results, the hydrolysis pat-
tern of abc has to be taken into account. HPLC 
spectra indicate that abc is predominantly 
cleaved between a and b (66%), and not be-
tween b and c (34%) (data not shown). As 
intrastrand splicing can only occur when the 
bc bond is cleaved first, it can only occur in 
34% of abc cleavages. Therefore, we expected 
that the isotope pattern would be predomi-
nantly determined by random recombination 
and that some enrichment in the M0 and M+2 
signals would occur as a consequence of pos-
sible intrastrand splicing of a-c. Remarkably, 
we observed 44% enrichment of M0 and M+2 
signals as a consequence of intrastrand splic-
ing (see above). Such a high degree of enrich-
ment is only possible if intrastrand splicing 
is highly preferred over random recombina-
tion. The proteasome creates N-terminal and 
C-terminal ligation partners almost simulta-
neously and as the two fragments are kept 
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together inside the confined space of the 
catalytic chamber, ligation is promoted. This 
likely explains why intrastrand splicing occurs 
preferentially and more efficiently than ran-
dom recombination. 
Validating splicing rules: investigating 
influenza n1
Next, we validated the determined splic-
ing rules by application to a polypeptide se-
quence of the neuraminidase 1 (N1) protein 
of Influenza A virus A/Puerto Rico/8/34 to 
mimic degradation of a real protein in vivo. 
In vitro, only peptides of limited lengths can 
be digested by 20S proteasome and therefore 
the 28-mer GSCFTIMTDGPSDGLASYKIFKIEK-
GKV (positions 221-248), which contained 
several N- and C-terminal splicing motifs, was 
selected for further analysis. Peptide 221-
248
 contained a cysteine residue on position 
223, which complicates LC-MS analysis due to 
poor ionization efficiencies and/or the forma-
tion of disulfide bonds. Therefore, C223 was 
replaced by a serine residue (Figure 4A). Pep-
tide 221-248/C223S (N1-1) contained several 
potential N- and C-terminal splicing precur-
sors in accordance with our splicing rules. 
The sequences GS, SS, TD, SD and AS are all 
type I N-terminal transpeptidation motifs, 
while SF, TI, GL and SY are in line with Type II 
rules (Figure 4B, underlined). Only KIF (Figure 
4B, underlined) was identified as a suitable 
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Figure 4 | Validating splicing rules: investigating influenza n1. A) Peptide 221-248/C223S (N1-1) de-
rived from the neuraminidase 1 protein of Influenza A virus A/Puerto Rico/8/34 B) N-terminal (blue 
and underlined) and C-terminal ligation motifs (red and underlined) predicted by the splicing rules. 
Sequences that can participate in ligation but that are not likely to do so in this particular peptide 
are underlined only. C) Cleavage sites in peptide 221-248 (indicated by vertical lines) and the most 
predominant hydrolysis products formed (indicated by horizontal lines), as measured by LC-MS. D) 
Relative occurrence of secondary cleavages in peptides 221-233 (GSSFTIMTDGPSD) and 234-248 
(GLASYKIFKIEKGKV). e) Relative contribution of different GLA-containing C-terminal fragments to total 
GLA ligation. F) HLA-A2.1 binding curves of peptides spliced from peptide 221-248/C223S (N1-1). 
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C-terminal ligation fragment, (KIE contains a 
second charged residue, which was shown to 
be detrimental for ligation in experiments de-
scribed above). In all our digestions, we have 
not observed cleavage within the first four 
residues from the N-terminus, which excludes 
GS and SS as suitable splicing precursors. Also 
SY must be rejected as splicing precursor, as 
SY directly precedes KIF and can therefore 
not participate in splicing with this C-terminal 
fragment. These restrictions leave six possible 
N-terminal precursors (indicated in blue) and 
one C-terminal ligation partner (indicated in 
red) in peptide N1-1 (Figure 4B) as predicted 
splicing sites.
Peptide N1-1
 was synthesized and incubated 
with proteasome and the resulting diges-
tion mixtures were analyzed by LC-MS. N1-1 
contained nine main cleavage sites as indi-
cated by the vertical lines (Figure 4C). Upon 
entering the proteasome, 90% of peptides 
were cleaved after D233, resulting in the ac-
cumulation of GSSFTIMTDGPSD (221-233) 
and GLASYKIFKIEKGKV (234-248) (Figures 
4C,D). After this initial cleavage step, peptides 
221-233 and 234-248 were both further pro-
cessed. Fragment 234-248 was cleaved with 
equal preference after Y238 or I243, and to a 
lesser extent after F241 or G246. This yielded 
a variety of secondary cleavage products, 
of which GLASYKIFKI, GLASY and KIFKI were 
the most prominent. Fragment 221-233 was 
further processed after D229, I226 or F224, 
resulting in the accumulation of GSSFTIMTD, 
GSSFTI and GSSF (Figures 4C,D). 
Table 1 shows all ligation products that could 
be identified in the digestion mixture. The 
identity of ligation products was confirmed by 
comparison with the corresponding synthetic 
peptide, as exemplified in Supplementary 
table 1 |  ligation products identified in the digestion mixture of peptide 221-248. 
Ligation product Ion count IC50 value
GSSF-KIFKI 1304 39 mM
GSSF-GLASY 477 > 1 mM
GSSF-GLASYKIFKIEKGKV 400 ND
GSSFTI-KIFKI 334 1 mM
GSSFTI-KIF 333 ND
GSSFTIMTDGPSD-KIFKI 328 ND
GSSF-KIF 319 ND
GSSF-KIFKIEKGKV 193 ND
GPSD-KIFKI 183 ND
GSSFTIMTDGPSD-KIFKIEKGKV 164 ND
GSSFTIMTD-GLASYKIFKIEKGKV 124 ND
GSSFTI-GLA 112 ND
GSSFTIMTD-KIFKI 109 ND
GSSF-GLASYKIFKI 104 ND
GSSFTI-KIFKIEKGKV 102 ND
GSSF-KIFKIEKG 79 ND
TIMTD-KIFKI 64 6.8 mM
TIMTDGPSD-KIFKI 56 49 mM
GSSFTIMTD-GLASY 40 ND
GSSFTI-GLASYKIFKI 38 ND
GSSFTIMTD-GLASYKIFKI 23 ND
ND: Not determined; a dash indicates the site of ligation. 
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Figure 4. Ligation was observed onto 4 dif-
ferent precursors of both type I (GSSFTIMTD 
and GSSFTIMTDGPSD) and type II (GSSF and 
GSSFTI). Peptides starting with either KIF or 
GLA served as C-terminal ligation partners, 
whereas only KIF was predicted by the model. 
GLA ligations mainly occurred with longer 
fragments (GLASYKIFKI and GLASYKIFKIEK-
GKV) (Figure 4E), which are rapidly formed 
during the initial cleavage step. In addition, 
GLA ligations were particularly favored over 
KIF ligations on position D229, which is sepa-
rated from GLA by only four amino acids and 
is often the site where the next cleavage oc-
curs. This suggests that GLA ligations occurred 
more efficiently than predicted because frag-
ments were highly abundant and their gener-
ation directly preceded N-terminal precursor 
processing. 
The analysis of ligation products indicates 
that the N-terminal ligation partner is the 
dominant factor determining ligation effi-
ciency. Ligation will only take place if the N-
terminal ligation precursor has a sequence 
that is suitable for ligation. Importantly, our 
splicing model accurately predicted the abil-
ity of peptides to serve as N-terminal ligation 
precursor for all cleavage sites. Ligation will 
preferentially occur with a suitable C-terminal 
ligation partner, but seems more dependent 
on the availability of peptides than on precise 
sequences. Whereas a hydrophobic amino 
acid on P2' seemed required, the P1' position 
was not limited to basic residues, but likely 
also allows for hydrophobic or small residues. 
Length was not a determining factor, as both 
short and long peptides were equally suited 
to serve as C-terminal ligation partners. 
Splicing rules predict the formation of 
potential antigens from influenza n1
To investigate the affinity of spliced products 
for HLA-A2.1, binding curves of all products 
that consisted of 14 residues or less and con-
tained at least one anchor residue (L/M/I on 
P2 and/or V/L/I on P9) were measured using 
an FP assay (Figure 4F, see Supplementary 
Information for details). Affinities (expressed 
as IC50 values) were defined as the concentra-
tion of peptide that inhibited 50% of tracer 
peptide binding and were determined for all 
binders (Table 1). Although N1-1 is a small 
protein fragment containing only 27 residues, 
N1-1 processing resulted in the splicing of 
four peptides that displayed affinity for HLA-
A2.1. The peptide TIMTD-KIFKI, which con-
tains both anchor residues and has the pro-
posed optimal length for binding to HLA-A2, 
had the highest affinity for HLA-A2.1 (Figure 
4F), with an IC50 value in the low micromolar 
range (Table 1). The splicing products GSSF-
KIFKI and TIMTDGPSD-KIFKI, which had either 
the optimal length or both anchor residues, 
displayed intermediate affinity and showed 
IC50 values in the high micromolar range. The 
peptide GSSFTI-KIFKI had only low affinity for 
HLA-A2.1, while the other splicing products 
that were studied showed no affinity (Table 
1). These data suggest that many potential 
HLA-A binding epitopes may be spliced from 
an average protein that contains 10 to 20 
times as many residues as N1-1. Peptides that 
are spliced by the proteasome may be sub-
jected to further processing by peptidases 
that reside in the cytosol and the endoplas-
mic reticulum. Therefore, peptides that do 
not display the right binding characteristics 
directly after proteasomal splicing, may be 
further processed to fit HLA-A molecules and 
be presented at the cell surface. 
Validating splicing mechanism: investigating 
influenza n1
Next, we set out to compare the efficiency 
and mechanism of ligation of the influenza A 
derived N1-1 peptide to the abc model pep-
tide described above. Ligation efficiency was 
defined as the percentage of precursor clea- 
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vages that resulted in a ligation event, and 
calculated from MS peak intensities. Total li-
gation efficiencies ranged from 5.7% to 59.5% 
for different N-terminal precursors (Table 2). 
The overall splicing efficiency was 10.9%, sug-
gesting that one transpeptidation product 
was formed every 9 times peptide 221-248 
was processed by the proteasome. These ef-
ficiencies are in the same range as ligation 
efficiencies determined for the abc peptide, 
suggesting that protein-derived peptides can 
be spliced efficiently by the proteasome. 
To determine whether ligation would occur 
randomly or via intrastrand splicing, we re-
placed G221 and G234 in peptide N1-1 with 
15N Glycine (Figure 5A, indicated in red). N1-1 
and 15NN1-1 were incubated with proteasome 
and the formation of (15N)GSSFTIMTD-(15N)
GLASYKIFKIEKGKV (x-z and 15Nx-15Nz; Figure 
5A) by the proteasome was studied by LC-MS. 
In the digestion mixture of N1-1, a peak with 
an m/z value of 655.9 (M0), corresponding 
to [x-z+4H]4+ could be detected (Figure 5B), 
whereas in the digestion mixture of 15NN1-1, 
a peak with a mass of +2 Dalton, correspond-
ing to [15Nx-15Nz+4H]4+, was detected (Figure 
5C). A 1:1 mixture of these digestion samples, 
in which x-z and 15Nx-15Nz are present in equal 
amounts, resulted in the MS pattern shown 
in Figure 5D. The observed isotope pattern 
(Figure 5D, grey bars) resembled the sum of 
Figures 5B and 5C (Figure 5D, black bars) and 
is the expected isotope pattern for complete 
intrastrand splicing. 
Next, a 1:1 mixture of N1-1 and 15NN1-1 was 
incubated with proteasome (Figure 5E). The 
observed isotope pattern (grey bars) is an 
intermediate between complete intrastrand 
splicing (black bars) and complete random 
recombination (white bars), suggesting that 
both random and intrastrand recombination 
occur. A high peptide concentration within 
the proteasomal catalytic chamber likely 
increases the chance that two polypeptide 
strands are degraded simultaneously, favor-
ing random recombination. We hypothesized 
that decreasing the precursor peptide con-
centration within the proteasome would shift 
the ratio between random recombination 
and intrastrand splicing towards intrastrand 
splicing. We expect that this shift is accom-
panied with only a minor decrease in ligation 
efficiency, as intrastrand splicing should be 
less effected by the peptide concentration as 
compared to random recombination. In ad-
dition, reducing the peptide concentration 
within the proteolytic chamber provides a 
better model for protein ligation in vivo, as 
the catalytic cavity is able to accommodate 
polypeptides between 25 and 30 kDa in size17 
and will therefore fit only one copy of most 
proteins. We incubated a 1:1 mixture of N1-1 
and 15NN1-1 with proteasome for longer time 
periods or with lower peptide concentra-
tions to decrease the concentration of N1-1 
within the proteasomal catalytic chamber 
(Figure 5F). Upon increasing the incubation 
time from 4 h to 16 h, the MS patterns shifted 
towards more intrastrand splicing. When the 
m/z peaks of M0 and M+1 were integrated, the 
ratio shifted towards less M+1, as less random 
recombination occurred and therefore fewer 
products with a mass of M+1 were formed. Af-
ter a 16 h incubation period, the resulting MS 
table 2 | ligation efficiencies of n-terminal precursors identified in peptide 221-248.
Ligation precusor Efficiency (%) Ligation precusor Efficiency (%)
GSSFTIMTDGPSD- 5.7 GSSF- 59.5
GSSFTIMTD- 7.3 Total 10.9
GSSFTI- 23.9
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Figure 5 | Validating splicing mechanism: investigating influenza n1. A) Formation of (15N)x-(15N)z from 
(15N)N1-1 (peptide 221-248/C223S from the neuraminidase 1 protein of Influenza A virus A/Puerto 
Rico/8/34) by the proteasome. 15N glycine residues are indicated in red. B) Mass spectrum of x-z, 
formed during digestion of N1-1 (left panel). Isotope pattern derived from the mass spectrum of x-z 
by integration of mass peaks (right panel). C) Mass spectrum of 15Nx-15Nz, formed during digestion 
of 15NN1-1 (left panel). Isotope pattern derived from the mass spectrum of 15Nx-15Nz by integration 
of mass peaks (right panel). D) Mass spectrum of a 1:1 mixture of digestion samples, in which x-z 
and 15Nx-15Nz are present in equal amounts (left panel). Observed and calculated isotope distribution 
patterns for intrastrand splicing (right panel). Grey bars represent the observed pattern; black bars 
represent the calculated isotope distribution pattern for intrastrand splicing of a 1:1 digestion mixture 
of N1-1 and 15NN1-1. e) Mass spectrum resulting from the digestion of a 1:1 mixture of N1-1 and 15NN1-
1 (left panel). Observed isotope pattern of a 1:1 digestion mixture of N1-1 and 15NN1-1 (right panel, 
grey bars), compared to the calculated isotope distribution patterns for random recombination (white 
bars) and intrastrand splicing (black bars). F) Mass spectra of samples resulting from the digestion of 
a 1:1 mixture of N1-1 and 15NN1-1 measured at different time points during the digestion (top panel). 
Observed isotope patterns of a 1:1 digestion mixture of N1-1 and 15NN1-1 measured at different time 
points during the digestion (4h, 8h, and 16h), compared to the calculated isotope distribution pattern 
for intrastrand splicing (black bars) (bottom panel). g) Ligation efficiencies of x-z formation from N1-1 
at the indicated concentrations of N1-1.
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spectrum closely resembled the calculated 
MS isotope pattern for complete intrastrand 
splicing (Figure 5F). Upon decreasing the con-
centration of N1-1 precursor in the sample, 
we observed only a minor decrease in ligation 
efficiencies for the formation of x-z (Figure 
5G). Using abc as a model peptide, the ef-
ficiency of a-abc formation, which can only 
be formed via random recombination of two 
separate peptides, decreased from 19% to 7% 
(>60% decrease) when the concentration of 
abc was decreased with a factor 4 (Figure 3B). 
The efficiency of x-z formation on the other 
hand only decreased with 25% upon lowering 
the N1-1 concentration 5-fold (Figure 5G). Col-
lectively, the observed shift in isotope pattern 
and the relative unchanged ligation efficien-
cies suggest that protein splicing occurs pre-
dominantly via intrastrand recombination.
DISCUSSIOn
Recently, it has become apparent that non-
contiguous antigens, that consist of two post-
translationally fused peptides are formed in 
cells and are presented to the immune system 
by MHC I.6-8 These epitopes are thought to be 
produced by the proteasome via a transpepti-
dation mechanism.7-9 As spliced antigens may 
mediate T cell responses to cancer, trans-
plants and viral infection, knowledge of their 
identity is important for vaccine development, 
T cell based therapeutic strategies as well as 
pharmacological immunosuppression.10 Novel 
epitopes are usually identified by cell surface 
elution, MS analysis and matching against 
protein databases.18,19 Alternatively, epitopes 
may be predicted from protein sequences20,21 
and tested for T cell receptor recognition, e.g. 
by incorporation into fluorescent MHC class 
I tetramers, which are subsequently used to 
stain T cells in fluorescence assisted cell sort-
ing (FACS) assays.22,23 However, as spliced an-
tigens are not contiguous and their formation 
requires post-translational splicing, they nei-
ther match existing databases nor can they be 
predicted from contiguous protein sequences. 
In the present study, we aimed at deciphering 
splicing rules that govern the production of 
non-contiguous antigens. Such rules will en-
able prediction and detection of spliced anti-
gens to elucidate their role in immunity. 
Splicing rules were determined for both the 
N- and C-terminal ligation fragments by ana-
lyzing proteasomal incubation samples from 
small libraries of both ligation partners using 
fluorescence polarization assays and LC-MS 
assays. Subsequently, these splicing rules 
were experimentally confirmed by applica-
tion to a 27-mer polypeptide derived from 
the neuraminidase 1 protein from Influenza 
A virus A/Puerto Rico/8/34. Previous reports 
hypothesized that the transpeptidation mech-
anism would implicate that splicing is not de-
termined by a particular sequence motif, but 
could occur at any major cleavage site.7,9 Our 
data are however in strong disagreement with 
this notion and indicate that splicing rules ex-
ist, with ligation efficiencies being primarily 
determined by the N-terminal ligation part-
ner. In general, N-terminal precursors pro-
moted ligation when fitting sub-optimally in 
the non-primed S1 and S2 pockets. Two types 
of N-terminal precursors showed highest liga-
tion efficiencies: precursors that I) contained 
aspartate or a polar uncharged residue on P1 
combined with a small or polar uncharged 
residue on P2 or II) combined a hydrophobic 
residue on P1 with a basic or small or, to a 
lesser extent, a polar uncharged residue on 
P2. Although the highest ligation efficiency 
was observed with C-terminal fragments 
that had a good fit in the primed S1', S2' and 
S3' pockets, structural requirements on the 
C-terminal ligation partner are less stringent, 
and ligation efficiency is rather determined 
by the presence than by the sequence of C-
terminal ligation partners. 
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Ligation can only take place if the C-terminal 
ligation partner is able to compete with water 
molecules that are constantly present in the 
active site.10,11 It has been hypothesized that 
splicing is most likely to occur with substrates 
that form intermediate esters with relatively 
long half-lives.11. Borrisenko and Groll sug-
gested that this relatively long half-life could 
result from a high affinity of the N-terminal 
precursor for the non-primed sites.11 Our 
data disagree with this hypothesis and sug-
gest that the half-life of the O-acyl enzyme 
intermediate is prolonged if the fit of the N-
terminal precursor in the non-primed pockets 
is suboptimal. Therefore, we propose a model 
in which a perfect fit may orientate the O-acyl 
enzyme intermediate such that the attack of a 
conserved water molecule on the intermedi-
ate ester is facilitated. A suboptimal fit of the 
N-terminal precursor, on the other hand, may 
prolong the half-life of the intermediate ester 
by influencing the orientation of the O-acyl 
enzyme intermediate, resulting in an inter-
mediate complex that cannot be hydrolyzed 
easily and is more prone to ligation. 
Our data indicate that a spliced product may 
be formed as often as once every 3 times a 
precursor peptide is processed (30% ligation 
efficiency). In previous studies, the ligation 
efficiencies of the splicing reactions for two 
described spliced epitopes were estimated to 
be 0.0002% to 0.01%.7,9 Notably, these low ef-
ficiencies were sufficient to produce epitopes 
that were presented at the cell surface by MHC 
class I leading to an immune response. As our 
data suggest that splicing can occur with high 
efficiency in vivo, many spliced epitopes are 
likely to be present on the cell surface of all 
antigen presenting cells and may contribute 
to immunity. This splicing mechanism would 
ensure that a more diverse peptide repertoire 
reaches the cell surface, which increases the 
chance of recognition by CD8+ T cells and ul-
timately of elimination of the malignant or 
infected cell by the immune system. 
The high splicing efficiencies observed in the 
present study imply that splicing rules must 
exist. If splicing would be a random process, 
high splicing efficiencies would result in the 
formation of high amounts of random (self)-
antigens. Such random formation of self-an-
tigens would hamper negative selection by 
cells in the thymus and cause auto-immuni-
ty.10 Similarly, random recombination of dif-
ferent proteins would result in the formation 
of randomly formed spliced products, which 
would also severely hamper negative selec-
tion. We therefore expected protein ligation 
in the proteasome to occur via intrastrand 
splicing. Our data suggest that intrastrand 
splicing of peptides is strongly preferred over 
random ligation. In addition, only intrastrand 
splicing was observed when the peptide con-
centration within the proteasomal catalytic 
chamber was lowered. A reduced peptide 
concentration within the proteasomal cham-
ber would provide a better model system for 
protein ligation in vivo. Only one copy of most 
proteins can physically fit into the confined 
space of the proteasomal catalytic cavity.17 
Experiments with ClpXP complexes, a pro-
teasome-like protease complex from E. coli, 
have shown that two substrates could bind 
ClpXP simultaneously, but that simultaneous 
translocation from both ends only rarely oc-
curred.24 The 20S proteasome from Thermo-
plasma acidophilum can bind two substrates. 
However, the apparent rate-limiting step in 
protein degradation is the threading of the 
substrate through the pore followed by trans-
location, but not proteolytic cleavage.25 It is 
likely that similar mechanisms underlie trans-
location in mammalian 26S proteasomes, 
which suggests that simultaneous proteolysis 
of two different proteins is a rare event. In ac-
cord with this, Dalet et al. have shown in a re-
cent study that random recombination occurs 
readily in vitro, but that in cells random re-
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combination occurs with much lower efficacy 
compared to intrastrand splicing.9 Together, 
these data suggest that protein ligation oc-
curs via intrastrand splicing in vivo, whereas 
the random recombination of proteins will 
rarely occur in vivo and is predominantly an 
in vitro artifact. 
In conclusion, we determined splicing rules 
for both the primed and the non-primed 
sites. Such rules will enable the prediction 
and detection of spliced antigens to elucidate 
their role in immunity. In addition, we show 
that splicing occurs via intrastrand recom-
bination with high efficiency and that many 
spliced products may be formed from a single 
protein, some of which are likely to be immu-
nogenic. Therefore, the data presented here 
suggest that protein splicing may play a much 
more significant role in immunity than previ-
ously assumed. 
mATerIAlS AnD meTHODS
Peptide building blocks were purchased from 
Novabiochem and appropriately functionalized 
resins from Applied Biosystems. 15N Glycine-N-
Fmoc was purchased from Cambridge Isotope 
Laboratories. All solvents were purchased from 
Biosolve at the highest grade available. All other 
chemicals were purchased from Aldrich at the 
highest available purity. All solvents and chemi-
cals were used as received. LC-MS analyses were 
carried out on a WATERS LCT mass spectrometer 
in line with a WATERS 2795 HPLC system and a 
WATERS 2996 photodiode array detector. HPLC 
purifications and analyses were performed on a 
Shimadzu LC-20AT prominence liquid chromatog-
raphy system, coupled to a Shimadzu SPD-20A 
prominence UV/Vis detector and a Shimadzu 
CTO-20A prominence column oven. 
Peptide synthesis
Peptides were synthesized using standard Fmoc-
based solid-phase peptide synthesis protocols 
and appropriately functionalized PEG-polyster-
ene Wang resins. Functionalized resins were sub-
jected to coupling cycles, in which deprotection 
of the Fmoc-group with piperidine/NMP (1/4 
v/v), was followed by coupling with 4 equivalents 
each of Fmoc protected amino acid, di-isopropyl 
ethylamine (dipea) and (Benzotriazol-1-yloxy)
tripyrrolidinophosphonium hexafluorophosphate 
(PyBop). Reactions were carried out in NMP at 
a volume of 1 mL/0.1 g of resin. After the final 
coupling step, the Fmoc group was removed and 
peptides were released from the resin and fully 
deprotected by treating the resin with TFA/H2O/
triisopropylsilane (93/5/2 v/v) for 2.5 h. Peptides 
were precipitated with cold diethylether/pen-
tane (3/1 v/v) and lyophilized from H2O/ACN/
HOAc (65/25/10 v/v). Peptides were purified by 
HPLC over an Atlantis® Preparative T3 column 
(5 mm; 20 x 150 mm; Waters) to > 99.5% purity 
using a linear gradient (5% to 50% acetonitrile 
in H2O containing 0.05% TFA).  Peptide-containg 
fractions were pooled and lyophilized.    
Proteasome purification
Proteasome was purified from bovine liver as 
described.5 After each step, proteasome purity 
was monitored by incubating fractions with a 
fluorescent proteasome activity probe, followed 
by SDS-PAGE and scanning of the resulting gel 
for fluorescence emission, as described.26 Briefly, 
bovine liver was homogenized in phosphate buff-
ered saline (PBS), followed by precipitation using 
40% saturated ammonium sulphate to remove 
unwanted proteins. The proteasome was subse-
quently precipitated by increasing the concentra-
tion of saturated ammonium sulphate to 60%. 
Following dialysis, the proteasome was further 
purified using a 10-40% sucrose gradient and 
anion exchange column chromatography, using 
DEAE Sephadex A25 resin. Proteasome contain-
ing fractions were pooled, concentrated and pro-
tein concentrations were determined using the 
Bradford assay (Biorad). 
FP ligation assay to determine transpeptidation 
rules for the primed sites
50 nmol of the peptide YLDWSY was incubated 
with 5 mg proteasome in the presence of 250 
nmol of XLPSV, KXPSV or KLXSV in ligation buf-
fer (50 mM Tris-HCl, pH 8.5) in a total volume 
of 75 mL for 16 h at 37°C. As a control, 50 nmol 
of the peptide YLDWSY was incubated with 5 mg 
proteasome only. The DMSO concentration in all 
incubation mixtures was 8%. Following incuba-
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tion, ligation mixtures were snap-frozen in liquid 
N2, lyophilized, dissolved in 50 mL DMSO and the 
volume was adjusted to 1 mL with H2O. Samples 
were purified over Strata™-X 33 mm polymeric re-
versed phase disposable columns (Phenomenex). 
To ensure equal input in all samples, 250 nmol 
of XLPSV, KXPSV or KLXSV was added to control 
samples prior to purification. Ligation products 
were eluted with ACN/H2O (2/3 v/v), lyophilized 
and dissolved in FP buffer (20 mM Tris pH 7.4, 
150 mM NaCl, 0.5 mg/ml BGG). Fluorescence 
polarization (FP) HLA-A2.1 binding assays with 
UV-mediated peptide exchange were performed 
as described previously14 with minor changes. 
The peptide KILGFVFJ1V (where J1 is UV-cleavable 
3-amino-3-(2-nitrophenyl)propionic acid) was 
used as conditional ligand and fluorescently la-
beled FLPSDCTMRFPSV (where TMR is maleimi-
do-linked tetramethylrhodamine) was used as 
tracer peptide. The ligation samples were used as 
competitor samples and binding curves of serial 
2-fold dilutions of the expected ligation products 
were determined as reference. Assays were per-
formed in 384-well low-volume black nonbinding 
surface assay plates (Corning 3820). Wells were 
loaded with 30mL total volume containing 0.5 mM 
HLA-A2.1-peptide complex, 1 nM tracer peptide 
and either 25% of each ligation or control sample 
or serial dilutions of the expected ligation prod-
ucts in FP buffer. The plate was spun for 1 min 
at 1000g at room temperature to ensure proper 
mixing of all components. To start UV-mediated 
cleavage of the conditional ligand and peptide 
exchange, the plate was placed under a 365-nm 
UV lamp at 10 cm distance (366 nm UV lamp, 2 
× 15 W blacklight blue tubes, l×w×h 505 × 140 × 
117 mm, Uvitec, UK) located in a cold room (4 
°C). After 30 min irradiation, the plate was sealed 
with thermowell sealing tape (Corning) and incu-
bated at room temperature for 24 hours, allow-
ing cleaved peptide fragments to dissociate and 
to be exchanged for competitor and/or tracer 
peptide. Subsequently, fluorescence polarization 
measurements were performed, as described.13 
The relative ligation efficiency was calculated by 
comparing each sample to the corresponding 
control sample and ligation efficiencies were re-
lated to the efficiency of YLDW-KLPSV formation, 
which was included in all experimental runs. Data 
were analyzed using GraphPad Prism software 
(GraphPad).
lC-mS assay to determine transpeptidation 
rules for the non-primed sites
50 nmol of the peptide YLGXSY or YLXLSY was in-
cubated with 5 mg proteasome in the presence of 
50 nmol RLPSV in ligation buffer (50 mM Tris-HCl, 
pH 8.5) in a total volume of 75 mL for 2h, 4h, 8h, 
16h or 24h at 37°C. The DMSO concentration in 
all incubation mixtures was 2.6%. Following incu-
bation, ligation mixtures were snap-frozen in liq-
uid N2, lyophilized and dissolved in ACN/H2O (1/1 
v/v). Samples were filtered over Strata™-X 33 mm 
polymeric reversed phase disposable columns 
(Phenomenex) to remove proteasomal proteins 
and eluted directly. Eluted fractions were ana-
lyzed by LC-MS using an XBridge BEH300 C18 
column (3.5 mm; 2.1 x 100 mm; Waters) using 
a linear gradient (5% to 50% acetonitrile in H2O 
containing 0.1% Formic acid). Ligation efficiencies 
were calculated using the following formula: Ef-
ficiency = IL/(IL+IH) × 100%, where IL is the peak 
intensity of the ligation product YLXX-RLPSV and 
IH is the peak intensity of the hydrolysis product 
YLXX. Ligation efficiencies were related to the ef-
ficiency of YLGL-RLPSV formation, which was in-
cluded in all experimental runs.
Investigating splicing efficiencies using a model 
peptide
The peptide YLGD|SY|RLPSV (a|b|c) (50 nmol, 
100 nmol or 200 nmol) was incubated with pro-
teasome (5 mg/ 50 nmol of peptide) in ligation 
buffer in a total volume of 75 mL for 2h, 4h or 8h. 
The DMSO concentration was 5.3% in all incuba-
tion mixtures. Incubation mixtures were snap-
frozen, lyophilized and dissolved in ACN/H2O (1/1 
v/v). Samples were filtered over Strata™-X 33 mm 
polymeric reversed phase disposable columns 
(Phenomenex) to remove proteasomal proteins 
and eluted directly. Eluted fractions were diluted 
1:1 with H2O and analyzed by HPLC using a Sym-
metry® C18 column (5 mm, 4.6 x 150 mm, Waters) 
using a linear gradient (5% to 50% acetonitrile in 
H2O containing 0.05% TFA). Spectra were ana-
lyzed using LCsolution software (Shimadzu). In-
tegrated peaks were normalized to the number 
of tyrosine residues the corresponding peptide 
contained. Ligation efficiencies for the formation 
of distinct ligation products were calculated us-
ing the following formula: Efficiency = IL/(ILT+IH) × 
100%, where IL is the integral of ligation product 
(a-a, a-c, a-ab or a-abc), ILT is the sum of the in-
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tegrals of all ligation products (a-a + a-c + a-ab 
+ a-abc) and IH is the integral of the hydrolysis 
product a. Overall splicing efficiencies were cal-
culated using the following formula: Efficiency 
= Ia-c/(IT-Iabc) × 100%, where Ia-c  is the integral of 
the ligation product a-c, and IT is the sum of all 
integrals and Iabc is the integral of the precursor 
peptide abc).
Investigating splicing mechanism using a model 
peptide
50 nmol YLGDSYRLGSV, 50 nmol YL15NGDSYR-
L15NGSV, or 50 nmol of a 1:1 mixture of both 
peptides was incubated with 5 mg proteasome in 
ligation buffer in a total volume of 75 mL for 2 h. 
The DMSO concentration was 1.3% in all incuba-
tion mixtures.  Incubation mixtures were snap-
frozen, lyophilized and dissolved in ACN/H2O (1/1 
v/v). Samples were filtered over Strata™-X 33 mm 
polymeric reversed phase disposable columns 
(Phenomenex) to remove proteasomal proteins 
and eluted directly with ACN/H2O (1/1 v/v). 
Eluted fractions were analyzed by LC-MS using an 
XBridge BEH300 C18 column (3.5 mm; 2.1 x 100 
mm; Waters) using a linear gradient (5% to 50% 
acetonitrile in H2O containing 0.1% Formic acid).
Investigating influenza n1 
Synthetic GSSFTIMTDGPSDGLASYKIFKIEKGKV 
(150 nmol) was incubated with 5 mg proteasome 
in ligation buffer in a total volume of 75 mL for 16 
h. To investigate the splicing mechanism, differ-
ent amounts of  GSSFTIMTDGPSDGLASYKIFKIEK-
GKV, 15NGSSFTIMTDGPSD15NGLASYKIFKIEKGKV, or 
a 1:1 mixture of both peptides were incubated 
with 5 mg proteasome in ligation buffer in a total 
volume of 75 mL for 4 h, 8 h or 16 h. Incubation 
mixtures were snap-frozen, lyophilized and dis-
solved in ACN/H2O (1/1 v/v). Samples were fil-
tered over Strata™-X 33 mm polymeric reversed 
phase disposable columns (Phenomenex) to re-
move proteasomal proteins and eluted directly 
with ACN/H2O (1/1 v/v). Eluted fractions were 
analyzed by LC-MS using an XBridge BEH300 C18 
column (3.5 mm; 2.1 x 100 mm; Waters) using a 
linear gradient (5% to 50% acetonitrile in H2O 
containing 0.1% Formic acid). To determine the 
affinities of spliced products for HLA-A2.1, an FP 
assay was performed as described above, with 
minor changes. 3-fold serial dilutions of synthetic 
products were used as competitor peptide and 
fluorescence polarization measurements were 
performed after a 4 h incubated period at room 
temperature. The binding affinity (IC50 value) of 
each spliced product was defined as the concen-
tration that inhibited 50% of tracer peptide bind-
ing. Data were analyzed using GraphPad Prism 
software (GraphPad).
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SUPPlemenTAry reSUlTS
Development of a fluorescence polarization 
assay to measure peptide ligation.
In order to screen small peptide libraries for 
their ability to participate in proteasomal 
transpeptidation reactions, we used a UV-me-
diated MHC exchange fluorescence polariza-
tion (FP) assay1,2 scoring for ligation efficiency. 
In this assay, HLA-A complexes loaded with 
a UV-cleavable peptide ligand are subjected 
to UV light, which cleaves the ligand, result-
ing in the generation of empty HLA-A.3 These 
empty HLA-A complexes are unstable, unless 
they are rescued by the addition of a ‘rescue’ 
peptide. When rescue is performed by adding 
both a fluorescent tracer peptide and increas-
ing concentrations of a ‘competitor’ peptide, 
the affinity of this competitor peptide can 
be determined.1,2 This assay was adapted so 
it could be used to determine the extent to 
which peptide ligation had taken place in a 
digestion mixture, resulting in potential HLA-
A2.1 epitopes. First, proteasome was incu-
bated with an N-terminal ligation precursor 
and a C-terminal ligation partner, resulting in 
the formation of both hydrolysis and trans-
peptidation products (Supplementary Figure 
+
N-terminal
precursor
C-terminal
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MHC class I
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Supplementary Figure 1 | Development of a fluorescence polarization ligation assay. A) Schematic 
overview of hydrolysis and transpeptidation reactions in the digestion mixture. B) Affinities of com-
ponents in the digestion mixture for MHC cass I. C) Schematic overview showing the fluorescence 
polarization assay used to determine ligation efficiencies in proteasomal digestion mixtures. 
A B
C
proteasome
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1A). This digestion mixture was used to res-
cue MHC class I. Peptides require two anchor 
residues to bind HLA-A2.1, one on the second 
position and one on the last position. Both 
N- and C-terminal precursors were designed 
such that they contained only one anchor 
residue and did not bind MHC class I (Supple-
mentary Figure 1B). Upon ligation, peptides 
with both anchor residues were formed, re-
sulting in a much-increased affinity for MHC 
class I (Supplementary Figure 1B). Therefore, 
competition with fluorescent tracer occurred 
only when transpeptidation products had 
been formed (Supplementary Figure 1C) and 
the relative amount of bound tracer inversely 
correlated to the efficiency of ligation in the 
corresponding digestion mixture. Samples 
were normalized to their respective control 
samples, in which ligation products could not 
be formed.
SUPPlemenTAry reFerenCeS
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Proc. Natl. Acad. Sci. U S A 105, 3825-3830 (2008).
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Supplementary figures
Supplementary Figure 2 | Hydrolysis rates of different n-terminal precursors. A) Amount of the 
hydrolysis product YLGX in proteasomal digestion mixtures of YLGX|SY after a 2h-incubation as 
measured by LC-MS. B) Amount of the hydrolysis product YLXL in proteasomal digestion mixtures of 
YLXL|SY after a 2h-incubation as measured by LC-MS. Cleavage sites are indicated with a vertical line. 
Supplementary Figure 3 | quantification of transpeptidation and splicing efficiencies using HPlC. 
HPLC spectra of proteasomal digestion mixtures of abc recorded at 280 nm after 2 h (red) and 8 h 
(black) incubations. Peaks were assigned to hydrolysis and ligation products using LC-MS. A dash indi-
cates the site of ligation. 
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Supplementary Figure 4 | Identification of splicing products in peptide 221-248/C223S. Comparison 
of synthetic GSSFKIFKI and the digestion mixture of peptide 221-248/C223S. Ion traces detected at 
342.7 m/z are compared (left panels) as well as in-line MS spectra of the peaks eluting at 22 to 23 
minutes. Spectra taken from these peaks were identical, confirming that GSSF-KIFKI was formed in the 
digestion mixture by proteasomal splicing. 
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Proteasomal splicing creates a novel type of antigen 
containing an isopeptide linkage
Celia r. Berkers,a Annemieke de Jong,a karianne g. Schuurman,a Jan A. J. geenevasen,b
Boris rodenkoa,* & Huib Ovaaa,*
jor Histocompatability Complex (MHC) class I 
proteins, known in humans as human leuko-
cyte antigen (HLA) class I.3 The proteasome 
generates peptides both from self and foreign 
proteins, which are subsequently transport-
ed into the endoplasmic reticulum, loaded 
onto MHC class I and transported to the cell 
surface. CD8+ T cells continuously scan the 
MHC I-peptide complexes on the cell surface, 
thereby receiving a blueprint of the intracellu-
lar protein content. This enables CD8+ T cells 
InTrODUCTIOn
The eukaryotic 26S proteasome is responsible 
for the degradation of redundant and misfold-
ed proteins and for the turnover of regulatory 
proteins involved in a wide range of cellular 
processes, including cell proliferation and 
survival, cell-cycle control and cellular stress 
responses.1,2 In addition, the proteasome is 
responsible for the generation of peptides 
that are presented on the cell surface by Ma-
aDepartment of Cell Biology II, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Neth-
erlands. bSynthetic Organic Chemistry Group, Van ‘t Hoff Institute For Molecular Sciences, University of Amster-
dam, Nieuwe Achtergracht 129, 1018 WS Amsterdam, The Netherlands.
Proteasomal transpeptidation reactions can occur particularly efficient if the C-terminal li-
gation partner has lysine or arginine at the site of ligation. As lysine has two amino groups 
that can theoretically both react with the O-acyl enzyme intermediate, this implies that 
the proteasome may be able to from isopeptide linkages. In the present study we use 
nmr to show for the first time that the proteasome can use both the α-amino group and 
the ε-amino group of lysine in transpeptidation reactions. The overall efficiency of εK-
ligation reactions is 10-fold lower as compared to α-ligation and should produce sufficient 
amounts of peptide to evoke a T cell response, suggesting that the proteasome can create 
a novel type of antigen that may play a role in immunity in vivo. In addition, we show that 
isopeptides have unique properties that discern them from normal epitopes. Isopeptides 
of various lengths can bind to HlA-A2.1 and HlA-A3 proteins with high affinity. In addi-
tion, isopeptides are more stable towards further proteasomal processing as compared to 
normal peptides. These properties are likely to increase the fraction of ε-ligated peptides 
that enters the endoplasmic reticulum, and that is loaded onto mHC class I and trans-
ported to the cell surface for CD8+ T cell surveillance. we postulate that the formation of 
epsilon linkages is a genuine post-translational modification resulting from transpeptida-
tion mechanisms.
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to sense viral infection or malignant transfor-
mation, which ultimately results in killing of 
the antigen presenting cell.
The 26S proteasome consists of a barrel-
shaped 20S core, complexed at one or both 
ends with 19S regulatory particles. The 19S 
caps deubiquitinate and unfold protein sub-
strates and regulate the entrance of sub-
strates into the 20S core, where the pro-
teolytic activity resides. The 20S catalytic 
chamber consists of four stacked heptameric 
rings and has an overall architecture of α(1-7)
β(1-7)β(1-7)α(1-7). Whereas the two outer 
α-rings regulate entry into the complex and 
provide anchor points for the attachment of 
19S regulatory caps, the actual catalytic activ-
ity resides within the inner β-rings. Once en-
tered into the 20S core, a protein is degraded 
via the action of three catalytically active sub-
units, termed β1, β2 and β5, which all have 
different cleavage specificities and which are 
responsible for the proteasomal caspase-like, 
tryptic and chymotryptic activities, respec-
tively. In lymphoid tissues these subunits are 
largely replaced by their immunoproteasome 
counterparts, termed β1i, β2i and β5i, to 
form the immunoproteasome.4 The latter has 
been hypothesized to favor the production 
of antigenic peptides,5 while the existence of 
hybrid ‘mixed-type’ proteasomes is now also 
well established.6,7
Recently, it has become apparent that the 
proteasome does not only produce contigu-
ous peptides for presentation on MHC class 
I. Non-contiguous antigens, in which two 
distant parts of a protein are excised and li-
gated together to form a novel peptide, are 
presented on the cell surface and can evoke 
immune responses.8-10 These non-contiguous 
antigens can be produced by the proteasome 
via a transpeptidation mechanism.9-11 During 
the transpeptidation event, an active site N-
terminal threonine hydroxyl group attacks the 
scissile peptide bond, resulting in the forma-
tion of an O-acyl enzyme intermediate and 
the release of the C-terminal part of the pep-
tide. In a second step, this intermediate ester 
is captured by an amino group of a second 
peptide (the ‘C-terminal ligation fragment’). 
This leads to the formation of a novel pep-
tide bond and a spliced peptide in which two 
separate peptide fragments are combined 
(See Chapter 3.1, Figure 1; Chapter 3.2, Figure 
1).12 Transpeptidation competes with normal 
hydrolysis, in which the intermediate ester is 
hydrolyzed by water molecules present in ex-
cess. Hydrolysis results in the release of the 
N-terminal part of the peptide, which can be 
further processed in subsequent degradation 
rounds. 
All peptides produced in the proteasomal cat-
alytic core have a free amino terminus and can 
therefore theoretically participate in ligation 
reactions as C-terminal ligation partner. In a 
previous study (Chapter 3.2), we observed the 
highest ligation efficiencies with peptides that 
had a basic amino acid (arginine or lysine) as 
their N-terminal residue. As lysine has a free 
amino group on the Cε position in addition to 
its free amino terminus, both the α-amine 
and the ε-amine are theoretically able to par-
ticipate in ligation reactions. Whereas ligation 
with the α-amine results in the formation 
of a normal peptide bond, ligation with the 
ε-amine results in the formation of an isopep-
tide. Isopeptide linkage-containing epitopes 
may have unique properties and may form 
a novel class of post-translationally modi-
fied peptides that can be presented on MHC 
class I. Isopeptide bonds are notoriously dif-
ficult to identify and have not been observed 
in epitopes so far. In this study, we show that 
both the α- and ε-amino groups of lysine can 
participate in ligation reactions and we show 
how the unique properties of these isopep-
tides may contribute to an increased MHC 
class I surface expression, strongly suggesting 
that ε-ligation may contribute to immunity in 
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vivo, even though sensitive methods to detect 
such linkages directly do not exist.
reSUlTS
The proteasome can form both normal and 
isopeptide bonds during splicing 
To investigate whether both the α- and the 
ε-amino group of lysine could react with 
the O-acyl enzyme intermediate during 
splicing reactions, unprotected and mono-
acetylated lysine were compared in splicing 
experiments. Only the unprotected α-amino 
group of Nε-acetylated lysine (Kε(Ac)) can par-
ticipate in ligation reactions, resulting in the 
formation of normal peptide bonds only. On 
the other hand, Nα-acetylated lysine (Kα(Ac)) 
can only react with the acyl-enzym inter-
mediate through its unprotected ε-amino 
group, resulting in the formation of isopep-
tide bond containing peptides. The peptide 
CTMRSLPRGTASSR is an N-terminally extended 
and fluorescently labeled version of the known 
splicing precursor peptide SLPRGTASSR.10 This 
precursor was subjected to proteasomal deg-
radation in the presence of proteasome in-
hibitors or lysine, followed by MALDI analysis. 
Peak heights in MALDI spectra could be semi-
quantitatively compared, as all C-terminal 
hydrolysis and ligation products formed dur-
ing these digestions contained a positively 
charged TMR (tetramethylrhodamine) label, 
which functioned as an ionization enhancer 
acting as the main determinant of signal in-
tensities. The precursor CTMRSLPRGTASSR (m/z 
1616, Figure 1A, top panel) disappeared upon 
incubation with purified 20S proteasome, 
while two peaks appeared at m/z 1372 and 
1214, which could be assigned to the hydro-
lysis products CTMRSLPRGTAS and CTMRSLPRGT, 
respectively (Figure 1A, second panel). Hydro-
lysis was completely abolished by the addi-
tion of the pan-proteasome inhibitor MG132, 
while the addition of the β5/β1 inhibitor 
bortezomib13 only hampered the formation of 
CTMRSLPRGTAS (m/z 1372), but not of 
CTMRSLPRGT (m/z 1214) (Figure 1A, third 
and fourth panel). This suggests that 
CTMRSLPRGTAS is formed by the β5 subunit, 
while CTMRSLPRGT is a β2 hydrolysis product. 
When excess lysine was added to the reaction 
mixture, direct ligation of lysine onto the pre-
cursor peptide occurred, as evidenced by the 
appearance of additional peaks at m/z 1500 
(Figure 1B, second panel) and m/z 1342 (data 
not shown). These peaks could be assigned to 
the β5 ligation product CTMRSLPRGTAS-K and 
the β2 ligation product CTMRSLPRGT-K (where 
a dash indicates the newly formed (iso)pep-
tide bond). Ligation efficiencies, defined as 
the percentage of cleavages that resulted in 
ligation as opposed to hydrolysis, were 26% 
and 13% for the β5 and β2 active sites, re-
spectively (Figure 1C). When either Kα(Ac) or 
Kε(Ac) was added to the digestion mixture, both 
MALDI spectra showed an additional peak at 
m/z 1542 (Figure 1B, third and fourth panel), 
which could be assigned to the β5 ligation 
product CTMRSLPRGTAS-KAc. Ligation efficien-
cies were estimated at 29% for peptide bond 
formation with Kε(Ac) and 33% for isopeptide 
bond formation with Kα(Ac) (Figure 1C). Forma-
tion of the β2 ligation product CTMRSLPRGT-KAc 
was only observed upon addition of Kε(Ac), with 
a ligation efficiency of 7% (Figure 1C). These 
data indicate that the α- and ε-amino groups 
of lysine are equally capable of participating 
in proteasomal splicing reactions in the β5 ac-
tive site, whereas the β2 active site only ac-
cepts α-amino groups. This strongly suggests 
that both peptide and isopeptide bonds can 
be formed during proteasomal splicing reac-
tions. 
The β5 site accepts α-acetylated peptides as 
C-terminal ligation partner
Having established that isopeptide bonds can 
be formed by the proteasome when single 
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amino acids are added to digestion mixtures, 
we investigated whether Nα-acetylated pep-
tides could serve as C-terminal ligation part-
ners. The N-terminal precursor YLGD|SY has 
been established as a β5 splicing precursor 
(where the vertical line indicates the site of 
cleavage; Chapter 3.2). YLGD|SY was incu-
bated with proteasome and a 5-fold excess 
of either unprotected or Nα-acetylated KLI 
or KLISV to form the hydrolysis product YLGD 
and the transpeptidation products YLGD-KLI/
YLGD-Kα(Ac)LI or YLGD-KLISV/YLGD-Kα(Ac)LISV 
(where a dash indicates the newly formed 
(iso)peptide bond). The resulting digestion 
mixtures were analyzed by LC-MS. Ligation 
with non-acetylated KLI and KLISV occurred 
with equal efficiency (Figure 1D), suggesting 
that peptide bond formation is independent 
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Figure 1 | The proteasome accepts α-acetylated amino acids and peptides as C-terminal ligation 
partner during splicing reactions. A) MALDI spectrum of CTMRSLPRGTASSR (top panel). MALDI spec-
tra of proteasomal digestion mixtures of CTMRSLPRGTASSR only (second panel), CTMRSLPRGTASSR and 
MG132 (third panel), and CTMRSLPRGTASSR and bortezomib (bottom panel). B) MALDI spectra of pro-
teasomal digestion mixtures of CTMRSLPRGTASSR only (top panel), CTMRSLPRGTASSR and lysine (second 
panel), CTMRSLPRGTASSR and Nε-acetylated lysine (third panel), and CTMRSLPRGTASSR and Nα-acetylated 
lysine (bottom panel). C) Ligation efficiencies for the formation of β2 and β5 ligation products by lysine 
and acetylated lysine, calculated from MALDI experiments. D) Ligation efficiencies for the formation 
of YLGD-KLISV and YLGD-KLI using non-acetylated or Nα-acetylated C-terminal ligation fragments. Li-
gation efficiencies were calculated from LC-MS experiments. Ligation efficiency was defined as the 
percentage of cleavage that resulted in ligation as opposed to hydrolysis. 
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of the length of the C-terminal ligation frag-
ment, as has been observed before (Chapter 
3.2). Ligation with Nε-acetylated peptides gave 
similar results compared to reactions using 
non-acetylated peptides (data not shown). Li-
gation of Nα-acetylated peptides on the other 
hand occurred with 10-fold lower efficiency 
compared to non-acetylated peptides (Figure 
1D), in contrast with results found with single 
amino acids. The length of the Nα-acetylated 
C-terminal ligation fragment did not influence 
ligation efficiency (Figure 1D), as was also ob-
served with non-acetylated peptides. Togeth-
er these data suggest that the proteasome 
can form isopeptide bonds between two pep-
tide fragments, but that it favors α-ligation 
over ε-ligation. 
ε-ligation can compete with α-ligation 
during proteasomal splicing events 
Next, we studied whether the ε-amino group 
of an N-terminal lysine residue can compete 
with the α-amino group for ligation when 
both amines are unprotected. To this end, 
a ligation experiment was performed using 
a C-terminal ligation fragment with a 15N-
enriched ε-amine. A ligation product con-
taining a 15N-enriched amide will result from 
ε-ligation, whereas α-ligation will result in a 
ligation product containing a 15N-enriched 
amino group (Figure 2A). As amides and 
amines are distinguishable by NMR spectros-
copy, this enabled us to study to which extent 
ε-ligation occurred. 15N-ε-Fmoc-Lys(Boc)-OH 
was synthesized and incorporated into Kε15NLI 
by standard solid phase peptide synthesis. 
Subsequently, a 5-fold excess of the N-termi-
nal precursor YLGD|SY was incubated with 
proteasome and Kε15NLI to form YLGD-Kε15NLI, 
where the dash indicates the newly formed 
(iso)peptide linkage. The resulting digestion 
mixture was analyzed using LC-MS. Figure 2B 
shows absorption spectra recorded at 280 
nm of the reaction mixture before incubation 
(left panel) and after incubation (second pan-
el). In addition to the N-terminal precursor 
YLGD|SY (eluting at 11.9 min), the hydrolysis 
product YLGD (eluting at 10.0 min) and dif-
ferent ligation products could be detected in 
the digestion mixture after incubation (Figure 
2B, second panel). MS analysis of the peak 
eluting at 13.7 min showed that this peak 
contained two peptides with masses of 821 
Da (M1) and 913.8 Da (M2) (Figure 2B, third 
panel), which corresponded to the ligation 
products YLGD-Kε15NLI and YLGD-YLGD. The 
peak eluting at 14.6 min. contained a third li-
gation product with a mass of 1163.6 Da (M3) 
(Figure 2B, fourth panel), corresponding to 
YLGD-YLGDSY. 
Next, the ligation mixture was purified us-
ing HPLC and as YLGD-Kε15NLI and YLGD-YLGD 
were co-eluting and thus not separated using 
HPLC, NMR spectra were recorded of the frac-
tion containing both peptides. First, we inves-
tigated whether both α-linked and ε-linked 
YLGD-Kε15NLI were formed during the ligation 
reaction. If both types of ligation would occur, 
a 15N NMR spectrum should show two distinct 
peaks, one corresponding to the amine, and 
one to the amide (Figure 2A). As direct detec-
tion of 15N atoms suffers from low sensitivity 
and long relaxation times,14 15N signals are 
usually inverse-detected via the proton signal 
in a 1H-15N heteronuclear single quantum co-
herence (HSQC) experiment using a fixed JH,N 
coupling constant. Whereas amide groups can 
be readily detected in an HSQC experiment 
via the 1JH,N coupling, NMR characterization of 
lysine NH3 groups via the 1JH,N coupling is chal-
lenging, due to rapid hydrogen exchange with 
water (Supplementary Information and Sup-
plementary Figure 1).15 In accordance, the 15N 
amine signal could not be detected in HSQC 
experiments using JH,N coupling constant rang-
ing from 55 to 90 Hz (data not shown), which 
covered the whole range of reported amine 
1JH,N coupling constants (55-80 Hz).14 When 
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HSQC measurement. 1H-15N correlations of the 
lysine NH3 group are often difficult to observe 
in HSQC experiments optimized for backbone 
amides, even when the water exchange rate 
is slow enough to permit their detection by 1H 
NMR.15 This is due to two factors. First, the 15N 
chemical shift of lysine NH3 groups resonates 
~ 90 ppm upfield from the backbone amide 
signals. As the rf strength that can be used for 
15N pulses is limited, application of a 15N 180° 
pulse at 115 ppm (close to the amide reso-
nance frequency) leads to an imperfect pulse 
at 30 ppm (close to the lysine NH3 resonance 
frequency) and therefore to loss of signal in-
tensity, and vice versa.15 With standard HSQC 
pulse programs it is therefore not possible 
to obtain maximal signal intensities for 15N 
amide and 15N amine groups simultaneously. 
Second, the 15N transverse relaxation of lysine 
NH3 groups has been shown to be highly af-
fected by water exchange, resulting in broad-
ening of 15N line shapes and a decrease in res-
olution and sensitivity,15 as visible in Figure 2C. 
Therefore, the relative amount of ε-ligation 
product compared to α-ligation product was 
estimated by quantifying the signal intensity 
of the newly formed 15N enriched amide bond 
Figure 2 | ε-ligation can compete with α-ligation during proteasomal splicing reactions. A) Scheme 
showing the proteasomal ligation reaction of YLGDSY with Kε15NLI. B) HPLC profile (UV detection at 280 
nm) of the ligation mixture before incubation (left panel) and after incubation (second panel). In-line 
MS spectra of the peaks eluting at 13.7 min (third panel) and 14.6 min (right panel). M1: YLGD-KLI; 
M2: YLGD-YLGD; M3: YLGD-YLGDSY.  C) 1H-15N HMQC spectrum of the ligation sample, recorded using 
JH ,N = 10 Hz. 1D projections of the 1H and 15N signals are shown on top and left axes, respectively. D) 
1H-15N HSQC spectrum of the ligation sample, recorded using 1JH ,N = 90 Hz. The 1D projection of the 
15N signal is shown on the left axis, the 1H spectrum of the ligation sample is shown on the top axis. 
Peaks were assigned as follows, 1: εK5, 2: not assigned, 3: L2/D4, 4: L2/D4, 4A: not assigned, 5: G3 (See 
Supplementary Information and Supplementary Figure 2 for details). e) Overlay of the 1H-15N HSQC 
spectra of the 15Nε-enriched ligation sample (red) and synthetic, non 15N enriched YLGDεKLI (black) 
F) Overlay of the 1H-15N HSQC spectra of the 15Nε enriched ligation sample (red), synthetic non 15N-
enriched YLGDαKLI (black, solid lines), and synthetic non 15N enriched YLGDYLGD (black, dotted lines). 
g) 1H spectrum of the ligation sample and integrals of peaks 4 and 4A. Peak 4 is attributed to L2 or D4 
and is present in the 1H spectra all products, whereas peak 4A is present in the 1H spectrum of YLGDεKLI 
only (Supplementary Figures 2 and 3) 
15N signals are on the other hand inverse- 
detected via long-range 2JH,N and 3JH,N couplings 
(JH,N = 0.3 to 16 Hz),
14 both amide and amine 
resonances can be measured simultaneously 
in a single experiment (Supplementary Infor-
mation and Supplementary Figure 1). There-
fore, we performed a 1H-15N HMQC measure-
ment, using a JH,N  coupling constant of 10 Hz. 
The resulting HMQC spectrum showed two 
peaks, with shifts of 7.85; 114.7 and 1.45; 
33.2 ppm (Figure 2C). Amines display a chem-
ical shift of 0 to 70 ppm, while amides have a 
chemical shift of 80 to 170 ppm, compared to 
a 15NH3 reference signal.14 This indicates that 
during proteasomal digestion of YLGDSY in 
the presence of Kε15NLI, ligation products con-
taining 15N-enriched amines and 15N-enriched 
amides were both formed. From these data 
we conclude that during proteasomal splicing 
reactions ε-ligation competes with α-ligation. 
ε-ligation occurs in 1 out of 10 ligation 
events 
Next, we set out to quantify the relative 
amount of ε-ligation product formed. It is 
however not possible to directly compare the 
15N amide and 15N amine signals in a single 
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using amide resonances within the peptide 
due to naturally abundant 15N as an internal 
reference. To ensure maximum signal inten-
sities of amide resonances, the YLGD-Kε15NLI 
containing fraction was analyzed again in an 
HSQC experiment using a 1JH,N coupling con-
stant of 90 Hz.16 In the resulting spectrum, 
one intense cross peak was visible at 7.86; 
114.7 ppm, which originated from the 15N 
enriched isopeptide amide in YLGD-εKLI (Fig-
ure 2D, peak 1). In addition, several weaker 
signals were detected, which originate from 
naturally abundant 15N amide signals of differ-
ent ligation products. 
The ligation sample contained the following 
ligation products: YLGD-αKLI, YLGD-εKLI and 
YLGD-YLGD as indicated by LC-MS (where a 
dash indicates the newly formed pepide bond 
and α/ε the type of linkage) (Figures 2B and 
2C). We synthesized these three peptides and 
recorded 1H and 1H-15N HSQC spectra as a ref-
erence to assign 1H-15N cross-peaks to one or 
more peptides (Supplementary Information 
and Supplementary Figure 2). An overlay of 
the 1H-15N HSQC spectra of the 15N enriched 
ligation sample and synthetic YLGDεKLI con-
firmed that peak 1 resulted from the 15N en-
riched εK5 resonance (Figure 2E). In addition, 
the overlay of HSQC spectra of the ligation 
sample, synthetic YLGDαKLI, and synthetic YL-
GDYLGD showed that all weaker signals could 
be attributed to naturally abundant 15N amide 
resonances in one or more ligation products 
(Figure 2F). In the HSQC spectrum of the liga-
tion sample, 56% of the signal of overlapping 
cross-peaks originated from YLGD-YLGD, while 
44% originated from YLGD-α/εKLI (Supplemen-
tary Information and Supplementary Figure 
3). We integrated the signals of the εK5 cross 
peak (peak 1) and the 4 most intense naturally 
abundant cross-peaks (peaks 2 to 5) and cal-
culated the signal intensity originating from 
YLGD-α/εKLI resonances only (Table 1; 44% of 
total integrals). Taking the abundance of 15N 
signals into account, the relative percentage 
of ε-ligation (YLGD-εKLI) versus α-ligation 
(YLGD-αKLI ) was estimated to be 10.3 ± 1.7% 
(average ± SD of peaks 2 to 5). This relative 
percentage of ε-ligation could also be derived 
from the 1H spectra of the ligation sample 
(Figure 2G). In this spectrum, the triplet at 
8.61 ppm originates from naturally abundant 
peak 4, which is present in all peptides, while 
the doublet at 8.49 ppm originates from natu-
rally abundant peak 4A, which is only present 
in YLGDεKLI (Supplementary Figure 2D). From 
the integral of these resonances, we derived 
that YLGD-εKLI constituted 6% of total ligation 
products (YLGD-YLGD + YLGD-αKLI + YLGD-
εKLI) and estimated the relative percentage 
of ε-ligation versus α-ligation to be 14%. Both 
percentages also correlate with the LC-MS ex-
periments described above, in which relative 
ε-ligation efficiencies of 10% were observed. 
Together, these data indicate that in one out 
of 8 to 10 ligation reactions ε-ligation oc-
curred as opposed to α-ligation. 
Peak Residue f2 (ppm) f1 (ppm) Total Integral YLGD-KLI only 15N abundance
1 εK5 7.8552 114.6679 209654420 209654420 98%
2 - 7.9136 118.6336 20745315 9127938 0.37%
3 L2/D4 8.1374 116.6248 20142896 8862874 0.37%
4 L2/D4 8.5903 121.4045 15826456 6963640 0.37%
5 G3 8.2106 106.3924 14876321 6545581 0.37%
table 1 | Integrals of 15n enriched and naturally abundant amide cross-peaks.
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Isopeptides have increased affinity for HlA-A 
complexes 
It is likely that epitopes containing an isopep-
tide linkage have binding affinities for HLA-A 
molecules that differ from their non-isopep-
tide counterparts. To test whether epitopes 
containing an isopeptide bond could still bind 
HLA-A complexes, we measured the affinity of 
a set of isopeptide bond-containing peptides 
for HLA-A2.1 and HLA-A3. Isopeptides were 
based on three known epitopes, GILGFVFTL 
(influenza matrix protein 1 58-66),17 NLVP-
MVATV (human cytomegalovirus pp65 495-
503),18 which are both presented on the cell 
surface by HLA-A2.1, and SLPRGTSTPK (spliced 
together from SP110 nuclear body protein 
296-301 and 286-289),10 which is presented 
by HLA-A3. As the length of an Nε-linked lysine 
residue in a peptide backbone is twice that of 
an Nα-linked lysine residue (See Figure 2A), 
we replaced two adjacent amino acid resi-
dues at different positions in the epitope by 
one Nε-linked K (Table 2).  To ensure binding, 
the anchor residues on P2 and P9 (P10 in case 
of SLPRGTSTPK) were not modified. 
To investigate binding to HLA-A2.1 or HLA-A3, 
a UV-mediated MHC exchange fluorescence 
polarization (FP) assay was used.19,20 In this as-
say, HLA-A2.1/HLA-A3 complexes loaded with 
a UV-cleavable peptide ligand are subjected 
to UV light, which cleaves the ligand, result-
ing in the generation of “empty” HLA-A2.1/
HLA-A3.21 These “empty” HLA-A2.1/HLA-A3 
complexes quickly disintegrate, unless they 
are rescued by the addition of a ‘rescue’ pep-
tide. When rescue is performed by adding 
both a fluorescent tracer peptide and increas-
ing concentrations of a ‘competitor’ peptide, 
the affinity of this competitor peptide can be 
measured.19,20 Binding curves of the NLVPM-
VATV-, SLPRGTSTPK- and GILGFVFTL-based 
isopeptides were measured (Figure 3, solid 
lines) and the affinities (expressed as IC50 val-
ues), defined as the concentration of peptide 
that inhibited 50% of tracer peptide binding, 
were determined (Table 2). For all poten-
tial epitopes, the presence of an isopeptide 
linkage did not abrogate HLA-A2.1/HLA-A3 
binding, as all peptides were able to bind to 
HLA-A2.1 or HLA-A3 complexes with similar 
Figure 3 | Isopeptides have increased affinity for HlA-A complexes. Binding curves of (iso)peptides 
based on the epitopes NLVPMVATV (specific for HLA-A2.1), SLPRGTSTPK (specific for HLA-A3) and GIL-
GFVFTL (specific for HLA-A2.1). (ε)K indicates the location of the isopeptide linkage. (α)K indicates a 
normally linked lysine residue. 
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affinities as the parent peptides (Table 2). In 
general, the isotope linkage was tolerated in 
the middle of the epitope (Figure 3, red and 
orange lines) or towards the N-terminus of the 
epitope (Figure 3, green lines) without loss of 
HLA class I affinity. When the isopeptide link-
age was shifted towards the C-terminal side 
of the epitope on the other hand, affinity 
decreased. For comparison, the affinities of 
GILGFVFTL-based epitopes with identical se-
quences but a normal peptide bond were de-
termined. As these peptides are 8 amino acids 
in length, they are expected to have low affin-
ity to HLA-A2.1, which only binds peptides of 
9-10 amino acids in length with high affinity. 
As can be judged from Figure 3 (dotted lines) 
and Table 2, the binding affinity of these 
GILGFVFTL-based peptides was decreased 
by a factor 40 to 200 compared to their iso-
peptide counterparts. Together, these data 
suggest that isopeptides are not only formed 
by the proteasome, but isopeptides of differ-
ent lengths can also be presented at the cell 
surface by different HLA class I alleles. In ad-
dition, the presence of an isopeptide linkage 
enables 8-mer isopeptides to bind HLA-A2.1/
HLA-A3 complexes with much increased af-
finity as compared to normal 8-mer peptides 
that do not contain an isopeptide linkage. 
Isopeptides have enhanced stability towards 
proteasomal degradation
Intramolecular isopeptide bonds have been 
shown to provide proteolytic stability to pili 
on the surface of Gram-positive bacteria,22-24 
suggesting that epitopes containing an iso-
peptide linkage may be less susceptible to 
processing by proteases. Therefore, we in-
vestigated whether isopeptides showed en-
hanced stability to proteasomal processing 
table 2 | iC50 values of different (iso)peptides for binding to HlA-A2.1 and HlA-A3.
Parent peptide Replaced 
positions
Isopeptide IC50 (mM) Peptide IC50 (mM)
GILGFVFTL - - 1.7 - -
3-4 GI(ε)KFVFTL ND GI(α)KFVFTL ND
4-5 GIL(ε)KVFTL 1.8 GIL(α)KVFTL 111
5-6 GILG(ε)KFTL 2.0 GILG(α)KFTL 509
6-7 GILGF(ε)KTL 4.8 GILGF(α)KTL 577
7-8 GILGFV(ε)KL 14.5 GILGFV(α)KL 601
NLVPMVATV - - 4.7
3-4 NL(ε)KMVATV 0.31
4-5 NLV(ε)KVATV 0.35
5-6 NLVP(ε)KATV ND
6-7 NLVPM(ε)KTV 0.71
7-8 NLVPMV(ε)KV 1.3
SLPRGTSTPK - - 0.19
3-4 SL(ε)KGTSTPK 0.44
4-5 SLP(ε)KTSTPK 0.42
5-6 SLPR(ε)KSTPK 0.35
6-7 SLPRG(ε)KTPK 0.20
7-8 SLPRGT(ε)KPK 0.55
8-9 SLPRGTS(ε)KK 1.9
(ε)K indicates the location of the isopeptide linkage. (α)K indicates a normally linked lysine residue. 
ND: not determined
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over normal peptides. First, we investigated 
peptides in which cleavage of the (iso)peptide 
bond was the only proteasomal cleavage oc-
curring. To this end, YLDWα/εKLISV and GILGFα/
εKTL were incubated with proteasome for 
time periods up to 16 h, followed by LC-MS 
analysis of the degradation mixtures (where 
α/ε indicates the location of the lysine Nα- 
or Nε-linkage). The amounts of the different 
input peptides were plotted as the percent-
age of total ion count versus time (Figure 4A). 
GILGFαKTL (dotted lines) was cleaved readily 
(t1/2 ~ 2 h), while GILGFεKTL (solid lines) was 
cleaved at a slower rate (t1/2 ~ 4 h). The differ-
ence in hydrolysis rate between Nα-linked and 
Nε-linked lysine residues was even more ap-
parent in YLDWKLISV. Whereas YLDWαKLISV 
was cleaved with a half-life of 6 h, less then 
5% of YLDWεKLISV was cleaved within 16 h. 
Next, we questioned whether isopeptides 
that were cleaved at positions other then at 
the isopeptide bond were also more stable 
to proteasomal processing compared to nor-
mal peptides. We incubated GIα/εKFVFTL, GILα/
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Figure 4 | Isopeptides show enhanced stability towards proteasomal degradation. A) Degradation of 
GILGFα/εKTL and YLDWα/εKLISV by the proteasome as a function of time. The amounts of input peptides 
and degradation products were quantified using LC-MS. The site of cleavage and the location of the 
lysine Nα- or Nε-linkage is indicated with a vertical line. B) Proteasomal degradation patterns of the 
indicated peptides. The amounts of input peptides and degradation products were quantified using 
LC-MS after incubation with proteasome for 16 h. Black bars indicate isopeptides and corresponding 
degradation products, grey bars indicate normal peptides and corresponding degradation products. 
The main site of cleavage is indicated with a vertical line. The location of the lysine Nα- or Nε-linkage 
is indicated with α or ε. Cleavage products are indicated by the site of cleavage relative to the lysine 
Nα- or Nε-linkage. UC: uncleaved input peptide.
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εKVFTL, GILGα/εKFTL and GILGFVα/εKL for 16 h 
with proteasome and analyzed the resulting 
digestion mixtures with LC-MS to assess the 
extent as well as the site of peptide cleavage. 
The amounts of input peptide and cleavage 
products were quantified by LC-MS and plot-
ted as the percentage of total ion count, which 
is a measure of total peptide content (Figure 
4B). Cleavage products were indicated by the 
site of cleavage relative to the lysine Nα- or 
Nε-linkage (e.g. +1 cleavage products result 
from cleavage 1 residue towards the C-termi-
nus from α/εK). For all peptides in which the 
isopeptide linkage was located towards the 
N-terminus from the site of cleavage, differ-
ences were found both in the rate and the site 
of hydrolysis. The difference between peptide 
and isopeptide processing was most appar-
ent when the isopeptide linkage was located 
within 1 to 2 residues of the site of cleavage 
(Figure 4B, top panel). The peptide GILGαKFTL 
was processed almost completely within 16 
h and was cleaved predominantly at the KF 
bond, which is located one residue towards 
the C-terminus from αK (+1 cleavage prod-
ucts). Only 20% of GILGεKFTL was processed 
within 16 h on the other hand, and the main 
cleavage site in GILGεKFTL was the FT bond lo-
cated two residues (corresponding to a length 
of three normal residues) from the isopeptide 
linkage (Figure 4B, top panel). Similar patterns 
were found when GILα/εKVFTL (Figure 4B, mid-
dle panel) and GIα/εKFVFTL (Figure 4B, lower 
panel) were compared. Both GILαKVFTL and 
GIαKFVFTL were completely processed within 
16 h, while only 50% and 90% of GILεKVFTL 
and GIεKFVFTL, respectively, were cleaved 
within the same time frame (Figure 4B). In 
line with results described above, the site 
of cleavage in isopeptides was located fur-
ther away from the lysine residue compared 
to the normal peptides. Whereas GILαKVFTL 
and GIαKFVFTL were cleaved preferably 2 and 
3 residues towards the C-terminus from the 
Nα-linked lysine, GILεKVFTL and GIεKFVFTL 
were cleaved 3 and 4 residues away from the 
Nε-linked lysine residue (Figure 4B). No dif-
ferences in peptide composition were found 
between digestion mixtures of GILGFVαKL and 
GILGFVεKL, which are the only peptides in this 
series in which the α/εK was located towards 
the C-terminus from the site of cleavage (data 
not shown). Together, these data suggest that 
peptides containing an isopeptide linkage are 
less susceptible to proteasomal degradation. 
This holds true both if the isopeptide linkage 
is the preferred site of cleavage and if the 
isopeptide linkage is located close to the pre-
ferred cleavage site. In addition, when pro-
teasomal processing of isopeptides did occur, 
the actual cleavage site was located further 
away from the εK residue compared to an αK 
resiude.
DISCUSSIOn
Recent studies have shown that proteasomal 
splicing reactions can create a novel type of 
antigen via a transpeptidation mechanism.8-11 
During proteasomal transpeptidation reac-
tions, a protein amide backbone linkage is 
attacked by one of the proteasomes catalytic 
N-terminal threonine residues, resulting in 
the formation of an O-acyl enzyme interme-
diate and the release of the C-terminal part 
of the protein. Subsequently, this intermedi-
ate ester reacts with an amino group, usually 
the amino terminus, from a second peptide 
(the ‘C-terminal ligation partner’), resulting in 
the formation of a novel peptide linkage and 
a spliced product.9,10 This transpeptidation re-
action can apparently compete with normal 
hydrolysis, in which water reacts with the 
intermediate ester,12 in such a way that suf-
ficiently new peptide can be formed to invoke 
an immune response against transpeptida-
tion products. Transpeptidation reactions can 
efficiently compete with hydrolysis if specific 
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structural requirements on the two ligating 
partners are met, as is discussed in Chapter 
3.2. Ligation occurs particularly efficient if the 
C-terminal ligation partner has a basic amino 
acid residue (lysine or arginine) at the N-ter-
minus (Chapter 3.2). As lysine has two amino 
groups that can theoretically both react with 
the O-acyl enzyme intermediate, this implies 
that the proteasome may be able to from iso-
peptide linkages.
In the present study we show for the first 
time that the proteasome can use both the 
α-amino group and the ε-amino group of 
lysine as a C-terminal ligation partner, sug-
gesting that also in vivo the proteasome can 
create an isopeptide linkage and form a novel 
type of antigen. When single amino acids are 
ligated onto a precursor peptide, both amino 
groups were equally reactive and capable of 
participating in ligation reactions. However, 
when peptide ligation was monitored by 
NMR, ε-ligation was found to be 10-fold less 
efficient as compared to α-ligation. Likely, a 
single lysine amino acid is capable of fitting 
into the S1' pocket in multiple orientations, 
thereby facilitating both α- and ε-ligation. A 
peptide on the other hand will adopt an ori-
entation whereby its P2' and P3' side chains fit 
in the S2' and S3' pockets. This may favor ori-
entation of the lysine residue in the S1' pocket 
in such a way that the α-amino group is po-
sitioned correctly for a nucleophilic attack 
on the intermediate ester bond, resulting in 
normal peptide bond formation, disfavoring 
alternative ε-ligation and isopeptide bond 
formation.
The data presented here also show that iso-
peptides have unique properties that discern 
them from normal epitopes. First, isopeptides 
of various lengths can bind different HLA al-
leles with high affinity. The isopeptide link-
age is tolerated in the middle and towards 
the N-terminus of different epitopes without 
loss of affinity for HLA-A2/A3 complexes. Only 
location of the isopeptide linkage towards the 
C-terminus of an epitope leads to loss of HLA-
A2/A3 affinity. In addition, the presence of an 
isopeptide linkage allows peptides that are 
comprised of only 8 amino acids to bind HLA-
A2/A3, whereas normally only peptides of 9 
to 11 residues in length bind HLA-A2/A3 com-
plexes with high affinity. Second, isopeptides 
are more stable towards further proteasomal 
processing compared to normal peptides. 
Degradation of isopeptides is slow compared 
to common peptides, both when the isopep-
tide bond itself is the preferred site of cleav-
age, and when the preferred site of cleavage 
is located close to the isopeptide linkage. In 
addition, the proteasome cleaves most iso-
peptides at a site that is located further away 
from the lysine residue compared to normal 
peptides. This indicates that proteasomal 
processing of isopeptides results in the gen-
eration of a peptide fragment in which the 
isopeptide linkage is still present and located 
towards the N-terminus of the peptide, favor-
ing affinity for HLA-A2/A3. Together, these 
properties are likely to increase the fraction of 
ε-ligated peptides that enters the endoplas-
mic reticulum, and that is loaded onto MHC 
class I and transported to the cell surface for 
CD8+ T cell surveillance. As isopeptides are 
more stable towards proteasomal degrada-
tion, we consider it likely that the isopeptide 
linkage also hampers hydrolysis by other (cy-
tosolic) proteases. Importantly, isopeptides 
that are formed and subsequently processed 
by the proteasome are likely to retain their 
isopeptide linkage at a location (towards the 
N-terminus) that does not affect HLA-A2/A3 
affinity. Therefore, we anticipate an increased 
chance that an isopeptide containing epitope 
is efficiently loaded onto MHC allowing it to 
reach the cell surface once it is formed.
It has been proposed that proteasomal an-
tigen splicing increases the diversity of the 
peptide repertoire available for presenta-
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tion on MHC class I.12,25 A greater diversity of 
epitopes increases the potential epitope rep-
ertoire that may be recognized by CD8+ T cells, 
which ultimately results in the elimination of 
infected or malignant cells.12 Increasing diver-
sity of T cell receptors by V(D)J recombination 
is essential for protection from a constantly 
changing bacterial and viral repertoire.25 In 
addition, proteasomal splicing may increase 
diversity on the protein level. The data pre-
sented here suggest that also proteasomal 
εK-ligation reactions may increase immune 
diversity. To date, three spliced epitopes have 
been described in vivo,8-10 suggesting that 
proteasomal splicing does occur in cells and 
with sufficient efficiency to evoke an immune 
response against spliced epitopes. The splic-
ing efficiencies of two of the three described 
epitopes have been calculated and one spliced 
epitope was estimated to be produced from 
~ 5 × 105  to 1 × 104 molecules of precursor 
peptide (0.0002% to 0.01% efficiency).9,11 This 
indicates that even very low splicing efficien-
cies lead to sufficient amounts of peptide for 
detection by CD8+ T cells. In a previous study, 
we have shown that splicing efficiencies can 
be several orders of magnitude higher if 
specific structural requirements for the two 
ligating partners are met (Chapter 4.2). We 
estimated that ligations reaction involving 
C-terminal fragments with a lysine residue 
at the site of ligation occurred with efficien-
cies of 1 to 10% (Chapter 4.2). This indicates 
that the overall efficiency of εK-ligation reac-
tions, which is 10-fold lower as compared to 
α-ligation, can be as high as 0.1 to 1%, de-
pending on the sequence of N- and C-terminal 
ligation partners, suggesting that one isopep-
tide may be formed from 100 to 1000 precur-
sor molecules. Since a large fraction of spliced 
isopeptide epitopes may be able to reach the 
cell surface as a result of their increased pro-
teolytic stability, ε-ligation should produce 
sufficient amounts of peptide to evoke a T cell 
response, suggesting that isopeptides may 
play a role in immunity in vivo. Thus although 
the epsilon linkage has not been evidenced 
before in MHC epitopes yet, which is easily 
explained by its difficult (and so far unantici-
pated) detection, we consider it more than 
likely that they will be detected, based on our 
in vitro experiments. With evidence of prote-
olytic stability and therefore accumulation of 
this modification we postulate it as a genuine 
post-translational modification resulting from 
transpeptidation mechanisms. We consider 
it likely that our in vitro findings will be vali-
dated in vivo soon. 
mATerIAlS AnD meTHODS
Peptide building blocks were purchased from 
Novabiochem and appropriately functionalized 
resins from Applied Biosystems. 15N-ε-L-Lysine HCl 
was purchased from C/D/N Isotopes Inc (Pointe-
Claire, QC, Canada). All solvents were purchased 
from Biosolve at the highest grade available. All 
other chemicals were purchased from Aldrich 
at the highest available purity. All solvents and 
chemicals were used as received. LC-MS analyses 
were carried out on a WATERS LCT mass spec-
trometer in line with a WATERS 2795 HPLC sys-
tem and a WATERS 2996 photodiode array detec-
tor. All 1H and 1H-15N HSQC (Heteronuclear Single 
Quantum Coherence) experiments were carried 
out in DMSO-d6 using a Bruker Avance 300 (1H: 
300 MHz, 15N: 30.4 MHz) spectrometer. HMQC 
(Heteronuclear Multiple Quantum Coherence) 
experiments were performed on a Bruker ARX 
400 (1H: 400 MHz, 15N: 40.5 MHz) spectrometer. 
NMR data were processed and analyzed using 
Bruker v2.1 Topspin software.
Peptide synthesis
Peptides were synthesized using standard Fmoc-
based solid-phase peptide synthesis protocols 
and appropriately functionalized PEG-polyster-
ene Wang resins. Functionalized resins were sub-
jected to coupling cycles, in which deprotection 
of the Fmoc-group with piperidine/NMP (1/4 
v/v), was followed by coupling with 4 equivalents 
each of Fmoc protected amino acid, di-isopropyl 
187
Chapter 3.3   |   Isopeptide linkage containing antigens
ethylamine (dipea) and (Benzotriazol-1-yloxy)
tripyrrolidinophosphonium hexafluorophosphate 
(PyBop). Reactions were carried out in NMP at 
a volume of 1 mL/0.1 g of resin. After the final 
coupling step, the Fmoc group was removed and 
peptides were either directly fully deprotected 
and released from the resin directly by treat-
ing the resin with TFA/H2O/triisopropylsilane 
(93/5/2 v/v) for 2.5 h or peptides were treated 
with 4 equivalents each of acetic anhydride and 
dipea for 40 minutes to acetylate the N-terminus 
prior to deprotection and release from the res-
in. Peptides containing Nε-linked lysine residues 
were synthesized using Boc-L-lysine(Fmoc)-OH. 
Incorporation of this building blocked followed 
by removal of the Fmoc group ensures that pep-
tide synthesis continues at the Lysine ε-amine 
group, resulting in isopeptide linkage containing 
peptides. Peptides were precipitated with cold 
diethylether/pentane (3/1 v/v) and lyophilized 
from H2O/ACN/HOAc (65/25/10 v/v).
Synthesis of 15n-ε-Fmoc-lys(Boc)-OH
Nα-(9-Fluorenyl)methoxycarbonyl-15Nε-tert-
butyloxycarbonyl-L-lysine was synthesized as de-
scribed.26 1H NMR (400 MHz, d6-dmso) δ = 12.53 
(bs, COOH), 7.91 (d, J=7.5 Hz, 2H, HAr), 7.73 (d, 
J=7.5 Hz, 2H, HAr), 7.62 (d, J=7.6 Hz, 1H, NH), 7.42 
(t, J=7.5 Hz, 2H, HAr), 7.33 (t, J=7.5 Hz, 2H, HAr), 
6.79 (dt, JNH=92 Hz, JHH=6.8 Hz, 1H, 15NεH), 4.29-
4.26 (m, 2H, OCH2), 4.24-4.20 (m, 1H, OCH2CH), 
3.93-3.88 (m, 1H, Hα), 2.91-2.78 (m, 2H, CH2), 
1.70-1.52 (m, 2H, CH2), 1.36 (s, 9H, C(CH3)3), 
1.33-1.27 (m, 4H, 2xCH2). 13C NMR APT (300 MHz, 
CDCl3) δ = 175.51 (COOH), 156.29 (2x CO), 143.74 
(2xCq-Ar), 141.30 (2xCq-Ar), 127.69 (2xCHAr), 127.08 
(2xCHAr), 125.14 (2xCHAr), 119.95 (2xCHAr), 79.57 
(CCH3), 67.04 (CH2O), 53.71 (CαH) 47.16 (CHCH2O), 
40.15 (CεH2, 1JCN=11 Hz), 31.76 (CβH2), 29.54 
(CδH2), 28.41 ((CH3)3), 22.31 (CγH2). 15N1H-HMQC 
(6.79 ppm, 83.7 ppm). MS (ESI): [M+H]+calc=470.2, 
[M+H]+found=470.1.
Proteasome purification
Proteasome was purified from bovine liver as 
described.4 After each step, proteasome purity 
was monitored by incubating fractions with a 
fluorescent proteasome activity probe, followed 
by SDS-PAGE and scanning of the resulting gel 
for fluorescence emission, as described.27 Briefly, 
bovine liver was homogenized in phosphate buff-
ered saline (PBS), followed by precipitation using 
40% saturated ammonium sulphate to remove 
unwanted proteins. The proteasome was subse-
quently precipitated by increasing the concentra-
tion of saturated ammonium sulphate to 60%. 
Following dialysis, the proteasome was further 
purified using a 10-40% sucrose gradient and 
anion exchange column chromatography, using 
DEAE Sephadex A25 resin. Proteasome contain-
ing fractions were pooled, concentrated and pro-
tein concentrations were determined using the 
Bradford assay (Biorad). 
mAlDI experiments
78 pmol CTMRSLPRGTASSR was incubated with 10 
mg proteasome in ligation buffer (50 mM Tris-HCl, 
pH 8.5) containing 6% DMSO for 16 h at 45°C. In 
different experiments, 100 mM MG132, 100 nM 
bortezomib, or 0.5 M lysine, 0.5 M Nα-acetylated 
lysine or 0.5 M Nε-acetylated lysine were added 
to the reaction mixture. Following incubation, re-
action mixtures were freeze-dried and dissolved 
in 50 mL acetonitrile/H2O (5:95 v/v) containing 
0.1 % TFA. Of this solution 10 mL was used for 
purification and desalting using reversed-phase 
ZipTip®C18
 tips (Millipore, C18, spherical silica, 
15 um, 200 A pore size). Peptide samples were 
bound to the ZipTip pipette tip by aspirating and 
dispensing 10 mL sample for approximately 20 cy-
cles until the solution appeared nearly colorless 
and the ZipTip pipette tip had turned pink due to 
retained labeled peptides. The ZipTip pipette tip 
was washed twice with 10 mL of 0.1% TFA. Re-
tained peptides were eluted by aspirating and 
dispensing 4 mL acetonitrile through the ZipTip 
pipette tip at least five times (the ZipTip pipette 
tip turned colorless). Eluates were analyzed by 
MALDI mass spectrometry. MALDI-TOF experi-
ments were carried out on an Autoflex, linear 
MALDI-TOF-MS (Bruker Daltonik GmbH, Bremen, 
Germany). Droplets of 0.5 mL 10 mg/ml 2,5-dihy-
droxybenzoic acid  (DHB, Bruker Daltonik) matrix 
solution in 0.1% TFA were spotted onto a MALDI 
target plate and 0.5 mL of the purified and desalt-
ed samples were pipetted into the DHB matrix 
droplets and left drying. For calibration, Peptide 
Calibration Standard (M 1046-3147 Da, Bruker 
Daltonik) was used. Spectra were analyzed with 
Bruker Daltonics FlexAnalysis Software. Ligation 
efficiencies were calculated using the following 
formula: Efficiency = IL/(IL+IH) × 100%, where IL is 
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the peak intensity of the ligation product and IH is 
the peak intensity of the hydrolysis product.  
Peptide ligation experiments
To compare acetylated and non-acetylated pep-
tides, 50 nmol of the peptide YLGDSY was incu-
bated with 250 nmol of (acetylated) C-terminal 
ligation fragment and 5 mg proteasome in a total 
volume of 75 mL ligation buffer (50 mM Tris-HCl, 
pH 8.5) containing 2% DMSO for 16 h at 37 °C. In-
cubation mixtures were snap-frozen, lyophilized, 
dissolved in DMSO/H2O/ACN (1/2/1 v/v) and fil-
tered over Strata™-X 33 mm polymeric reversed 
phase disposable columns (Phenomenex). Eluted 
fractions were analyzed by LC-MS.
For NMR experiments, 16 mmol ε(15N)KLI was incu-
bated with 80 mmol YLGDSY and 2.8 mg protea-
some in 23.2 mL ligation buffer containing 4.8% 
DMSO for 24 h at 37°C. The reaction mixture was 
snap-frozen, lyophilized, dissolved in 12 mL ac-
etonitrile/H2O (1:1) and filtered over a Strata™-X 
33 mm polymeric reversed phase disposable 
column (Phenomenex) to remove proteasomal 
proteins. The filtrate was lyophilized again, dis-
solved in 7.5 mL DMSO/H2O (1:4) and diluted and 
purified by HPLC over an Atlantis® Preparative 
T3 column (5 mm; 20 x 150 mm; Waters) using 
a linear gradient (5% to 50% acetonitrile in H2O 
containing 0.05% TFA). HPLC purifications were 
performed on a Shimadzu LC-20AT prominence 
liquid chromatography system, coupled to a Shi-
madzu SPD-20A prominence UV/Vis detector 
and a Shimadzu CTO-20A prominence column 
oven. The YLGD-ε(15N)KLI containing fraction was 
lyophilized and dissolved in 0.4 mL DMSO-d6 for 
NMR spectroscopy analysis. Reference spectra 
of synthetic YLGDαKLI, YLGDεKLI and YLGDYLGD 
were recorded using a 50 mM peptide solution 
in DMSO-d6. HSQC experiments were performed 
using a Bruker preprogrammed gradient en-
hanced echo-antiecho HSQC pulse program28,29 
(hsqcetgp, avance-version, 2D H-1/X correlation 
via double inept transfer, phase sensitive us-
ing Echo/Antiecho-TPPI gradient selection with 
decoupling during acquisition, using trim pulses 
in inept transfer) optimized for the detection of 
15N signals and 15N signals were compared to a 
15NH3 reference signal. The relative percentage of 
ε-ligation versus α-ligation was calculated using 
the following formula: Efficiency of ε-ligation = I1/
(0.44×IN) × 0.37/98 × 100%, where I1 is the inte-
gral of the 15Nε-enriched peak 1, IN is the integral 
of peak N, resulting from a naturally abundant 
amide resonance, 0.44 is the fraction YLGD-α/εKLI 
in the ligation sample as compared to total pep-
tide content, 0.37 is the percentage of naturally 
abundant 15N and 98 is the percentage of 15N en-
richment of 15Nε-enriched peak 1. The efficiency 
of ε-ligation was calculated for peaks 2 to 5 and 
averaged.  
Fluorescence polarization HlA-A2.1 and HlA-A3 
binding assay
Fluorescence polarization (FP) HLA-A2.1 and 
HLA-A3 binding assays with UV-mediated pep-
tide exchange were performed as described pre-
viously19,20 with minor changes. For the HLA-A2.1 
binding assay, KILGFVFJ1V (where J1 is UV-cleav-
able 3-amino-3-(2-nitrophenyl)propionic acid) 
was used as conditional ligand and fluorescently 
labeled FLPSDCTMRFPSV (where TMR is maleimi-
do-linked tetramethylrhodamine) was used as 
tracer peptide. For the HLA-A3 binding assay, 
RIYRJ1GATR was used as conditional ligand and 
KVPCTMRALINK was used as tracer peptide. Se-
rial 2- or 3-fold dilutions of different (iso)pep-
tides were used as competitor peptides. Assays 
were performed in 384-well low-volume black 
nonbinding surface assay plates (Corning 3820). 
Wells were loaded with 15 or 30mL total volume 
containing 0.5 mM HLA-A-peptide complex, 1 
nM tracer peptide and serial dilutions of com-
petitor peptide in PBS containing 0.5 mg/mL 
bovine γ-globulin. The plate was spun for 1 min 
at 1000g at room temperature to ensure proper 
mixing of all components. To start UV-mediated 
cleavage of the conditional ligand and peptide 
exchange, the plate was placed under a 365-nm 
UV lamp at 10 cm distance (366 nm UV lamp, 2 
× 15 W blacklight blue tubes, l×w×h 505 × 140 × 
117 mm, Uvitec, UK) located in a cold room (4 
°C). After 30 min irradiation, the plate was sealed 
with thermowell sealing tape (Corning) and incu-
bated at room temperature for 4 hours, allow-
ing cleaved peptide fragments to dissociate and 
to be exchanged for competitor and/or tracer 
peptide. Subsequently, fluorescence polarization 
measurements were performed, as described.19 
The binding affinity (IC50 value) of each competi-
tor peptide was defined as the concentration that 
inhibited 50% of tracer peptide binding. Data 
were analyzed using GraphPad Prism software 
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(GraphPad).
(Iso)peptide stability assays
50 nmol YLDWαKLISV or YLDWεKLISV was incu-
bated with 5 mg proteasome in ligation buffer 
containing 1-2% DMSO at 37 °C for different 
time periods up to 26 h. Incubation mixtures 
were snap-frozen, lyophilized and filtered over 
Strata™-X 33 mm polymeric reversed phase dis-
posable columns (Phenomenex). Filtered sam-
ples were analyzed by LC-MS.
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Supplementary information
SUPPlemenTAry reSUlTS
1h-15n HSqC and HmqC experiments 
As direct detection of 15N by NMR is difficult 
due to low naturally abundance of 15N, low 
relative sensitivity and low relaxation times, 
the 15N signal is frequently inverse-detected in 
1H-15N HSQC (Heteronuclear Single Quantum 
Correlation) or HMQC (Heteronuclear Mul-
tiple Quantum Correlation) experiments. The 
correlation data provided by either HSQC or 
HMQC experiments are essentially equivalent 
and provide the same information. In inverse-
detected experiments, 1H nuclei that couple 
to 15N nuclei are used for both the excitation 
and the detection of the 15N signal. The 15N 
signal is therefore detected via the 1H signal. 
The resulting 2D spectrum contains one cros-
speak for each proton that couples to a spe-
cific 15N nucleus. Depending on the coupling 
constant J that is used in the experiment, 
1H-15N coupling through one bond (1JH,N ~ 90 
Hz)1 or through bonds (two or three bonds; 
JH,N =  0.3 to 16 Hz)1 is utilized (Supplementary 
Figure 1). When coupling through one bond 
is utilized, the resulting 2D spectrum contains 
one cross-peak for each proton that is directly 
attached to a nitrogen. When coupling over 
multiple-bonds (2J or 3J) is utilized on the 
other hand, cross peaks are between protons 
and nitrogen atoms that can be either two or 
three bonds away. 
In protein NMR, 1H-15N HSQC experiments 
are routinely performed to detect backbone 
amide resonances. Each residue in a protein, 
with the exception of proline, has an amide 
proton that is directly attached to a nitrogen 
and can therefore be used to inversely detect 
the 15N signal. We performed 1H-15N HSQC 
experiments (J = 90 Hz) to detect backbone 
amide resonances in small peptides. In these 
experiments, both naturally abundant back-
Supplementary Figure 1 | Detection of amine and amide groups in HSqC experiments. Scheme 
showing 1H-15N couplings (J) that can be used to detect lysine’s amide and amine groups in 1H-15N HSQC 
and HMQC experiments. Protons that exchange with the solvent are indicated in blue, other relevant 
protons are indicated in black, 15N enriched nitrogen is indicated in red. Naturally abundant backbone 
amide groups (indicated in black) can be detected via the 1J coupling (via the directly attached pro-
ton), while the amide group of a Nε-linked lysine residue can be detected via 1H-15N coupling through 
one bond (1J) or through multiple bonds (2J or 3J). As amino groups readily exchange protons with the 
solvent, the 15N amine resonance cannot be inversely detected via the directly attached protons (1J 
coupling). Lysine’s free amino 15Nε signal can be detected by utilizing 1H-15N coupling through multiple 
bonds.
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bone amide resonances and 15N enriched 
Nε-linked lysine amide resonances can be 
detected (Supplementary Figure 1). By com-
paring the signal intensities of the naturally 
abundant backbone amide resonances to the 
intensity of the 15N enriched Nε-linked lysine 
signal, the relative amounts of different pep-
tides in the sample can be determined.
Whereas amide groups can be readily de-
tected in an HSQC experiment via the 1JH,N 
coupling (J = 90 Hz), NMR characterization 
of lysine’s free amino groups via the 1JH,N 
coupling is challenging. In aqueous solution, 
amino groups rapidly exchange protons with 
the solvent (Supplementary Figure 1), which 
hampers the detection of the amino protons 
in 1H experiments and therefore the detec-
tion of amino 15Nε signals via these protons. 
Lysine’s free amino 15Nε signal can be detect-
ed via protons that do not exchange with the 
solvent, e.g. the protons attached to lysine’s 
Cδ or Cε. Also the amide resonance of 15Nε-
linked lysine can be detected via these pro-
tons (Supplementary Figure 1). To visualize 
the 15N enriched amide and amine resonances 
simultaneously, we therefore performed an 
HMQC experiment with a coupling constant 
of 10 Hz. In this experiment, the 15N signal is 
detected via long range 2JH,N and 3JH,N couplings 
and the cross peaks are between the 15N en-
riched lysine Nε and the protons attached to 
the lysine Cε and/or Cδ. Therefore, the result-
ing 2D spectrum of this experiment will show 
both the 15N enriched amide and amine reso-
nances. The amide and amine signal intensi-
ties measured in this experiment can however 
not be compared quantitatively, as explained 
in the main text.  
Assignment of 1h-15n cross-peaks
To assign 1H-15N cross-peaks to one or more 
peptides, we synthesized YLGDαKLI, YLGDεKLI 
and YLGDYLGD and recorded 1H and 1H-15N 
HSQC spectra as a reference (Supplementary 
Figure 2). In the HSQC reference spectra of 
both YLGDαKLI and YLGDYLGD all backbone 
amides are visible as separate cross-peaks, 
while in the spectrum of YLGDεKLI two back-
bone amide peaks overlap (Supplementary 
Figure 2). In all spectra several 1H-15N cross-
correlations could be attributed to specific 
residues. Three cross-correlations were vis-
ible  in all three spectra (8.2; 106, 8.1; 116, 
and 8.6; 121 ppm, Supplementary Figure 2D). 
Glycine 15N signals resonate somewhat up-
field (at 106 ppm) compared to other amino 
acids.2 In addition, glycine amide protons are 
expected to show triplets in 1H spectra due to 
the presence of two protons on Cα. The cross-
peaks at 8.2; 106 ppm showed this upfield 
shift and characteristic splitting pattern (see 
1H spectra in Supplementary Figures 2B and 
2C) and we therefore attributed this signal to 
G3, which is present in all peptides. As all pep-
tides have YLGD as their first four residues, 
the other overlapping signals likely also origi-
nated from this part of the peptides (L2 and 
D4). The 1H spectrum of YLGDYLGD (Supple-
mentary Figure 2C) showed a second triplet 
at 8.0 ppm, and therefore the correspond-
ing cross-peak in the 1H-15N HSQC spectrum 
(8.0; 105 ppm) was attributed to G7. The 1H 
spectrum of YLGDεKLI (Supplementary Figure 
2B) showed a second triplet at 7.86 ppm. As 
this splitting is expected for ε-linked K amide 
protons (due to the presence of two protons 
on the adjacent Cδ), the corresponding cross-
peak in the 1H-15N HSQC spectrum  (7.8; 114.6 
ppm) was attributed to εK5. 
estimation of the relative abundance of dif-
ferent ligation products in the ligation sam-
ple
As the most intense cross peaks due to natural-
ly abundant amide resonances originate from 
all three peptides present in the ligation sam-
ple (Figure 2F), an estimation of the relative 
amounts of products in this sample is needed 
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to estimate the efficiency of ε-ligation. To this 
end, the 1H reference spectra of YLGDαKLI, 
YLGDεKLI and YLGDYLGD were compared to 
the 1H spectrum of the ligation mixture (Sup-
plementary Figure 3). All peptides contained 
one or two tyrosine residues, of which the 
Hδ and Hε protons are resonating at 7.0 and 
6.6 ppm, respectively. Whereas YLGDKLI and 
YLGDεKLI show near identical resonances for 
Y1 Hδ and Hε (Supplementary Figures 3A and 
3B), the 1H spectrum of YLGDYLGD shows ad-
ditional resonances for Y5, which are shifted 
somewhat downfield compared to Y1 and 
have equal intensities (Supplementary Figure 
3C). The sum of the 1H spectra of YLGDYLGD 
and YLGDαKLI (Supplementary Figure 3D) or 
YLGDεKLI (data not shown) indicates that the 
integrals of the Y1 signals are twice as high as 
the integrals of the Y5 signals if equal amounts 
of both peptides are used, as expected. In the 
1H spectrum of the ligation sample, the inte-
grals of Y1 are only 1.8 times as intense as the 
integrals from Y5 (Supplementary Figure 3E). 
Therefore, we concluded that in the HSQC 
spectrum of the ligation sample, 56% of the 
signal of overlapping cross-peaks originated 
from YLGD-YLGD, while 44% originated from 
YLGD-α/εKLI. In addition to the amount of pep-
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Supplementary Figure 2 | HSqC spectra of reference peptides. A-C) 1H-15N HSQC spectra of YLGD(α)
KLI (A) YLGD(ε)KLI (B) YLGDYLGD (C). 1H spectra of the corresponding peptides are shown on the top 
axis. D) Overlay of 1H-15N HSQC spectra of YLGD(α)KLI, YLGD(ε)KLI, and YLGDYLGD. 
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tide, the intensity of any 1H-15N cross-peak de-
pends on the abundance of 15N nuclei in these 
peptides. The naturally abundance of 15N and 
thus of any 15N amide is 0.37%, whereas the 
newly formed Lys Nε-linkage is 98% 15N en-
riched.
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Supplementary Figure 3 | 1H spectra of refer-
ence peptides and the ligation sample. 1H spec-
tra and integrals of indicated peaks of A) YLGD(α)
KLI B) YLGD(ε)KLI C) YLGDYLGD D) YLGD(α)KLI + 
YLGDYLGD (1:1) e) Ligation sample.
Chapter 3.4
Summary and prospects: 
proteasome splicing

197
Summary and prospects: proteasome splicing
Following malignant transformation or viral 
infection, a broad repertoire of antigenic pep-
tides is presented on the cell surface by MHC 
class I, enabling CD8+ T cells to sense the 
change in intracellular protein content, which 
eventually leads to killing of the antigen pre-
senting cell. The 26S proteasome is respon-
sible for the generation of these antigenic 
peptides in vivo. Recently, it has become ap-
parent that not only contiguous antigens, but 
also non-contiguous antigens, that consist of 
two post-translationally fused peptides, can 
be presented to the immune system. The liga-
tion that produces these epitopes is thought 
to be catalyzed by the proteasome in vivo via 
a transpeptidation mechanism, which makes 
it likely that splicing is not a random event, 
but governed by distinct splicing rules. The 
elucidation of such splicing rules will facilitate 
the prediction and detection of spliced anti-
gens, which will enable studying the roles of 
such spliced epitopes in immunity. 
To be able to study proteasome splicing on 
a molecular level, large amounts of purified 
proteasome are required. In chapter 2.3 we 
described how the fluorescent proteasome 
activity probes described in chapter 1 can be 
used to monitor proteasome purity during 
large scale proteasome isolation from bovine 
liver and spleen. Using mass spectrometry, 
we subsequently showed that highly puri-
fied preparations of either constitutive or im-
munoproteasome could be obtained via this 
method. In chapter 3.2, we used these protea-
some preparations to decipher splicing rules. 
By analyzing proteasome digestion mixtures 
of small libraries of potential ligation partners, 
we were able to show that splicing motifs ex-
ist. Subsequently, we confirmed and refined 
these motifs by application to a polypeptide 
derived from the Influenza A neuraminidase 1 
protein. In addition, we showed that protea-
somal splicing reactions can occur with high 
efficiencies of up to 30% in vitro if structural 
requirements for proteasome splicing are 
met by both ligation partners and that many 
spliced epitopes may be formed from a single 
protein. Finally, we examined the mechanism 
of splicing reactions, and showed that in vivo, 
intrastrand splicing of peptides derived from 
the same protein is likely preferred over ran-
dom ligation of peptides derived from differ-
ent proteins. In chapter 3.3, we investigated 
in more detail a specific type of proteasomal 
ligation reaction, in which the C-terminal 
ligation partner has lysine at the site of liga-
tion. As lysine has two amino groups that can 
theoretically both participate in proteasomal 
transpeptidation reactions, this implies that 
the proteasome may be able to from isopep-
tide linkages. Using NMR, we showed that 
both the α- and the ε-amino groups of lysine 
were able to participate in ligation reactions, 
and we could determine that ε-ligation was 
favored over α-ligation in 10% of all splicing 
reactions involving lysine at the site of liga-
tion. This suggested that the proteasome can 
create isopeptide linkages and may therefore 
form a novel type of antigen that may play 
a role in immunity in vivo. In addition, we 
showed that isopeptide linkage containing 
epitopes have unique properties that discern 
them from normal epitopes. First, isopeptides 
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of various lengths can bind to HLA-A2.1 and 
HLA-A3 proteins with high affinity. Second, 
isopeptides are more stable towards further 
proteasomal processing as compared to nor-
mal peptides. The combination of these prop-
erties suggests that a large fraction of isopep-
tide epitopes may reach the cell surface to 
evoke an immune response. 
The data described in chapters 3.2 and 3.3 
collectively indicate that different types of 
proteasomal ligation reactions readily occur 
in vitro. The efficiencies of these reactions 
are high compared to the estimated ligation 
efficiencies of splicing reactions described 
in vivo, suggesting that proteasomal splic-
ing reactions may occur more frequently 
than assumed thus far and may significantly 
contribute to immunity in vivo. To date, only 
three spliced epitopes have been described in 
vivo, as identifying spliced antigens de novo 
is not possible with the methodologies cur-
rently used to identify novel antigens. Novel 
epitopes can be identified by cell surface elu-
tion of all self- and foreign epitopes, followed 
by MS analysis and matching against protein 
databases. Alternatively, epitopes may be pre-
dicted from protein sequences and tested for 
T cell receptor recognition, e.g. by incorpora-
tion into fluorescent MHC class I tetramers, 
which are subsequently used to stain T cells 
in Fluorescence assisted cell sorting (FACS) 
assays. However, as spliced antigens are not 
contiguous and their formation requires post-
translational splicing, they neither match ex-
isting databases nor can they be predicted 
from contiguous protein sequences, which 
hampers their identification. The splicing 
rules deduced in chapter 3.2 should facilitate 
the identification of more spliced epitopes, 
and several types of experiments that aim at 
identifying both normal and εK linked spliced 
antigens are currently ongoing. 
To show that our splicing rules can predict 
splicing in vivo, we have expressed optimized 
precursor peptides in cells. If the predicted 
proteasomal splicing reactions occur, spliced 
epitopes are formed, loaded onto MHC class 
I and transported to the cell surface, where 
they can be identified using two strategies. 
The first strategy is based on elution of all 
epitopes from the cell surface, followed by 
LC-MS analysis. The successful identification 
of spliced epitopes requires the ability to de-
tect and sequence low femtomolar amounts 
of individual peptides in highly complex mix-
tures eluted from the cell surface. Typically, 
the number of copies of a particular peptide 
presented by MHC molecules on a single cell 
ranges from 1 to 10.000, and therefore, MS 
identification of spliced epitopes is very chal-
lenging. Very low copy numbers of MHC-pre-
sented epitopes can already activate CD8+ T 
cells, and T cell activation assays can there-
fore also be used to identify spliced epitopes. 
To perform these assays, mice transgenic for 
HLA-A2 (A2-Kb) are first vaccinated with the 
anticipated splicing product to obtain specific 
CD8+ T cells. These T cells are subsequently 
added to the cells that are transfected with 
an optimized precursor peptide in vitro. The 
presence of the expected splicing product on 
the cell surface will activate the T cells, which 
can be monitored in interferon-γ release as-
says. Although T cell activation assays are very 
sensitive, the expected spliced product has to 
be immunogenic to evoke a T cell response, 
which may complicate the identification of 
predicted spliced products. Finally, vaccina-
tion experiments are currently ongoing to 
show that splicing occurs readily in vivo. In 
these experiments, mice are first vaccinated 
with a DNA vaccine encoding splicing pre-
cursors. At the top of the immune response, 
blood is analyzed for the presence of T cells 
that are reactive against the spliced product. 
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Identifying isopeptide linkage containing 
epitopes in vivo is even more challenging, 
as mass spectrometry cannot distinguish be-
tween Nε- and Nα-linked lysine residues. Iso-
peptide epitopes have unique properties that 
can be used to distinguish them from normal 
peptides, but the amounts of epitope that are 
eluted from the surface of antigen presenting 
cells is generally not sufficient to perform sec-
ondary assays. Therefore, only T cell activa-
tion assays can be used to identify this novel 
type of antigen and we are currently in the 
process of peptide vaccinating HLA-A2 trans-
genic mice with both normal epitopes and 
isopeptide epitopes to generate T cells that 
are specific for either normal or isopeptide 
epitopes. By using these T cells in combina-
tion with cells that are transfected with an op-
timized splicing precursor peptide, we hope 
to identify isopeptide epitopes in vivo
Finally, studies are currently ongoing that 
will further refine the splicing rules that are 
postulated in this thesis. Application of the 
methods developed in chapter 3.2 to immu-
noproteasomal digestion mixtures will likely 
generate a set of splicing rules for the im-
munoproteasome. In addition, knowledge of 
proteasomal cleavage sites will allow a more 
accurate prediction of both C- and N-terminal 
ligation partners. Algorithms that predict pro-
teasomal cleavage are available, but they did 
not accurately predict hydrolysis of our model 
peptides. By analyzing a larger set of splicing 
precursors, rules that predict proteasomal 
cleavage can likely be deduced. We expect 
that the studies presented in this thesis will 
aid the discovery of novel spliced epitopes 
and that they will contribute to unraveling 
the role of spliced epitopes and isopeptide 
antigens in vivo. 
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Proteasoom activiteit in de breedste zin van 
het woord is het onderwerp van dit proef-
schrift. In de cel worden voortduren eiwitten 
gevormd en weer afgebroken om processen 
die van belang zijn voor het normaal functio-
neren van de cel te sturen. De afbraak van ei-
witten in een cel wordt strak gereguleerd door 
het ubiquitine proteasoom systeem, waarbij 
de daadwerkelijke eiwitafbraak plaatsvindt in 
en door het proteasoom. Het proteasoom is 
een groot eiwitcomplex, dat verantwoordelijk 
is voor het overgrote deel van de eiwitafbraak 
in een cel. In het proteasoom worden eiwit-
ten afgebroken tot kleinere stukjes, genaamd 
peptides, die vervolgens door andere pro-
teases afgebroken worden tot aminozuren, 
de bouwstenen van eiwitten. De precieze 
activiteit van het proteasoom wordt bepaald 
door de activiteit van zes verschillende actieve 
‘subunits’ die ieder na andere aminozuurse-
quenties knippen. Naast gewoon (constitu-
tief) proteasoom bestaat er ook een vorm 
die vooral aanwezig is in weefsels die een rol 
spelen in het immuunsysteem: het immuno-
proteasoom. 
Het proteasoom is niet alleen verant-
woordelijk voor de afbraak van eiwitten die 
een sleutelrol spelen in processen als de cel 
cyclus, cel differentiatie, signaal transduc-
tie en apoptose, het proteasoom speelt ook 
een rol in immuniteit. Een breed repertoire 
aan antigene peptiden wordt gepresenteerd 
op het celoppervlakte aan het immuunsys-
teem door Major Histocompatibility Com-
plex (MHC) klasse I eiwit complexen. Deze 
peptiden worden gegenereerd door het pro-
teasoom en kunnen afkomstig zijn van zowel 
lichaamseigen als lichaamsvreemde eiwitten. 
Zo wordt als het ware een blauwdruk van de 
celinhoud getoond aan het immuunsysteem. 
Dit stelt CD8+ cytotoxische T cellen in staat 
veranderingen in de cel als gevolg van bijvoor-
beeld maligne transformatie of een virale in-
fectie op te merken. De herkenning van een 
lichaamsvreemd of abnormaal peptide door 
CD8+ cellen leidt uiteindelijk tot de eliminatie 
van een maligne of geïnfecteerde cel. 
Het remmen van het proteasoom verstoort 
vele regulatoire processen in de cel, wat uit-
eindelijk tot celdood kan leiden. Dit maakt het 
proteasoom tot een aantrekkelijk farmacolo-
gisch target. De observatie dat kanker cellen 
gevoeliger zijn voor proteasoomremming dan 
normale cellen heeft geleid tot de ontwikkel-
ing van verscheidene proteasoomremmers 
voor de behandeling van kanker. Het medicijn 
velcade®, waarin de proteasoomremmer bort-
ezomib het actieve ingrediënt is, wordt ge-
bruikt voor de behandeling van de ziekte van 
Kahler (multipel myeloom) en van mantelcel 
lymfoom, een agressieve en ongewone vorm 
van non-Hodgkin lymfoom. Behandeling met 
bortezomib kan echter leiden tot substantiële 
bijwerkingen en ook treedt resistentie tegen 
bortezomib regelmatig op. Daarom is het be-
langrijk te zoeken naar nieuwe proteasoom-
remmers die beter getolereerd worden en/of 
werkzaam zijn in cellen die resistent zijn tegen 
bortezomib. Verscheidene tweede-generatie 
proteasoomremmers, die onder andere ver-
schillen in hun remmingsmechanisme en sub-
unit specificiteit, worden momenteel getest 
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in klinische trials. Voorbeelden van deze rem-
mers zijn marizomib en CEP-18770. Nu ver-
schillende proteasoomremmers beschikbaar 
komen voor klinisch gebruik, is het van groot 
belang om optimale behandelmethodes te 
definiëren en de meest geschikte remmer 
voor een bepaalde patiënt te bepalen. Hier-
voor zijn accurate methodes nodig die ge-
bruikt kunnen worden om de specificiteit en 
effectiviteit van deze verschillende remmers 
in patiënten te monitoren. Voor de meest 
gangbare methode die momenteel wordt ge-
bruikt om proteasoomactiviteit te meten is 
het echter noodzakelijk om cellen te lyseren 
(open te breken) voordat activiteitsmetingen 
uitgevoerd kunnen worden. Het lyseren van 
cellen leidt ertoe dat het proteasoom uit zijn 
regulatoire omgeving gehaald wordt, wat 
de proteasoomactiviteit kan beïnvloeden. 
Andere methodes kunnen alleen gebruikt 
worden in genetisch gemodificeerde cellen of 
organismen, wat het monitoren van patiënten 
die behandeld worden met proteasoomrem-
mers uitsluit. 
In hoofdstuk 1 beschrijf ik de ontwikkeling en 
karakterisatie van verschillende proteasoom 
probes, synthetische verbindingen die cova-
lent binden aan actieve proteasoomsubunits 
en een label bevatten waardoor ze gevisua-
liseerd kunnen worden. Deze probes kunnen 
gebruikt worden om proteasoomactiviteit te 
bestuderen in vele soorten weefsels en met 
een breed scala aan technieken. 
Hoofdstuk 1.2 beschrijft de ontwikkeling van 
een gedansyleerde proteasoom probe die in 
combinatie met op SDS-PAGE gebaseerde as-
says gebruikt kan worden om proteasoomac-
tiviteit te monitoren. Deze probe is de eerste 
in zijn soort die gebruikt kon worden om de 
activiteit van bortezomib in intacte cellen 
te bestuderen zonder de noodzaak om be-
werkelijke radiolabeling procedures uit te 
voeren. De gelabelde subunits kunnen een-
voudig zichtbaar gemaakt worden door te 
immunoblotten met een antilichaam tegen 
de dansyl groep. We vonden substantiële ver-
schillen tussen de specificiteit van bortezomib 
in intacte cellen en die in gelyseerde cellen. 
Dit benadrukt de noodzaak om bioassays te 
ontwikkelen die uitgevoerd kunnen worden in 
levende cellen om de accuraatheid van zulke 
me-tingen te kunnen waarborgen. 
In hoofdstuk 1.3 beschrijf ik de verdere op-
timalisatie van deze gedansyleerde protea-
soom probe, door vervanging van de dansyl 
groep door fluorophoren met een hogere 
quantum yield. Hierdoor kan de resulte-
rende SDS-PAGE gel direct gescand worden 
om fluorescente emissie van de gelabelde 
proteasoomsubunits te meten. Om effec-
tieve proteasoom probes met goede bio-
chemische en biofysische eigenschappen 
te kunnen selecteren, hebben we een se-
rie probes met verschillende fluorescente 
groepen gesynthetiseerd. Twee verschillende 
probes bleken geschikt om proteasoom- 
activiteit te bestuderen in celextracten, in-
tacte cellen en weefsels afkomstig van mui-
zen. Bovendien kunnen deze probes ook ge-
bruikt worden in confocale microscopy assays 
en flow cytometrie assays om proteasoomac-
tiviteit direct in cellen te kunnen detecteren. 
Hoofdstuk 2 concentreert zich op de toe- 
passing van deze fluorescente proteasoom 
probes. We hebben de effecten van verschil-
lende proteasoom remmers in preklinische 
studies en klinische trials bestudeerd. Daar-
naast hebben we deze probes gebruikt om 
proteasoom te zuiveren en proteasoom activ-
iteit en compositie te analyseren in verschil-
lende weefsels. 
In hoofdstuk 2.1 vergelijken we de effecten 
van bortezomib en de nieuwe proteasoom 
remmer CEP-18770 in een aantal in vitro en 
preklinische ex vivo modellen. CEP-18770 
doet hetzelfde als en lijkt zelfs op bortezomib. 
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In een panel van cellysaten en cellijnen waren 
beide proteasoomremmers equipotent in het 
remmen van verschillende proteasoomacti-
viteiten. In een preklinisch model van de ziek-
te van Kahler werd proteasoomactiviteit in 
normale, gezonde weefsels door beide rem-
mers evenveel geremd. Echter, de remming 
van tumor proteasoomactiviteit door CEP-
18770 was significant hoger dan de remming 
die bortezomib bewerkstelligde. Daarnaast 
laten we zien dat CEP-18770 behandeling in 
staat is om proteasoom te remmen in een 
bortezomib resistente multiple myeloom cel-
lijn. Deze resistentie is verworven door lang-
durige blootstelling aan bortezomib in vitro 
en wordt veroorzaakt door een specifieke 
mutatie in een van de actieve subunits van 
het proteasoom. CEP-18770 kon bovendien 
apoptose veroorzaken in deze cellen.
Marizomib is een proteasoomremmer die 
momenteel geëvalueerd wordt in fase I klini-
sche trials. Daardoor is het mogelijk om de 
respons van patiënten op behandeling met 
marizomib gedetailleerd te bestuderen. In 
hoofdstuk 2.2 laten we zien dat fluorescente 
proteasoom probes gebruikt kunnen worden 
om de proteasoom remming te meten in 
zowel ‘packed whole blood’ (PWB, bloed 
zonder plasma dat voornamelijk uit rode 
bloedcellen bestaat) als in ‘peripheral blood 
mononuclear cells’ (PBMCs, witte bloedcel-
len), afkomstig van ratten die behandeld zijn 
met bortezomib of marizomib. Daarnaast heb-
ben we een methode ontwikkeld waarmee 
fluorescente probes gebruikt kunnen worden 
om bloed samples van patiënten die behan-
deld worden met marizomib te bestuderen. 
We laten zien dat PWB, dat voor meer dan 
98% uit rode bloed cellen bestaat, anders rea-
geert op proteasoomremmers en minder snel 
herstelt van proteasoomremming in verge-
lijking met PBMCs. Deze data waarschuwen 
tegen het gebruik van PWB als een model-
systeem om de effecten van proteasoomrem-
mers in proefdieren of patiënten te monito-
ren, zoals nu routinematig gedaan wordt. 
Daarnaast hebben we fluorescente protea-
soom probes gebruikt om aan te tonen dat 
de initiële proteasoomactiviteit in patiënten 
voor de start van de behandeling een factor 
is die de gevoeligheid van patiënten voor pro-
teasoomremmers bepaalt. Daarnaast bepaalt 
het vermogen van cellen om hun proteasoom 
activiteitsprofiel te veranderen in reactie op 
behandeling met marizomib de gevoeligheid 
van cellen voor marizomib. Proteasoomrem-
mers die intraveneus worden toegediend ver-
zadigen waarschijnlijk eerst het constitutieve 
proteasoom in rode bloedcellen voordat 
tumorcellen bereikt worden. Specifieke im-
munoproteasoomremmers verzadigen rode 
bloedcellen waarschijnlijk bij relatief lage con-
centraties en zouden daarom in de toekomst 
een goed alternatief kunnen bieden voor de 
behandeling van tumoren met een hoge in-
trinsieke immunoproteasoomactiviteit. 
In hoofdstuk 2.3 ten slotte beschrijf ik hoe 
fluorescente proteasoom probes gebruikt 
kunnen worden om tijdens het isoleren van 
proteasoom uit runderlever en –milt, de zui-
verheid van dit proteasoom te kunnen moni-
toren. Met behulp van massaspectrometrie 
hebben we vervolgens laten zien dat zuiver 
constitutief of immunoproteasoom via deze 
methode verkregen kan worden. Daarnaast 
hebben we de relatieve subunitsamenstelling 
van gepurificeerd runderlever en -milt pro-
teasoom met massaspectrometrie bepaald.
De vindingen beschreven in hoofdstuk 2 la-
ten zien dat chemische proteasoom probes 
gebruikt kunnen worden om proteasoomac-
tiviteit op een betrouwbare manier te meten 
in een grote variëteit aan samples, zowel in 
preklinische diermodellen als in patiënten tij-
dens klinische trials. Daarnaast kunnen deze 
probes mogelijk de respons van patiënten 
op verschillende proteasoomremmers voor-
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spellen, wat kan bijdragen aan therapie op 
maat om het therapeutische potentieel van 
dit type medicijn te verbeteren en betere be-
handelresultaten voor patiënten te bewerk-
stelligen. 
In hoofdstuk 3 wordt proteasoomactiviteit 
op moleculair niveau bestudeerd en wordt 
gekeken naar de rol van het proteasoom in 
het immuunsysteem. Recente studies heb-
ben nieuwe epitopen geïdentificeerd die 
bestaan uit twee aparte delen van een eiwit 
die eerst losgeknipt zijn en vervolgens weer 
aan elkaar geplakt gesplicet om een nieuw 
peptide te vormen. De ligatiereactie die deze 
verknipte gesplicete epitopen produceert 
vindt plaats in en wordt gekatalyseerd door 
het proteasoom via een zogeheten transpep-
tidatiemechanisme. Dat mechanisme maakt 
het aannemelijk dat peptide splicing geen 
willekeurig proces is, maar gedicteerd wordt 
door specifieke regels. Het ophelderen van 
deze regels zal het voorspellen en identifi-
ceren van gesplicete antigenen vergemakke-
lijken. Pas als de identiteit van meer gesplicete 
epitopen bekend is, kan hun rol in immuniteit 
nauwkeurig bestudeerd worden. 
In hoofdstuk 3.2 wordt het moleculaire 
mechanisme van proteasomale antigen spli-
cing bestudeerd, en worden regels opgesteld 
die deze antigen splicing kunnen voorspellen. 
Door kleine peptide bibliotheken met mogelij-
ke splicing partners te incuberen met protea-
soom, en deze reactiemengsels vervolgens te 
analyseren, hebben we laten zien dat splicing 
motieven bestaan. Specifieke aminozuurse-
quenties bevorderden splicing, terwijl andere 
juist verhinderden dat splicing reacties plaats-
vonden. Daarna hebben we deze splicing 
motieven bevestigd en verfijnd door de regels 
toe te passen op een polypeptide afgeleid van 
een viraal eiwit van het Influenza A/PR/8/34 
virus (een H1N1 griepvirus, net als de mexi-
caanse griep). Daarnaast hebben we laten 
zien dat splicing reacties in het proteasoom 
heel efficiënt kunnen verlopen, met efficiën-
ties tot 30% in vitro, als aan de structurele 
eisen voor proteasoom splicing voldaan wordt 
door beide splicing partners. Ook hebben we 
aangetoond dat een groot aantal gesplicete 
epitopen gevormd kan worden uit een enkel 
eiwit. Tot slot hebben we het mechanisme 
van splicing reacties bestudeerd en hebben 
laten zien dat splicing bij voorkeur gebeurt 
met twee peptiden die afkomstig zijn van het-
zelfde eiwit. Willekeurige recombinatie van 
peptiden die afkomstig zijn van verschillende 
eiwitten vindt dus waarschijnlijk nauwelijks 
plaats in vivo. 
In hoofdstuk 3.3 laten we zien dat als een 
lysine residu betrokken is bij de ligatiereac-
tie, proteasoom splicing een nieuw type an-
tigen, dat een isopeptide binding bevat, kan 
creëren. Lysine heeft twee amino groepen 
(een α- en een ε-amino groep) die theore-
tisch allebei kunnen participeren in ligatie-
reacties. Dit impliceert dat het proteasoom 
naast normale peptide bindingen, waarin de 
α-amino groep betrokken is bij ligatie, ook an-
tigenen kan vormen met een isopeptide bin-
ding (als de ε-amino groep participeert in de 
ligatiereactie). Met behulp van NMR hebben 
we laten zien dat zowel de α- als de ε-amino 
groep van lysine betrokken kan zijn bij ligatie-
reacties in het proteasoom. Ook konden we 
bepalen dat isopeptide vorming geprefereerd 
wordt over α-ligatie in 10% van alle splicing 
reacties waarin een lysine betrokken was op 
de plek van ligatie. Dit suggereert dat het 
proteasoom een nieuw type antigen vormt 
dat een rol zou kunnen spelen in immuniteit. 
Daarnaast hebben we laten zien dat epitopen 
die een isopeptide binding bevatten unieke 
eigenschappen hebben, die hen onderscheidt 
van normale epitopen. Zo kunnen isopep-
tiden met verschillende lengtes met hoge af-
finiteit binden aan MHC klasse I. Ook worden 
isopeptiden minder snel afgebroken door het 
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proteasoom in vergelijking met normale pep-
tiden. De combinatie van deze eigenschappen 
suggereert dat een groot deel van de isopep-
tide epitopen die gevormd worden ook het 
celoppervlakte kan bereiken om daar een im-
muunrespons op te wekken. 
Gezamenlijk geven de data die beschreven 
worden in hoofdstuk 3.2 en 3.3. aan dat ver-
schillende typen ligatiereacties in het pro-
teasoom kunnen plaatsvinden in vitro. De 
efficiënties van deze reacties zijn hoog (tot 
30%) vergeleken bij de geschatte efficiënties 
voor de formatie van de gesplicete epitopen 
die tot nu toe beschreven zijn (0.0002-0.01%). 
Dit suggereert dat proteasomale splicing re-
acties veel vaker plaatsvinden dan tot nu toe 
werd aangenomen en dus een significante 
bijdrage zouden kunnen leveren aan immu-
niteit in vivo. Tot nu toe zijn pas drie gesplice-
te epitopen beschreven in vivo. Dit is niet ver-
wonderlijk als je bedenkt dat identificatie van 
deze epitopen niet mogelijk is met de huidige 
methodes die gebruikt worden om nieuwe 
antigenen te identificeren. Nieuwe epitopen 
kunnen worden geïdentificeerd door elutie 
van het celoppervlakte, gevolgd door analyse 
met massaspectrometrie, waarbij pepitdes 
gematchet worden tegen databases met ei-
witsequenties. Een alternatieve methode is 
het voorspellen van epitopen uitgaande van 
sequenties van bijvoorbeeld virale eiwitten. 
Vervolgens wordt dan getest of reactieve 
CD8+ T cellen tegen deze epitopen gevonden 
kunnen worden in muizen die gevaccineerd 
zijn met het desbetreffende virale eiwit. In 
het geval van gesplicete epitopen echter, 
bestaan de gevormde antigenen niet uit een 
aaneengesloten stuk eiwit, maar is een post-
translationele splicing reactie noodzakelijk om 
deze epitopen te vormen. Daardoor kunnen 
deze peptiden niet gematchet worden tegen 
databases die alleen aaneengesloten eiwitse-
quenties bevatten. Bovendien kunnen ze niet 
voorspeld worden op basis van aaneengeslo-
ten sequenties alleen. De splicing regels die 
beschreven staan in hoofdstuk 3.2 maken het 
voorspellen van gesplicete epitopen mogelijk. 
Dit zou de identificatie van meer gesplicete 
epitopen moeten vergemakkelijken. Ik ver-
wacht dat de studies die beschreven staan in 
dit proefschrift zullen bijdragen aan de ont-
dekking van nieuwe gesplicete epitopen en 
aan het ontrafelen van mogelijke functies van 
gesplicete epitopen en isopeptide antigenen 
in vivo.
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